{"parse":{"title":"Ovarian cancer","pageid":414192,"revid":860575868,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox\" style=\"width:22em\"><tbody><tr><th colspan=\"2\" style=\"text-align:center;font-size:125%;font-weight:bold;background:#ccc\">Ovarian cancer</th></tr><tr><td colspan=\"2\" style=\"text-align:center\">\n<a href=\"/wiki/File:Mucinous_lmp_ovarian_tumour_intermed_mag.jpg\" class=\"image\"><img alt=\"Mucinous lmp ovarian tumour intermed mag.jpg\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b8/Mucinous_lmp_ovarian_tumour_intermed_mag.jpg/300px-Mucinous_lmp_ovarian_tumour_intermed_mag.jpg\" width=\"300\" height=\"200\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b8/Mucinous_lmp_ovarian_tumour_intermed_mag.jpg/450px-Mucinous_lmp_ovarian_tumour_intermed_mag.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b8/Mucinous_lmp_ovarian_tumour_intermed_mag.jpg/600px-Mucinous_lmp_ovarian_tumour_intermed_mag.jpg 2x\" data-file-width=\"4272\" data-file-height=\"2848\" /></a></td></tr><tr><td colspan=\"2\" style=\"text-align:center\">\n<a href=\"/wiki/Micrograph\" title=\"Micrograph\">Micrograph</a> of a mucinous ovarian carcinoma <a href=\"/wiki/H%26E_stain\" title=\"H&amp;E stain\">stained by H&amp;E</a>.</td></tr><tr><th scope=\"row\"><a href=\"/wiki/Specialty_(medicine)\" title=\"Specialty (medicine)\">Specialty</a></th><td>\n<a href=\"/wiki/Oncology\" title=\"Oncology\">Oncology</a>, <a href=\"/wiki/Gynecology\" class=\"mw-redirect\" title=\"Gynecology\">gynecology</a></td></tr><tr><th scope=\"row\">Symptoms</th><td>\n<b>Early</b>: vague<sup id=\"cite_ref-NCI2014TxPt_1-0\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup><br /><b>Later</b>: bloating, <a href=\"/wiki/Pelvic_pain\" title=\"Pelvic pain\">pelvic pain</a>, abdominal swelling, loss of appetite<sup id=\"cite_ref-NCI2014TxPt_1-1\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup></td></tr><tr><th scope=\"row\">Usual onset</th><td>\nUsual age of diagnosis 63 years old<sup id=\"cite_ref-NCI2016Onset_2-0\" class=\"reference\"><a href=\"#cite_note-NCI2016Onset-2\">&#91;2&#93;</a></sup></td></tr><tr><th scope=\"row\">Types</th><td>\nOvarian carcinoma, <a href=\"/wiki/Germ_cell_tumor\" title=\"Germ cell tumor\">germ cell tumor</a>, <a href=\"/wiki/Sex_cord_stromal_tumor\" class=\"mw-redirect\" title=\"Sex cord stromal tumor\">sex cord stromal tumor</a><sup id=\"cite_ref-WCR2014_3-0\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup></td></tr><tr><th scope=\"row\"><a href=\"/wiki/Risk_factor\" title=\"Risk factor\">Risk factors</a></th><td>\n<a href=\"/wiki/Nulliparity\" class=\"mw-redirect\" title=\"Nulliparity\">Never having children</a>, <a href=\"/wiki/Hormone_therapy\" title=\"Hormone therapy\">hormone therapy</a> after <a href=\"/wiki/Menopause\" title=\"Menopause\">menopause</a>, <a href=\"/wiki/Fertility_medication\" title=\"Fertility medication\">fertility medication</a>, <a href=\"/wiki/Obesity\" title=\"Obesity\">obesity</a>, genetics<sup id=\"cite_ref-NCI2014PrePt_4-0\" class=\"reference\"><a href=\"#cite_note-NCI2014PrePt-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-WCR2014_3-1\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-NCI2014PrePro_5-0\" class=\"reference\"><a href=\"#cite_note-NCI2014PrePro-5\">&#91;5&#93;</a></sup></td></tr><tr><th scope=\"row\"><a href=\"/wiki/Diagnostic_method\" class=\"mw-redirect\" title=\"Diagnostic method\">Diagnostic method</a></th><td>\n<a href=\"/wiki/Tissue_biopsy\" class=\"mw-redirect\" title=\"Tissue biopsy\">Tissue biopsy</a><sup id=\"cite_ref-NCI2014TxPt_1-2\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup></td></tr><tr><th scope=\"row\">Treatment</th><td>\nSurgery, <a href=\"/wiki/Radiation_therapy\" title=\"Radiation therapy\">radiation therapy</a>, <a href=\"/wiki/Chemotherapy\" title=\"Chemotherapy\">chemotherapy</a><sup id=\"cite_ref-NCI2014TxPt_1-3\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup></td></tr><tr><th scope=\"row\">Prognosis</th><td>\n<a href=\"/wiki/Five-year_survival_rate\" title=\"Five-year survival rate\">Five-year survival rate</a> c. 45% (US)<sup id=\"cite_ref-SEER2014_6-0\" class=\"reference\"><a href=\"#cite_note-SEER2014-6\">&#91;6&#93;</a></sup></td></tr><tr><th scope=\"row\">Frequency</th><td>\n1.2 million (2015)<sup id=\"cite_ref-GBD2015Pre_7-0\" class=\"reference\"><a href=\"#cite_note-GBD2015Pre-7\">&#91;7&#93;</a></sup></td></tr><tr><th scope=\"row\">Deaths</th><td>\n161,100 (2015)<sup id=\"cite_ref-GBD2015De_8-0\" class=\"reference\"><a href=\"#cite_note-GBD2015De-8\">&#91;8&#93;</a></sup></td></tr></tbody></table>\n<p><b>Ovarian cancer</b> is a <a href=\"/wiki/Cancer\" title=\"Cancer\">cancer</a> that forms in or on an <a href=\"/wiki/Ovary\" title=\"Ovary\">ovary</a>.<sup id=\"cite_ref-NCI2014PrePt_4-1\" class=\"reference\"><a href=\"#cite_note-NCI2014PrePt-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-harrisons9th_9-0\" class=\"reference\"><a href=\"#cite_note-harrisons9th-9\">&#91;9&#93;</a></sup> It results in abnormal <a href=\"/wiki/Cells_(biology)\" class=\"mw-redirect\" title=\"Cells (biology)\">cells</a> that have the ability to invade or <a href=\"/wiki/Metastasis\" title=\"Metastasis\">spread</a> to other parts of the body.<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup> When this process begins, there may be no or only vague symptoms.<sup id=\"cite_ref-NCI2014TxPt_1-4\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup> Symptoms become more noticeable as the cancer progresses.<sup id=\"cite_ref-NCI2014TxPt_1-5\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup> These symptoms may include bloating, <a href=\"/wiki/Pelvic_pain\" title=\"Pelvic pain\">pelvic pain</a>, <a href=\"/wiki/Ascites\" title=\"Ascites\">abdominal swelling</a>, and <a href=\"/wiki/Anorexia_(symptom)\" title=\"Anorexia (symptom)\">loss of appetite</a>, among others.<sup id=\"cite_ref-NCI2014TxPt_1-6\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup> Common areas to which the cancer may spread include the <a href=\"/wiki/Peritoneum\" title=\"Peritoneum\">lining of the abdomen</a>, <a href=\"/wiki/Lymph_node\" title=\"Lymph node\">lymph nodes</a>, <a href=\"/wiki/Lungs\" class=\"mw-redirect\" title=\"Lungs\">lungs</a>, and <a href=\"/wiki/Liver\" title=\"Liver\">liver</a>.<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup>\n</p><p>The risk of ovarian cancer increases in women who have <a href=\"/wiki/Ovulate\" class=\"mw-redirect\" title=\"Ovulate\">ovulated</a> more over their lifetime. This includes those who have <a href=\"/wiki/Nulliparity\" class=\"mw-redirect\" title=\"Nulliparity\">never had children</a>, those who begin ovulation at a younger age and those who reach menopause at an older age.<sup id=\"cite_ref-WCR2014_3-2\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup> Other risk factors include <a href=\"/wiki/Hormone_therapy\" title=\"Hormone therapy\">hormone therapy</a> after <a href=\"/wiki/Menopause\" title=\"Menopause\">menopause</a>, <a href=\"/wiki/Fertility_medication\" title=\"Fertility medication\">fertility medication</a>, and <a href=\"/wiki/Obesity\" title=\"Obesity\">obesity</a>.<sup id=\"cite_ref-NCI2014PrePt_4-2\" class=\"reference\"><a href=\"#cite_note-NCI2014PrePt-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-NCI2014PrePro_5-1\" class=\"reference\"><a href=\"#cite_note-NCI2014PrePro-5\">&#91;5&#93;</a></sup> Factors that decrease risk include <a href=\"/wiki/Hormonal_birth_control\" class=\"mw-redirect\" title=\"Hormonal birth control\">hormonal birth control</a>, <a href=\"/wiki/Tubal_ligation\" title=\"Tubal ligation\">tubal ligation</a>, and <a href=\"/wiki/Breast_feeding\" class=\"mw-redirect\" title=\"Breast feeding\">breast feeding</a>.<sup id=\"cite_ref-NCI2014PrePro_5-2\" class=\"reference\"><a href=\"#cite_note-NCI2014PrePro-5\">&#91;5&#93;</a></sup> About 10% of cases are related to inherited genetic risk; women with mutations in the genes <i><a href=\"/wiki/BRCA1\" title=\"BRCA1\">BRCA1</a></i> or <i><a href=\"/wiki/BRCA2\" title=\"BRCA2\">BRCA2</a></i> have about a 50% chance of developing the disease.<sup id=\"cite_ref-WCR2014_3-3\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup> The most common type of ovarian cancer, comprising more than 95% of cases, is ovarian carcinoma.<sup id=\"cite_ref-WCR2014_3-4\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup> There are five main subtypes of ovarian carcinoma, of which <a href=\"/wiki/High-grade_serous_carcinoma\" title=\"High-grade serous carcinoma\">high-grade serous carcinoma</a> is the most common.<sup id=\"cite_ref-WCR2014_3-5\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup> These tumors are believed to start in the cells covering the ovaries,<sup id=\"cite_ref-WCR2014_3-6\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup> though some may form at the <a href=\"/wiki/Fallopian_tube\" title=\"Fallopian tube\">Fallopian tubes</a>.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup> Less common types of ovarian cancer include <a href=\"/wiki/Germ_cell_tumor\" title=\"Germ cell tumor\">germ cell tumors</a> and <a href=\"/wiki/Sex_cord_stromal_tumor\" class=\"mw-redirect\" title=\"Sex cord stromal tumor\">sex cord stromal tumors</a>.<sup id=\"cite_ref-WCR2014_3-7\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup> A diagnosis of ovarian cancer is confirmed through a <a href=\"/wiki/Biopsy\" title=\"Biopsy\">biopsy</a> of tissue, usually removed during surgery.<sup id=\"cite_ref-NCI2014TxPt_1-7\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup>\n</p><p><a href=\"/wiki/Screening_(medicine)\" title=\"Screening (medicine)\">Screening</a> is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of <a href=\"/wiki/False_positives_and_false_negatives\" title=\"False positives and false negatives\">false positive tests</a> may lead to unneeded surgery, which is accompanied by its own risks.<sup id=\"cite_ref-Gros2018_14-0\" class=\"reference\"><a href=\"#cite_note-Gros2018-14\">&#91;14&#93;</a></sup> Those at very high risk may have their ovaries removed as a preventive measure.<sup id=\"cite_ref-NCI2014PrePt_4-3\" class=\"reference\"><a href=\"#cite_note-NCI2014PrePt-4\">&#91;4&#93;</a></sup> If caught and treated in an early stage, ovarian cancer is often curable.<sup id=\"cite_ref-NCI2014TxPt_1-8\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup> Treatment usually includes some combination of surgery, <a href=\"/wiki/Radiation_therapy\" title=\"Radiation therapy\">radiation therapy</a>, and <a href=\"/wiki/Chemotherapy\" title=\"Chemotherapy\">chemotherapy</a>.<sup id=\"cite_ref-NCI2014TxPt_1-9\" class=\"reference\"><a href=\"#cite_note-NCI2014TxPt-1\">&#91;1&#93;</a></sup> Outcomes depend on the extent of the disease, the subtype of cancer present, and other medical conditions.<sup id=\"cite_ref-Gib2016_15-0\" class=\"reference\"><a href=\"#cite_note-Gib2016-15\">&#91;15&#93;</a></sup><sup id=\"cite_ref-WCR2014_3-8\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup> The overall <a href=\"/wiki/Five-year_survival_rate\" title=\"Five-year survival rate\">five-year survival rate</a> in the United States is 45%.<sup id=\"cite_ref-SEER2014_6-1\" class=\"reference\"><a href=\"#cite_note-SEER2014-6\">&#91;6&#93;</a></sup> Outcomes are worse in the developing world.<sup id=\"cite_ref-WCR2014_3-9\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup>\n</p><p>In 2012, new cases occurred in 239,000 women.<sup id=\"cite_ref-WCR2014_3-10\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup> In 2015 it was present in 1.2 million women and resulted in 161,100 deaths worldwide.<sup id=\"cite_ref-GBD2015De_8-1\" class=\"reference\"><a href=\"#cite_note-GBD2015De-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-GBD2015Pre_7-1\" class=\"reference\"><a href=\"#cite_note-GBD2015Pre-7\">&#91;7&#93;</a></sup>  Among women it is the seventh-most common cancer and the eighth-most common cause of death from cancer.<sup id=\"cite_ref-WCR2014_3-11\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup> The typical age of diagnosis is 63.<sup id=\"cite_ref-NCI2016Onset_2-1\" class=\"reference\"><a href=\"#cite_note-NCI2016Onset-2\">&#91;2&#93;</a></sup> Death from ovarian cancer is more common in North America and Europe than in Africa and Asia.<sup id=\"cite_ref-WCR2014_3-12\" class=\"reference\"><a href=\"#cite_note-WCR2014-3\">&#91;3&#93;</a></sup>\n</p>\n<div class=\"toclimit-3\"><div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Signs_and_symptoms\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Signs and symptoms</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#Early_symptoms\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">Early symptoms</span></a></li>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#Later_symptoms\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">Later symptoms</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Children\"><span class=\"tocnumber\">1.3</span> <span class=\"toctext\">Children</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Risk_factors\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Risk factors</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#Hormones\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">Hormones</span></a></li>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Genetics\"><span class=\"tocnumber\">2.2</span> <span class=\"toctext\">Genetics</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Environmental_factors\"><span class=\"tocnumber\">2.3</span> <span class=\"toctext\">Environmental factors</span></a></li>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Other\"><span class=\"tocnumber\">2.4</span> <span class=\"toctext\">Other</span></a></li>\n<li class=\"toclevel-2 tocsection-10\"><a href=\"#Protective_factors\"><span class=\"tocnumber\">2.5</span> <span class=\"toctext\">Protective factors</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#Pathophysiology\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Pathophysiology</span></a></li>\n<li class=\"toclevel-1 tocsection-12\"><a href=\"#Diagnosis\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Diagnosis</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-13\"><a href=\"#Examination\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">Examination</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-14\"><a href=\"#Risk_scoring\"><span class=\"tocnumber\">4.1.1</span> <span class=\"toctext\">Risk scoring</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-2 tocsection-15\"><a href=\"#Pathology\"><span class=\"tocnumber\">4.2</span> <span class=\"toctext\">Pathology</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-16\"><a href=\"#Epithelial_carcinoma\"><span class=\"tocnumber\">4.2.1</span> <span class=\"toctext\">Epithelial carcinoma</span></a>\n<ul>\n<li class=\"toclevel-4 tocsection-17\"><a href=\"#Serous_carcinoma\"><span class=\"tocnumber\">4.2.1.1</span> <span class=\"toctext\">Serous carcinoma</span></a></li>\n<li class=\"toclevel-4 tocsection-18\"><a href=\"#Small-cell_carcinoma\"><span class=\"tocnumber\">4.2.1.2</span> <span class=\"toctext\">Small-cell carcinoma</span></a>\n<ul>\n<li class=\"toclevel-5 tocsection-19\"><a href=\"#Primary_peritoneal_carcinoma\"><span class=\"tocnumber\">4.2.1.2.1</span> <span class=\"toctext\">Primary peritoneal carcinoma</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-4 tocsection-20\"><a href=\"#Clear-cell_carcinoma\"><span class=\"tocnumber\">4.2.1.3</span> <span class=\"toctext\">Clear-cell carcinoma</span></a></li>\n<li class=\"toclevel-4 tocsection-21\"><a href=\"#Clear-cell_adenocarcinoma\"><span class=\"tocnumber\">4.2.1.4</span> <span class=\"toctext\">Clear-cell adenocarcinoma</span></a></li>\n<li class=\"toclevel-4 tocsection-22\"><a href=\"#Endometrioid\"><span class=\"tocnumber\">4.2.1.5</span> <span class=\"toctext\">Endometrioid</span></a>\n<ul>\n<li class=\"toclevel-5 tocsection-23\"><a href=\"#Malignant_mixed_m\u00fcllerian_tumor_(carcinosarcoma)\"><span class=\"tocnumber\">4.2.1.5.1</span> <span class=\"toctext\">Malignant mixed m\u00fcllerian tumor (carcinosarcoma)</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-4 tocsection-24\"><a href=\"#Mucinous\"><span class=\"tocnumber\">4.2.1.6</span> <span class=\"toctext\">Mucinous</span></a>\n<ul>\n<li class=\"toclevel-5 tocsection-25\"><a href=\"#Mucinous_adenocarcinoma\"><span class=\"tocnumber\">4.2.1.6.1</span> <span class=\"toctext\">Mucinous adenocarcinoma</span></a></li>\n<li class=\"toclevel-5 tocsection-26\"><a href=\"#Pseudomyxoma_peritonei\"><span class=\"tocnumber\">4.2.1.6.2</span> <span class=\"toctext\">Pseudomyxoma peritonei</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-4 tocsection-27\"><a href=\"#Undifferentiated_epithelial\"><span class=\"tocnumber\">4.2.1.7</span> <span class=\"toctext\">Undifferentiated epithelial</span></a>\n<ul>\n<li class=\"toclevel-5 tocsection-28\"><a href=\"#Malignant_Brenner_tumor\"><span class=\"tocnumber\">4.2.1.7.1</span> <span class=\"toctext\">Malignant Brenner tumor</span></a></li>\n<li class=\"toclevel-5 tocsection-29\"><a href=\"#Transitional_cell_carcinoma\"><span class=\"tocnumber\">4.2.1.7.2</span> <span class=\"toctext\">Transitional cell carcinoma</span></a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li class=\"toclevel-3 tocsection-30\"><a href=\"#Sex_cord-stromal_tumor\"><span class=\"tocnumber\">4.2.2</span> <span class=\"toctext\">Sex cord-stromal tumor</span></a>\n<ul>\n<li class=\"toclevel-4 tocsection-31\"><a href=\"#Granulosa_cell_tumor\"><span class=\"tocnumber\">4.2.2.1</span> <span class=\"toctext\">Granulosa cell tumor</span></a>\n<ul>\n<li class=\"toclevel-5 tocsection-32\"><a href=\"#Adult_granulosa_cell_tumor\"><span class=\"tocnumber\">4.2.2.1.1</span> <span class=\"toctext\">Adult granulosa cell tumor</span></a></li>\n<li class=\"toclevel-5 tocsection-33\"><a href=\"#Juvenile_granulosa_cell_tumor\"><span class=\"tocnumber\">4.2.2.1.2</span> <span class=\"toctext\">Juvenile granulosa cell tumor</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-4 tocsection-34\"><a href=\"#Sertoli-Leydig_cell_tumor\"><span class=\"tocnumber\">4.2.2.2</span> <span class=\"toctext\">Sertoli-Leydig cell tumor</span></a></li>\n<li class=\"toclevel-4 tocsection-35\"><a href=\"#Sclerosing_stromal_tumors\"><span class=\"tocnumber\">4.2.2.3</span> <span class=\"toctext\">Sclerosing stromal tumors</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-3 tocsection-36\"><a href=\"#Germ_cell_tumor\"><span class=\"tocnumber\">4.2.3</span> <span class=\"toctext\">Germ cell tumor</span></a>\n<ul>\n<li class=\"toclevel-4 tocsection-37\"><a href=\"#Dysgerminoma\"><span class=\"tocnumber\">4.2.3.1</span> <span class=\"toctext\">Dysgerminoma</span></a></li>\n<li class=\"toclevel-4 tocsection-38\"><a href=\"#Choriocarcinoma\"><span class=\"tocnumber\">4.2.3.2</span> <span class=\"toctext\">Choriocarcinoma</span></a></li>\n<li class=\"toclevel-4 tocsection-39\"><a href=\"#Immature_(solid)_teratoma\"><span class=\"tocnumber\">4.2.3.3</span> <span class=\"toctext\">Immature (solid) teratoma</span></a></li>\n<li class=\"toclevel-4 tocsection-40\"><a href=\"#Mature_teratoma_(dermoid_cyst)\"><span class=\"tocnumber\">4.2.3.4</span> <span class=\"toctext\">Mature teratoma (dermoid cyst)</span></a></li>\n<li class=\"toclevel-4 tocsection-41\"><a href=\"#Yolk_sac_tumor/endodermal_sinus_tumor\"><span class=\"tocnumber\">4.2.3.5</span> <span class=\"toctext\">Yolk sac tumor/endodermal sinus tumor</span></a></li>\n<li class=\"toclevel-4 tocsection-42\"><a href=\"#Embryonal_carcinoma\"><span class=\"tocnumber\">4.2.3.6</span> <span class=\"toctext\">Embryonal carcinoma</span></a></li>\n<li class=\"toclevel-4 tocsection-43\"><a href=\"#Polyembryoma\"><span class=\"tocnumber\">4.2.3.7</span> <span class=\"toctext\">Polyembryoma</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-3 tocsection-44\"><a href=\"#Squamous_cell_carcinoma\"><span class=\"tocnumber\">4.2.4</span> <span class=\"toctext\">Squamous cell carcinoma</span></a></li>\n<li class=\"toclevel-3 tocsection-45\"><a href=\"#Mixed_tumors\"><span class=\"tocnumber\">4.2.5</span> <span class=\"toctext\">Mixed tumors</span></a></li>\n<li class=\"toclevel-3 tocsection-46\"><a href=\"#Secondary_ovarian_cancer\"><span class=\"tocnumber\">4.2.6</span> <span class=\"toctext\">Secondary ovarian cancer</span></a></li>\n<li class=\"toclevel-3 tocsection-47\"><a href=\"#Low_malignant_potential_tumors\"><span class=\"tocnumber\">4.2.7</span> <span class=\"toctext\">Low malignant potential tumors</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-2 tocsection-48\"><a href=\"#Staging\"><span class=\"tocnumber\">4.3</span> <span class=\"toctext\">Staging</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-49\"><a href=\"#FIGO\"><span class=\"tocnumber\">4.3.1</span> <span class=\"toctext\">FIGO</span></a></li>\n<li class=\"toclevel-3 tocsection-50\"><a href=\"#AJCC/TNM\"><span class=\"tocnumber\">4.3.2</span> <span class=\"toctext\">AJCC/TNM</span></a></li>\n<li class=\"toclevel-3 tocsection-51\"><a href=\"#Grading\"><span class=\"tocnumber\">4.3.3</span> <span class=\"toctext\">Grading</span></a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-52\"><a href=\"#Screening\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Screening</span></a></li>\n<li class=\"toclevel-1 tocsection-53\"><a href=\"#Prevention\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Prevention</span></a></li>\n<li class=\"toclevel-1 tocsection-54\"><a href=\"#Management\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">Management</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-55\"><a href=\"#Surgery\"><span class=\"tocnumber\">7.1</span> <span class=\"toctext\">Surgery</span></a></li>\n<li class=\"toclevel-2 tocsection-56\"><a href=\"#Chemotherapy\"><span class=\"tocnumber\">7.2</span> <span class=\"toctext\">Chemotherapy</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-57\"><a href=\"#Platinum-sensitive_or_platinum-resistant\"><span class=\"tocnumber\">7.2.1</span> <span class=\"toctext\">Platinum-sensitive or platinum-resistant</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-2 tocsection-58\"><a href=\"#Radiation_therapy\"><span class=\"tocnumber\">7.3</span> <span class=\"toctext\">Radiation therapy</span></a></li>\n<li class=\"toclevel-2 tocsection-59\"><a href=\"#Hormonal_therapy\"><span class=\"tocnumber\">7.4</span> <span class=\"toctext\">Hormonal therapy</span></a></li>\n<li class=\"toclevel-2 tocsection-60\"><a href=\"#Immunotherapy\"><span class=\"tocnumber\">7.5</span> <span class=\"toctext\">Immunotherapy</span></a></li>\n<li class=\"toclevel-2 tocsection-61\"><a href=\"#Follow-up\"><span class=\"tocnumber\">7.6</span> <span class=\"toctext\">Follow-up</span></a></li>\n<li class=\"toclevel-2 tocsection-62\"><a href=\"#Palliative_care\"><span class=\"tocnumber\">7.7</span> <span class=\"toctext\">Palliative care</span></a></li>\n<li class=\"toclevel-2 tocsection-63\"><a href=\"#Psychosocial_care\"><span class=\"tocnumber\">7.8</span> <span class=\"toctext\">Psychosocial care</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-64\"><a href=\"#Prognosis\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Prognosis</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-65\"><a href=\"#Prognostic_factors\"><span class=\"tocnumber\">8.1</span> <span class=\"toctext\">Prognostic factors</span></a></li>\n<li class=\"toclevel-2 tocsection-66\"><a href=\"#Survival_rates\"><span class=\"tocnumber\">8.2</span> <span class=\"toctext\">Survival rates</span></a></li>\n<li class=\"toclevel-2 tocsection-67\"><a href=\"#Recurrence_rates\"><span class=\"tocnumber\">8.3</span> <span class=\"toctext\">Recurrence rates</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-68\"><a href=\"#Epidemiology\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">Epidemiology</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-69\"><a href=\"#United_States\"><span class=\"tocnumber\">9.1</span> <span class=\"toctext\">United States</span></a></li>\n<li class=\"toclevel-2 tocsection-70\"><a href=\"#United_Kingdom\"><span class=\"tocnumber\">9.2</span> <span class=\"toctext\">United Kingdom</span></a></li>\n<li class=\"toclevel-2 tocsection-71\"><a href=\"#Ethnicity\"><span class=\"tocnumber\">9.3</span> <span class=\"toctext\">Ethnicity</span></a></li>\n<li class=\"toclevel-2 tocsection-72\"><a href=\"#Older_women\"><span class=\"tocnumber\">9.4</span> <span class=\"toctext\">Older women</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-73\"><a href=\"#In_pregnancy\"><span class=\"tocnumber\">10</span> <span class=\"toctext\">In pregnancy</span></a></li>\n<li class=\"toclevel-1 tocsection-74\"><a href=\"#Other_animals\"><span class=\"tocnumber\">11</span> <span class=\"toctext\">Other animals</span></a></li>\n<li class=\"toclevel-1 tocsection-75\"><a href=\"#Research\"><span class=\"tocnumber\">12</span> <span class=\"toctext\">Research</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-76\"><a href=\"#Screening_2\"><span class=\"tocnumber\">12.1</span> <span class=\"toctext\">Screening</span></a></li>\n<li class=\"toclevel-2 tocsection-77\"><a href=\"#Prognosis_research\"><span class=\"tocnumber\">12.2</span> <span class=\"toctext\">Prognosis research</span></a></li>\n<li class=\"toclevel-2 tocsection-78\"><a href=\"#Immunotherapy_2\"><span class=\"tocnumber\">12.3</span> <span class=\"toctext\">Immunotherapy</span></a></li>\n<li class=\"toclevel-2 tocsection-79\"><a href=\"#Pharmacology\"><span class=\"tocnumber\">12.4</span> <span class=\"toctext\">Pharmacology</span></a></li>\n<li class=\"toclevel-2 tocsection-80\"><a href=\"#Hormones_and_radiation\"><span class=\"tocnumber\">12.5</span> <span class=\"toctext\">Hormones and radiation</span></a></li>\n<li class=\"toclevel-2 tocsection-81\"><a href=\"#Inflammation\"><span class=\"tocnumber\">12.6</span> <span class=\"toctext\">Inflammation</span></a></li>\n<li class=\"toclevel-2 tocsection-82\"><a href=\"#Clinical_trials\"><span class=\"tocnumber\">12.7</span> <span class=\"toctext\">Clinical trials</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-83\"><a href=\"#References\"><span class=\"tocnumber\">13</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-84\"><a href=\"#Further_reading\"><span class=\"tocnumber\">14</span> <span class=\"toctext\">Further reading</span></a></li>\n<li class=\"toclevel-1 tocsection-85\"><a href=\"#External_links\"><span class=\"tocnumber\">15</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n</div>\n<h2><span class=\"mw-headline\" id=\"Signs_and_symptoms\">Signs and symptoms</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=1\" title=\"Edit section: Signs and symptoms\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Early_symptoms\">Early symptoms</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=2\" title=\"Edit section: Early symptoms\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:Site_of_ovarian_cancer.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/0/0b/Site_of_ovarian_cancer.png/290px-Site_of_ovarian_cancer.png\" width=\"290\" height=\"165\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/0/0b/Site_of_ovarian_cancer.png/435px-Site_of_ovarian_cancer.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/0b/Site_of_ovarian_cancer.png/580px-Site_of_ovarian_cancer.png 2x\" data-file-width=\"1513\" data-file-height=\"859\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Site_of_ovarian_cancer.png\" class=\"internal\" title=\"Enlarge\"></a></div>Site of ovarian cancer</div></div></div>\n<p>Early <a href=\"/wiki/Medical_sign\" title=\"Medical sign\">signs</a> and <a href=\"/wiki/Symptoms\" class=\"mw-redirect\" title=\"Symptoms\">symptoms</a> of ovarian cancer may be absent or subtle. In most cases, symptoms exist for several months before being recognized and <a href=\"/wiki/Diagnosis\" title=\"Diagnosis\">diagnosed</a>.<sup id=\"cite_ref-Harrisons_16-0\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-CDCsep2016_17-0\" class=\"reference\"><a href=\"#cite_note-CDCsep2016-17\">&#91;17&#93;</a></sup> Symptoms can be misdiagnosed as <a href=\"/wiki/Irritable_bowel_syndrome\" title=\"Irritable bowel syndrome\">irritable bowel syndrome</a>.<sup id=\"cite_ref-Jayson_18-0\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> The early stages of ovarian cancer tend to be painless. Symptoms can vary based on the subtype.<sup id=\"cite_ref-Harrisons_16-1\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Low malignant potential (LMP) tumors, also known as borderline tumors, do not cause an increase in <a href=\"/wiki/CA125\" class=\"mw-redirect\" title=\"CA125\">CA125</a> levels and are not identifiable with an ultrasound. The typical symptoms of an LMP tumor can include abdominal distension or pelvic pain. Particularly large masses tend to be benign or borderline.<sup id=\"cite_ref-Hoffman35_19-0\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-Harrisons_16-2\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p><p>The most typical symptoms of ovarian cancer include <a href=\"/wiki/Bloating\" title=\"Bloating\">bloating</a>, abdominal or pelvic pain or discomfort, back pain, <a href=\"/wiki/Irregular_menstruation\" title=\"Irregular menstruation\">irregular menstruation</a> or postmenopausal vaginal bleeding, pain or bleeding after or during <a href=\"/wiki/Sexual_intercourse\" title=\"Sexual intercourse\">sexual intercourse</a>, <a href=\"/wiki/Anorexia_(symptom)\" title=\"Anorexia (symptom)\">loss of appetite</a>, <a href=\"/wiki/Fatigue_(medical)\" class=\"mw-redirect\" title=\"Fatigue (medical)\">fatigue</a>, <a href=\"/wiki/Diarrhea\" title=\"Diarrhea\">diarrhea</a>, <a href=\"/wiki/Indigestion\" title=\"Indigestion\">indigestion</a>, <a href=\"/wiki/Heartburn\" title=\"Heartburn\">heartburn</a>, <a href=\"/wiki/Constipation\" title=\"Constipation\">constipation</a>, <a href=\"/wiki/Nausea\" title=\"Nausea\">nausea</a>, <a href=\"/wiki/Satiety\" class=\"mw-redirect\" title=\"Satiety\">feeling full</a>, and possibly urinary symptoms (including <a href=\"/wiki/Polyuria\" title=\"Polyuria\">frequent urination</a> and <a href=\"/wiki/Urinary_urgency\" title=\"Urinary urgency\">urgent urination</a>).<sup id=\"cite_ref-CDCsep2016_17-1\" class=\"reference\"><a href=\"#cite_note-CDCsep2016-17\">&#91;17&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Later_symptoms\">Later symptoms</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=3\" title=\"Edit section: Later symptoms\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The growing mass may cause pain if <a href=\"/wiki/Ovarian_torsion\" title=\"Ovarian torsion\">ovarian torsion</a> develops. Symptoms can be caused by a mass pressing on the other abdominopelvic organs or from metastases.<sup id=\"cite_ref-Harrisons_16-3\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-:0_20-0\" class=\"reference\"><a href=\"#cite_note-:0-20\">&#91;20&#93;</a></sup><sup id=\"cite_ref-:7_21-0\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> If these symptoms start to occur more often or more severely than usual, especially after no significant history of such symptoms, ovarian cancer is considered.<sup id=\"cite_ref-Harrisons_16-4\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-Hoffman35_19-1\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Metastases may cause a <a href=\"/wiki/Sister_Mary_Joseph_nodule\" title=\"Sister Mary Joseph nodule\">Sister Mary Joseph nodule</a>.<sup id=\"cite_ref-:7_21-1\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Rarely, <a href=\"/wiki/Teratoma\" title=\"Teratoma\">teratomas</a> can cause <a href=\"/wiki/Growing_teratoma_syndrome\" title=\"Growing teratoma syndrome\">growing teratoma syndrome</a> or <a href=\"/w/index.php?title=Peritoneal_gliomatosis&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Peritoneal gliomatosis (page does not exist)\">peritoneal gliomatosis</a>.<sup id=\"cite_ref-:7_21-2\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>  Some experience <a href=\"/wiki/Menometrorrhagia\" title=\"Menometrorrhagia\">menometrorrhagia</a> and <a href=\"/wiki/Dysfunctional_uterine_bleeding\" class=\"mw-redirect\" title=\"Dysfunctional uterine bleeding\">abnormal vaginal bleeding</a> after menopause in most cases. Other common symptoms include <a href=\"/wiki/Hirsutism\" title=\"Hirsutism\">hirsutism</a>, abdominal pain, <a href=\"/wiki/Virilization\" title=\"Virilization\">virilization</a>, and an <a href=\"/wiki/Adnexal_mass\" title=\"Adnexal mass\">adnexal mass</a>.<sup id=\"cite_ref-:8_22-0\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Children\">Children</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=4\" title=\"Edit section: Children\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In adolescents or children with ovarian tumors, symptoms can include severe abdominal pain, irritation of the <a href=\"/wiki/Peritoneum\" title=\"Peritoneum\">peritoneum</a>, or <a href=\"/wiki/Hemorrhage\" class=\"mw-redirect\" title=\"Hemorrhage\">bleeding</a>.<sup id=\"cite_ref-Current_23-0\" class=\"reference\"><a href=\"#cite_note-Current-23\">&#91;23&#93;</a></sup> Symptoms of sex cord-stromal tumors produce <a href=\"/wiki/Hormone\" title=\"Hormone\">hormone</a>s that can affect the development of <a href=\"/wiki/Secondary_sex_characteristics\" class=\"mw-redirect\" title=\"Secondary sex characteristics\">secondary sex characteristics</a>. Sex cord-stromal tumors  in prepubertal children may be manifested by <a href=\"/wiki/Precocious_puberty\" title=\"Precocious puberty\">early puberty</a>; abdominal pain and distension are also common. Adolescents with sex cord-stromal tumors may experience <a href=\"/wiki/Amenorrhea\" title=\"Amenorrhea\">amenorrhea</a>. As the cancer becomes more advanced, it can cause <a href=\"/wiki/Ascites\" title=\"Ascites\">an accumulation of fluid</a> in the abdomen. If the malignancy has not been diagnosed by the time it causes ascites, it is typically diagnosed shortly thereafter.<sup id=\"cite_ref-Harrisons_16-5\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Advanced cancers can also cause abdominal masses, lymph node masses, or <a href=\"/wiki/Pleural_effusion\" title=\"Pleural effusion\">pleural effusion</a>.<sup id=\"cite_ref-:7_21-3\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Risk_factors\">Risk factors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=5\" title=\"Edit section: Risk factors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Ovarian cancer is related to the amount of time spent ovulating. Thus <a href=\"/wiki/Nulliparity\" class=\"mw-redirect\" title=\"Nulliparity\">not having children</a> is a risk factor for ovarian cancer, likely because ovulation is suppressed via pregnancy.  During ovulation, cells are constantly stimulated to divide while ovulatory cycles continue. Therefore, <a href=\"/wiki/Nulliparity\" class=\"mw-redirect\" title=\"Nulliparity\">people who have not borne children</a> are at twice the risk of ovarian cancer than those who have. A longer period of ovulation caused by early <a href=\"/wiki/Menarche\" title=\"Menarche\">first menstruation</a> and late <a href=\"/wiki/Menopause\" title=\"Menopause\">menopause</a> is also a risk factor.<sup id=\"cite_ref-Hoffman35_19-2\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-CRUKRisks_24-0\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup><sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup> Both obesity and hormone replacement therapy also raise the risk.<sup id=\"cite_ref-Harrisons_16-6\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p><p>The risk of developing ovarian cancer is less for women who have fewer menstrual cycles, no menstrual cycles, <a href=\"/wiki/Breast_feeding\" class=\"mw-redirect\" title=\"Breast feeding\">breast feeding</a>, take oral contraceptives, have multiple pregnancies, and have a pregnancy at an early age.  The risk of developing ovarian cancer is reduced in women who have had <a href=\"/wiki/Tubal_ligation\" title=\"Tubal ligation\">tubal ligation</a> (colloquially known as having one's \"tubes tied\"), both ovaries removed, or <a href=\"/wiki/Hysterectomy\" title=\"Hysterectomy\">hysterectomy</a> (an operation in which the uterus, and sometimes the cervix, is removed).<sup id=\"cite_ref-CDCsep2016_17-2\" class=\"reference\"><a href=\"#cite_note-CDCsep2016-17\">&#91;17&#93;</a></sup> Age is also a risk factor.<sup id=\"cite_ref-Harrisons_16-7\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-Gib2016_15-1\" class=\"reference\"><a href=\"#cite_note-Gib2016-15\">&#91;15&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Hormones\">Hormones</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=6\" title=\"Edit section: Hormones\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Use of fertility medication may contribute to borderline ovarian tumor formation, but the link between the two is disputed and difficult to study.<sup id=\"cite_ref-Jayson_18-1\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Fertility drugs may be associated with a higher risk of borderline tumors.<sup id=\"cite_ref-:7_21-4\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Those who have been treated for infertility but remain nulliparous are at higher risk for epithelial ovarian cancer; however, those who are successfully treated for infertility and subsequently give birth are at no higher risk. This may be due to shedding of precancerous cells during pregnancy but the cause remains unclear.<sup id=\"cite_ref-Hoffman35_19-3\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> The risk factor may instead be infertility itself, not the treatment.<sup id=\"cite_ref-CRUKRisks_24-1\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup>\n</p><p>Hormonal conditions such as <a href=\"/wiki/Polycystic_ovary_syndrome\" title=\"Polycystic ovary syndrome\">polycystic ovary syndrome</a> and <a href=\"/wiki/Endometriosis\" title=\"Endometriosis\">endometriosis</a> are associated with ovarian cancer, but the link is not completely confirmed.<sup id=\"cite_ref-Jayson_18-2\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup>  Postmenopausal hormone replacement therapy (HRT) with estrogen likely increases the risk of ovarian cancer. The association has not been confirmed in a large-scale study,<sup id=\"cite_ref-Hoffman35_19-4\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> but notable studies including the <a href=\"/wiki/Million_Women_Study\" title=\"Million Women Study\">Million Women Study</a> have supported this link. Postmenopausal HRT with combined estrogen and progesterone may increase contemporaneous risk if used for over 5 years, but this risk returns to normal after cessation of therapy.<sup id=\"cite_ref-CRUKRisks_24-2\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> Estrogen HRT with or without progestins increases the risk of endometrioid and serous tumors but lowers the risk of mucinous tumors. Higher doses of estrogen increase this risk.<sup id=\"cite_ref-:7_21-5\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Endometriosis is another risk factor for ovarian cancer,<sup id=\"cite_ref-CRUKRisks_24-3\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> as is pain with menstruation. Endometriosis is associated with clear-cell and endometrioid subtypes, low-grade serous tumors, stage I and II tumors, grade 1 tumors, and lower mortality.<sup id=\"cite_ref-:7_21-6\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>Before menopause, obesity can increase a person's risk of ovarian cancer, but this risk is not present after menopause. This risk is also relevant in those who are both obese and have never used HRT. A similar association with ovarian cancer appears in taller people.<sup id=\"cite_ref-CRUKRisks_24-4\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Genetics\">Genetics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=7\" title=\"Edit section: Genetics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Further information: <a href=\"/wiki/Hereditary_breast%E2%80%93ovarian_cancer_syndrome\" title=\"Hereditary breast\u2013ovarian cancer syndrome\">Hereditary breast\u2013ovarian cancer syndrome</a></div>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:PedigreechartC.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/3/31/PedigreechartC.png/290px-PedigreechartC.png\" width=\"290\" height=\"215\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/3/31/PedigreechartC.png/435px-PedigreechartC.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/3/31/PedigreechartC.png/580px-PedigreechartC.png 2x\" data-file-width=\"700\" data-file-height=\"518\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:PedigreechartC.png\" class=\"internal\" title=\"Enlarge\"></a></div>People with ovarian or breast cancer in a pedigree chart of a family</div></div></div>\n<p>A family history of ovarian cancer is a risk factor for ovarian cancer. People with <a href=\"/wiki/Hereditary_nonpolyposis_colon_cancer\" class=\"mw-redirect\" title=\"Hereditary nonpolyposis colon cancer\">hereditary nonpolyposis colon cancer</a> (Lynch syndrome), and those with BRCA-1 and BRCA-2 genetic abnormalities are at increased risk.\n</p><p>The major genetic risk factor for ovarian cancer is a mutation in <i>BRCA1</i> or <i>BRCA2</i> <a href=\"/wiki/DNA_mismatch_repair\" title=\"DNA mismatch repair\">DNA mismatch repair</a> genes, which is present in 10% of ovarian cancer cases. Only one <a href=\"/wiki/Allele\" title=\"Allele\">allele</a> need be mutated to place a person at high risk. The gene can be inherited through either the maternal or paternal line, but has variable <a href=\"/wiki/Penetrance\" title=\"Penetrance\">penetrance</a>.<sup id=\"cite_ref-Harrisons_16-8\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-Hoffman35_19-5\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Though mutations in these genes are usually associated with increased risk of breast cancer, they also carry a substantial lifetime risk of ovarian cancer, a risk that peaks in a person's 40s and 50s. The lowest risk cited is 30% and the highest 60%.<sup id=\"cite_ref-Jayson_18-3\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-Harrisons_16-9\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-Hoffman35_19-6\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Mutations in BRCA1 have a lifetime risk of developing ovarian cancer of 15\u201345%.<sup id=\"cite_ref-:7_21-7\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Mutations in <i>BRCA2</i> are less risky than those with <i>BRCA1</i>, with a lifetime risk of 10% (lowest risk cited) to 40% (highest risk cited).<sup id=\"cite_ref-Harrisons_16-10\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-:7_21-8\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> On average, BRCA-associated cancers develop 15 years before their sporadic counterparts, because people who inherit the mutations on one copy of their gene only need one mutation to start the process of carcinogenesis, whereas people with two normal genes would need to acquire two mutations.<sup id=\"cite_ref-Hoffman35_19-7\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>In the United States, five of 100 women with a <a href=\"/wiki/First-degree_relative\" class=\"mw-redirect\" title=\"First-degree relative\">first-degree relative</a> with ovarian cancer will eventually get ovarian cancer themselves, placing those with affected family members at triple the risk of women with unaffected family members. Seven of 100 women with two or more relatives with ovarian cancer will eventually get ovarian cancer.<sup id=\"cite_ref-Hoffman35_19-8\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-NCIPrevention_27-0\" class=\"reference\"><a href=\"#cite_note-NCIPrevention-27\">&#91;27&#93;</a></sup> In general, 5\u201310% of ovarian cancer cases have a genetic cause.<sup id=\"cite_ref-Hoffman35_19-9\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> BRCA mutations are associated with high-grade serous nonmucinous epithelial ovarian cancer.<sup id=\"cite_ref-:7_21-9\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>A strong family history of <a href=\"/wiki/Endometrial_cancer\" title=\"Endometrial cancer\">endometrial cancer</a>, <a href=\"/wiki/Colon_cancer\" class=\"mw-redirect\" title=\"Colon cancer\">colon cancer</a>, or other <a href=\"/wiki/Gastrointestinal_cancer\" title=\"Gastrointestinal cancer\">gastrointestinal cancers</a> may indicate the presence of a syndrome known as <a href=\"/wiki/Hereditary_nonpolyposis_colorectal_cancer\" title=\"Hereditary nonpolyposis colorectal cancer\">hereditary nonpolyposis colorectal cancer</a> (also known as Lynch syndrome), which confers a higher risk for developing a number of cancers, including ovarian cancer. Lynch syndrome is caused by mutations in mismatch repair genes, including <i><a href=\"/wiki/MSH2\" title=\"MSH2\">MSH2</a>, <a href=\"/wiki/MLH1\" title=\"MLH1\">MLH1</a>, <a href=\"/w/index.php?title=MLH6&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"MLH6 (page does not exist)\">MLH6</a>, <a href=\"/wiki/PMS1\" title=\"PMS1\">PMS1</a></i>, and <i><a href=\"/wiki/PMS2\" title=\"PMS2\">PMS2</a></i>.<sup id=\"cite_ref-Harrisons_16-11\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> The risk of ovarian cancer for an individual with Lynch syndrome is between 10 and 12 percent.<sup id=\"cite_ref-Harrisons_16-12\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-Hoffman35_19-10\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> People of <a href=\"/wiki/Icelandic_people\" class=\"mw-redirect\" title=\"Icelandic people\">Icelandic descent</a>, <a href=\"/wiki/European_Jews\" class=\"mw-redirect\" title=\"European Jews\">European Jewish descent</a>/<a href=\"/wiki/Ashkenazi_Jews\" title=\"Ashkenazi Jews\">Ashkenazi Jewish descent</a>, and <a href=\"/wiki/Hungarian_people\" class=\"mw-redirect\" title=\"Hungarian people\">Hungarian descent</a> are at higher risk for epithelial ovarian cancer.<sup id=\"cite_ref-Hoffman35_19-11\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Estrogen receptor beta gene (<a href=\"/wiki/ESR2\" class=\"mw-redirect\" title=\"ESR2\">ESR2</a>) seems to be a key to pathogenesis and response to therapy.<sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup> Other genes that have been associated with ovarian cancer are <i><a href=\"/wiki/BRIP1\" title=\"BRIP1\">BRIP1</a></i>, <i><a href=\"/wiki/MSH6\" title=\"MSH6\">MSH6</a></i>, <i><a href=\"/wiki/RAD51C\" title=\"RAD51C\">RAD51C</a></i> and <i><a href=\"/w/index.php?title=RAD51D&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"RAD51D (page does not exist)\">RAD51D</a></i>.<sup id=\"cite_ref-Norquist2015_29-0\" class=\"reference\"><a href=\"#cite_note-Norquist2015-29\">&#91;29&#93;</a></sup> <i><a href=\"/wiki/CDH1_(gene)\" title=\"CDH1 (gene)\">CDH1</a></i>, <i><a href=\"/wiki/CHEK2\" title=\"CHEK2\">CHEK2</a></i>, <i><a href=\"/wiki/PALB2\" title=\"PALB2\">PALB2</a></i> and <i><a href=\"/wiki/RAD50_(gene)\" class=\"mw-redirect\" title=\"RAD50 (gene)\">RAD50</a></i> have also been associated with ovarian cancer.<sup id=\"cite_ref-Kuusisto2011_30-0\" class=\"reference\"><a href=\"#cite_note-Kuusisto2011-30\">&#91;30&#93;</a></sup>\n</p><p>Several rare genetic disorders are associated with specific subtypes of ovarian cancer. <a href=\"/wiki/Peutz%E2%80%93Jeghers_syndrome\" title=\"Peutz\u2013Jeghers syndrome\">Peutz\u2013Jeghers syndrome</a>, a rare genetic disorder, also predisposes people to <a href=\"/wiki/Sex_cord_tumour_with_annular_tubules\" title=\"Sex cord tumour with annular tubules\">sex cord tumour with annular tubules</a>.<sup id=\"cite_ref-Jayson_18-4\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-Harrisons_16-13\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> <a href=\"/wiki/Ollier_disease\" title=\"Ollier disease\">Ollier disease</a> and <a href=\"/wiki/Maffucci_syndrome\" title=\"Maffucci syndrome\">Maffucci syndrome</a> are associated with <a href=\"/wiki/Granulosa_cell_tumor\" class=\"mw-redirect\" title=\"Granulosa cell tumor\">granulosa cell tumors</a> in children and may also be associated with Sertoli-Leydig tumors. Benign fibromas are associated with <a href=\"/wiki/Nevoid_basal_cell_carcinoma_syndrome\" class=\"mw-redirect\" title=\"Nevoid basal cell carcinoma syndrome\">nevoid basal cell carcinoma syndrome</a>.<sup id=\"cite_ref-Harrisons_16-14\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Environmental_factors\">Environmental factors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=8\" title=\"Edit section: Environmental factors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Industrialized nations, with the exception of Japan, have high rates of epithelial ovarian cancer, which may be due to diet in those countries. <a href=\"/wiki/White_people\" title=\"White people\">Caucasian</a> are at a 30\u201340% higher risk for ovarian cancer when compared to <a href=\"/wiki/Black_people\" title=\"Black people\">Black</a> and <a href=\"/wiki/Hispanic_people\" class=\"mw-redirect\" title=\"Hispanic people\">Hispanic people</a>, likely due to socioeconomic factors; white women tend to have fewer children and different rates of gynecologic surgeries that affect risk for ovarian cancer.<sup id=\"cite_ref-Hoffman35_19-12\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p><a href=\"/wiki/Cohort_study\" title=\"Cohort study\">Cohort studies</a> have found a correlation between dairy consumption and ovarian cancer, but <a href=\"/wiki/Case-control_study\" class=\"mw-redirect\" title=\"Case-control study\">case-control studies</a> do not show this correlation. There is mixed evidence regarding the effect of <a href=\"/wiki/Red_meat\" title=\"Red meat\">red meat</a> and <a href=\"/wiki/Processed_meat\" title=\"Processed meat\">processed meat</a> in ovarian cancer.<sup id=\"cite_ref-:7_21-10\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>Tentative evidence suggests that <a href=\"/wiki/Talc\" title=\"Talc\">talc</a>, <a href=\"/wiki/Pesticides\" class=\"mw-redirect\" title=\"Pesticides\">pesticides</a>, and <a href=\"/wiki/Herbicides\" class=\"mw-redirect\" title=\"Herbicides\">herbicides</a> increase the risk of ovarian cancer.<sup id=\"cite_ref-31\" class=\"reference\"><a href=\"#cite_note-31\">&#91;31&#93;</a></sup> The American Cancer Society notes that as of now, no study has been able to accurately link any single chemical in the environment, or in the human diet, directly to mutations that cause ovarian cancer.<sup id=\"cite_ref-32\" class=\"reference\"><a href=\"#cite_note-32\">&#91;32&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Other\">Other</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=9\" title=\"Edit section: Other\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Alcohol consumption does not appear to be related to ovarian cancer.<sup id=\"cite_ref-:7_21-11\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-33\" class=\"reference\"><a href=\"#cite_note-33\">&#91;33&#93;</a></sup> Other factors that have been investigated, such as  <a href=\"/wiki/Smoking\" title=\"Smoking\">smoking</a>, low levels of <a href=\"/wiki/Vitamin_D\" title=\"Vitamin D\">vitamin D</a> in the blood,<sup id=\"cite_ref-34\" class=\"reference\"><a href=\"#cite_note-34\">&#91;34&#93;</a></sup> presence of inclusion <a href=\"/wiki/Ovarian_cysts\" class=\"mw-redirect\" title=\"Ovarian cysts\">ovarian cysts</a>, and infection with <a href=\"/wiki/Human_papilloma_virus\" class=\"mw-redirect\" title=\"Human papilloma virus\">human papilloma virus</a> (the cause of some cases of <a href=\"/wiki/Cervical_cancer\" title=\"Cervical cancer\">cervical cancer</a>), have been disproven as risk factors for ovarian cancer.<sup id=\"cite_ref-Jayson_18-5\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-:7_21-12\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> The carcinogenicity of <a href=\"/wiki/Perineum\" title=\"Perineum\">perineal</a> <a href=\"/wiki/Talc\" title=\"Talc\">talc</a> is controversial, because it can act as an irritant if it travels through the reproductive tract to the ovaries.<sup id=\"cite_ref-:7_21-13\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-Hoffman35_19-13\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-CRUKRisks_24-5\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> <a href=\"/wiki/Case-control_study\" class=\"mw-redirect\" title=\"Case-control study\">Case-control studies</a> have shown that use of perineal talc does increase the risk of ovarian cancer, but using talc more often does not create a greater risk.<sup id=\"cite_ref-:7_21-14\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Use of <a href=\"/wiki/Talc\" title=\"Talc\">talc</a> elsewhere on the body is unrelated to ovarian cancer.<sup id=\"cite_ref-CRUKRisks_24-6\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup>  <a href=\"/wiki/Sitting\" title=\"Sitting\">Sitting</a> regularly for prolonged periods is associated with higher mortality from epithelial ovarian cancer. The risk is not negated by regular exercise, though it is lowered.<sup id=\"cite_ref-Biswas_35-0\" class=\"reference\"><a href=\"#cite_note-Biswas-35\">&#91;35&#93;</a></sup>\n</p><p>Increased age (up to the 70s) is a risk factor for epithelial ovarian cancer because more mutations in cells can accumulate and eventually cause cancer. Those over 80 are at slightly lower risk.<sup id=\"cite_ref-Hoffman35_19-14\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p><a href=\"/wiki/Smoking\" title=\"Smoking\">Smoking</a> tobacco is associated with a higher risk of <a href=\"/wiki/Mucinous_tumor\" class=\"mw-redirect\" title=\"Mucinous tumor\">mucinous ovarian cancer</a>; after <a href=\"/wiki/Smoking_cessation\" title=\"Smoking cessation\">smoking cessation</a>, the risk eventually returns to normal.A diet high in animal fats may be associated with ovarian cancer, but the connection is unclear. Diet seems to play a very small role, if any, in ovarian cancer risk.<sup id=\"cite_ref-CRUKRisks_24-7\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> \nHigher levels of <a href=\"/wiki/C-reactive_protein\" title=\"C-reactive protein\">C-reactive protein</a> are associated with a higher risk of developing ovarian cancer.<sup id=\"cite_ref-:7_21-15\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Protective_factors\">Protective factors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=10\" title=\"Edit section: Protective factors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Suppression of ovulation, which would otherwise cause damage to the <a href=\"/wiki/Ovarian_epithelium\" class=\"mw-redirect\" title=\"Ovarian epithelium\">ovarian epithelium</a> and, consequently, <a href=\"/wiki/Inflammation\" title=\"Inflammation\">inflammation</a>, is generally protective. This effect can be achieved by <a href=\"/wiki/Multiparity\" class=\"mw-redirect\" title=\"Multiparity\">having children</a>, taking <a href=\"/wiki/Combined_oral_contraceptive\" class=\"mw-redirect\" title=\"Combined oral contraceptive\">combined oral contraceptives</a>, and <a href=\"/wiki/Breast_feeding\" class=\"mw-redirect\" title=\"Breast feeding\">breast feeding</a>, all of which are protective factors.<sup id=\"cite_ref-Harrisons_16-15\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> A longer period of breastfeeding correlates with a larger decrease in the risk of ovarian cancer.<sup id=\"cite_ref-CRUKRisks_24-8\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> Each birth decreases risk of ovarian cancer more, and this effect is seen with up to five births. Combined oral contraceptives reduce the risk of ovarian cancer by up to 50%, and the protective effect of combined oral contraceptives can last 25\u201330 years after they are discontinued.<sup id=\"cite_ref-Hoffman35_19-15\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-CRUKRisks_24-9\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> Regular use of <a href=\"/wiki/Aspirin\" title=\"Aspirin\">aspirin</a> or <a href=\"/wiki/Paracetamol\" title=\"Paracetamol\">acetaminophen</a> (paracetamol) may be associated with a lower risk of ovarian cancer; other <a href=\"/wiki/NSAIDs\" class=\"mw-redirect\" title=\"NSAIDs\">NSAIDs</a> do not seem to have a similar protective effect.<sup id=\"cite_ref-:7_21-16\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p><a href=\"/wiki/Tubal_ligation\" title=\"Tubal ligation\">Tubal ligation</a> is protective because <a href=\"/wiki/Carcinogen\" title=\"Carcinogen\">carcinogens</a> are unable to reach the ovary and <a href=\"/wiki/Fimbria_(female_reproductive_system)\" class=\"mw-redirect\" title=\"Fimbria (female reproductive system)\">fimbriae</a> via the vagina, uterus, and Fallopian tubes.<sup id=\"cite_ref-Harrisons_16-16\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Tubal ligation is also protective in women with the BRCA1 mutation, but not the BRCA2 mutation.<sup id=\"cite_ref-:7_21-17\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> <a href=\"/wiki/Hysterectomy\" title=\"Hysterectomy\">Hysterectomy</a> reduces the risk, and removal of both Fallopian tubes and ovaries (bilateral <a href=\"/wiki/Salpingo-oophorectomy\" class=\"mw-redirect\" title=\"Salpingo-oophorectomy\">salpingo-oophorectomy</a>) dramatically reduces the risk of not only ovarian cancer, but breast cancer as well.<sup id=\"cite_ref-Jayson_18-6\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> This is still a topic of research, as the link between hysterectomy and lower ovarian cancer risk is controversial. The reasons that hysterectomy may be protective have not been elucidated as of 2015.<sup id=\"cite_ref-CRUKRisks_24-10\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup>\n</p><p>A diet that includes large amounts of <a href=\"/wiki/Carotene\" title=\"Carotene\">carotene</a>, <a href=\"/wiki/Fiber\" title=\"Fiber\">fiber</a>, and <a href=\"/wiki/Vitamin\" title=\"Vitamin\">vitamins</a> with low amounts of fat\u2014specifically, a diet with non-starchy vegetables (e.g. <a href=\"/wiki/Broccoli\" title=\"Broccoli\">broccoli</a> and <a href=\"/wiki/Onion\" title=\"Onion\">onions</a>)\u2014may be protective,<sup id=\"cite_ref-Hoffman35_19-16\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> though research is still ongoing in this area.<sup id=\"cite_ref-CRUKRisks_24-11\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> Higher caffeine intake and consumption of more than two cups of tea a day have both been associated with lower ovarian cancer risk.<sup id=\"cite_ref-:7_21-18\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Smoking tobacco is protective for sex cord-stromal tumors.<sup id=\"cite_ref-:8_22-1\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Pathophysiology\">Pathophysiology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=11\" title=\"Edit section: Pathophysiology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<table class=\"wikitable sortable\" align=\"right\" style=\"width: 50%\">\n<caption>Mutations found in ovarian cancer subtypes<sup id=\"cite_ref-Jayson_18-7\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-:7_21-19\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-DeVita100_36-0\" class=\"reference\"><a href=\"#cite_note-DeVita100-36\">&#91;36&#93;</a></sup>\n</caption>\n<tbody><tr>\n<th>Gene mutated\n</th>\n<th>Mutation type\n</th>\n<th>Subtype\n</th>\n<th>Prevalence\n</th></tr>\n<tr>\n<td><i><a href=\"/wiki/AKT1\" title=\"AKT1\">AKT1</a></i>\n</td>\n<td>amplification\n</td>\n<td>\n</td>\n<td>3%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/AKT2\" title=\"AKT2\">AKT2</a></i>\n</td>\n<td>amplification/mutation\n</td>\n<td>\n</td>\n<td>6%,<sup id=\"cite_ref-Jayson_18-8\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> 20%<sup id=\"cite_ref-DeVita100_36-1\" class=\"reference\"><a href=\"#cite_note-DeVita100-36\">&#91;36&#93;</a></sup>\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/ARID1A\" title=\"ARID1A\">ARID1A</a></i>\n</td>\n<td>point mutation\n</td>\n<td>endometrioid and clear cell\n</td>\n<td>\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/BECN1\" title=\"BECN1\">BECN1</a></i>\n</td>\n<td>deletion\n</td>\n<td>\n</td>\n<td>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/BRAF_(gene)\" title=\"BRAF (gene)\"><i>BRAF</i></a>\n</td>\n<td>point mutation\n</td>\n<td>low-grade serous\n</td>\n<td>0.5%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/BRCA1\" title=\"BRCA1\">BRCA1</a></i>\n</td>\n<td>nonsense mutation\n</td>\n<td>high-grade serous\n</td>\n<td>5%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/BRCA2\" title=\"BRCA2\">BRCA2</a></i>\n</td>\n<td>frameshift mutation\n</td>\n<td>high-grade serous\n</td>\n<td>3%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/CCND1\" class=\"mw-redirect\" title=\"CCND1\">CCND1</a></i>\n</td>\n<td>amplification\n</td>\n<td>\n</td>\n<td>4%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/CCND2\" class=\"mw-redirect\" title=\"CCND2\">CCND2</a></i>\n</td>\n<td>upregulation\n</td>\n<td>\n</td>\n<td>15%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/CCNE1\" class=\"mw-redirect\" title=\"CCNE1\">CCNE1</a></i>\n</td>\n<td>amplification\n</td>\n<td>\n</td>\n<td>20%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/CDK12\" title=\"CDK12\">CDK12</a></i>\n</td>\n<td>\n</td>\n<td>high-grade serous\n</td>\n<td>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/P16_(gene)\" class=\"mw-redirect\" title=\"P16 (gene)\"><i>CDKN2A</i></a>\n</td>\n<td>downregulation (30%) and deletion (2%)\n</td>\n<td>\n</td>\n<td>32%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/CTNNB1\" class=\"mw-redirect\" title=\"CTNNB1\">CTNNB1</a></i>\n</td>\n<td>\n</td>\n<td>clear cell\n</td>\n<td>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/DICER1\" class=\"mw-redirect\" title=\"DICER1\">DICER1</a>\n</td>\n<td>missense mutation (somatic)\n</td>\n<td>nonepithelial\n</td>\n<td>29%\n</td></tr>\n<tr>\n<td><a href=\"/wiki/DYNLRB1\" title=\"DYNLRB1\">DYNLRB1</a> (km23)\n</td>\n<td>mutation\n</td>\n<td>\n</td>\n<td>42%\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Epidermal_growth_factor_receptor\" title=\"Epidermal growth factor receptor\">EGFR</a>\n</td>\n<td>amplification/overexpression\n</td>\n<td>\n</td>\n<td>20%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/ERBB2\" class=\"mw-redirect\" title=\"ERBB2\">ERBB2</a></i> (Her2/neu)\n</td>\n<td>amplification/overexpression\n</td>\n<td>mucinous and low-grade serous\n</td>\n<td>30%\n</td></tr>\n<tr>\n<td><a href=\"/w/index.php?title=FMS_(gene)&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"FMS (gene) (page does not exist)\">FMS</a>\n</td>\n<td>coexpression with <a href=\"/w/index.php?title=CSF-1&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CSF-1 (page does not exist)\">CSF-1</a>\n</td>\n<td>\n</td>\n<td>50%\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Forkhead_box_L2\" title=\"Forkhead box L2\">FOXL2</a>\n</td>\n<td>point mutation (402 C to G)\n</td>\n<td>adult granulosa cell\n</td>\n<td>~100%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/JAG1\" title=\"JAG1\">JAG1</a></i>\n</td>\n<td>amplification\n</td>\n<td>\n</td>\n<td>2%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/JAG2\" title=\"JAG2\">JAG2</a></i>\n</td>\n<td>amplification\n</td>\n<td>\n</td>\n<td>3%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/KRAS\" title=\"KRAS\">KRAS</a></i>\n</td>\n<td>amplification\n</td>\n<td>mucinous and low-grade serous\n</td>\n<td>11%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/MAML1\" title=\"MAML1\">MAML1</a></i>\n</td>\n<td>amplification and point mutation\n</td>\n<td>\n</td>\n<td>2%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/MAML2\" title=\"MAML2\">MAML2</a></i>\n</td>\n<td>amplification and point mutation\n</td>\n<td>\n</td>\n<td>4%\n</td></tr>\n<tr>\n<td><i><a href=\"/w/index.php?title=MAML3&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"MAML3 (page does not exist)\">MAML3</a></i>\n</td>\n<td>amplification\n</td>\n<td>\n</td>\n<td>2%\n</td></tr>\n<tr>\n<td><a href=\"/wiki/MLH1\" title=\"MLH1\">MLH1</a>\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>1%\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Nuclear_factor_1\" class=\"mw-redirect\" title=\"Nuclear factor 1\"><i>NF1</i></a>\n</td>\n<td>deletion (8%) and point mutation (4%)\n</td>\n<td>high-grade serous\n</td>\n<td>12%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/NOTCH3\" class=\"mw-redirect\" title=\"NOTCH3\">NOTCH3</a></i>\n</td>\n<td>amplification and point mutation\n</td>\n<td>\n</td>\n<td>11%\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Neuroblastoma_RAS_viral_oncogene_homolog\" title=\"Neuroblastoma RAS viral oncogene homolog\"><i>NRAS</i></a>\n</td>\n<td>\n</td>\n<td>low-grade serous\n</td>\n<td>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/PIK3C3\" title=\"PIK3C3\">PIK3C3</a> (PI3K3)\n</td>\n<td>amplification/mutation\n</td>\n<td>\n</td>\n<td>12\u201320%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/PIK3CA\" class=\"mw-redirect\" title=\"PIK3CA\">PIK3CA</a></i>\n</td>\n<td>amplification\n</td>\n<td>endometrioid and clear cell\n</td>\n<td>18%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/PPP2R1A\" title=\"PPP2R1A\">PPP2R1A</a></i>\n</td>\n<td>\n</td>\n<td>endometrioid and clear cell\n</td>\n<td>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/PTEN_(gene)\" title=\"PTEN (gene)\"><i>PTEN</i></a>\n</td>\n<td>deletion\n</td>\n<td>endometrioid and clear cell\n</td>\n<td>7%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/RB1\" class=\"mw-redirect\" title=\"RB1\">RB1</a></i>\n</td>\n<td>deletion (8%) and point mutation (2%)\n</td>\n<td>\n</td>\n<td>10%\n</td></tr>\n<tr>\n<td><a href=\"/wiki/TGF-%CE%B2\" class=\"mw-redirect\" title=\"TGF-\u03b2\">TGF-\u03b2</a>\n</td>\n<td>mutation/overexpression\n</td>\n<td>\n</td>\n<td>12%\n</td></tr>\n<tr>\n<td><i><a href=\"/wiki/TP53\" class=\"mw-redirect\" title=\"TP53\">TP53</a></i>\n</td>\n<td>mutation/overexpression\n</td>\n<td>high-grade serous\n</td>\n<td>20\u201350%\n</td></tr>\n<tr>\n<td><a href=\"/w/index.php?title=T%CE%B2RI&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"T\u03b2RI (page does not exist)\">T\u03b2RI</a>\n</td>\n<td>mutation\n</td>\n<td>\n</td>\n<td>33%\n</td></tr>\n<tr>\n<td><a href=\"/w/index.php?title=T%CE%B2RII&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"T\u03b2RII (page does not exist)\">T\u03b2RII</a>\n</td>\n<td>mutation\n</td>\n<td>\n</td>\n<td>25%\n</td></tr>\n<tr>\n<td><a href=\"/wiki/USP36\" title=\"USP36\">USP36</a>\n</td>\n<td>overexpression\n</td>\n<td>\n</td>\n<td>\n</td></tr></tbody></table>\n<p>Ovarian cancer forms when errors in normal ovarian <a href=\"/wiki/Cell_cycle\" title=\"Cell cycle\">cell growth</a> occur. Usually, when cells grow old or get damaged, they <a href=\"/wiki/Apoptosis\" title=\"Apoptosis\">die</a>, and new cells take their place. Cancer starts when new cells form unneeded, and old or damaged cells do not die as they should. The buildup of extra cells often forms a mass of tissue called a growth or tumor. These abnormal cancer cells have many <a href=\"/wiki/Genetic_mutation\" class=\"mw-redirect\" title=\"Genetic mutation\">genetic abnormalities</a> that cause them to grow excessively.<sup id=\"cite_ref-NCIGenetics_37-0\" class=\"reference\"><a href=\"#cite_note-NCIGenetics-37\">&#91;37&#93;</a></sup> When an ovary <a href=\"/wiki/Ovulation\" title=\"Ovulation\">releases an egg</a>, the <a href=\"/wiki/Ovarian_follicle\" title=\"Ovarian follicle\">egg follicle</a> bursts open and becomes the <a href=\"/wiki/Corpus_luteum\" title=\"Corpus luteum\">corpus luteum</a>. This structure needs to be repaired by dividing cells in the ovary.<sup id=\"cite_ref-CRUKRisks_24-12\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> Continuous ovulation for a long time means more repair of the ovary by dividing cells, which can acquire mutations in each division.<sup id=\"cite_ref-Hoffman35_19-17\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>Overall, the most common gene mutations in ovarian cancer occur in <i><a href=\"/wiki/Nuclear_factor_1\" class=\"mw-redirect\" title=\"Nuclear factor 1\">NF1</a>, BRCA1, BRCA2, </i>and <i><a href=\"/wiki/CDK12\" title=\"CDK12\">CDK12</a></i>. Type I ovarian cancers, which tend to be less aggressive, tend to have <a href=\"/wiki/Microsatellite_instability\" title=\"Microsatellite instability\">microsatellite instability</a> in several genes, including both oncogenes (most notably <i><a href=\"/wiki/BRAF_(gene)\" title=\"BRAF (gene)\">BRAF</a></i>  and <i><a href=\"/wiki/KRAS\" title=\"KRAS\">KRAS</a></i>) and tumor suppressors (most notably <i><a href=\"/wiki/PTEN_(gene)\" title=\"PTEN (gene)\">PTEN</a></i>).<sup id=\"cite_ref-Jayson_18-9\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> The most common mutations in Type I cancers are <i>KRAS, BRAF, ERBB2, PTEN, PIK3CA,</i> and <i>ARID1A.</i><sup id=\"cite_ref-:7_21-20\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Type II cancers, the more aggressive type, have different genes mutated, including <i><a href=\"/wiki/P53\" title=\"P53\">p53</a>, BRCA1</i>, and <i>BRCA2</i>.<sup id=\"cite_ref-Jayson_18-10\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Low-grade cancers tend to have mutations in KRAS, whereas cancers of any grade that develop from low malignant potential tumors tend to have mutations in p53.<sup id=\"cite_ref-Hoffman35_19-18\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Type I cancers tend to develop from precursor lesions, whereas Type II cancers can develop from a <a href=\"/w/index.php?title=Serous_tubal_intraepithelial_carcinoma&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Serous tubal intraepithelial carcinoma (page does not exist)\">serous tubal intraepithelial carcinoma</a>.<sup id=\"cite_ref-:7_21-21\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> <a href=\"/wiki/Serous_cancer\" class=\"mw-redirect\" title=\"Serous cancer\">Serous cancers</a> that have BRCA mutations also inevitably have p53 mutations, indicating that the removal of both functional genes is important for cancer to develop.<sup id=\"cite_ref-Hoffman35_19-19\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>In 50% of high-grade serous cancers, homologous recombination DNA repair is dysfunctional, as are the <a href=\"/wiki/Notch_signaling_pathway\" title=\"Notch signaling pathway\">notch</a> and <a href=\"/wiki/FOXM1\" title=\"FOXM1\">FOXM1</a> signaling pathways. They also almost always have p53 mutations. Other than this, mutations in high-grade serous carcinoma are hard to characterize beyond their high degree of <a href=\"/wiki/Genomic_instability\" class=\"mw-redirect\" title=\"Genomic instability\">genomic instability</a>. <i>BRCA1</i> and <i>BRCA2</i> are essential for homologous recombination DNA repair, and <a href=\"/wiki/Germline_mutation\" title=\"Germline mutation\">germline mutations</a> in these genes are found in about 15% of people with ovarian cancer.<sup id=\"cite_ref-Jayson_18-11\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> The most common mutations in BRCA1 and BRCA2 are the <a href=\"/wiki/Frameshift_mutations\" class=\"mw-redirect\" title=\"Frameshift mutations\">frameshift mutations</a> that originated in a small <a href=\"/wiki/Founder_effect\" title=\"Founder effect\">founding population</a> of Ashkenazi Jews.<sup id=\"cite_ref-Hoffman35_19-20\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>Almost 100% of rare mucinous carcinomas have mutations in <i>KRAS</i> and amplifications of <i>ERBB2</i> (also known as <i>Her2/neu</i>).<sup id=\"cite_ref-Jayson_18-12\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Overall, 20% of ovarian cancers have mutations in <i>Her2/neu</i>.<sup id=\"cite_ref-Harrisons_16-17\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p><p>Serous carcinomas may develop from <a href=\"/w/index.php?title=Serous_tubal_intraepithelial_carcinoma&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Serous tubal intraepithelial carcinoma (page does not exist)\">serous tubal intraepithelial carcinoma</a>, rather than developing spontaneously from ovarian tissue. Other carcinomas develop from <a href=\"/w/index.php?title=Cortical_inclusion_cysts&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Cortical inclusion cysts (page does not exist)\">cortical inclusion cysts</a>, which are groups of epithelial ovarian cells inside the <a href=\"/wiki/Stroma_(animal_tissue)\" class=\"mw-redirect\" title=\"Stroma (animal tissue)\">stroma</a>.<sup id=\"cite_ref-Hoffman35_19-21\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Diagnosis\">Diagnosis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=12\" title=\"Edit section: Diagnosis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Examination\">Examination</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=13\" title=\"Edit section: Examination\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:POvarianCA.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/c/c4/POvarianCA.png/290px-POvarianCA.png\" width=\"290\" height=\"217\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/c/c4/POvarianCA.png/435px-POvarianCA.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/c/c4/POvarianCA.png/580px-POvarianCA.png 2x\" data-file-width=\"1152\" data-file-height=\"863\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:POvarianCA.png\" class=\"internal\" title=\"Enlarge\"></a></div>A very large ovarian cancer as seen on CT</div></div></div>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"/wiki/File:Serous_carcinoma_cytology.jpg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/0/02/Serous_carcinoma_cytology.jpg/220px-Serous_carcinoma_cytology.jpg\" width=\"220\" height=\"147\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/0/02/Serous_carcinoma_cytology.jpg/330px-Serous_carcinoma_cytology.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/02/Serous_carcinoma_cytology.jpg/440px-Serous_carcinoma_cytology.jpg 2x\" data-file-width=\"4272\" data-file-height=\"2848\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Serous_carcinoma_cytology.jpg\" class=\"internal\" title=\"Enlarge\"></a></div><a href=\"/wiki/Micrograph\" title=\"Micrograph\">Micrograph</a> of <a href=\"/wiki/Serous_carcinoma\" title=\"Serous carcinoma\">serous carcinoma</a>, a type of ovarian cancer, diagnosed in <a href=\"/wiki/Peritoneal_fluid\" title=\"Peritoneal fluid\">peritoneal fluid</a></div></div></div>\n<p>Diagnosis of ovarian cancer starts with a physical examination (including a <a href=\"/wiki/Pelvic_examination\" title=\"Pelvic examination\">pelvic examination</a>), a blood test (for <a href=\"/wiki/CA-125\" title=\"CA-125\">CA-125</a> and sometimes other markers), and <a href=\"/wiki/Transvaginal_ultrasound\" class=\"mw-redirect\" title=\"Transvaginal ultrasound\">transvaginal ultrasound</a>.<sup id=\"cite_ref-Harrisons_16-18\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Sometimes a <a href=\"/wiki/Rectovaginal_examination\" title=\"Rectovaginal examination\">rectovaginal examination</a> is used to help plan a surgery.<sup id=\"cite_ref-Hoffman35_19-22\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> The diagnosis must be confirmed with surgery to inspect the <a href=\"/wiki/Abdominal_cavity\" title=\"Abdominal cavity\">abdominal cavity</a>, take <a href=\"/wiki/Biopsies\" class=\"mw-redirect\" title=\"Biopsies\">biopsies</a> (tissue samples for <a href=\"/wiki/Histopathology\" title=\"Histopathology\">microscopic analysis</a>), and look for cancer cells in the abdominal fluid. This helps to determine if an ovarian mass is <a href=\"/wiki/Benign\" class=\"mw-redirect\" title=\"Benign\">benign</a> or malignant.<sup id=\"cite_ref-Harrisons_16-19\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p><p>Ovarian cancer's early stages (I/II) are difficult to diagnose because most symptoms are nonspecific and thus of little use in diagnosis; as a result, it is rarely diagnosed until it spreads and advances to later stages (III/IV).<sup id=\"cite_ref-38\" class=\"reference\"><a href=\"#cite_note-38\">&#91;38&#93;</a></sup> Additionally, symptoms of ovarian cancer may appear similar to <a href=\"/wiki/Irritable_bowel_syndrome\" title=\"Irritable bowel syndrome\">irritable bowel syndrome</a>. In patients in whom pregnancy is a possibility, <a href=\"/wiki/BHCG\" class=\"mw-redirect\" title=\"BHCG\">BHCG</a> level can be measured during the diagnosis process. Serum <a href=\"/wiki/Alpha-fetoprotein\" title=\"Alpha-fetoprotein\">alpha-fetoprotein</a>, <a href=\"/wiki/Neuron-specific_enolase\" class=\"mw-redirect\" title=\"Neuron-specific enolase\">neuron-specific enolase</a>, and <a href=\"/wiki/Lactate_dehydrogenase\" title=\"Lactate dehydrogenase\">lactate dehydrogenase</a> can be measured in young girls and adolescents with suspected ovarian tumors as younger patients are more likely to have malignant germ cell tumors.<sup id=\"cite_ref-Harrisons_16-20\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-:7_21-22\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>A physical examination, including a pelvic examination, and a pelvic ultrasound (transvaginal or otherwise) are both essential for diagnosis: physical examination may reveal increased abdominal girth and/or <a href=\"/wiki/Ascites\" title=\"Ascites\">ascites</a> (fluid within the abdominal cavity), while pelvic examination may reveal an ovarian or abdominal mass.<sup id=\"cite_ref-Jayson_18-13\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> An adnexal mass is a significant finding that often indicates ovarian cancer, especially if it is fixed, nodular, irregular, solid, and/or bilateral. 13\u201321% of adnexal masses are caused by malignancy; however, there are other benign causes of adnexal masses, including <a href=\"/wiki/Follicular_cyst_of_ovary\" title=\"Follicular cyst of ovary\">ovarian follicular cyst</a>, <a href=\"/wiki/Leiomyoma\" title=\"Leiomyoma\">leiomyoma</a>, <a href=\"/wiki/Endometriosis\" title=\"Endometriosis\">endometriosis</a>, <a href=\"/wiki/Ectopic_pregnancy\" title=\"Ectopic pregnancy\">ectopic pregnancy</a>, <a href=\"/wiki/Hydrosalpinx\" title=\"Hydrosalpinx\">hydrosalpinx</a>, <a href=\"/w/index.php?title=Tuboovarian_abscess&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Tuboovarian abscess (page does not exist)\">tuboovarian abscess</a>, <a href=\"/wiki/Ovarian_torsion\" title=\"Ovarian torsion\">ovarian torsion</a>, <a href=\"/wiki/Dermoid_cyst\" title=\"Dermoid cyst\">dermoid cyst</a>, <a href=\"/wiki/Cystadenoma\" title=\"Cystadenoma\">cystadenoma</a> (serous or mucinous), <a href=\"/w/index.php?title=Diverticular_abscess&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Diverticular abscess (page does not exist)\">diverticular</a> or <a href=\"/w/index.php?title=Appendiceal_abscess&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Appendiceal abscess (page does not exist)\">appendiceal</a> <a href=\"/wiki/Abscess\" title=\"Abscess\">abscess</a>, <a href=\"/wiki/Nerve_sheath_tumor\" title=\"Nerve sheath tumor\">nerve sheath tumor</a>, <a href=\"/wiki/Pelvic_kidney\" title=\"Pelvic kidney\">pelvic kidney</a>, <a href=\"/w/index.php?title=Ureteral_diverticulum&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Ureteral diverticulum (page does not exist)\">ureteral</a> or <a href=\"/wiki/Bladder_diverticulum\" class=\"mw-redirect\" title=\"Bladder diverticulum\">bladder diverticulum</a>, <a href=\"/w/index.php?title=Benign_cystic_mesothelioma_of_the_peritoneum&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Benign cystic mesothelioma of the peritoneum (page does not exist)\">benign cystic mesothelioma of the peritoneum</a>, <a href=\"/wiki/Peritoneal_tuberculosis\" class=\"mw-redirect\" title=\"Peritoneal tuberculosis\">peritoneal tuberculosis</a>, or <a href=\"/wiki/Paraovarian_cyst\" title=\"Paraovarian cyst\">paraovarian cyst</a>. Ovaries that can be felt are also a sign of ovarian cancer in postmenopausal women. Other parts of a physical examination for suspected ovarian cancer can include a <a href=\"/wiki/Breast_examination\" class=\"mw-redirect\" title=\"Breast examination\">breast examination</a> and a <a href=\"/wiki/Digital_rectal_exam\" class=\"mw-redirect\" title=\"Digital rectal exam\">digital rectal exam</a>. Palpation of the <a href=\"/wiki/Supraclavicular_lymph_nodes\" title=\"Supraclavicular lymph nodes\">supraclavicular</a>, <a href=\"/wiki/Axillary_lymph_nodes\" title=\"Axillary lymph nodes\">axillary</a>, and <a href=\"/wiki/Inguinal_lymph_node\" class=\"mw-redirect\" title=\"Inguinal lymph node\">inguinal</a> <a href=\"/wiki/Lymph_node\" title=\"Lymph node\">lymph nodes</a> may reveal <a href=\"/wiki/Lymphadenopathy\" title=\"Lymphadenopathy\">lymphadenopathy</a>, which can be indicative of metastasis. Another indicator may be the presence of a <a href=\"/wiki/Pleural_effusion\" title=\"Pleural effusion\">pleural effusion</a>, which can be noted on <a href=\"/wiki/Auscultation\" title=\"Auscultation\">auscultation</a>.<sup id=\"cite_ref-:7_21-23\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>When an ovarian malignancy is included in a list of diagnostic possibilities, a limited number of laboratory tests are indicated. A complete blood count and serum electrolyte test is usually obtained;<sup id=\"cite_ref-Miller_39-0\" class=\"reference\"><a href=\"#cite_note-Miller-39\">&#91;39&#93;</a></sup> when an ovarian cancer is present, these tests often show <a href=\"/wiki/Thrombocytosis\" class=\"mw-redirect\" title=\"Thrombocytosis\">a high number of platelets</a> (20\u201325% of people) and <a href=\"/wiki/Hyponatremia\" title=\"Hyponatremia\">low blood sodium levels</a> due to chemical signals secreted by the tumor.<sup id=\"cite_ref-Hoffman35_19-23\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> A positive test for <a href=\"/wiki/Inhibin_A\" class=\"mw-redirect\" title=\"Inhibin A\">inhibin A</a> and <a href=\"/wiki/Inhibin_B\" class=\"mw-redirect\" title=\"Inhibin B\">inhibin B</a> can indicate a granulosa cell tumor.<sup id=\"cite_ref-:7_21-24\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>A blood test for a marker molecule called CA-125 is useful in differential diagnosis and in follow up of the disease, but it by itself has not been shown to be an effective method to screen for early-stage ovarian cancer due to its unacceptable low sensitivity and specificity.<sup id=\"cite_ref-Miller_39-1\" class=\"reference\"><a href=\"#cite_note-Miller-39\">&#91;39&#93;</a></sup> CA-125 levels in premenopausal people over 200 U/mL may indicate ovarian cancer, as may any elevation in CA-125 above 35 U/mL in post-menopausal people. CA-125 levels are not accurate in early stage ovarian cancer, as fully half of stage I ovarian cancer patients have a normal CA-125 level.<sup id=\"cite_ref-:7_21-25\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-Hoffman35_19-24\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> CA-125 may also be elevated in benign (non-cancerous) conditions, including <a href=\"/wiki/Endometriosis\" title=\"Endometriosis\">endometriosis</a>, <a href=\"/wiki/Pregnancy\" title=\"Pregnancy\">pregnancy</a>, <a href=\"/wiki/Uterine_fibroids\" class=\"mw-redirect\" title=\"Uterine fibroids\">uterine fibroids</a>, <a href=\"/wiki/Menstruation\" title=\"Menstruation\">menstruation</a>, <a href=\"/wiki/Ovarian_cysts\" class=\"mw-redirect\" title=\"Ovarian cysts\">ovarian cysts</a>, <a href=\"/wiki/Systemic_lupus_erythematosus\" title=\"Systemic lupus erythematosus\">systemic lupus erythematosus</a>, <a href=\"/wiki/Liver_disease\" title=\"Liver disease\">liver disease</a>, <a href=\"/wiki/Inflammatory_bowel_disease\" title=\"Inflammatory bowel disease\">inflammatory bowel disease</a>, <a href=\"/wiki/Pelvic_inflammatory_disease\" title=\"Pelvic inflammatory disease\">pelvic inflammatory disease</a>, and <a href=\"/wiki/Leiomyoma\" title=\"Leiomyoma\">leiomyoma</a>.<sup id=\"cite_ref-:7_21-26\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-40\" class=\"reference\"><a href=\"#cite_note-40\">&#91;40&#93;</a></sup>  <a href=\"/wiki/HE4\" class=\"mw-redirect\" title=\"HE4\">HE4</a> is another candidate for ovarian cancer testing, though it has not been extensively tested. Other tumor markers for ovarian cancer include <a href=\"/wiki/CA19-9\" title=\"CA19-9\">CA19-9</a>, <a href=\"/w/index.php?title=CA72-4&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"CA72-4 (page does not exist)\">CA72-4</a>, <a href=\"/wiki/CA15-3\" class=\"mw-redirect\" title=\"CA15-3\">CA15-3</a>, <a href=\"/w/index.php?title=Immunosuppressive_acidic_protein&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Immunosuppressive acidic protein (page does not exist)\">immunosuppressive acidic protein</a>, <a href=\"/w/index.php?title=Haptoglobin-alpha&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Haptoglobin-alpha (page does not exist)\">haptoglobin-alpha</a>, <a href=\"/w/index.php?title=OVX1&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"OVX1 (page does not exist)\">OVX1</a>, <a href=\"/wiki/Mesothelin\" title=\"Mesothelin\">mesothelin</a>, <a href=\"/wiki/Lysophosphatidic_acid\" title=\"Lysophosphatidic acid\">lysophosphatidic acid</a>, <a href=\"/wiki/Osteopontin\" title=\"Osteopontin\">osteopontin</a>, and <a href=\"/wiki/Fibroblast_growth_factor_23\" title=\"Fibroblast growth factor 23\">fibroblast growth factor 23</a>.<sup id=\"cite_ref-:7_21-27\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>Use of blood test panels may help in diagnosis.<sup id=\"cite_ref-:7_21-28\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-Miller_39-2\" class=\"reference\"><a href=\"#cite_note-Miller-39\">&#91;39&#93;</a></sup> The OVA1 panel includes CA-125, <a href=\"/wiki/Beta-2_microglobulin\" title=\"Beta-2 microglobulin\">beta-2 microglobulin</a>, <a href=\"/wiki/Transferrin\" title=\"Transferrin\">transferrin</a>, <a href=\"/wiki/Apolipoprotein_A1\" title=\"Apolipoprotein A1\">apolipoprotein A1</a>, and <a href=\"/wiki/Transthyretin\" title=\"Transthyretin\">transthyretin</a>. OVA1 above 5.0 in premenopausal people and 4.4 in postmenopausal people indicates a high risk for cancer.<sup id=\"cite_ref-Hoffman35_19-25\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> A different set of laboratory tests is used for detecting sex cord-stromal tumors. High levels of <a href=\"/wiki/Testosterone\" title=\"Testosterone\">testosterone</a> or <a href=\"/wiki/Dehydroepiandrosterone_sulfate\" title=\"Dehydroepiandrosterone sulfate\">dehydroepiandrosterone sulfate</a>, combined with other symptoms and high levels of <a href=\"/wiki/Inhibin_A\" class=\"mw-redirect\" title=\"Inhibin A\">inhibin A</a> and <a href=\"/wiki/Inhibin-beta_subunits\" class=\"mw-redirect\" title=\"Inhibin-beta subunits\">inhibin B</a> can be indicative of an SCST of any type.<sup id=\"cite_ref-:8_22-2\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>Current research is looking at ways to consider tumor marker <a href=\"/wiki/Proteomics\" title=\"Proteomics\">proteomics</a> in combination with other indicators of disease (i.e. radiology and/or symptoms) to improve diagnostic accuracy. The challenge in such an approach is that the disparate prevalence of ovarian cancer means that even testing with very high sensitivity and specificity will still lead to a number of false positive results, which in turn may lead to issues such as performing surgical procedures in which cancer is not found intraoperatively.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (March 2018)\">citation needed</span></a></i>&#93;</sup> <a href=\"/wiki/Genomics\" title=\"Genomics\">Genomics</a> approaches have not yet been developed for ovarian cancer.<sup id=\"cite_ref-:7_21-29\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p><a href=\"/wiki/CT_scanning\" class=\"mw-redirect\" title=\"CT scanning\">CT scanning</a> is preferred to assess the extent of the tumor in the abdominopelvic cavity, though <a href=\"/wiki/Magnetic_resonance_imaging\" title=\"Magnetic resonance imaging\">magnetic resonance imaging</a> can also be used.<sup id=\"cite_ref-Jayson_18-14\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> CT scanning can also be useful for finding <a href=\"/w/index.php?title=Omental_caking&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Omental caking (page does not exist)\">omental caking</a> or differentiating fluid from solid tumor in the abdomen, especially in low malignant potential tumors. However, it may not detect smaller tumors. Sometimes, a <a href=\"/wiki/Chest_radiograph\" title=\"Chest radiograph\">chest x-ray</a> is used to detect metastases in the chest or <a href=\"/wiki/Pleural_effusion\" title=\"Pleural effusion\">pleural effusion</a>. Another test for metastatic disease, though it is infrequently used, is a <a href=\"/wiki/Barium_enema\" class=\"mw-redirect\" title=\"Barium enema\">barium enema</a>, which can show if the rectosigmoid colon is involved in the disease. <a href=\"/wiki/Positron_emission_tomography\" title=\"Positron emission tomography\">Positron emission tomography</a>, <a href=\"/wiki/Bone_scan\" class=\"mw-redirect\" title=\"Bone scan\">bone scans</a>, and <a href=\"/wiki/Paracentesis\" title=\"Paracentesis\">paracentesis</a> are of limited use; in fact, paracentesis can cause metastases to form at the needle insertion site and may not provide useful results.<sup id=\"cite_ref-Hoffman35_19-26\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> However, paracentesis can be used in cases where there is no pelvic mass and ascites is still present.<sup id=\"cite_ref-Hoffman35_19-27\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> A physician suspecting ovarian cancer may also perform <a href=\"/wiki/Mammography\" title=\"Mammography\">mammography</a> or an <a href=\"/wiki/Endometrial_biopsy\" title=\"Endometrial biopsy\">endometrial biopsy</a> (in the case of abnormal bleeding) to assess the possibility of breast malignancies and endometrial malignancy, respectively. <a href=\"/wiki/Vaginal_ultrasonography\" title=\"Vaginal ultrasonography\">Vaginal ultrasonography</a> is often the first-line imaging study performed when an adnexal mass is found. Several characteristics of an adnexal mass indicate ovarian malignancy; they usually are solid, irregular, multilocular, and/or large; and they typically have papillary features, central vessels, and/or irregular internal septations.<sup id=\"cite_ref-:7_21-30\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> However, SCST has no definitive characteristics on radiographic study.<sup id=\"cite_ref-:8_22-3\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>To definitively diagnose ovarian cancer, a surgical procedure to inspect the abdomen is required. This can be an open procedure (<a href=\"/wiki/Laparotomy\" title=\"Laparotomy\">laparotomy</a>, incision through the <a href=\"/wiki/Abdominal_wall\" title=\"Abdominal wall\">abdominal wall</a>) or <a href=\"/wiki/Keyhole_surgery\" class=\"mw-redirect\" title=\"Keyhole surgery\">keyhole surgery</a> (<a href=\"/wiki/Laparoscopy\" title=\"Laparoscopy\">laparoscopy</a>). During this procedure, suspicious tissue is removed and sent for <a href=\"/wiki/Histopathology\" title=\"Histopathology\">microscopic analysis</a>. Usually, this includes a unilateral <a href=\"/wiki/Salpingo-oophorectomy\" class=\"mw-redirect\" title=\"Salpingo-oophorectomy\">salpingo-oophorectomy</a>, removal of a single affected ovary and Fallopian tube. Fluid from the abdominal cavity can also be analyzed for cancerous <a href=\"/wiki/Cell_(biology)\" title=\"Cell (biology)\">cells</a>. If cancer is found, this procedure can also be used to determine the extent of its spread (which is a form of <a href=\"/wiki/Tumor_staging\" class=\"mw-redirect\" title=\"Tumor staging\">tumor staging</a>).<sup id=\"cite_ref-Harrisons_16-21\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Risk_scoring\">Risk scoring</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=14\" title=\"Edit section: Risk scoring\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p><span id=\"RMI\"></span>A widely recognized method of estimating the risk of malignant ovarian cancer is the risk of malignancy index (RMI), calculated based on an initial <a href=\"/wiki/Medical_diagnosis#Other_diagnostic_procedure_methods\" title=\"Medical diagnosis\">workup</a>.<sup id=\"cite_ref-Jayson_18-15\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-NICE2011_41-0\" class=\"reference\"><a href=\"#cite_note-NICE2011-41\">&#91;41&#93;</a></sup> An RMI score of over 200 or 250 is generally felt to indicate high risk for ovarian cancer.<sup id=\"cite_ref-Jayson_18-16\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-:7_21-31\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>The RMI is calculated as:\n</p>\n<dl><dd>RMI = ultrasound score x menopausal score x CA-125 level in U/ml.<sup id=\"cite_ref-Jayson_18-17\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup></dd></dl>\n<p>Two methods can be used to determine the ultrasound score and menopausal score, with the resultant scores being referred to as RMI 1 and RMI 2, respectively, depending on what method is used.\n</p>\n<table class=\"wikitable\">\n\n<tbody><tr>\n<th style=\"width:32%;\">Feature\n</th>\n<th style=\"width:34%;\">RMI 1<sup id=\"cite_ref-Jayson_18-18\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup>\n</th>\n<th style=\"width:34%;\">RMI 2<sup id=\"cite_ref-:7_21-32\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-42\" class=\"reference\"><a href=\"#cite_note-42\">&#91;42&#93;</a></sup>\n</th></tr>\n<tr>\n<td>\n<p>Ultrasound abnormalities:\n</p>\n<ul><li>multilocular cyst</li>\n<li>solid areas</li>\n<li>ascites</li>\n<li>intra-abdominal metastases</li></ul>\n</td>\n<td><div class=\"plainlist\">\n<ul><li>0 = no abnormality</li>\n<li>1 = one abnormality</li>\n<li>3 = two or more abnormalities</li></ul>\n</div>\n</td>\n<td><div class=\"plainlist\">\n<ul><li>0 = none</li>\n<li>1 = one abnormality</li>\n<li>4 = two or more abnormalities</li></ul>\n</div>\n</td></tr>\n<tr>\n<td>Menopausal score\n</td>\n<td><div class=\"plainlist\">\n<ul><li>1 = premenopausal</li>\n<li>3 = postmenopausal</li></ul>\n</div>\n</td>\n<td><div class=\"plainlist\">\n<ul><li>1 = premenopausal</li>\n<li>4 = postmenopausal</li></ul>\n</div>\n</td></tr>\n<tr>\n<td>CA-125\n</td>\n<td>Quantity in U/ml\n</td>\n<td>Quantity in U/ml\n</td></tr></tbody></table>\n<p>Another method for quantifying risk of ovarian cancer is the Risk of Ovarian Cancer Algorithm (ROCA), observes levels over time and  determines if they are increasing rapidly enough to warrant transvaginal ultrasound.<sup id=\"cite_ref-Hoffman35_19-28\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> The Risk of Ovarian Malignancy algorithm uses CA-125 levels and <a href=\"/wiki/HE4\" class=\"mw-redirect\" title=\"HE4\">HE4</a> levels to calculate the risk of ovarian cancer; it may be more effective than RMI. The IOTA models can be used to estimate the probability that an adnexal tumor is malignant.<sup id=\"cite_ref-43\" class=\"reference\"><a href=\"#cite_note-43\">&#91;43&#93;</a></sup> They include LR2 risk model, The Simple Rules risk (SRrisk) calculation and Assessment of Different Neoplasias in the Adnexa (ADNEX) model that can be used to assess risk of malignancy in an adnexal mass, based on its characteristics and risk factors. The QCancer (Ovary) algorithm is used to predict likelihood of ovarian cancer from risk factors.<sup id=\"cite_ref-:7_21-33\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Pathology\">Pathology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=15\" title=\"Edit section: Pathology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:Incidence_of_ovarian_cancers_by_histopathology.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/Incidence_of_ovarian_cancers_by_histopathology.png/290px-Incidence_of_ovarian_cancers_by_histopathology.png\" width=\"290\" height=\"342\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/Incidence_of_ovarian_cancers_by_histopathology.png/435px-Incidence_of_ovarian_cancers_by_histopathology.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a2/Incidence_of_ovarian_cancers_by_histopathology.png/580px-Incidence_of_ovarian_cancers_by_histopathology.png 2x\" data-file-width=\"2674\" data-file-height=\"3155\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Incidence_of_ovarian_cancers_by_histopathology.png\" class=\"internal\" title=\"Enlarge\"></a></div>Ovarian cancers in women aged 20+, with area representing relative incidence and color representing five-year relative survival rate<sup id=\"cite_ref-SEER6215ch16_44-0\" class=\"reference\"><a href=\"#cite_note-SEER6215ch16-44\">&#91;44&#93;</a></sup></div></div></div>\n<p>Ovarian cancers are classified according to the microscopic appearance of their structures (<a href=\"/wiki/Histology\" title=\"Histology\">histology</a> or <a href=\"/wiki/Histopathology\" title=\"Histopathology\">histopathology</a>). Histology dictates many aspects of clinical treatment, management, and <a href=\"/wiki/Prognosis\" title=\"Prognosis\">prognosis</a>. The gross pathology of ovarian cancers is very similar regardless of histologic type: tumors have solid and cystic masses.<sup id=\"cite_ref-Hoffman35_19-29\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> According to <a href=\"/wiki/Surveillance_Epidemiology_and_End_Results\" class=\"mw-redirect\" title=\"Surveillance Epidemiology and End Results\">SEER</a>, the types of ovarian cancers in women age 20 and over are:<sup id=\"cite_ref-SEER6215ch16_44-1\" class=\"reference\"><a href=\"#cite_note-SEER6215ch16-44\">&#91;44&#93;</a></sup>\n</p>\n<table class=\"wikitable\">\n<tbody><tr>\n<th>Percent of<br /> ovarian cancers<br /> in women<br /> age 20+\n</th>\n<th>Percent of<br /> ovarian cancers<br /> in women<br /> age 20+ by\n<p>subdivision\n</p>\n</th>\n<th><a href=\"/wiki/Histology\" title=\"Histology\">Histology</a>\n</th>\n<th>Five-year<br /><a href=\"/wiki/Relative_survival_rate\" class=\"mw-redirect\" title=\"Relative survival rate\">RSR</a>\n</th></tr>\n<tr>\n<td>89.7\n</td>\n<td>\n</td>\n<td><a href=\"/wiki/Surface_epithelial-stromal_tumor\" title=\"Surface epithelial-stromal tumor\">Surface epithelial-stromal tumor</a> (<a href=\"/wiki/Adenocarcinoma\" title=\"Adenocarcinoma\">adenocarcinoma</a>)\n</td>\n<td>54.4\n</td></tr>\n<tr>\n<td>\n</td>\n<td>26.4\n</td>\n<td><a href=\"/wiki/Papillary_serous_cystadenocarcinoma\" title=\"Papillary serous cystadenocarcinoma\">Papillary serous cystadenocarcinoma</a>\n</td>\n<td>21.0\n</td></tr>\n<tr>\n<td>\n</td>\n<td>15.9\n</td>\n<td>\"Borderline\" adenocarcinoma <br />(underestimated - short data collection interval)\n</td>\n<td>98.2\n</td></tr>\n<tr>\n<td>\n</td>\n<td>12.6\n</td>\n<td>Adenocarcinoma, not otherwise specified\n</td>\n<td>18.3\n</td></tr>\n<tr>\n<td>\n</td>\n<td>9.8\n</td>\n<td><a href=\"/wiki/Endometrioid_tumor\" title=\"Endometrioid tumor\">Endometrioid tumor</a>\n</td>\n<td>70.9\n</td></tr>\n<tr>\n<td>\n</td>\n<td>5.8\n</td>\n<td><a href=\"/wiki/Serous_cystadenocarcinoma\" title=\"Serous cystadenocarcinoma\">Serous cystadenocarcinoma</a>\n</td>\n<td>44.2\n</td></tr>\n<tr>\n<td>\n</td>\n<td>5.5\n</td>\n<td><a href=\"/wiki/Papilloma\" title=\"Papilloma\">Papillary</a>\n</td>\n<td>21.0\n</td></tr>\n<tr>\n<td>\n</td>\n<td>4.2\n</td>\n<td><a href=\"/wiki/Mucinous_cystadenocarcinoma\" title=\"Mucinous cystadenocarcinoma\">Mucinous cystadenocarcinoma</a>\n</td>\n<td>77.7\n</td></tr>\n<tr>\n<td>\n</td>\n<td>4.0\n</td>\n<td><a href=\"/wiki/Clear-cell_ovarian_tumor\" class=\"mw-redirect\" title=\"Clear-cell ovarian tumor\">Clear-cell ovarian tumor</a>\n</td>\n<td>61.5\n</td></tr>\n<tr>\n<td>\n</td>\n<td>3.4\n</td>\n<td><a href=\"/wiki/Mucinous_adenocarcinoma\" class=\"mw-redirect\" title=\"Mucinous adenocarcinoma\">Mucinous adenocarcinoma</a>\n</td>\n<td>49.1\n</td></tr>\n<tr>\n<td>\n</td>\n<td>1.3\n</td>\n<td><a href=\"/wiki/Cystadenocarcinoma\" title=\"Cystadenocarcinoma\">Cystadenocarcinoma</a>\n</td>\n<td>50.7\n</td></tr>\n<tr>\n<td>5.5\n</td>\n<td>\n</td>\n<td><a href=\"/wiki/Carcinoma\" title=\"Carcinoma\">Carcinoma</a>\n</td>\n<td>\n</td></tr>\n<tr>\n<td>\n</td>\n<td>4.1\n</td>\n<td>Carcinoma not otherwise specified\n</td>\n<td>26.8\n</td></tr>\n<tr>\n<td>\n</td>\n<td>1.1\n</td>\n<td><a href=\"/wiki/Sex_cord-stromal_tumour\" class=\"mw-redirect\" title=\"Sex cord-stromal tumour\">Sex cord-stromal tumour</a>\n</td>\n<td>87.8\n</td></tr>\n<tr>\n<td>\n</td>\n<td>0.3\n</td>\n<td>Other carcinomas, specified\n</td>\n<td>37.3\n</td></tr>\n<tr>\n<td>1.7\n</td>\n<td>\n</td>\n<td><a href=\"/wiki/Mullerian_tumor\" class=\"mw-redirect\" title=\"Mullerian tumor\">Mullerian tumor</a>\n</td>\n<td>29.8\n</td></tr>\n<tr>\n<td>1.5\n</td>\n<td>\n</td>\n<td><a href=\"/wiki/Germ_cell_tumor\" title=\"Germ cell tumor\">Germ cell tumor</a>\n</td>\n<td>91.0\n</td></tr>\n<tr>\n<td>\n</td>\n<td>0.8\n</td>\n<td><a href=\"/wiki/Teratoma\" title=\"Teratoma\">Teratoma</a>\n</td>\n<td>89.1\n</td></tr>\n<tr>\n<td>\n</td>\n<td>0.5\n</td>\n<td><a href=\"/wiki/Dysgerminoma\" title=\"Dysgerminoma\">Dysgerminoma</a>\n</td>\n<td>96.8\n</td></tr>\n<tr>\n<td>\n</td>\n<td>0.3\n</td>\n<td>Other, specified\n</td>\n<td>85.1\n</td></tr>\n<tr>\n<td>0.6\n</td>\n<td>\n</td>\n<td>Not otherwise specified\n</td>\n<td>23.0\n</td></tr>\n<tr>\n<td>0.5\n</td>\n<td>\n</td>\n<td>Epidermoid (<a href=\"/wiki/Squamous_cell_carcinoma\" title=\"Squamous cell carcinoma\">squamous cell carcinoma</a>)\n</td>\n<td>51.3\n</td></tr>\n<tr>\n<td>0.2\n</td>\n<td>\n</td>\n<td><a href=\"/wiki/Brenner_tumor\" class=\"mw-redirect\" title=\"Brenner tumor\">Brenner tumor</a>\n</td>\n<td>67.9\n</td></tr>\n<tr>\n<td>0.2\n</td>\n<td>\n</td>\n<td>Other, specified\n</td>\n<td>71.7\n</td></tr></tbody></table>\n<p>Ovarian cancers are histologically and genetically divided into type I or type II. Type I cancers are of low histological grade, and include endometrioid, mucinous, and clear-cell carcinomas. Type II cancers are of higher histological grade and include serous carcinoma and carcinosarcoma.<sup id=\"cite_ref-Jayson_18-19\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Epithelial_carcinoma\">Epithelial carcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=16\" title=\"Edit section: Epithelial carcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:Ovarian_carcinoma.JPG\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Ovarian_carcinoma.JPG/290px-Ovarian_carcinoma.JPG\" width=\"290\" height=\"172\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Ovarian_carcinoma.JPG/435px-Ovarian_carcinoma.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Ovarian_carcinoma.JPG/580px-Ovarian_carcinoma.JPG 2x\" data-file-width=\"2995\" data-file-height=\"1781\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Ovarian_carcinoma.JPG\" class=\"internal\" title=\"Enlarge\"></a></div>A pathological specimen of ovarian carcinoma</div></div></div>\n<p><a href=\"/wiki/Surface_epithelial-stromal_tumour\" class=\"mw-redirect\" title=\"Surface epithelial-stromal tumour\">Surface epithelial-stromal tumour</a>, also known as ovarian epithelial carcinoma, is the most common type of ovarian cancer, representing approximately 90% of ovarian cancers. It includes <a href=\"/wiki/Serous_tumour\" title=\"Serous tumour\">serous tumour</a>, <a href=\"/wiki/Endometrioid_tumor\" title=\"Endometrioid tumor\">endometrioid tumor</a>, and <a href=\"/wiki/Mucinous\" class=\"mw-redirect\" title=\"Mucinous\">mucinous</a> <a href=\"/wiki/Cystadenocarcinoma\" title=\"Cystadenocarcinoma\">cystadenocarcinoma</a>. Less common tumors are malignant <a href=\"/wiki/Brenner_tumor\" class=\"mw-redirect\" title=\"Brenner tumor\">Brenner tumor</a> and <a href=\"/wiki/Transitional_cell_carcinoma_of_the_ovary\" title=\"Transitional cell carcinoma of the ovary\">transitional cell carcinoma of the ovary</a>. Epithelial ovarian cancers develop from the <a href=\"/wiki/Epithelium\" title=\"Epithelium\">epithelium</a>, a layer of cells that covers the ovary.<sup id=\"cite_ref-:1_45-0\" class=\"reference\"><a href=\"#cite_note-:1-45\">&#91;45&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Serous_carcinoma\">Serous carcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=17\" title=\"Edit section: Serous carcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<p>Most people with epithelial ovarian carcinoma, about two-thirds, have a <a href=\"/wiki/Serous_carcinoma\" title=\"Serous carcinoma\">serous carcinoma</a>,<sup id=\"cite_ref-Jayson_18-20\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> though this proportion is estimated as high as 80%.<sup id=\"cite_ref-:7_21-34\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-Levy_46-0\" class=\"reference\"><a href=\"#cite_note-Levy-46\">&#91;46&#93;</a></sup> Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to chemotherapy or hormonal treatments.<sup id=\"cite_ref-Jayson_18-21\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Serous carcinomas are thought to begin in the <a href=\"/wiki/Fallopian_tube\" title=\"Fallopian tube\">Fallopian tube</a>.<sup id=\"cite_ref-:1_45-1\" class=\"reference\"><a href=\"#cite_note-:1-45\">&#91;45&#93;</a></sup> Histologically, serous adenocarcinomas have <a href=\"/wiki/Psammoma_body\" title=\"Psammoma body\">psammoma bodies</a>. Low-grade serous adenocarcinomas resemble Fallopian tube epithelium, whereas high-grade serous adenocarcinomas show <a href=\"/wiki/Anaplasia\" title=\"Anaplasia\">anaplasia</a> and <a href=\"/wiki/Nuclear_atypia\" title=\"Nuclear atypia\">nuclear atypia</a>.<sup id=\"cite_ref-Hoffman35_19-30\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>50% of the time, serous carcinomas are bilateral, and in 85% of cases, they have spread beyond the ovary at the time of diagnosis. Most have a diameter over 15&#160;cm.<sup id=\"cite_ref-Levy_46-1\" class=\"reference\"><a href=\"#cite_note-Levy-46\">&#91;46&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Small-cell_carcinoma\">Small-cell carcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=18\" title=\"Edit section: Small-cell carcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<p><a href=\"/wiki/Small-cell_carcinoma\" title=\"Small-cell carcinoma\">Small-cell</a> ovarian carcinoma is rare and aggressive, with two main subtypes: hypercalcemic and pulmonary. It is typically fatal within 2 years of diagnosis. Hypercalcemic small cell ovarian carcinoma overwhelmingly affects those in their 20s, causes <a href=\"/wiki/Hypercalcaemia\" title=\"Hypercalcaemia\">high blood calcium levels</a>, and affects one ovary. Pulmonary small cell ovarian cancer usually affects both ovaries of older women and looks like <a href=\"/wiki/Small-cell_carcinoma\" title=\"Small-cell carcinoma\">oat-cell carcinoma of the lung</a>.<sup id=\"cite_ref-Hoffman35_19-31\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h6><span class=\"mw-headline\" id=\"Primary_peritoneal_carcinoma\">Primary peritoneal carcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=19\" title=\"Edit section: Primary peritoneal carcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h6>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Primary_peritoneal_carcinoma\" title=\"Primary peritoneal carcinoma\">Primary peritoneal carcinoma</a></div><p>Primary peritoneal carcinomas develop from the <a href=\"/wiki/Peritoneum\" title=\"Peritoneum\">peritoneum</a>, a membrane that covers the <a href=\"/wiki/Abdominal_cavity\" title=\"Abdominal cavity\">abdominal cavity</a> that has the same embryonic origin as the ovary. They are often discussed and classified with ovarian cancers when they affect the ovary.<sup id=\"cite_ref-:1_45-2\" class=\"reference\"><a href=\"#cite_note-:1-45\">&#91;45&#93;</a></sup><sup id=\"cite_ref-47\" class=\"reference\"><a href=\"#cite_note-47\">&#91;47&#93;</a></sup> They can develop even after the ovaries have been removed and may appear similar to <a href=\"/wiki/Mesothelioma\" title=\"Mesothelioma\">mesothelioma</a>.<sup id=\"cite_ref-Hoffman35_19-32\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><h5><span class=\"mw-headline\" id=\"Clear-cell_carcinoma\">Clear-cell carcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=20\" title=\"Edit section: Clear-cell carcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<p><a href=\"/wiki/Clear-cell_ovarian_carcinoma\" title=\"Clear-cell ovarian carcinoma\">Clear-cell ovarian carcinomas</a> do not typically respond well to chemotherapy and may be related to endometriosis.<sup id=\"cite_ref-Jayson_18-22\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> They represent approximately 5% of all endometrial cancers. Japanese women develop clear-cell ovarian cancer more frequently than other groups of women.<sup id=\"cite_ref-:7_21-35\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Clear-cell_adenocarcinoma\">Clear-cell adenocarcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=21\" title=\"Edit section: Clear-cell adenocarcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:Clear_cell_carcinoma_hobnail_cells.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/9/99/Clear_cell_carcinoma_hobnail_cells.png/290px-Clear_cell_carcinoma_hobnail_cells.png\" width=\"290\" height=\"363\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/9/99/Clear_cell_carcinoma_hobnail_cells.png/435px-Clear_cell_carcinoma_hobnail_cells.png 1.5x, //upload.wikimedia.org/wikipedia/commons/9/99/Clear_cell_carcinoma_hobnail_cells.png 2x\" data-file-width=\"490\" data-file-height=\"613\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Clear_cell_carcinoma_hobnail_cells.png\" class=\"internal\" title=\"Enlarge\"></a></div>Hobnail cells seen in a clear cell carcinoma sample</div></div></div>\n<p>Clear-cell adenocarcinomas are histopathologically similar to other <a href=\"/wiki/Clear_cell_carcinoma\" title=\"Clear cell carcinoma\">clear cell carcinomas</a>, with <a href=\"/wiki/Clear_cell\" title=\"Clear cell\">clear cells</a> and <a href=\"/wiki/Hobnail_cell\" title=\"Hobnail cell\">hobnail cells</a>. They represent approximately 5\u201310% of epithelial ovarian cancers and are associated with endometriosis in the pelvic cavity. They are typically early-stage and therefore curable by surgery, but advanced clear-cell adenocarcinomas (approximately 20%) have a poor prognosis and are often resistant to platinum chemotherapy.<sup id=\"cite_ref-Hoffman35_19-33\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Endometrioid\">Endometrioid</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=22\" title=\"Edit section: Endometrioid\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<p>Endometrioid adenocarcinomas make up approximately 15\u201320% of epithelial ovarian cancers. Because they are typically low-grade, endometrioid adenocarcinomas have a good prognosis. These tumors frequently co-occur with <a href=\"/wiki/Endometriosis\" title=\"Endometriosis\">endometriosis</a> or endometrial cancer.<sup id=\"cite_ref-Hoffman35_19-34\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h6><span id=\"Malignant_mixed_m.C3.BCllerian_tumor_.28carcinosarcoma.29\"></span><span class=\"mw-headline\" id=\"Malignant_mixed_m\u00fcllerian_tumor_(carcinosarcoma)\">Malignant mixed m\u00fcllerian tumor (carcinosarcoma)</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=23\" title=\"Edit section: Malignant mixed m\u00fcllerian tumor (carcinosarcoma)\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h6>\n<p>Mixed m\u00fcllerian tumors make up less than 1% of ovarian cancer. They have epithelial and mesenchymal cells visible and tend to have a poor prognosis.<sup id=\"cite_ref-Hoffman35_19-35\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Mucinous\">Mucinous</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=24\" title=\"Edit section: Mucinous\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<p>Mucinous tumors include mucinous adenocarcinoma and mucinous cystadenocarcinoma.<sup id=\"cite_ref-Hoffman35_19-36\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h6><span class=\"mw-headline\" id=\"Mucinous_adenocarcinoma\">Mucinous adenocarcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=25\" title=\"Edit section: Mucinous adenocarcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h6>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Mucinous_adenocarcinoma\" class=\"mw-redirect\" title=\"Mucinous adenocarcinoma\">Mucinous adenocarcinoma</a></div>\n<p>Mucinous adenocarcinomas make up 5\u201310% of epithelial ovarian cancers. Histologically, they are similar to intestinal or cervical adenocarcinomas, and are often actually metastases of <a href=\"/wiki/Appendiceal_cancer\" class=\"mw-redirect\" title=\"Appendiceal cancer\">appendiceal</a> or <a href=\"/wiki/Colon_cancer\" class=\"mw-redirect\" title=\"Colon cancer\">colon cancers</a>. Advanced mucinous adenocarcinomas have a poor prognosis, generally worse than serous tumors, and are often resistant to platinum chemotherapy, though they are rare.<sup id=\"cite_ref-Hoffman35_19-37\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h6><span class=\"mw-headline\" id=\"Pseudomyxoma_peritonei\">Pseudomyxoma peritonei</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=26\" title=\"Edit section: Pseudomyxoma peritonei\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h6>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Pseudomyxoma_peritonei\" title=\"Pseudomyxoma peritonei\">Pseudomyxoma peritonei</a></div>\n<p><i>Pseudomyxoma peritonei</i> refers to a collection of encapsulated mucous or gelatinous material in the abdominopelvic cavity, which is very rarely caused by a primary mucinous ovarian tumor. More commonly, it is associated with ovarian metastases of intestinal cancer.<sup id=\"cite_ref-Hoffman35_19-38\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Undifferentiated_epithelial\">Undifferentiated epithelial</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=27\" title=\"Edit section: Undifferentiated epithelial\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<p>Undifferentiated cancers - those where the cell type cannot be determined - make up about 10% of epithelial ovarian cancers and have a comparatively poor prognosis.<sup id=\"cite_ref-Hoffman35_19-39\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-:1_45-3\" class=\"reference\"><a href=\"#cite_note-:1-45\">&#91;45&#93;</a></sup> When examined under the microscope, these tumors have very abnormal cells that are arranged in clumps or sheets. Usually there are recognizable clumps of serous cells inside the tumor.<sup id=\"cite_ref-Hoffman35_19-40\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h6><span class=\"mw-headline\" id=\"Malignant_Brenner_tumor\">Malignant Brenner tumor</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=28\" title=\"Edit section: Malignant Brenner tumor\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h6>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Brenner_tumor\" class=\"mw-redirect\" title=\"Brenner tumor\">Brenner tumor</a></div>\n<p>Malignant Brenner tumors are rare. Histologically, they have dense fibrous stroma with areas of transitional epithelium, and some squamous differentiation. To be classified as a malignant Brenner tumor, it must have Brenner tumor foci and transitional cell carcinoma. The transitional cell carcinoma component is typically poorly differentiated and resembles urinary tract cancer.<sup id=\"cite_ref-Hoffman35_19-41\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h6><span class=\"mw-headline\" id=\"Transitional_cell_carcinoma\">Transitional cell carcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=29\" title=\"Edit section: Transitional cell carcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h6>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Transitional_cell_carcinoma\" title=\"Transitional cell carcinoma\">Transitional cell carcinoma</a></div>\n<p>Transitional cell carcinomas represent less than 5% of ovarian cancers. Histologically, they appear similar to <a href=\"/wiki/Bladder_carcinoma\" class=\"mw-redirect\" title=\"Bladder carcinoma\">bladder carcinoma</a>. The prognosis is intermediate - better than most epithelial cancers but worse than malignant Brenner tumors.<sup id=\"cite_ref-Hoffman35_19-42\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Sex_cord-stromal_tumor\">Sex cord-stromal tumor</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=30\" title=\"Edit section: Sex cord-stromal tumor\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Sex_cord-stromal_tumor\" class=\"mw-redirect\" title=\"Sex cord-stromal tumor\">Sex cord-stromal tumor</a></div>\n<p><a href=\"/wiki/Sex_cord-stromal_tumour\" class=\"mw-redirect\" title=\"Sex cord-stromal tumour\">Sex cord-stromal tumor</a>, including <a href=\"/wiki/Estrogen\" title=\"Estrogen\">estrogen</a>-producing <a href=\"/wiki/Granulosa_cell_tumor\" class=\"mw-redirect\" title=\"Granulosa cell tumor\">granulosa cell tumor</a>, the benign <a href=\"/wiki/Thecoma\" title=\"Thecoma\">thecoma</a>, and virilizing <a href=\"/wiki/Sertoli-Leydig_cell_tumor\" class=\"mw-redirect\" title=\"Sertoli-Leydig cell tumor\">Sertoli-Leydig cell tumor</a> or <a href=\"/wiki/Arrhenoblastoma\" class=\"mw-redirect\" title=\"Arrhenoblastoma\">arrhenoblastoma</a>, accounts for 7% of ovarian cancers. They occur most frequently in women between 50 and 69 years of age, but can occur in women of any age, including young girls. They are not typically aggressive and are usually unilateral;<sup id=\"cite_ref-Harrisons_16-22\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> they are therefore usually treated with surgery alone. Sex cord-stromal tumors are the main hormone-producing ovarian tumors.<sup id=\"cite_ref-:8_22-4\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>Several different cells from the <a href=\"/wiki/Mesenchyme\" title=\"Mesenchyme\">mesenchyme</a> can give rise to sex-cord or stromal tumors. These include <a href=\"/wiki/Fibroblast\" title=\"Fibroblast\">fibroblasts</a> and endocrine cells. The symptoms of a sex-cord or stromal ovarian tumor can differ from other types of ovarian cancer. Common signs and symptoms include <a href=\"/wiki/Ovarian_torsion\" title=\"Ovarian torsion\">ovarian torsion</a>, <a href=\"/wiki/Hemorrhage\" class=\"mw-redirect\" title=\"Hemorrhage\">hemorrhage</a> from or rupture of the tumor, an abdominal mass, and hormonal disruption. In children, <a href=\"/wiki/Precocious_puberty#Isosexual_and_heterosexual\" title=\"Precocious puberty\">isosexual precocious pseudopuberty</a> may occur with granulosa cell tumors since they produce estrogen. These tumors cause abnormalities in menstruation (<a href=\"/wiki/Menometrorrhagia\" title=\"Menometrorrhagia\">excessive bleeding</a>, <a href=\"/wiki/Oligomenorrhea\" title=\"Oligomenorrhea\">infrequent menstruation</a>, or <a href=\"/wiki/Amenorrhea\" title=\"Amenorrhea\">no menstruation</a>) or postmenopausal bleeding. Because these tumors produce estrogen, they can cause or occur at the same time as <a href=\"/wiki/Endometrial_cancer\" title=\"Endometrial cancer\">endometrial cancer</a> or <a href=\"/wiki/Breast_cancer\" title=\"Breast cancer\">breast cancer</a>. Other sex-cord/stromal tumors present with distinct symptoms. Sertoli-Leydig cell tumors cause <a href=\"/wiki/Virilization\" title=\"Virilization\">virilization</a> and <a href=\"/wiki/Hirsutism\" title=\"Hirsutism\">excessive hair growth</a> due to the production of <a href=\"/wiki/Testosterone\" title=\"Testosterone\">testosterone</a> and <a href=\"/wiki/Androstenedione\" title=\"Androstenedione\">androstenedione</a>, which can also cause <a href=\"/wiki/Cushing%27s_syndrome\" title=\"Cushing&#39;s syndrome\">Cushing's syndrome</a> in rare cases. Also, sex-cord stromal tumors occur that do not cause a hormonal imbalance, including benign fibromas, which cause ascites and <a href=\"/wiki/Hydrothorax\" title=\"Hydrothorax\">hydrothorax</a>.<sup id=\"cite_ref-Harrisons_16-23\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> With germ cell tumors, sex cord-stromal tumors are the most common ovarian cancer diagnosed in women under 20.<sup id=\"cite_ref-:8_22-5\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Granulosa_cell_tumor\">Granulosa cell tumor</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=31\" title=\"Edit section: Granulosa cell tumor\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<p>Granulosa cell tumors are the most common sex-cord stromal tumors, making up 70% of cases, and are divided into two histologic subtypes: adult granulosa cell tumors, which develop in women over 50, and juvenile granulosa tumors, which develop before puberty or before the age of 30. Both develop in the <a href=\"/wiki/Ovarian_follicle\" title=\"Ovarian follicle\">ovarian follicle</a> from a population of cells that surrounds <a href=\"/w/index.php?title=Germinal_cell&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Germinal cell (page does not exist)\">germinal cells</a>.<sup id=\"cite_ref-:8_22-6\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h6><span class=\"mw-headline\" id=\"Adult_granulosa_cell_tumor\">Adult granulosa cell tumor</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=32\" title=\"Edit section: Adult granulosa cell tumor\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h6>\n<p>Adult granulosa cell tumors are characterized by later onset (30+ years, 50 on average). These tumors produce high levels of estrogen, which causes its characteristic symptoms: <a href=\"/wiki/Menometrorrhagia\" title=\"Menometrorrhagia\">menometrorrhagia</a>; <a href=\"/wiki/Endometrial_hyperplasia\" title=\"Endometrial hyperplasia\">endometrial hyperplasia</a>; <a href=\"/wiki/Breast_pain\" title=\"Breast pain\">tender</a>, <a href=\"/wiki/Breast_enlargement\" title=\"Breast enlargement\">enlarged breasts</a>; <a href=\"/wiki/Vaginal_bleeding\" title=\"Vaginal bleeding\">postmenopausal bleeding</a>; and <a href=\"/wiki/Amenorrhoea\" class=\"mw-redirect\" title=\"Amenorrhoea\">secondary amenorrhea</a>. The mass of the tumor can cause other symptoms, including abdominal pain and distension, or symptoms similar to an <a href=\"/wiki/Ectopic_pregnancy\" title=\"Ectopic pregnancy\">ectopic pregnancy</a> if the tumor bleeds and ruptures.<sup id=\"cite_ref-:8_22-7\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h6><span class=\"mw-headline\" id=\"Juvenile_granulosa_cell_tumor\">Juvenile granulosa cell tumor</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=33\" title=\"Edit section: Juvenile granulosa cell tumor\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h6>\n<h5><span class=\"mw-headline\" id=\"Sertoli-Leydig_cell_tumor\">Sertoli-Leydig cell tumor</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=34\" title=\"Edit section: Sertoli-Leydig cell tumor\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<p>Sertoli-Leydig tumors are most common in women before the age of 30, and particularly common before puberty.<sup id=\"cite_ref-:8_22-8\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Sclerosing_stromal_tumors\">Sclerosing stromal tumors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=35\" title=\"Edit section: Sclerosing stromal tumors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<p>Sclerosing stromal tumors  typically occur in girls before puberty or women before the age of 30.<sup id=\"cite_ref-:8_22-9\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Germ_cell_tumor\">Germ cell tumor</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=36\" title=\"Edit section: Germ cell tumor\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Germ_cell_tumor\" title=\"Germ cell tumor\">Germ cell tumor</a></div>\n<p>Germ cell tumors of the ovary develop from the ovarian <a href=\"/wiki/Germ_cells\" class=\"mw-redirect\" title=\"Germ cells\">germ cells</a>.<sup id=\"cite_ref-:1_45-4\" class=\"reference\"><a href=\"#cite_note-:1-45\">&#91;45&#93;</a></sup> <a href=\"/wiki/Germ_cell_tumor\" title=\"Germ cell tumor\">Germ cell tumor</a> accounts for about 30% of ovarian tumors, but only 5% of ovarian cancers, because most germ-cell tumors are <a href=\"/wiki/Teratoma\" title=\"Teratoma\">teratomas</a> and most teratomas are benign. Malignant teratomas tend to occur in older women, when one of the germ layers in the tumor develops into a <a href=\"/wiki/Squamous_cell_carcinoma\" title=\"Squamous cell carcinoma\">squamous cell carcinoma</a>.<sup id=\"cite_ref-Harrisons_16-24\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Germ-cell tumors tend to occur in young women (20s\u201330s) and girls, making up 70% of the ovarian cancer seen in that age group.<sup id=\"cite_ref-Current_23-1\" class=\"reference\"><a href=\"#cite_note-Current-23\">&#91;23&#93;</a></sup> Germ-cell tumors can include dysgerminomas, teratomas, yolk sac tumors/endodermal sinus tumors, and choriocarcinomas, when they arise in the ovary. Some germ-cell tumors have an <a href=\"/wiki/Isochromosome\" title=\"Isochromosome\">isochromosome</a> 12, where one arm of chromosome 12 is deleted and replaced with a duplicate of the other.<sup id=\"cite_ref-Harrisons_16-25\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Most germ-cell cancers have a better prognosis than other subtypes and are more sensitive to chemotherapy. They are more likely to be stage I at diagnosis.<sup id=\"cite_ref-:8_22-10\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup> Overall, they metastasize more frequently than epithelial ovarian cancers. In addition, the cancer markers used vary with tumor type: <a href=\"/wiki/Choriocarcinomas\" class=\"mw-redirect\" title=\"Choriocarcinomas\">choriocarcinomas</a> are monitored with <a href=\"/wiki/Beta-HCG\" class=\"mw-redirect\" title=\"Beta-HCG\">beta-HCG</a> and endodermal sinus tumors with <a href=\"/wiki/Alpha-fetoprotein\" title=\"Alpha-fetoprotein\">alpha-fetoprotein</a>.<sup id=\"cite_ref-Harrisons_16-26\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p><p>Germ-cell tumors are typically discovered when they become large, palpable masses. However, like sex cord tumors, they can cause ovarian torsion or hemorrhage and, in children, isosexual precocious puberty. They frequently metastasize to nearby lymph nodes, especially para-aortic and pelvic lymph nodes.<sup id=\"cite_ref-Harrisons_16-27\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> The most common symptom of germ cell tumors is <a href=\"/wiki/Abdominal_pain\" title=\"Abdominal pain\">subacute abdominal pain</a> caused by the tumor bleeding, <a href=\"/wiki/Necrosis\" title=\"Necrosis\">necrotizing</a>, or stretching the <a href=\"/w/index.php?title=Ovarian_capsule&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Ovarian capsule (page does not exist)\">ovarian capsule</a>. If the tumor ruptures, causes significant bleeding, or torses the ovary, it can cause <a href=\"/wiki/Acute_abdomen\" title=\"Acute abdomen\">acute abdominal pain</a>, which occurs in less than 10% of those with germ-cell tumors. They can also secrete hormones which change the <a href=\"/wiki/Menstrual_cycle\" title=\"Menstrual cycle\">menstrual cycle</a>. In 25% of germ-cell tumors, the cancer is discovered during a <a href=\"/wiki/Well-woman_examination\" title=\"Well-woman examination\">routine examination</a> and does not cause symptoms.<sup id=\"cite_ref-:8_22-11\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>Diagnosing germ cell tumors may be difficult because the normal menstrual cycle and <a href=\"/wiki/Puberty\" title=\"Puberty\">puberty</a> can cause pain and pelvic symptoms, and a young woman may even believe these symptoms to be those of pregnancy, and not seek treatment due to the stigma of <a href=\"/wiki/Teenage_pregnancy\" title=\"Teenage pregnancy\">teen pregnancy</a>. Blood tests for alpha-fetoprotein, <a href=\"/wiki/Karyotype\" title=\"Karyotype\">karyotype</a>, human chorionic gonadotropin, and liver function are used to diagnose germ cell tumor and potential co-occurring gonadal dysgenesis. A germ cell tumor may be initially mistaken for a benign <a href=\"/wiki/Ovarian_cyst\" title=\"Ovarian cyst\">ovarian cyst</a>.<sup id=\"cite_ref-:8_22-12\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Dysgerminoma\">Dysgerminoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=37\" title=\"Edit section: Dysgerminoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Dysgerminoma\" title=\"Dysgerminoma\">Dysgerminoma</a></div>\n<p>Dysgerminoma accounts for 35% of ovarian cancer in young women and is the most likely germ cell tumor to metastasize to the lymph nodes; nodal metastases occur in 25\u201330% of cases.<sup id=\"cite_ref-Current_23-2\" class=\"reference\"><a href=\"#cite_note-Current-23\">&#91;23&#93;</a></sup><sup id=\"cite_ref-:8_22-13\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup> These tumors may have mutations in <a href=\"/wiki/CD117\" title=\"CD117\">the <i>KIT</i> gene</a>, a mutation known for its role in <a href=\"/wiki/Gastrointestinal_stromal_tumor\" title=\"Gastrointestinal stromal tumor\">gastrointestinal stromal tumor</a>. <a href=\"/wiki/Swyer_syndrome\" class=\"mw-redirect\" title=\"Swyer syndrome\">People with an XY karyotype and ovaries</a> (<a href=\"/wiki/Gonadal_dysgenesis\" title=\"Gonadal dysgenesis\">gonadal dysgenesis</a>) or an X,0 karyotype and ovaries (<a href=\"/wiki/Turner_syndrome\" title=\"Turner syndrome\">Turner syndrome</a>) who develop a unilateral dysgerminoma are at risk for a <a href=\"/wiki/Gonadoblastoma\" title=\"Gonadoblastoma\">gonadoblastoma</a> in the other ovary, and in this case, both ovaries are usually removed when a unilateral dysgerminoma is discovered to avoid the risk of another malignant tumor. Gonadoblastomas in people with Swyer or Turner syndrome become malignant in approximately 40% of cases. However, in general, dysgerminomas are bilateral 10\u201320% of the time.<sup id=\"cite_ref-Harrisons_16-28\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-:8_22-14\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>They are composed of cells that cannot <a href=\"/wiki/Cellular_differentiation\" title=\"Cellular differentiation\">differentiate</a> further and develop directly from germ cells or from gonadoblastomas. Dysgerminomas contain <a href=\"/wiki/Syncytiotrophoblast\" title=\"Syncytiotrophoblast\">syncytiotrophoblasts</a> in approximately 5% of cases, and can therefore cause elevated hCG levels. On gross appearance, dysgerminomas are typically pink to tan-colored, have multiple lobes, and are solid. Microscopically, they appear identical to <a href=\"/wiki/Seminoma\" title=\"Seminoma\">seminomas</a> and very close to <a href=\"/wiki/Embryonic_germ_cell\" class=\"mw-redirect\" title=\"Embryonic germ cell\">embryonic primordial germ cells</a>, having large, polyhedral, rounded <a href=\"/wiki/Clear_cell\" title=\"Clear cell\">clear cells</a>. The nuclei are uniform and round or square with prominent <a href=\"/wiki/Nucleolus\" title=\"Nucleolus\">nucleoli</a> and the <a href=\"/wiki/Cytoplasm\" title=\"Cytoplasm\">cytoplasm</a> has high levels of <a href=\"/wiki/Glycogen\" title=\"Glycogen\">glycogen</a>. Inflammation is another prominent histologic feature of dysgerminomas.<sup id=\"cite_ref-:8_22-15\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Choriocarcinoma\">Choriocarcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=38\" title=\"Edit section: Choriocarcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Choriocarcinoma\" title=\"Choriocarcinoma\">Choriocarcinoma</a></div>\n<p>Choriocarcinoma can occur as a primary ovarian tumor developing from a germ cell, though it is usually a gestational disease that metastasizes to the ovary. Primary ovarian choriocarcinoma has  a poor prognosis and can occur without a pregnancy. They produce high levels of hCG and can cause <a href=\"/wiki/Precocious_puberty\" title=\"Precocious puberty\">early puberty</a> in children or <a href=\"/wiki/Menometrorrhagia\" title=\"Menometrorrhagia\">menometrorrhagia</a> (irregular, heavy menstruation) after menarche.<sup id=\"cite_ref-:8_22-16\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h5><span id=\"Immature_.28solid.29_teratoma\"></span><span class=\"mw-headline\" id=\"Immature_(solid)_teratoma\">Immature (solid) teratoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=39\" title=\"Edit section: Immature (solid) teratoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Immature_teratoma\" title=\"Immature teratoma\">Immature teratoma</a></div><p>Immature, or solid, teratomas are the most common type of ovarian germ cell tumor, making up 40\u201350% of cases. Teratomas are characterized by the presence of disorganized tissues arising from all three embryonic <a href=\"/wiki/Germ_layer\" title=\"Germ layer\">germ layers</a>: <a href=\"/wiki/Ectoderm\" title=\"Ectoderm\">ectoderm</a>, <a href=\"/wiki/Mesoderm\" title=\"Mesoderm\">mesoderm</a>, and <a href=\"/wiki/Endoderm\" title=\"Endoderm\">endoderm</a>; immature teratomas also have undifferentiated <a href=\"/wiki/Stem_cell\" title=\"Stem cell\">stem cells</a> that make them more malignant than mature teratomas (dermoid cysts). The different tissues are visible on gross pathology and often include bone, cartilage, hair, <a href=\"/wiki/Mucus\" title=\"Mucus\">mucus</a>, or <a href=\"/wiki/Sebaceous_gland\" title=\"Sebaceous gland\">sebum</a>, but these tissues are not visible from the outside, which appears to be a solid mass with lobes and cysts. Histologically, they have large amounts of <a href=\"/wiki/Neuroectoderm\" title=\"Neuroectoderm\">neuroectoderm</a> organized into sheets and tubules along with <a href=\"/wiki/Neuroglia\" title=\"Neuroglia\">glia</a>; the amount of neural tissue determines the histologic grade. Immature teratomas usually only affect one ovary (10% co-occur with dermoid cysts) and usually metastasize throughout the peritoneum. They can also cause mature teratoma implants to grow throughout the abdomen in a disease called <a href=\"/wiki/Growing_teratoma_syndrome\" title=\"Growing teratoma syndrome\">growing teratoma syndrome</a>; these are usually benign but will continue to grow during chemotherapy, and often necessitate further surgery. Unlike mature teratomas, immature teratomas form many <a href=\"/wiki/Adhesion_(medicine)\" title=\"Adhesion (medicine)\">adhesions</a>, making them less likely to cause ovarian torsion. There is no specific marker for immature teratomas, but <a href=\"/wiki/Carcinoembryonic_antigen\" title=\"Carcinoembryonic antigen\">carcinoembryonic antigen</a> (CEA), CA-125, CA19-9, or AFP can sometimes indicate an immature teratoma.<sup id=\"cite_ref-:8_22-17\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>Stage I teratomas make up the majority (75%) of cases and have the best prognosis, with 98% of patients surviving 5 years; if a Stage I tumor is also grade 1, it can be treated with unilateral surgery only. Stage II though IV tumors make up the remaining quarter of cases and have a worse prognosis,  with 73\u201388% of patients surviving 5 years.<sup id=\"cite_ref-:8_22-18\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h5><span id=\"Mature_teratoma_.28dermoid_cyst.29\"></span><span class=\"mw-headline\" id=\"Mature_teratoma_(dermoid_cyst)\">Mature teratoma (dermoid cyst)</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=40\" title=\"Edit section: Mature teratoma (dermoid cyst)\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Dermoid_cyst\" title=\"Dermoid cyst\">Dermoid cyst</a></div>\n<p>Mature teratomas, or dermoid cysts, are rare tumors consisting of mostly benign tissue that develop after menopause. The tumors consist of disorganized tissue with nodules of malignant tissue, which can be of various types. The most common malignancy is <a href=\"/wiki/Squamous-cell_carcinoma\" class=\"mw-redirect\" title=\"Squamous-cell carcinoma\">squamous cell carcinoma</a>, but <a href=\"/wiki/Adenocarcinoma\" title=\"Adenocarcinoma\">adenocarcinoma</a>, <a href=\"/wiki/Basal-cell_carcinoma\" title=\"Basal-cell carcinoma\">basal-cell carcinoma</a>, <a href=\"/wiki/Carcinoid\" title=\"Carcinoid\">carcinoid tumor</a>, <a href=\"/wiki/Neuroectodermal_tumor\" title=\"Neuroectodermal tumor\">neuroectodermal tumor</a>, <a href=\"/wiki/Melanoma\" title=\"Melanoma\">malignant melanoma</a>, <a href=\"/wiki/Sarcoma\" title=\"Sarcoma\">sarcoma</a>, <a href=\"/wiki/Sebaceous_carcinoma\" title=\"Sebaceous carcinoma\">sebaceous tumor</a>, and <a href=\"/wiki/Struma_ovarii\" title=\"Struma ovarii\">struma ovarii</a> can also be part of the dermoid cyst. They are treated with surgery and adjuvant platinum chemotherapy or radiation.<sup id=\"cite_ref-:8_22-19\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h5><span id=\"Yolk_sac_tumor.2Fendodermal_sinus_tumor\"></span><span class=\"mw-headline\" id=\"Yolk_sac_tumor/endodermal_sinus_tumor\">Yolk sac tumor/endodermal sinus tumor</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=41\" title=\"Edit section: Yolk sac tumor/endodermal sinus tumor\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Yolk_sac_tumor\" class=\"mw-redirect\" title=\"Yolk sac tumor\">Yolk sac tumor</a></div>\n<p><a href=\"/wiki/Yolk_sac\" title=\"Yolk sac\">Yolk sac</a> tumors, formerly called endodermal sinus tumors, make up approximately 10\u201320% of ovarian germ cell malignancies, and have the worst prognosis of all ovarian germ cell tumors. They occur both before menarche (in one-third of cases) and after menarche (the remaining two-thirds of cases). Half of people with yolk sac tumors are diagnosed in stage I. Typically, they are unilateral until metastasis, which occurs within the peritoneal cavity and via the bloodstream to the lungs. Yolk sac tumors grow quickly and recur easily, and are not easily treatable once they have recurred. Stage I yolk sac tumors are highly treatable, with a 5-year disease free survival rate of 93%, but stage II-IV tumors are less treatable, with survival rates of 64\u201391%.<sup id=\"cite_ref-:8_22-20\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>Their gross appearance is solid, friable, and yellow, with necrotic and hemorrhagic areas. They also often contain cysts that can degenerate or rupture. Histologically, yolk sac tumors are characterized by the presence of <a href=\"/wiki/Schiller%E2%80%93Duval_body\" title=\"Schiller\u2013Duval body\">Schiller-Duval bodies</a> (which are pathognomonic for yolk sac tumors) and a reticular pattern. Yolk sac tumors commonly secrete <a href=\"/wiki/Alpha-fetoprotein\" title=\"Alpha-fetoprotein\">alpha-fetoprotein</a> and can be <a href=\"/wiki/Immunohistochemistry\" title=\"Immunohistochemistry\">immunohistochemically</a> stained for its presence; the level of alpha-fetoprotein in the blood is a useful marker of recurrence.<sup id=\"cite_ref-:8_22-21\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Embryonal_carcinoma\">Embryonal carcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=42\" title=\"Edit section: Embryonal carcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Embryonal_carcinoma\" title=\"Embryonal carcinoma\">Embryonal carcinoma</a></div>\n<p>Embryonal carcinomas, a rare tumor type usually found in mixed tumors, develop directly from germ cells but are not terminally differentiated; in rare cases they may develop in dysgenetic gonads. They can develop further into a variety of other neoplasms, including choriocarcinoma, yolk sac tumor, and teratoma. They occur in younger people, with an average age at diagnosis of 14, and secrete both alpha-fetoprotein (in 75% of cases) and hCG.<sup id=\"cite_ref-:8_22-22\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>Histologically, embryonal carcinoma appears similar to the <a href=\"/wiki/Embryonic_disc\" title=\"Embryonic disc\">embryonic disc</a>, made up of epithelial, <a href=\"/wiki/Anaplasia\" title=\"Anaplasia\">anaplastic</a> cells in disorganized sheets, with gland-like spaces and papillary structures.<sup id=\"cite_ref-:8_22-23\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h5><span class=\"mw-headline\" id=\"Polyembryoma\">Polyembryoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=43\" title=\"Edit section: Polyembryoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h5>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Polyembryoma\" title=\"Polyembryoma\">Polyembryoma</a></div>\n<p>Polyembryomas, the most immature form of teratoma and very rare ovarian tumors, are histologically characterized by having several <a href=\"/wiki/Embryo\" title=\"Embryo\">embryo</a>-like bodies with structures resembling a <a href=\"/w/index.php?title=Germ_disk&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Germ disk (page does not exist)\">germ disk</a>, <a href=\"/wiki/Yolk_sac\" title=\"Yolk sac\">yolk sac</a>, and <a href=\"/wiki/Amniotic_sac\" title=\"Amniotic sac\">amniotic sac</a>. <a href=\"/wiki/Syncytiotrophoblast\" title=\"Syncytiotrophoblast\">Syncytiotrophoblast giant cells</a> also occur in polyembryomas.<sup id=\"cite_ref-:8_22-24\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Squamous_cell_carcinoma\">Squamous cell carcinoma</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=44\" title=\"Edit section: Squamous cell carcinoma\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>Primary ovarian squamous cell carcinomas are rare and have a poor prognosis when advanced. More typically, ovarian squamous cell carcinomas are cervical metastases, areas of differentiation in an endometrioid tumor, or derived from a mature teratoma.<sup id=\"cite_ref-Hoffman35_19-43\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Mixed_tumors\">Mixed tumors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=45\" title=\"Edit section: Mixed tumors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>Mixed tumors contain elements of more than one of the above classes of tumor histology. To be classed as a mixed tumor, the minor type must make up more than 10% of the tumor.<sup id=\"cite_ref-:7_21-36\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Though mixed carcinomas can have any combination of cell types, mixed ovarian cancers are typically serous/endometrioid or clear cell/endometrioid.<sup id=\"cite_ref-Hoffman35_19-44\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Mixed germ cell tumors make up approximately 25\u201330% of all germ cell ovarian cancers, with combinations of dysgerminoma, yolk sac tumor, and/or immature teratoma. The prognosis and treatment vary based on the component cell types.<sup id=\"cite_ref-:8_22-25\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Secondary_ovarian_cancer\">Secondary ovarian cancer</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=46\" title=\"Edit section: Secondary ovarian cancer\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>Ovarian cancer can also be a secondary cancer, the result of <a href=\"/wiki/Metastasis\" title=\"Metastasis\">metastasis</a> from a primary cancer elsewhere in the body.<sup id=\"cite_ref-Harrisons_16-29\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> About 7% of ovarian cancers are due to metastases, while the rest are primary cancers.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (November 2014)\">citation needed</span></a></i>&#93;</sup> Common primary cancers are <a href=\"/wiki/Breast_cancer\" title=\"Breast cancer\">breast cancer</a>, <a href=\"/wiki/Colon_cancer\" class=\"mw-redirect\" title=\"Colon cancer\">colon cancer</a>, <a href=\"/wiki/Appendiceal_cancer\" class=\"mw-redirect\" title=\"Appendiceal cancer\">appendiceal cancer</a>, and <a href=\"/wiki/Stomach_cancer\" title=\"Stomach cancer\">stomach cancer</a> (primary gastric cancers that metastasize to the ovary are called <a href=\"/wiki/Krukenberg_tumor\" title=\"Krukenberg tumor\">Krukenberg tumors</a>).<sup id=\"cite_ref-Harrisons_16-30\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Krukenberg tumors have signet ring cells and mucinous cells.<sup id=\"cite_ref-Hoffman35_19-45\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Endometrial cancer and lymphomas can also metastasize to the ovary.<sup id=\"cite_ref-Levy_46-2\" class=\"reference\"><a href=\"#cite_note-Levy-46\">&#91;46&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Low_malignant_potential_tumors\">Low malignant potential tumors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=47\" title=\"Edit section: Low malignant potential tumors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>Low malignant potential ovarian tumors, also called borderline tumors, have some benign and some malignant features.<sup id=\"cite_ref-Hoffman35_19-46\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> LMP tumors make up approximately 10%-15% of all ovarian tumors.<sup id=\"cite_ref-:7_21-37\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-:1_45-5\" class=\"reference\"><a href=\"#cite_note-:1-45\">&#91;45&#93;</a></sup> They develop earlier than epithelial ovarian cancer, around the age of 40\u201349. They typically do not have extensive invasion; 10% of LMP tumors have areas of stromal microinvasion (&lt;3mm, &lt;5% of tumor). LMP tumors have other abnormal features, including increased mitosis, <a href=\"/wiki/Pleomorphism_(cytology)\" title=\"Pleomorphism (cytology)\">changes in cell size or nucleus size</a>, <a href=\"/wiki/Nuclear_atypia\" title=\"Nuclear atypia\">abnormal nuclei</a>, cell stratification, and <a href=\"/w/index.php?title=Papillary_projections&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Papillary projections (page does not exist)\">small projections on cells</a> (papillary projections). Serous and/or mucinous characteristics can be seen on histological examination, and serous histology makes up the overwhelming majority of advanced LMP tumors. More than 80% of LMP tumors are Stage I; 15% are stage II and III and less than 5% are stage IV.<sup id=\"cite_ref-Hoffman35_19-47\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Implants of LMP tumors are often non-invasive.<sup id=\"cite_ref-:1_45-6\" class=\"reference\"><a href=\"#cite_note-:1-45\">&#91;45&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Staging\">Staging</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=48\" title=\"Edit section: Staging\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Ovarian cancer is staged using the <a href=\"/wiki/International_Federation_of_Gynecology_and_Obstetrics\" class=\"mw-redirect\" title=\"International Federation of Gynecology and Obstetrics\">FIGO</a> staging system and uses information obtained after surgery, which can include a total <a href=\"/wiki/Hysterectomy\" title=\"Hysterectomy\">abdominal hysterectomy</a> via <a href=\"/wiki/Laparotomy\" title=\"Laparotomy\">midline laparotomy</a>, <a href=\"/wiki/Salpingoophorectomy\" title=\"Salpingoophorectomy\">removal of (usually) both ovaries and Fallopian tubes</a>, <a href=\"/wiki/Omentectomy\" class=\"mw-redirect\" title=\"Omentectomy\">(usually) the omentum</a>, <a href=\"/wiki/Pelvic_washing\" class=\"mw-redirect\" title=\"Pelvic washing\">pelvic (peritoneal) washings</a>, assessment of <a href=\"/wiki/Retroperitoneal_lymph_node_dissection\" title=\"Retroperitoneal lymph node dissection\">retroperitoneal lymph nodes</a> (including the <a href=\"/w/index.php?title=Pelvic_lymph_nodes&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Pelvic lymph nodes (page does not exist)\">pelvic</a> and <a href=\"/wiki/Paraaortic_lymph_node\" class=\"mw-redirect\" title=\"Paraaortic lymph node\">para-aortic lymph nodes</a>), <a href=\"/wiki/Appendectomy\" title=\"Appendectomy\">appendectomy</a> in suspected mucinous tumors, and pelvic/peritoneal biopsies for <a href=\"/wiki/Cytopathology\" title=\"Cytopathology\">cytopathology</a>.<sup id=\"cite_ref-Jayson_18-23\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-Harrisons_16-31\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-:7_21-38\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-SGO_48-0\" class=\"reference\"><a href=\"#cite_note-SGO-48\">&#91;48&#93;</a></sup> Around 30% of ovarian cancers that appear confined to the ovary have metastasized microscopically, which is why even stage-I cancers must be staged completely.<sup id=\"cite_ref-Harrisons_16-32\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> 22% of cancers presumed to be stage I are observed to have lymphatic metastases.<sup id=\"cite_ref-:7_21-39\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> The AJCC stage is the same as the FIGO stage. The AJCC staging system describes the extent of the primary tumor (T), the absence or presence of <a href=\"/wiki/Metastasis\" title=\"Metastasis\">metastasis</a> to nearby <a href=\"/wiki/Lymph_nodes\" class=\"mw-redirect\" title=\"Lymph nodes\">lymph nodes</a> (N), and the absence or presence of distant metastasis (M).<sup id=\"cite_ref-A_49-0\" class=\"reference\"><a href=\"#cite_note-A-49\">&#91;49&#93;</a></sup> The most common stage at diagnosis is stage IIIc, with over 70% of diagnoses.<sup id=\"cite_ref-Harrisons_16-33\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"FIGO\">FIGO</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=49\" title=\"Edit section: FIGO\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:Tumor_deposet.JPG\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/2/21/Tumor_deposet.JPG/290px-Tumor_deposet.JPG\" width=\"290\" height=\"217\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/2/21/Tumor_deposet.JPG/435px-Tumor_deposet.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/21/Tumor_deposet.JPG/580px-Tumor_deposet.JPG 2x\" data-file-width=\"2592\" data-file-height=\"1936\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Tumor_deposet.JPG\" class=\"internal\" title=\"Enlarge\"></a></div>Ovarian adenocarcinoma deposit in the <a href=\"/wiki/Mesentery\" title=\"Mesentery\">mesentery</a> of the small bowel</div></div></div>\n<table class=\"wikitable\">\n<caption>FIGO stages of ovarian cancer<sup id=\"cite_ref-Jayson_18-24\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-SGO_48-1\" class=\"reference\"><a href=\"#cite_note-SGO-48\">&#91;48&#93;</a></sup>\n</caption>\n<tbody><tr>\n<th>Stage\n</th>\n<th>\n</th>\n<th>\n</th>\n<th>\n</th>\n<th>Description\n</th></tr>\n<tr>\n<td>I\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>Cancer is completely limited to the ovary\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IA\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>involves one ovary, capsule intact, no tumor on ovarian surface, negative washings\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IB\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>involves both ovaries; capsule intact; no tumor on ovarian surface; negative washings\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IC\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>tumor involves one or both ovaries\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IC1\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>surgical spill\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IC2\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>capsule has ruptured or tumor on ovarian surface\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IC3\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>positive ascites or washings\n</td></tr>\n<tr>\n<td>II\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>pelvic extension of the tumor (must be confined to the pelvis) or primary peritoneal tumor, involves one or both ovaries\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IIA\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>tumor found on uterus or fallopian tubes\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IIB\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>tumor elsewhere in the pelvis\n</td></tr>\n<tr>\n<td>III\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>cancer found outside the pelvis or in the retroperitoneal lymph nodes, involves one or both ovaries\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IIIA\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>metastasis in retroperitoneal lymph nodes or microscopic extrapelvic metastasis\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>IIIA1\n</td>\n<td>\n</td>\n<td>metastasis in retroperitoneal lymph nodes\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>IIIA1(i)\n</td>\n<td>the metastasis is less than 10&#160;mm in diameter\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>IIIA1(ii)\n</td>\n<td>the metastasis is greater than 10&#160;mm in diameter\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>IIIA2\n</td>\n<td>\n</td>\n<td>microscopic metastasis in the peritoneum, regardless of retroperitoneal lymph node status\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IIIB\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>metastasis in the peritoneum less than or equal to 2&#160;cm in diameter, regardless of retroperitoneal lymph node status; or metastasis to liver or spleen capsule\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IIIC\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>metastasis in the peritoneum greater than 2&#160;cm in diameter, regardless of retroperitoneal lymph node status; or metastasis to liver or spleen capsule\n</td></tr>\n<tr>\n<td>IV\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>distant metastasis (i.e. outside of the peritoneum)\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IVA\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>pleural effusion containing cancer cells\n</td></tr>\n<tr>\n<td>\n</td>\n<td>IVB\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>metastasis to distant organs (including the parenchyma of the spleen or liver), or metastasis to the inguinal and extra-abdominal lymph nodes\n</td></tr></tbody></table>\n<ul class=\"gallery mw-gallery-traditional\">\n\t\t<li class=\"gallerybox\" style=\"width: 155px\"><div style=\"width: 155px\">\n\t\t\t<div class=\"thumb\" style=\"width: 150px;\"><div style=\"margin:25.5px auto;\"><a href=\"/wiki/File:Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/5/56/Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg/120px-Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg.png\" width=\"120\" height=\"99\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/5/56/Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg/180px-Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/56/Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg/240px-Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg.png 2x\" data-file-width=\"375\" data-file-height=\"310\" /></a></div></div>\n\t\t\t<div class=\"gallerytext\">\n<p>Stage 1 ovarian cancer\n</p>\n\t\t\t</div>\n\t\t</div></li>\n\t\t<li class=\"gallerybox\" style=\"width: 155px\"><div style=\"width: 155px\">\n\t\t\t<div class=\"thumb\" style=\"width: 150px;\"><div style=\"margin:28px auto;\"><a href=\"/wiki/File:Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/19/Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg/120px-Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg.png\" width=\"120\" height=\"94\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/19/Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg/180px-Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/19/Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg/240px-Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg.png 2x\" data-file-width=\"375\" data-file-height=\"295\" /></a></div></div>\n\t\t\t<div class=\"gallerytext\">\n<p>Stage 2 ovarian cancer\n</p>\n\t\t\t</div>\n\t\t</div></li>\n\t\t<li class=\"gallerybox\" style=\"width: 155px\"><div style=\"width: 155px\">\n\t\t\t<div class=\"thumb\" style=\"width: 150px;\"><div style=\"margin:15px auto;\"><a href=\"/wiki/File:Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg/119px-Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg.png\" width=\"119\" height=\"120\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg/178px-Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg/237px-Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg.png 2x\" data-file-width=\"375\" data-file-height=\"379\" /></a></div></div>\n\t\t\t<div class=\"gallerytext\">\n<p>Stage 3 ovarian cancer\n</p>\n\t\t\t</div>\n\t\t</div></li>\n\t\t<li class=\"gallerybox\" style=\"width: 155px\"><div style=\"width: 155px\">\n\t\t\t<div class=\"thumb\" style=\"width: 150px;\"><div style=\"margin:15px auto;\"><a href=\"/wiki/File:Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/68/Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg/111px-Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg.png\" width=\"111\" height=\"120\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/68/Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg/167px-Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/68/Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg/222px-Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg.png 2x\" data-file-width=\"375\" data-file-height=\"405\" /></a></div></div>\n\t\t\t<div class=\"gallerytext\">\n<p>Stage 4 ovarian cancer\n</p>\n\t\t\t</div>\n\t\t</div></li>\n</ul>\n<h4><span id=\"AJCC.2FTNM\"></span><span class=\"mw-headline\" id=\"AJCC/TNM\">AJCC/TNM</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=50\" title=\"Edit section: AJCC/TNM\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>The AJCC/TNM staging system indicates where the tumor has developed, spread to lymph nodes, and metastasis.<sup id=\"cite_ref-:7_21-40\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p>\n<table class=\"wikitable\">\n<caption>AJCC/TNM stages of ovarian cancer<sup id=\"cite_ref-:7_21-41\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</caption>\n<tbody><tr>\n<th>Stage\n</th>\n<th>\n</th>\n<th>\n</th>\n<th>Description\n</th></tr>\n<tr>\n<td>T\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>Primary tumor\n</td></tr>\n<tr>\n<td>\n</td>\n<td>Tx\n</td>\n<td>\n</td>\n<td>Cannot be assessed\n</td></tr>\n<tr>\n<td>\n</td>\n<td>T0\n</td>\n<td>\n</td>\n<td>No evidence\n</td></tr>\n<tr>\n<td>\n</td>\n<td>T1\n</td>\n<td>\n</td>\n<td>Tumor limited to ovary/ovaries\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>T1a\n</td>\n<td>One ovary with intact capsule, no surface tumor, and negative ascites/peritoneal washings\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>T1b\n</td>\n<td>Both ovaries with intact capsules, no surface tumor, and negative ascites/peritoneal washings\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>T1c\n</td>\n<td>One or both ovaries with ruptured capsule or capsules, surface tumor, positive ascites/peritoneal washings\n</td></tr>\n<tr>\n<td>\n</td>\n<td>T2\n</td>\n<td>\n</td>\n<td>Tumor is in ovaries and pelvis (extension or implantation)\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>T2a\n</td>\n<td>Expansion to uterus or Fallopian tubes, negative ascites/peritoneal washings\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>T2b\n</td>\n<td>Expansion in other pelvic tissues, negative ascites/peritoneal washings\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>T2c\n</td>\n<td>Expansion to any pelvic tissue, positive ascites/peritoneal washings\n</td></tr>\n<tr>\n<td>\n</td>\n<td>T3\n</td>\n<td>\n</td>\n<td>Tumor is in ovaries and has metastasized outside the pelvis to the peritoneum (including the liver capsule)\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>T3a\n</td>\n<td>Microscopic metastasis\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>T3b\n</td>\n<td>Macroscopic metastasis less than 2&#160;cm diameter\n</td></tr>\n<tr>\n<td>\n</td>\n<td>\n</td>\n<td>T3c\n</td>\n<td>Macroscopic metastasis greater than 2&#160;cm diameter\n</td></tr>\n<tr>\n<td>N\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>Regional lymph node metastasis\n</td></tr>\n<tr>\n<td>\n</td>\n<td>Nx\n</td>\n<td>\n</td>\n<td>Cannot be assessed\n</td></tr>\n<tr>\n<td>\n</td>\n<td>N0\n</td>\n<td>\n</td>\n<td>No metastasis\n</td></tr>\n<tr>\n<td>\n</td>\n<td>N1\n</td>\n<td>\n</td>\n<td>Metastasis present\n</td></tr>\n<tr>\n<td>M\n</td>\n<td>\n</td>\n<td>\n</td>\n<td>Distant metastasis\n</td></tr>\n<tr>\n<td>\n</td>\n<td>M0\n</td>\n<td>\n</td>\n<td>No metastasis\n</td></tr>\n<tr>\n<td>\n</td>\n<td>M1\n</td>\n<td>\n</td>\n<td>Metastasis present (excluding liver capsule, including liver parenchyma and cytologically confirmed pleural effusion)\n</td></tr></tbody></table>\n<p>The AJCC/TNM stages can be correlated with the FIGO stages:<sup id=\"cite_ref-:7_21-42\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p>\n<table class=\"wikitable\">\n<tbody><tr>\n<th>FIGO\n</th>\n<th>T\n</th>\n<th>N\n</th>\n<th>M\n</th></tr>\n<tr>\n<td>I\n</td>\n<td>T1\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IA\n</td>\n<td>T1a\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IB\n</td>\n<td>T1b\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IC\n</td>\n<td>T1c\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>II\n</td>\n<td>T2\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IIA\n</td>\n<td>T2a\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IIB\n</td>\n<td>T2b\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IIC\n</td>\n<td>T2c\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>III\n</td>\n<td>T3\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IIIA\n</td>\n<td>T3a\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IIIB\n</td>\n<td>T3b\n</td>\n<td>N0\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IIIC\n</td>\n<td>T3c\n</td>\n<td>N0/N1\n</td>\n<td>M0\n</td></tr>\n<tr>\n<td>IV\n</td>\n<td>Any\n</td>\n<td>Any\n</td>\n<td>M1\n</td></tr></tbody></table>\n<h4><span class=\"mw-headline\" id=\"Grading\">Grading</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=51\" title=\"Edit section: Grading\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>Grade 1 tumors have well differentiated cells (look very similar to the normal tissue) and are the ones with the best prognosis. Grade 2 tumors are also called moderately well-differentiated and they are made up of cells that resemble the normal tissue. Grade 3 tumors have the worst prognosis and their cells are abnormal, referred to as poorly differentiated.<sup id=\"cite_ref-50\" class=\"reference\"><a href=\"#cite_note-50\">&#91;50&#93;</a></sup>\n</p><p>Metastasis in ovarian cancer is very common in the abdomen, and occurs via exfoliation, where cancer cells burst through the ovarian capsule and are able to move freely throughout the peritoneal cavity. Ovarian cancer metastases usually grow on the surface of organs rather than the inside; they are also common on the omentum and the peritoneal lining. Cancer cells can also travel through the <a href=\"/wiki/Lymphatic_system\" title=\"Lymphatic system\">lymphatic system</a> and metastasize to lymph nodes connected to the ovaries via blood vessels; i.e. the lymph nodes along the <a href=\"/wiki/Suspensory_ligament_of_ovary\" title=\"Suspensory ligament of ovary\">infundibulopelvic ligament</a>, the <a href=\"/wiki/Broad_ligament_of_the_uterus\" title=\"Broad ligament of the uterus\">broad ligament</a>, and the <a href=\"/wiki/Round_ligament_of_uterus\" title=\"Round ligament of uterus\">round ligament</a>. The most commonly affected groups include the <a href=\"/wiki/Paraaortic_lymph_node\" class=\"mw-redirect\" title=\"Paraaortic lymph node\">paraaortic</a>, <a href=\"/w/index.php?title=Hypogastric_lymph_node&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Hypogastric lymph node (page does not exist)\">hypogastric</a>, <a href=\"/wiki/External_iliac_lymph_nodes\" title=\"External iliac lymph nodes\">external iliac</a>, <a href=\"/w/index.php?title=Obturator_lymph_nodes&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Obturator lymph nodes (page does not exist)\">obturator</a>, and <a href=\"/wiki/Inguinal_lymph_node\" class=\"mw-redirect\" title=\"Inguinal lymph node\">inguinal lymph nodes</a>. Usually, ovarian cancer does not metastasize to the liver, lung, brain, or kidneys unless it is recurrent disease; this differentiates ovarian cancer from many other forms of cancer.<sup id=\"cite_ref-Hoffman35_19-48\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Screening\">Screening</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=52\" title=\"Edit section: Screening\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>There is no simple and reliable way to test for ovarian cancer in women who do not have any signs or symptoms. Screening is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of false positive tests may lead to unneeded surgery, which is accompanied by its own risks.<sup id=\"cite_ref-Gros2018_14-1\" class=\"reference\"><a href=\"#cite_note-Gros2018-14\">&#91;14&#93;</a></sup> The <a href=\"/wiki/Pap_test\" title=\"Pap test\">Pap test</a> does not screen for ovarian cancer.<sup id=\"cite_ref-CDCsep2016_17-3\" class=\"reference\"><a href=\"#cite_note-CDCsep2016-17\">&#91;17&#93;</a></sup> \n</p><p>Ovarian cancer is usually only palpable in advanced stages.<sup id=\"cite_ref-Hoffman35_19-49\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>  Screening is not recommended using <a href=\"/wiki/CA-125\" title=\"CA-125\">CA-125</a> measurements, <a href=\"/wiki/HE4\" class=\"mw-redirect\" title=\"HE4\">HE4</a> levels, ultrasound, or adnexal palpation in women who are at average risk. Risk of developing ovarian cancer in those with genetic factors can be reduced. Those with a genetic predisposition may benefit from screening. This high risk group has benefited with earlier detection.<sup id=\"cite_ref-Jayson_18-25\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-Harrisons_16-34\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-Harrisons82_51-0\" class=\"reference\"><a href=\"#cite_note-Harrisons82-51\">&#91;51&#93;</a></sup>\n</p><p>Ovarian cancer has low prevalence, even in the high-risk group of women from the ages of 50 to 60 (about one in 2000), and screening of women with average risk is more likely to give ambiguous results than detect a problem which requires treatment. Because ambiguous results are more likely than detection of a treatable problem, and because the usual response to ambiguous results is invasive interventions, in women of average risk, the potential harms of having screening without an indication outweigh the potential benefits. The purpose of screening is to diagnose ovarian cancer at an early stage, when it is more likely to be treated successfully.<sup id=\"cite_ref-Harrisons_16-35\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-Harrisons82_51-1\" class=\"reference\"><a href=\"#cite_note-Harrisons82-51\">&#91;51&#93;</a></sup>\n</p><p>Screening with <a href=\"/wiki/Transvaginal_ultrasound\" class=\"mw-redirect\" title=\"Transvaginal ultrasound\">transvaginal ultrasound</a>, pelvic examination, and CA-125 levels can be used instead of preventive surgery in women who have BRCA1 or BRCA2 mutations. This strategy has shown some success.<sup id=\"cite_ref-Hoffman35_19-50\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Prevention\">Prevention</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=53\" title=\"Edit section: Prevention\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>People with strong genetic risk for ovarian cancer may consider the surgical removal of their ovaries as a preventive measure. This is often done after completion of childbearing years. This reduces the chances of developing both breast cancer (by around 50%) and ovarian cancer (by about 96%) in people at high risk. Women with <i>BRCA</i> gene mutations usually also have their Fallopian tubes removed at the same time (salpingo-oophorectomy), since they also have an increased risk of <a href=\"/wiki/Fallopian_tube_cancer\" title=\"Fallopian tube cancer\">Fallopian tube cancer</a>. However, these statistics may overestimate the risk reduction because of how they have been studied.<sup id=\"cite_ref-Harrisons_16-36\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-Harrisons82_51-2\" class=\"reference\"><a href=\"#cite_note-Harrisons82-51\">&#91;51&#93;</a></sup>\n</p><p>People with a significant family history for ovarian cancer are often referred to a <a href=\"/wiki/Genetic_counselor\" class=\"mw-redirect\" title=\"Genetic counselor\">genetic counselor</a> to see if  testing for BRCA mutations would be beneficial.<sup id=\"cite_ref-Hoffman35_19-51\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> The use of oral contraceptives, the absence of 'periods' during the menstrual cycle, and tubal ligation reduce the risk.<sup id=\"cite_ref-CibulaWidschwendter2010_52-0\" class=\"reference\"><a href=\"#cite_note-CibulaWidschwendter2010-52\">&#91;52&#93;</a></sup>\nThere may an association of developing ovarian cancer and ovarian stimulation during infertility treatments. Endometriosis has been linked to ovarian cancers. <a href=\"/wiki/Human_papillomavirus_infection\" title=\"Human papillomavirus infection\">Human papillomavirus infection</a>, smoking, and <a href=\"/wiki/Talc\" title=\"Talc\">talc</a> have not been identified as increasing the risk for developing ovarian cancer.<sup id=\"cite_ref-Jayson_18-26\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Management\">Management</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=54\" title=\"Edit section: Management\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Once it is determined that ovarian, fallopian tube, or primary peritoneal cancer is present, treatment is scheduled by a gynecologic oncologist (a physician trained to treat cancers of a woman\u2019s reproductive system). Gynecologic oncologists can perform surgery on and give chemotherapy to women with ovarian cancer. A treatment plan is developed.<sup id=\"cite_ref-CDCfeb2017_53-0\" class=\"reference\"><a href=\"#cite_note-CDCfeb2017-53\">&#91;53&#93;</a></sup>\n</p><p>Treatment usually involves <a href=\"/wiki/Surgery\" title=\"Surgery\">surgery</a> and <a href=\"/wiki/Chemotherapy\" title=\"Chemotherapy\">chemotherapy</a>, and sometimes <a href=\"/wiki/Radiotherapy\" class=\"mw-redirect\" title=\"Radiotherapy\">radiotherapy</a>, regardless of the subtype of ovarian cancer.<sup id=\"cite_ref-:1_45-7\" class=\"reference\"><a href=\"#cite_note-:1-45\">&#91;45&#93;</a></sup><sup id=\"cite_ref-54\" class=\"reference\"><a href=\"#cite_note-54\">&#91;54&#93;</a></sup> Surgical treatment may be sufficient for well-differentiated malignant tumors and confined to the ovary. Addition of chemotherapy may be required for more aggressive tumors confined to the ovary. For patients with advanced disease, a combination of surgical reduction with a combination chemotherapy regimen is standard. Borderline tumors, even following spread outside of the ovary, are managed well with surgery, and chemotherapy is not seen as useful.<sup id=\"cite_ref-:2_55-0\" class=\"reference\"><a href=\"#cite_note-:2-55\">&#91;55&#93;</a></sup> <a href=\"/w/index.php?title=Second-look_surgery&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Second-look surgery (page does not exist)\">Second-look surgery</a> and <a href=\"/wiki/Maintenance_chemotherapy\" class=\"mw-redirect\" title=\"Maintenance chemotherapy\">maintenance chemotherapy</a> have not been shown to provide benefit.<sup id=\"cite_ref-Hoffman35_19-52\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Surgery\">Surgery</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=55\" title=\"Edit section: Surgery\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Surgery\" title=\"Surgery\">Surgery</a> has been the standard of care for decades and may be necessary in obtaining a specimen for <a href=\"/wiki/Medical_diagnosis\" title=\"Medical diagnosis\">diagnosis</a>.  The surgery depends upon the extent of nearby invasion of other tissues by the cancer when it is diagnosed. This extent of the cancer is described by assigning it a stage, the presumed type, and the grade of cancer. The gynecological surgeon may  remove one (unilateral oophorectomy) or both ovaries (bilateral oophorectomy). The Fallopian tubes (salpingectomy), uterus (hysterectomy), and the <a href=\"/wiki/Greater_omentum\" title=\"Greater omentum\">omentum</a> (omentectomy) may also be removed. Typically, all of these organs are removed.<sup id=\"cite_ref-CanadianCS2017_56-0\" class=\"reference\"><a href=\"#cite_note-CanadianCS2017-56\">&#91;56&#93;</a></sup>\n</p><p>For low-grade, unilateral stage-IA cancers, only the involved ovary (which must be unruptured) and Fallopian tube will be removed. This can be done especially in young people who wish to preserve their fertility. However, a risk of microscopic metastases exists and staging must be completed.<sup id=\"cite_ref-Jayson_18-27\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> If any metastases are found, a second surgery to remove the remaining ovary and uterus is needed.<sup id=\"cite_ref-:2_55-1\" class=\"reference\"><a href=\"#cite_note-:2-55\">&#91;55&#93;</a></sup> <a href=\"/wiki/Tranexamic_acid\" title=\"Tranexamic acid\">Tranexamic acid</a> can be administered prior to surgery to reduce the need for blood transfusions due to blood loss during the surgery.<sup id=\"cite_ref-:7_21-43\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>If a tumor in a premenopausal woman is determined to be a low malignant potential tumor during surgery, and it is clearly stage I cancer, only the affected ovary is removed. For postmenopausal women with low malignant potential tumors, hysterectomy with bilateral salpingo-oophorectomy is still the preferred option. During staging, the appendix can be examined or removed. This is particularly important with mucinous tumors.<sup id=\"cite_ref-Hoffman35_19-53\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> In children or adolescents with ovarian cancer, surgeons typically attempt to preserve one ovary to allow for the completion of <a href=\"/wiki/Puberty\" title=\"Puberty\">puberty</a>, but if the cancer has spread, this is not always possible. Dysgerminomas in particular tend to affect both ovaries: 8\u201315% of dysgerminomas are present in both ovaries.<sup id=\"cite_ref-Current_23-3\" class=\"reference\"><a href=\"#cite_note-Current-23\">&#91;23&#93;</a></sup> People with low-grade (well-differentiated) tumors are typically treated only with surgery,<sup id=\"cite_ref-Harrisons_16-37\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> which is often curative.<sup id=\"cite_ref-:1_45-8\" class=\"reference\"><a href=\"#cite_note-:1-45\">&#91;45&#93;</a></sup> In general, germ cell tumors can be treated with unilateral surgery unless the cancer is widespread or fertility is not a factor.<sup id=\"cite_ref-:8_22-26\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>In advanced cancers, where complete removal is not an option, as much tumor as possible is removed in a procedure called <a href=\"/wiki/Debulking\" title=\"Debulking\">debulking</a> surgery. This surgery is not always successful, and is less likely to be successful in women with extensive metastases in the peritoneum, stage- IV disease, cancer in the <a href=\"/wiki/Porta_hepatis\" title=\"Porta hepatis\">transverse fissure of the liver</a>, <a href=\"/wiki/Mesentery\" title=\"Mesentery\">mesentery</a>, or diaphragm, and large areas of ascites. Debulking surgery is usually only done once.<sup id=\"cite_ref-Jayson_18-28\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> More complete debulking is associated with better outcomes: women with no macroscopic evidence of disease after debulking have a median survival of 39 months, as opposed to 17 months with less complete surgery.<sup id=\"cite_ref-Harrisons_16-38\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> By removing metastases, many cells that are resistant to chemotherapy are removed, and any clumps of cells that have died are also removed. This allows chemotherapy to better reach the remaining cancer cells, which are more likely to be fast-growing and therefore chemosensitive.<sup id=\"cite_ref-Hoffman35_19-54\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>Interval debulking surgery is another protocol used, where neoadjuvant chemotherapy is given, debulking surgery is performed, and chemotherapy is finished after debulking.<sup id=\"cite_ref-:2_55-2\" class=\"reference\"><a href=\"#cite_note-:2-55\">&#91;55&#93;</a></sup> Though no definitive studies have been completed, it is shown to be approximately equivalent to primary debulking surgery in terms of survival, and shows slightly lower morbidity.<sup id=\"cite_ref-Hoffman35_19-55\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>There are several different surgical procedures that can be employed to treat ovarian cancer. For stage I and II cancer, laparascopic (keyhole) surgery can be used, but metastases may not be found. For advanced cancer, laparoscopy is not used, since debulking metastases requires access to the entire peritoneal cavity. Depending on the extent of the cancer, procedures may include a bilateral salpingo-oophorectomy, biopsies throughout the peritoneum and abdominal lymphatic system, <a href=\"/wiki/Omentectomy\" class=\"mw-redirect\" title=\"Omentectomy\">omentectomy</a>, <a href=\"/wiki/Splenectomy\" title=\"Splenectomy\">splenectomy</a>, <a href=\"/wiki/Bowel_resection\" title=\"Bowel resection\">bowel resection</a>, <a href=\"/w/index.php?title=Diaphragm_resection&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Diaphragm resection (page does not exist)\">diaphragm stripping or resection</a>, <a href=\"/wiki/Appendectomy\" title=\"Appendectomy\">appendectomy</a>, or even a posterior <a href=\"/wiki/Pelvic_exenteration\" title=\"Pelvic exenteration\">pelvic exenteration</a>.<sup id=\"cite_ref-Hoffman35_19-56\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>To fully stage ovarian cancer, <a href=\"/wiki/Lymphadenectomy\" title=\"Lymphadenectomy\">lymphadenectomy</a> can be included in the surgery, but a significant survival benefit to this practice may not happen.<sup id=\"cite_ref-Jayson_18-29\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> This is particularly important in germ cell tumors because they frequently metastasize to nearby lymph nodes.<sup id=\"cite_ref-Harrisons_16-39\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p><p>If ovarian cancer recurs, secondary surgery is sometimes a treatment option. This depends on how easily the tumor can be removed, how much fluid has accumulated in the abdomen, and overall health.<sup id=\"cite_ref-Jayson_18-30\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> It can be helpful in people who had their first surgery done by a generalist and in epithelial ovarian cancer.<sup id=\"cite_ref-:7_21-44\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Secondary surgery can be effective in dysgerminomas and immature teratomas.<sup id=\"cite_ref-:8_22-27\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>The major side effect of an oophorectomy in younger women is early <a href=\"/wiki/Menopause\" title=\"Menopause\">menopause</a>, which can cause <a href=\"/wiki/Osteoporosis\" title=\"Osteoporosis\">osteoporosis</a>. After surgery, hormone replacement therapy can be considered, especially in younger women. This therapy can consist of a combination of estrogen and progesterone, or estrogen alone. Estrogen alone is safe after hysterectomy; when the uterus is still present, unopposed estrogen dramatically raises the risk of <a href=\"/wiki/Endometrial_cancer\" title=\"Endometrial cancer\">endometrial cancer</a>.<sup id=\"cite_ref-Jayson_18-31\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Estrogen therapy after surgery does not change survival rates.<sup id=\"cite_ref-:7_21-45\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> People having ovarian cancer surgery are typically hospitalized afterwards for 3\u20134 days and spend around a month recovering at home.<sup id=\"cite_ref-57\" class=\"reference\"><a href=\"#cite_note-57\">&#91;57&#93;</a></sup> Surgery outcomes are best at hospitals that do a large number of ovarian cancer surgeries.<sup id=\"cite_ref-Hoffman35_19-57\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>It is unclear if <a href=\"/wiki/Laparoscopy\" title=\"Laparoscopy\">laparoscopy</a> or <a href=\"/wiki/Laparotomy\" title=\"Laparotomy\">laparotomy</a> is better or worse for FIGO stage I ovarian cancer.<sup id=\"cite_ref-58\" class=\"reference\"><a href=\"#cite_note-58\">&#91;58&#93;</a></sup> There is also no apparent difference between total abdominal hysterectomy and supracervical hysterectomy for advanced cancers. Approximately 2.8% of people having a first surgery for advanced ovarian cancer die within two weeks of the surgery (2.8% <a href=\"/wiki/Perioperative_mortality\" title=\"Perioperative mortality\">perioperative mortality</a> rate).<sup id=\"cite_ref-:7_21-46\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> More aggressive surgeries are associated with better outcomes in advanced (stage III or IV) ovarian cancer.<sup id=\"cite_ref-Hoffman35_19-58\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Chemotherapy\">Chemotherapy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=56\" title=\"Edit section: Chemotherapy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Chemotherapy\" title=\"Chemotherapy\">Chemotherapy</a> has been a general <a href=\"/wiki/Standard_of_care\" title=\"Standard of care\">standard of care</a> for ovarian cancer for decades, although with variable protocols. Chemotherapy is used after surgery to treat any residual disease, if appropriate.  In some cases, there may be reason to perform chemotherapy first, followed by surgery. This is called \"neoadjuvant chemotherapy\", and is common when a tumor cannot be completely removed or optimally debulked via surgery. Though it has not been shown to increase survival, it can reduce the risk of complications after surgery. If a unilateral salpingo-oophorectomy or other surgery is performed, additional chemotherapy, called \"adjuvant chemotherapy\", can be given.<sup id=\"cite_ref-Jayson_18-32\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-:7_21-47\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Adjuvant chemotherapy is used in stage 1 cancer typically if the tumor is of a high histologic grade (grade 3) or the highest substage (stage 1c), provided the cancer has been optimally staged during surgery.<sup id=\"cite_ref-:7_21-48\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-:2_55-3\" class=\"reference\"><a href=\"#cite_note-:2-55\">&#91;55&#93;</a></sup> <a href=\"/wiki/Bevacizumab\" title=\"Bevacizumab\">Bevacizumab</a> may be used as an adjuvant chemotherapy if the tumor is not completely removed during surgery or if the cancer is stage IV; it can extend progression-free survival but has not been shown to extend overall survival.<sup id=\"cite_ref-:7_21-49\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Chemotherapy is curative in approximately 20% of advanced ovarian cancers;<sup id=\"cite_ref-Hoffman35_19-59\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> it is more often curative with malignant germ cell tumors than epithelial tumors.<sup id=\"cite_ref-:8_22-28\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>Chemotherapy in ovarian cancer typically consists of <a href=\"/wiki/Platins\" class=\"mw-redirect\" title=\"Platins\">platins</a>, a group of <a href=\"/wiki/Platinum\" title=\"Platinum\">platinum</a>-based drugs, combined with non-platins. Common therapies can include <a href=\"/wiki/Paclitaxel\" title=\"Paclitaxel\">paclitaxel</a>, <a href=\"/wiki/Cisplatin\" title=\"Cisplatin\">cisplatin</a>, <a href=\"/wiki/Topotecan\" title=\"Topotecan\">topotecan</a>, doxorubicin, <a href=\"/wiki/Epirubicin\" title=\"Epirubicin\">epirubicin</a>, and <a href=\"/wiki/Gemcitabine\" title=\"Gemcitabine\">gemcitabine</a>. <a href=\"/wiki/Carboplatin\" title=\"Carboplatin\">Carboplatin</a> is typically given in combination with either <a href=\"/wiki/Paclitaxel\" title=\"Paclitaxel\">paclitaxel</a> or <a href=\"/wiki/Docetaxel\" title=\"Docetaxel\">docetaxel</a>; the typical combination is carboplatin with paclitaxel.<sup id=\"cite_ref-Jayson_18-33\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-:7_21-50\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Carboplatin is superior to cisplatin in that it is less toxic and has fewer side effects, generally allowing for an improved quality of life in comparison, though both are similarly effective.<sup id=\"cite_ref-:7_21-51\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Three-drug regimens have not been found to be more effective,<sup id=\"cite_ref-Jayson_18-34\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> and platins alone or nonplatins alone are less effective than platins and nonplatins in combination.<sup id=\"cite_ref-:7_21-52\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Chemotherapy can be given <a href=\"/wiki/Chemotherapy#Delivery\" title=\"Chemotherapy\">intravenously</a> or <a href=\"/wiki/Intraperitoneal_chemotherapy\" class=\"mw-redirect\" title=\"Intraperitoneal chemotherapy\">in the peritoneal cavity</a>.<sup id=\"cite_ref-Harrisons_16-40\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Though intraperitoneal chemotherapy is associated with longer progression-free survival and overall survival, it also causes more adverse side effects than intravenous chemotherapy.<sup id=\"cite_ref-:7_21-53\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> It is mainly used when the cancer has been optimally debulked. Intraperitoneal chemotherapy can be highly effective because ovarian cancer mainly spreads inside the peritoneal cavity, and higher doses of the drugs can reach the tumors this way.<sup id=\"cite_ref-Hoffman35_19-60\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>Chemotherapy can cause <a href=\"/wiki/Anemia\" title=\"Anemia\">anemia</a>; intravenous iron has been found to be more effective than oral <a href=\"/wiki/Iron_supplement\" title=\"Iron supplement\">iron supplements</a> in reducing the need for <a href=\"/wiki/Blood_transfusion\" title=\"Blood transfusion\">blood transfusions</a>.<sup id=\"cite_ref-:7_21-54\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Typical cycles of treatment involve one treatment every 3 weeks, repeated for 6 weeks or more.<sup id=\"cite_ref-:3_59-0\" class=\"reference\"><a href=\"#cite_note-:3-59\">&#91;59&#93;</a></sup> Fewer than 6 weeks (cycles) of treatment is less effective than 6 weeks or more.<sup id=\"cite_ref-:7_21-55\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Germ-cell malignancies are treated differently than other ovarian cancers&#160;\u2014 a regimen of <a href=\"/wiki/Bleomycin\" title=\"Bleomycin\">bleomycin</a>, <a href=\"/wiki/Etoposide\" title=\"Etoposide\">etoposide</a>, and cisplatin (BEP) is used with 5 days of chemotherapy administered every 3 weeks for 3 to 4 cycles.<sup id=\"cite_ref-Harrisons_16-41\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-:8_22-29\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup> Chemotherapy for germ cell tumors has not been shown to cause <a href=\"/wiki/Amenorrhoea\" class=\"mw-redirect\" title=\"Amenorrhoea\">amenorrhea</a>, infertility, <a href=\"/wiki/Congenital_disorder\" class=\"mw-redirect\" title=\"Congenital disorder\">birth defects</a>, or <a href=\"/wiki/Miscarriage\" title=\"Miscarriage\">miscarriage</a>.<sup id=\"cite_ref-:8_22-30\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup> <a href=\"/wiki/Maintenance_chemotherapy\" class=\"mw-redirect\" title=\"Maintenance chemotherapy\">Maintenance chemotherapy</a> has not been shown to be effective.<sup id=\"cite_ref-:7_21-56\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>In people with <i>BRCA</i> mutations, platinum chemotherapy is more effective.<sup id=\"cite_ref-Jayson_18-35\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Germ-cell tumors and malignant sex-cord/stromal tumors are treated with chemotherapy, though dysgerminomas and sex-cord tumors are not typically very responsive.<sup id=\"cite_ref-Harrisons_16-42\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-Current_23-4\" class=\"reference\"><a href=\"#cite_note-Current-23\">&#91;23&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Platinum-sensitive_or_platinum-resistant\">Platinum-sensitive or platinum-resistant</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=57\" title=\"Edit section: Platinum-sensitive or platinum-resistant\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>If ovarian cancer recurs, it is considered partially platinum-sensitive or platinum-resistant, based on the time since the last recurrence treated with platins: partially platinum-sensitive cancers recurred 6\u201312 months after last treatment, and platinum-resistant cancers have an interval of less than 6 months. Second-line chemotherapy can be given after the cancer becomes symptomatic, because no difference in survival is seen between treating asymptomatic (elevated CA-125) and symptomatic recurrences.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Identifying_reliable_sources_(medicine)\" title=\"Wikipedia:Identifying reliable sources (medicine)\"><span title=\"Material near this tag needs references to reliable medical sources. (November 2017)\">medical citation needed</span></a></i>&#93;</sup>\n</p><p>For platinum-sensitive tumors, platins are the drugs of choice for second-line chemotherapy, in combination with other cytotoxic agents. Regimens include carboplatin combined with <a href=\"/wiki/Doxorubicin#Liposomal_formulations\" title=\"Doxorubicin\">pegylated liposomal doxorubicin</a>, <a href=\"/wiki/Gemcitabine\" title=\"Gemcitabine\">gemcitabine</a>, or <a href=\"/wiki/Paclitaxel\" title=\"Paclitaxel\">paclitaxel</a>.<sup id=\"cite_ref-Harrisons_16-43\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Carboplatin-doublet therapy can be combined with paclitaxel for increased efficacy in some cases. Another potential adjuvant therapy for platinum-sensitive recurrences is <a href=\"/wiki/Olaparib\" title=\"Olaparib\">olaparib</a>, which may improve <a href=\"/wiki/Progression-free_survival\" title=\"Progression-free survival\">progression-free survival</a> but has not been shown to improve <a href=\"/wiki/Overall_survival\" class=\"mw-redirect\" title=\"Overall survival\">overall survival</a>.<sup id=\"cite_ref-:7_21-57\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> (<a href=\"/wiki/Olaparib\" title=\"Olaparib\">Olaparib</a>, a <a href=\"/wiki/PARP_inhibitor\" title=\"PARP inhibitor\">PARP inhibitor</a>, was approved by the <a href=\"/wiki/US_FDA\" class=\"mw-redirect\" title=\"US FDA\">US FDA</a> for use in BRCA-associated ovarian cancer that had previously been treated with chemotherapy.<sup id=\"cite_ref-60\" class=\"reference\"><a href=\"#cite_note-60\">&#91;60&#93;</a></sup>) For recurrent germ cell tumors, an additional 4 cycles of BEP chemotherapy is the first-line treatment for those tho have been treated with surgery or platins.\n</p><p>If the tumor is determined to be platinum-resistant, <a href=\"/wiki/Vincristine\" title=\"Vincristine\">vincristine</a>, <a href=\"/wiki/Dactinomycin\" title=\"Dactinomycin\">dactinomycin</a>, and <a href=\"/wiki/Cyclophosphamide\" title=\"Cyclophosphamide\">cyclophosphamide</a> (VAC) or some combination of paclitaxel, gemcitabine, and <a href=\"/wiki/Oxaliplatin\" title=\"Oxaliplatin\">oxaliplatin</a> may be used as a second-line therapy.<sup id=\"cite_ref-:8_22-31\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>For platinum-resistant tumors, there are no high-efficacy chemotherapy options. Single-drug regimens (doxorubicin or <a href=\"/wiki/Topotecan\" title=\"Topotecan\">topotecan</a>) do not have high response rates,<sup id=\"cite_ref-Jayson_18-36\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> but single-drug regimens of topotecan, pegylated liposomal doxorubicin, or gemcitabine are used in some cases.<sup id=\"cite_ref-Harrisons_16-44\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-:7_21-58\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Topotecan cannot be used in people with an intestinal blockage. Paclitaxel used alone is another possible regimen, or it may be combined with liposomal doxorubicin, gemcitabine, cisplatin, topotecan, <a href=\"/wiki/Etoposide\" title=\"Etoposide\">etoposide</a>, or <a href=\"/wiki/Cyclophosphamide\" title=\"Cyclophosphamide\">cyclophosphamide</a>.<sup id=\"cite_ref-:3_59-1\" class=\"reference\"><a href=\"#cite_note-:3-59\">&#91;59&#93;</a></sup> ( See also Palliative care below.)\n</p>\n<h3><span class=\"mw-headline\" id=\"Radiation_therapy\">Radiation therapy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=58\" title=\"Edit section: Radiation therapy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Dysgerminomas are most effectively treated with radiation,<sup id=\"cite_ref-Current_23-5\" class=\"reference\"><a href=\"#cite_note-Current-23\">&#91;23&#93;</a></sup> though this can cause infertility and is being phased out in favor of chemotherapy.<sup id=\"cite_ref-Harrisons_16-45\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Radiation therapy does not improve survival in people with well-differentiated tumors.<sup id=\"cite_ref-Harrisons_16-46\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p><p>In stage 1c and 2 cancers, radiation therapy is used after surgery if there is the possibility of residual disease in the pelvis but the abdomen is cancer-free. Radiotherapy can also be used in palliative care of advanced cancers. A typical course of radiotherapy for ovarian cancer is 5 days a week for 3\u20134 weeks. Common side effects of radiotherapy include diarrhea, constipation, and frequent urination.<sup id=\"cite_ref-:4_61-0\" class=\"reference\"><a href=\"#cite_note-:4-61\">&#91;61&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Hormonal_therapy\">Hormonal therapy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=59\" title=\"Edit section: Hormonal therapy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Despite the fact that 60% of ovarian tumors have <a href=\"/wiki/Estrogen_receptor\" title=\"Estrogen receptor\">estrogen receptors</a>, ovarian cancer is only rarely responsive to hormonal treatments. Estrogen alone does not have an effect on the cancer, and <a href=\"/wiki/Tamoxifen\" title=\"Tamoxifen\">tamoxifen</a> and <a href=\"/wiki/Letrozole\" title=\"Letrozole\">letrozole</a> are rarely effective.<sup id=\"cite_ref-Jayson_18-37\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> \"Some women with borderline malignancy ovarian cancer and stromal ovarian cancer may receive hormonal therapy.\"<sup id=\"cite_ref-CanadianCS2017_56-1\" class=\"reference\"><a href=\"#cite_note-CanadianCS2017-56\">&#91;56&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Immunotherapy\">Immunotherapy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=60\" title=\"Edit section: Immunotherapy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Immunotherapy is a topic of current research in ovarian cancer. In some cases, the antibody drug <a href=\"/wiki/Bevacizumab\" title=\"Bevacizumab\">bevacizumab</a>, though still a topic of active research, is used to treat advanced cancer along with chemotherapy.<sup id=\"cite_ref-:2_55-4\" class=\"reference\"><a href=\"#cite_note-:2-55\">&#91;55&#93;</a></sup> It has been approved for this use in the European Union.<sup id=\"cite_ref-:6_62-0\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Follow-up\">Follow-up</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=61\" title=\"Edit section: Follow-up\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Specific follow-up depends on, for example, the type and stage of ovarian cancer, the treatment, and the presence of any symptoms. Usually, a check-up appointment is made about every 2 to 3 months initially, followed by twice per year for up to 5 years.<sup id=\"cite_ref-63\" class=\"reference\"><a href=\"#cite_note-63\">&#91;63&#93;</a></sup> For epithelial ovarian cancers, the most common test upon follow-up is CA-125 level. However, treatment based only on elevated CA-125 levels and not any symptoms can increase side effects without any prolongation of life, so the implication of the outcome of a CA-125 test can be discussed before taking it.<sup id=\"cite_ref-ACSfollowup_64-0\" class=\"reference\"><a href=\"#cite_note-ACSfollowup-64\">&#91;64&#93;</a></sup> The recommendation as of 2014 is  recurrent cancer may be present if the CA-125 level is twice normal.<sup id=\"cite_ref-Jayson_18-38\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Treating a recurrence detected by CA-125 does not improve survival.<sup id=\"cite_ref-:7_21-59\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>For women with <a href=\"/w/index.php?title=Germ-cell_tumor&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Germ-cell tumor (page does not exist)\">germ-cell tumors</a>, follow-up tests generally include <a href=\"/wiki/Alpha-fetoprotein\" title=\"Alpha-fetoprotein\">alpha-fetoprotein</a> (AFP) and/or <a href=\"/wiki/Human_chorionic_gonadotropin\" title=\"Human chorionic gonadotropin\">human chorionic gonadotropin</a>. For women with <a href=\"/wiki/Stromal_cancer\" class=\"mw-redirect\" title=\"Stromal cancer\">stromal cancers</a>, tests for hormones like estrogen, testosterone, and <a href=\"/wiki/Inhibin\" class=\"mw-redirect\" title=\"Inhibin\">inhibin</a> are sometimes helpful.<sup id=\"cite_ref-ACSfollowup_64-1\" class=\"reference\"><a href=\"#cite_note-ACSfollowup-64\">&#91;64&#93;</a></sup> Inhibin can also be useful for monitoring the progress of sex-cord tumors, along with <a href=\"/wiki/Mullerian_inhibiting_substance\" class=\"mw-redirect\" title=\"Mullerian inhibiting substance\">mullerian inhibiting substance</a>. AFP can also be used to monitor Sertoli-Leydig tumors.<sup id=\"cite_ref-Harrisons_16-47\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> In dysgerminomas, <a href=\"/wiki/Lactate_dehydrogenase\" title=\"Lactate dehydrogenase\">lactate dehydrogenase</a> and its two <a href=\"/wiki/Isozyme\" title=\"Isozyme\">isozymes</a> (<a href=\"/w/index.php?title=LDH-1&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"LDH-1 (page does not exist)\">LDH-1</a> and <a href=\"/w/index.php?title=LDH-2&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"LDH-2 (page does not exist)\">LDH-2</a>) are used to test for recurrence.<sup id=\"cite_ref-:8_22-32\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>Women with ovarian cancer may not need routine surveillance imaging to monitor the cancer unless new symptoms appear or <a href=\"/wiki/Tumor_markers\" class=\"mw-redirect\" title=\"Tumor markers\">tumor markers</a> begin rising.<sup id=\"cite_ref-SGOfive_65-0\" class=\"reference\"><a href=\"#cite_note-SGOfive-65\">&#91;65&#93;</a></sup> Imaging without these indications is discouraged because it is unlikely to detect a recurrence, improve survival, and because it has its own costs and side effects.<sup id=\"cite_ref-SGOfive_65-1\" class=\"reference\"><a href=\"#cite_note-SGOfive-65\">&#91;65&#93;</a></sup> However, CT imaging can be used if desired, though this is not common.<sup id=\"cite_ref-Jayson_18-39\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> If a tumor is easily imaged, imaging may be used to monitor the progress of treatment.<sup id=\"cite_ref-66\" class=\"reference\"><a href=\"#cite_note-66\">&#91;66&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Palliative_care\">Palliative care</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=62\" title=\"Edit section: Palliative care\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Palliative_care\" title=\"Palliative care\">Palliative care</a> focuses on relieving symptoms and increasing or maintaining quality of life. This type of treatment's purpose is not to cure the cancer but to make the woman more comfortable while living with cancer that can not be cured. It has been recommended as part of the treatment plan for any person with advanced ovarian cancer or patients with significant symptoms.<sup id=\"cite_ref-67\" class=\"reference\"><a href=\"#cite_note-67\">&#91;67&#93;</a></sup> In platinum-refractory and platinum-resistant cases, other palliative chemotherapy is the main treatment.<sup id=\"cite_ref-Hoffman35_19-61\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-CanadianCS2017_56-2\" class=\"reference\"><a href=\"#cite_note-CanadianCS2017-56\">&#91;56&#93;</a></sup>\n</p><p>Palliative care can entail treatment of symptoms and complications of the cancer, including pain, nausea, constipation, ascites, <a href=\"/wiki/Bowel_obstruction\" title=\"Bowel obstruction\">bowel obstruction</a>, <a href=\"/wiki/Edema\" title=\"Edema\">edema</a>, <a href=\"/wiki/Pleural_effusion\" title=\"Pleural effusion\">pleural effusion</a>, and <a href=\"/wiki/Mucositis\" title=\"Mucositis\">mucositis</a>.  Especially if the cancer advances and becomes incurable, treatment of symptoms becomes one of the main goals of therapy.  Palliative care can also entail helping with decision-making such as if or when <a href=\"/wiki/Hospice_care\" class=\"mw-redirect\" title=\"Hospice care\">hospice care</a> is appropriate, and the preferred place for the patient at end of life care.<sup id=\"cite_ref-:7_21-60\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>Bowel obstruction can be treated with <a href=\"/wiki/Palliative_surgery\" class=\"mw-redirect\" title=\"Palliative surgery\">palliative surgery</a> (<a href=\"/wiki/Colostomy\" title=\"Colostomy\">colostomy</a>, <a href=\"/wiki/Ileostomy\" title=\"Ileostomy\">ileostomy</a>, or internal bypass) or medicine, but surgery has been shown to increase survival time.<sup id=\"cite_ref-Jayson_18-40\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-:7_21-61\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Palliative surgery may result in <a href=\"/wiki/Short_bowel_syndrome\" title=\"Short bowel syndrome\">short bowel syndrome</a>, <a href=\"/wiki/Enterocutaneous_fistula\" title=\"Enterocutaneous fistula\">enterocutaneous fistula</a>, or re-obstruction; or may not be possible due to the extent of obstruction.<sup id=\"cite_ref-Hoffman35_19-62\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Other treatments of complications can include <a href=\"/wiki/Total_parenteral_nutrition\" class=\"mw-redirect\" title=\"Total parenteral nutrition\">total parenteral nutrition</a>, a <a href=\"/w/index.php?title=Low-residue_diet&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Low-residue diet (page does not exist)\">low-residue diet</a>, palliative <a href=\"/wiki/Gastrostomy\" title=\"Gastrostomy\">gastrostomy</a>, and adequate pain control.<sup id=\"cite_ref-Jayson_18-41\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Bowel obstruction can also be treated with <a href=\"/wiki/Octreotide\" title=\"Octreotide\">octreotide</a> when palliative surgery is not an option. Cancer can also block the <a href=\"/wiki/Ureters\" class=\"mw-redirect\" title=\"Ureters\">ureters</a>, which can be relieved by a <a href=\"/wiki/Nephrostomy\" title=\"Nephrostomy\">nephrostomy</a> or a <a href=\"/wiki/Ureteric_stent\" title=\"Ureteric stent\">ureteric stent</a>. Ascites can be relieved by repeated <a href=\"/wiki/Paracentesis\" title=\"Paracentesis\">paracentesis</a> or placement of a <a href=\"/wiki/Drain_(surgery)\" title=\"Drain (surgery)\">drain</a> to increase comfort.<sup id=\"cite_ref-:5_68-0\" class=\"reference\"><a href=\"#cite_note-:5-68\">&#91;68&#93;</a></sup> Pleural effusions can  be treated in a similar manner, with repeated <a href=\"/wiki/Thoracentesis\" title=\"Thoracentesis\">thoracentesis</a>, <a href=\"/wiki/Pleurodesis\" title=\"Pleurodesis\">pleurodesis</a>, or placement of a drain.<sup id=\"cite_ref-Hoffman35_19-63\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>Radiation therapy can be used as part of the palliative care of advanced ovarian cancer, since it can help to shrink tumors that are causing symptoms.<sup id=\"cite_ref-CanadianCS2017_56-3\" class=\"reference\"><a href=\"#cite_note-CanadianCS2017-56\">&#91;56&#93;</a></sup> Palliative radiotherapy typically lasts for only a few treatments, a much shorter course of therapy than non-palliative radiotherapy.<sup id=\"cite_ref-:4_61-1\" class=\"reference\"><a href=\"#cite_note-:4-61\">&#91;61&#93;</a></sup> It is also used for palliation of chemotherapy-resistant germ cell tumors.<sup id=\"cite_ref-:8_22-33\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Psychosocial_care\">Psychosocial care</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=63\" title=\"Edit section: Psychosocial care\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Ovarian cancer has a significant effect on <a href=\"/wiki/Quality_of_life\" title=\"Quality of life\">quality of life</a>, psychological health and well-being. Interventions are available to help with the needs and social support. Many ovarian cancer survivors report a good quality of life and <a href=\"/wiki/Optimism\" title=\"Optimism\">optimism</a>. Others reported a \"spiritual change\" that helped them find <a href=\"/wiki/Meaning_of_life\" title=\"Meaning of life\">meaning</a> during their experience. Others have described their loss of faith after their diagnosis with ovarian cancer. Those who have gone through treatment sometimes experience <a href=\"/wiki/Social_isolation\" title=\"Social isolation\">social isolation</a> but benefit from having relationships with other survivors. <a href=\"/wiki/Frustration\" title=\"Frustration\">Frustration</a> and <a href=\"/wiki/Guilt_(emotion)\" title=\"Guilt (emotion)\">guilt</a> have been described by some who have expressed their inability to care for their family.<sup id=\"cite_ref-:9_69-0\" class=\"reference\"><a href=\"#cite_note-:9-69\">&#91;69&#93;</a></sup>\n</p><p><a href=\"/wiki/Self-esteem\" title=\"Self-esteem\">Self-esteem</a> and <a href=\"/wiki/Body_image\" title=\"Body image\">body image</a> changes can occur due to <a href=\"/wiki/Hair_loss\" title=\"Hair loss\">hair loss</a>, removal of ovaries and other reproductive structures, and <a href=\"/wiki/Scar\" title=\"Scar\">scars</a>. There is some improvement after hair grows in. Sexual issues can develop. The removal of ovaries results in surgically-induced <a href=\"/wiki/Menopause\" title=\"Menopause\">menopause</a> that can result in <a href=\"/wiki/Dyspareunia\" title=\"Dyspareunia\">painful intercourse</a>, vaginal dryness, loss of <a href=\"/wiki/Hypoactive_sexual_desire_disorder\" title=\"Hypoactive sexual desire disorder\">sexual desire</a> and being tired. Though prognosis is better for younger survivors, the impact on sexuality can still be substantial.<sup id=\"cite_ref-:9_69-1\" class=\"reference\"><a href=\"#cite_note-:9-69\">&#91;69&#93;</a></sup>\n</p><p><a href=\"/wiki/Anxiety\" title=\"Anxiety\">Anxiety</a>, <a href=\"/wiki/Depression_(mood)\" title=\"Depression (mood)\">depression</a> and <a href=\"/wiki/Distress_in_cancer_caregiving\" title=\"Distress in cancer caregiving\">distress</a> is present in those surviving ovarian cancer at higher rates than in the general population.<sup id=\"cite_ref-:9_69-2\" class=\"reference\"><a href=\"#cite_note-:9-69\">&#91;69&#93;</a></sup><sup id=\"cite_ref-70\" class=\"reference\"><a href=\"#cite_note-70\">&#91;70&#93;</a></sup> The same psychosocial problems can develop in family members. Emotional effects can include a <a href=\"/wiki/Death_anxiety_(psychology)\" title=\"Death anxiety (psychology)\">fear of death</a>, <a href=\"/wiki/Sadness\" title=\"Sadness\">sadness</a>, memory problems and difficulty in concentrating. When optimism was adopted by those at the beginning of their treatment, they were less likely to develop distress. Those who have fear of the cancer recurring may have difficulty in expressing <a href=\"/wiki/Joy\" title=\"Joy\">joy</a> even when disease-free. The more treatments that a woman undergoes, the more likely the loss of <a href=\"/wiki/Hope\" title=\"Hope\">hope</a> is expressed. Women often can cope and reduce negative psychosocial effects by a number of strategies. Activities such as traveling, spending additional time with family and friends, ignoring <a href=\"/wiki/Statistics\" title=\"Statistics\">statistics</a>, journaling and increasing involvement in <a href=\"/wiki/Spirituality\" title=\"Spirituality\">spirituall</a>y-based events are adaptive.<sup id=\"cite_ref-:9_69-3\" class=\"reference\"><a href=\"#cite_note-:9-69\">&#91;69&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Prognosis\">Prognosis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=64\" title=\"Edit section: Prognosis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:Relative_survival_of_ovarian_cancer_by_stage.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/c/c8/Relative_survival_of_ovarian_cancer_by_stage.png/290px-Relative_survival_of_ovarian_cancer_by_stage.png\" width=\"290\" height=\"208\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/c/c8/Relative_survival_of_ovarian_cancer_by_stage.png/435px-Relative_survival_of_ovarian_cancer_by_stage.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/c/c8/Relative_survival_of_ovarian_cancer_by_stage.png/580px-Relative_survival_of_ovarian_cancer_by_stage.png 2x\" data-file-width=\"657\" data-file-height=\"471\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Relative_survival_of_ovarian_cancer_by_stage.png\" class=\"internal\" title=\"Enlarge\"></a></div>Relative <a href=\"/wiki/Five-year_survival\" class=\"mw-redirect\" title=\"Five-year survival\">five-year survival</a> of invasive epithelial ovarian cancer by stage<sup id=\"cite_ref-ACS_71-0\" class=\"reference\"><a href=\"#cite_note-ACS-71\">&#91;71&#93;</a></sup></div></div></div>\n<p>Ovarian cancer usually has a relatively poor <a href=\"/wiki/Prognosis\" title=\"Prognosis\">prognosis</a>. It is disproportionately deadly because it lacks any clear early detection or screening test, meaning most cases are not diagnosed until they have reached advanced stages.<sup id=\"cite_ref-SGOfive_65-2\" class=\"reference\"><a href=\"#cite_note-SGOfive-65\">&#91;65&#93;</a></sup><sup id=\"cite_ref-Jayson_18-42\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup>\n</p><p>Ovarian cancer metastasizes early in its development, often before it has been diagnosed. High-grade tumors metastasize more readily than low-grade tumors. Typically, tumor cells begin to metastasize by growing in the peritoneal cavity.<sup id=\"cite_ref-Harrisons_16-48\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> More than 60% of women presenting with ovarian cancer have stage-III or stage-IV cancer, when it has already spread beyond the ovaries. Ovarian cancers shed cells into the naturally occurring fluid within the abdominal cavity. These cells can then implant on other abdominal (peritoneal) structures, including the uterus, <a href=\"/wiki/Urinary_bladder\" title=\"Urinary bladder\">urinary bladder</a>, <a href=\"/wiki/Bowel\" class=\"mw-redirect\" title=\"Bowel\">bowel</a>,  <a href=\"/wiki/Mesentery\" title=\"Mesentery\">lining of the bowel wall</a>, and <a href=\"/wiki/Greater_omentum\" title=\"Greater omentum\">omentum</a>, forming new tumor growths before cancer is even suspected.\n</p><p>The five-year survival rate for all stages of ovarian cancer is 46%; the one-year survival rate is 72% and the ten-year survival rate is 35%.<sup id=\"cite_ref-72\" class=\"reference\"><a href=\"#cite_note-72\">&#91;72&#93;</a></sup> For cases where a diagnosis is made early in the disease, when the cancer is still confined to the primary site, the five-year survival rate is 92.7%.<sup id=\"cite_ref-SEER_73-0\" class=\"reference\"><a href=\"#cite_note-SEER-73\">&#91;73&#93;</a></sup> About 70% of women with advanced disease respond to initial treatment, most of whom attain complete remission, but half of these women experience a recurrence 1\u20134 years after treatment.<sup id=\"cite_ref-Harrisons_16-49\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> <a href=\"/wiki/Brain_metastasis\" title=\"Brain metastasis\">Brain metastasis</a> is more common in stage III/IV cancer but can still occur in cancers staged at I/II. People with brain metastases survive a median of 8.2 months, though surgery, chemotherapy, and <a href=\"/wiki/Whole_brain_radiotherapy\" title=\"Whole brain radiotherapy\">whole brain radiation therapy</a> can improve survival.<sup id=\"cite_ref-:7_21-62\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>Ovarian cancer survival varies significantly with subtype. Dysgerminomas have a very favorable prognosis. In early stages, they have a five-year survival rate of 96.9%.<sup id=\"cite_ref-Current_23-6\" class=\"reference\"><a href=\"#cite_note-Current-23\">&#91;23&#93;</a></sup> Around two-thirds of dysgerminomas are diagnosed at stage I.<sup id=\"cite_ref-:8_22-34\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup> Stage-III dysgerminomas have a five-year survival of 61%; when treated with BEP chemotherapy after incomplete surgical removal, dysgerminomas have a 95% two-year survival rate. Sex-cord-stromal malignancies also have a favorable prognosis; because they are slow-growing, even those with metastatic disease can survive a decade or more.<sup id=\"cite_ref-Harrisons_16-50\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Low malignant potential tumors usually only have a bad prognosis when there are invasive tumor implants found in the peritoneal cavity.<sup id=\"cite_ref-Hoffman35_19-64\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>Complications of ovarian cancer can include spread of the cancer to other organs, progressive function loss of various organs, ascites, and intestinal obstructions, which can be fatal. Intestinal obstructions in multiple sites are the most common proximate cause of death.<sup id=\"cite_ref-Jayson_18-43\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Intestinal obstruction in ovarian cancer can either be a true obstruction, where tumor blocks the <a href=\"/wiki/Intestinal_lumen\" class=\"mw-redirect\" title=\"Intestinal lumen\">intestinal lumen</a>, or a pseudo-obstruction, when tumor prevents normal <a href=\"/wiki/Peristalsis\" title=\"Peristalsis\">peristalsis</a>.<sup id=\"cite_ref-74\" class=\"reference\"><a href=\"#cite_note-74\">&#91;74&#93;</a></sup> Continuous accumulation of ascites can be treated by placing a drain that can be self-drained.<sup id=\"cite_ref-Jayson_18-44\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Prognostic_factors\">Prognostic factors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=65\" title=\"Edit section: Prognostic factors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>There are a number of <a href=\"/w/index.php?title=Prognostic_factor&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Prognostic factor (page does not exist)\">prognostic factors</a> in ovarian cancer. Positive prognostic factors - those indicating better chances of survival - include no residual disease after surgery (stage III/IV), complete macroscopic resection (stage IV), BRCA2 mutations, young age (under 45 years), nonserous type, low histologic grade, early stage, co-occurrence with endometrial cancer, and low CA-125 levels. There is conflicting evidence for BRCA1 as a prognostic factor. Conversely, negative prognostic factors - those that indicate a worse chance of survival - include rupture of the ovarian capsule during surgery, older age (over 45 years), mucinous type, stage IV, high histologic grade, clear cell type, upper abdominal involvement, high CA-125 levels, the presence of tumor cells in the blood, and elevated <a href=\"/wiki/Cyclooxygenase_2\" class=\"mw-redirect\" title=\"Cyclooxygenase 2\">cyclooxygenase-2</a>.<sup id=\"cite_ref-:7_21-63\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p><p>Expression of various mRNAs can also be prognostic for ovarian cancer. High levels of <a href=\"/wiki/Drosha\" title=\"Drosha\">Drosha</a> and <a href=\"/wiki/Dicer\" title=\"Dicer\">Dicer</a> are associated with improved survival, whereas high levels of <a href=\"/w/index.php?title=Let-7b&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Let-7b (page does not exist)\">let-7b</a>, <a href=\"/wiki/HIF1A\" title=\"HIF1A\">HIF1A</a>, <a href=\"/wiki/EPH_receptor_A1\" title=\"EPH receptor A1\">EphA1</a>, and <a href=\"/wiki/Poly_ADP_ribose_polymerase\" class=\"mw-redirect\" title=\"Poly ADP ribose polymerase\">poly(ADP-ribose) polymerase</a> are associated with worse survival. Cancers that are positive for <a href=\"/wiki/WT1\" title=\"WT1\">WT1</a> carry a worse prognosis; estrogen-receptor positive cancers have a better prognosis.<sup id=\"cite_ref-:7_21-64\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Survival_rates\">Survival rates</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=66\" title=\"Edit section: Survival rates\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Overall five-year survival rates for all types of ovarian cancer are presented below by stage and histologic grade:<sup id=\"cite_ref-Harrisons_16-51\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p>\n<table class=\"wikitable\" align=\"left\" style=\"text-align: center; margin-right: 10px;\">\n<tbody><tr>\n<th>Stage\n</th>\n<th>Survival\n</th></tr>\n<tr>\n<td>I\n</td>\n<td>90\u201395%\n</td></tr>\n<tr>\n<td>II\n</td>\n<td>70\u201380%\n</td></tr>\n<tr>\n<td>III\n</td>\n<td>20\u201350%\n</td></tr>\n<tr>\n<td>IV\n</td>\n<td>1\u20135%\n</td></tr></tbody></table>\n<table class=\"wikitable\" align=\"left\" style=\"text-align: center;\">\n<tbody><tr>\n<th>Histologic grade\n</th>\n<th>Survival\n</th></tr>\n<tr>\n<td>Low grade\n</td>\n<td>88%\n</td></tr>\n<tr>\n<td>Intermediate grade\n</td>\n<td>58%\n</td></tr>\n<tr>\n<td>High grade\n</td>\n<td>27%\n</td></tr></tbody></table>\n<div style=\"clear:both;\"></div>\n<p>The survival rates given below are for the different types of ovarian cancer, according to <a href=\"/wiki/American_Cancer_Society\" title=\"American Cancer Society\">American Cancer Society</a>.<sup id=\"cite_ref-ACS_71-1\" class=\"reference\"><a href=\"#cite_note-ACS-71\">&#91;71&#93;</a></sup> They come from the <a href=\"/wiki/National_Cancer_Institute\" title=\"National Cancer Institute\">National Cancer Institute</a>, SEER, and are based on patients diagnosed from 2004 to 2010.\n</p>\n<table class=\"wikitable\" align=\"left\" style=\"text-align: center; margin-right: 10px;\">\n<tbody><tr>\n<th colspan=\"2\">Invasive epithelial ovarian cancer\n</th></tr>\n<tr>\n<th>Stage\n</th>\n<th>Relative five-year<br />survival rate\n</th></tr>\n<tr>\n<td>I\n</td>\n<td>90%\n</td></tr>\n<tr>\n<td>IA\n</td>\n<td>94%\n</td></tr>\n<tr>\n<td>IB\n</td>\n<td>92%\n</td></tr>\n<tr>\n<td>IC\n</td>\n<td>85%\n</td></tr>\n<tr>\n<td>II\n</td>\n<td>70%\n</td></tr>\n<tr>\n<td>IIA\n</td>\n<td>78%\n</td></tr>\n<tr>\n<td>IIB\n</td>\n<td>73%\n</td></tr>\n<tr>\n<td>III\n</td>\n<td>39%\n</td></tr>\n<tr>\n<td>IIIA\n</td>\n<td>59%\n</td></tr>\n<tr>\n<td>IIIB\n</td>\n<td>52%\n</td></tr>\n<tr>\n<td>IIIC\n</td>\n<td>39%\n</td></tr>\n<tr>\n<td>IV\n</td>\n<td>17%\n</td></tr></tbody></table>\n<table class=\"wikitable\" align=\"left\" style=\"text-align: center; margin-right: 10px;\">\n<tbody><tr>\n<th colspan=\"2\">Ovarian stromal tumors\n</th></tr>\n<tr>\n<th>Stage\n</th>\n<th>Relative five-year<br />survival rate\n</th></tr>\n<tr>\n<td>I\n</td>\n<td>95%\n</td></tr>\n<tr>\n<td>II\n</td>\n<td>78%\n</td></tr>\n<tr>\n<td>III\n</td>\n<td>65%\n</td></tr>\n<tr>\n<td>IV\n</td>\n<td>35%\n</td></tr></tbody></table>\n<table class=\"wikitable\" align=\"left\" style=\"text-align: center; margin-right: 10px;\">\n<tbody><tr>\n<th colspan=\"2\">Germ cell tumors of the ovary\n</th></tr>\n<tr>\n<th>Stage\n</th>\n<th>Relative 5-yr<br />Survival Rate\n</th></tr>\n<tr>\n<td>I\n</td>\n<td>98%\n</td></tr>\n<tr>\n<td>II\n</td>\n<td>94%\n</td></tr>\n<tr>\n<td>III\n</td>\n<td>87%\n</td></tr>\n<tr>\n<td>IV\n</td>\n<td>69%\n</td></tr></tbody></table>\n<table class=\"wikitable\" align=\"left\" style=\"text-align: center; margin-right: 10px;\">\n<tbody><tr>\n<th colspan=\"2\">Fallopian tube carcinoma\n</th></tr>\n<tr>\n<th>Stage\n</th>\n<th>Relative five-year<br />survival rate\n</th></tr>\n<tr>\n<td>I\n</td>\n<td>87%\n</td></tr>\n<tr>\n<td>II\n</td>\n<td>86%\n</td></tr>\n<tr>\n<td>III\n</td>\n<td>52%\n</td></tr>\n<tr>\n<td>IV\n</td>\n<td>40%\n</td></tr></tbody></table>\n<table class=\"wikitable\" align=\"left\" style=\"text-align: center; margin-right: 10px;\">\n<tbody><tr>\n<th colspan=\"2\">Low malignant potential tumors<sup id=\"cite_ref-Hoffman35_19-65\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</th></tr>\n<tr>\n<th>Stage\n</th>\n<th>Relative five-year<br />survival rate\n</th></tr>\n<tr>\n<td>I\n</td>\n<td>99%\n</td></tr>\n<tr>\n<td>II\n</td>\n<td>98%\n</td></tr>\n<tr>\n<td>III\n</td>\n<td>96%\n</td></tr>\n<tr>\n<td>IV\n</td>\n<td>77%\n</td></tr></tbody></table>\n<div style=\"clear:both;\"></div>\n<h3><span class=\"mw-headline\" id=\"Recurrence_rates\">Recurrence rates</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=67\" title=\"Edit section: Recurrence rates\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Ovarian cancer frequently recurs after treatment. Overall, in a 5-year period, 20% of stage I and II cancers recur. Most recurrences are in the abdomen.<sup id=\"cite_ref-Hoffman35_19-66\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> If a recurrence occurs in advanced disease, it typically occurs within 18 months of initial treatment (18 months <a href=\"/wiki/Progression-free_survival\" title=\"Progression-free survival\">progression-free survival</a>). Recurrences can be treated, but the disease-free interval tends to shorten and chemoresistance increases with each recurrence.<sup id=\"cite_ref-Jayson_18-45\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> When a dysgerminoma recurs, it is most likely to recur within a year of diagnosis, and other malignant germ cell tumors recur within 2 years 90% of the time. Germ cell tumors other than dysgerminomas have a poor prognosis when they relapse, with a 10% long-term survival rate.<sup id=\"cite_ref-:8_22-35\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup> Low malignant potential tumors rarely relapse, even when fertility-sparing surgery is the treatment of choice. 15% of LMP tumors relapse after unilateral surgery in the previously unaffected ovary, and they are typically easily treated with surgery. More advanced tumors may take up to 20 years to relapse, if they relapse at all, and are only treated with surgery unless the tumor has changed its histological characteristics or grown very quickly. In these cases, and when there is significant ascites, chemotherapy may also be used. Relapse is usually indicated by rising CA-125 levels and then progresses to symptomatic relapse within 2\u20136 months.<sup id=\"cite_ref-Hoffman35_19-67\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Recurrent sex cord-stromal tumors are typically unresponsive to treatment but not aggressive.<sup id=\"cite_ref-:8_22-36\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p>It is the most deadly gynecologic cancer.<sup id=\"cite_ref-Hoffman35_19-68\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Epidemiology\">Epidemiology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=68\" title=\"Edit section: Epidemiology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:Ovary_cancer_world_map_-_Death_-_WHO2004.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/0/03/Ovary_cancer_world_map_-_Death_-_WHO2004.svg/290px-Ovary_cancer_world_map_-_Death_-_WHO2004.svg.png\" width=\"290\" height=\"128\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/0/03/Ovary_cancer_world_map_-_Death_-_WHO2004.svg/435px-Ovary_cancer_world_map_-_Death_-_WHO2004.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/03/Ovary_cancer_world_map_-_Death_-_WHO2004.svg/580px-Ovary_cancer_world_map_-_Death_-_WHO2004.svg.png 2x\" data-file-width=\"940\" data-file-height=\"415\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Ovary_cancer_world_map_-_Death_-_WHO2004.svg\" class=\"internal\" title=\"Enlarge\"></a></div><a href=\"/wiki/Age_adjustment\" title=\"Age adjustment\">Age-standardized</a> death from ovarian cancer per 100,000&#160;inhabitants in 2004<sup id=\"cite_ref-75\" class=\"reference\"><a href=\"#cite_note-75\">&#91;75&#93;</a></sup><style data-mw-deduplicate=\"TemplateStyles:r853264625\">.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{list-style-type:none;margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li,.mw-parser-output .refbegin-hanging-indents>dl>dd{margin-left:0;padding-left:3.2em;text-indent:-3.2em;list-style:none}.mw-parser-output .refbegin-100{font-size:100%}</style><div class=\"refbegin columns references-column-count references-column-count-2\" style=\"-moz-column-count: 2; -webkit-column-count: 2; column-count: 2;\"> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #b3b3b3; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;no data</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffff65; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;less than 0.6</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #fff200; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;0.6\u20131.2</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffdc00; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;1.2\u20131.8</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffc600; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;1.8\u20132.4</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffb000; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;2.4\u20133</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff9a00; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;3\u20133.6</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff8400; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;3.6\u20134.2</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff6e00; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;4.2\u20134.8</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff5800; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;4.8\u20135.4</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff4200; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;5.4\u20136</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff2c00; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;6\u20137</div> <div class=\"legend\" style=\"-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column\"><span class=\"legend-color\" style=\"display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #cb0000; color:black; font-size:100%; text-align:center;\">&#160;</span>&#160;more than 7</div> </div></div></div></div>\n<p>In 2014, the number of new cases that occurred in developed countries was about 9.4 per 100,000, compared to 5.0 per 100,000 in developing countries.<sup id=\"cite_ref-Jayson_18-46\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Globally, about 160,000 people died from ovarian cancer in 2010. This was an increase from 113,000 in 1990.<sup id=\"cite_ref-Loz_2012_76-0\" class=\"reference\"><a href=\"#cite_note-Loz_2012-76\">&#91;76&#93;</a></sup> The number of new cases per year in Europe is approximately 5\u201315 per 100,000 women.<sup id=\"cite_ref-:7_21-65\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> In Europe, <a href=\"/wiki/Lithuania\" title=\"Lithuania\">Lithuania</a>, <a href=\"/wiki/Latvia\" title=\"Latvia\">Latvia</a>, <a href=\"/wiki/Ireland\" title=\"Ireland\">Ireland</a>, <a href=\"/wiki/Slovakia\" title=\"Slovakia\">Slovakia</a>, and the <a href=\"/wiki/Czech_Republic\" title=\"Czech Republic\">Czech Republic</a> have the highest incidences of ovarian cancer, whereas <a href=\"/wiki/Portugal\" title=\"Portugal\">Portugal</a> and <a href=\"/wiki/Cyprus\" title=\"Cyprus\">Cyprus</a> have the lowest incidences.<sup id=\"cite_ref-:7_21-66\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> In 2008, the five-year survival rate was 44%. This has increased since 1977 when the survival rate was 36%.<sup id=\"cite_ref-:9_69-4\" class=\"reference\"><a href=\"#cite_note-:9-69\">&#91;69&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"United_States\">United States</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=69\" title=\"Edit section: United States\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div class=\"thumb tleft\"><div class=\"thumbinner\" style=\"width:292px;\"><a href=\"/wiki/File:Ovarian_cancer_by_age_group.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/e/e0/Ovarian_cancer_by_age_group.png/290px-Ovarian_cancer_by_age_group.png\" width=\"290\" height=\"274\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/e/e0/Ovarian_cancer_by_age_group.png 1.5x\" data-file-width=\"373\" data-file-height=\"353\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Ovarian_cancer_by_age_group.png\" class=\"internal\" title=\"Enlarge\"></a></div>Ovarian cancer cases diagnosed by age group in the US<sup id=\"cite_ref-SEER_73-1\" class=\"reference\"><a href=\"#cite_note-SEER-73\">&#91;73&#93;</a></sup></div></div></div>\n<p>In 2010, in the United States, an estimated 21,880 new cases were diagnosed and 13,850 women died of ovarian cancer. Around 1,800 of the new diagnoses were sex-cord or stromal tumors.<sup id=\"cite_ref-Harrisons_16-52\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup>\n</p><p>In 2014, over 220,000 diagnoses of epithelial ovarian cancer were made yearly.<sup id=\"cite_ref-Jayson_18-47\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> The overall lifetime risk in the US is around 1.6%<sup id=\"cite_ref-Harrisons_16-53\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-:7_21-67\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> In the US, ovarian cancer affects 1.3\u20131.4% and is the cause of death of about 1% of women.<sup id=\"cite_ref-Hoffman35_19-69\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-merck_77-0\" class=\"reference\"><a href=\"#cite_note-merck-77\">&#91;77&#93;</a></sup> In the United States, it is also the fifth-most common cancer in women but the fourth-most common cause of cancer death.<sup id=\"cite_ref-:7_21-68\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> This decrease made it the ninth-most common cancer in women.<sup id=\"cite_ref-Hoffman35_19-70\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup>\n</p><p>The risks from developing specific types of ovarian cancer varies. Germ cell tumors and sex cord-stromal tumors are less common than epithelial tumors. The number of new cases a year in the US is 0.4 per 100,000 women and 0.2 per 100,000 women, respectively. In young people, sex-cord stromal tumors and germ cell tumors total 1% of overall ovarian cancer.<sup id=\"cite_ref-:8_22-37\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup> Ovarian cancer represents approximately 4% of cancers diagnosed in women.<sup id=\"cite_ref-:7_21-69\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"United_Kingdom\">United Kingdom</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=70\" title=\"Edit section: United Kingdom\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>It is the 5th most common cancer in UK women.<sup id=\"cite_ref-:7_21-70\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-CRUKRisks_24-13\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> In the UK, the incidence rate over the whole population is 21.6 per 100,000.\n</p><p>In the United Kingdom as of 2014, approximately 7,000\u20137,100 yearly diagnoses with 4,200 deaths.<sup id=\"cite_ref-Jayson_18-48\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-CRUKRisks_24-14\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> The risk in the UK is similar, at 1.7%. <a href=\"/wiki/Ashkenazi_Jew\" class=\"mw-redirect\" title=\"Ashkenazi Jew\">Ashkenazi Jewish</a> women carry mutated <i>BRCA</i> alleles five times more often than the rest of the population, giving them a higher risk developing ovarian cancer.<sup id=\"cite_ref-Jayson_18-49\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> It is the fifth-leading cause of cancer-related deaths in the US in 2008 and estimated to be 15,000.<sup id=\"cite_ref-Harrisons_16-54\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup><sup id=\"cite_ref-merck_77-1\" class=\"reference\"><a href=\"#cite_note-merck-77\">&#91;77&#93;</a></sup> Ovarian cancer is the fifth-most common cancer in women in the UK (around 7,100 women were diagnosed with the disease in 2011), and it is the fifth-most common cause of cancer death in women (around 4,300 women died in 2012).<sup id=\"cite_ref-78\" class=\"reference\"><a href=\"#cite_note-78\">&#91;78&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Ethnicity\">Ethnicity</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=71\" title=\"Edit section: Ethnicity\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Black women have twice the risk for sex cord-stromal tumors compared to non-Black women.<sup id=\"cite_ref-:8_22-38\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Older_women\">Older women</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=72\" title=\"Edit section: Older women\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In the US, the incidence rate in women over 50 is approximately 33 per 100,000.<sup id=\"cite_ref-79\" class=\"reference\"><a href=\"#cite_note-79\">&#91;79&#93;</a></sup> The rate of ovarian cancer between 1993 and 2008 decreased in women of the 40\u201349 age cohort and in the 50\u201364 age cohort.<sup id=\"cite_ref-Jayson_18-50\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Ovarian cancer is most commonly diagnosed after menopause,<sup id=\"cite_ref-CRUKRisks_24-15\" class=\"reference\"><a href=\"#cite_note-CRUKRisks-24\">&#91;24&#93;</a></sup> between the ages of 60 and 64. Ninety percent of ovarian cancer occurs in women over the age of 45 and 80% in women over 50.<sup id=\"cite_ref-:7_21-71\" class=\"reference\"><a href=\"#cite_note-:7-21\">&#91;21&#93;</a></sup> Older women are more likely to present with advanced ovarian cancer.<sup id=\"cite_ref-Gib2016_15-2\" class=\"reference\"><a href=\"#cite_note-Gib2016-15\">&#91;15&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"In_pregnancy\">In pregnancy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=73\" title=\"Edit section: In pregnancy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Malignant germ cell tumors are the type of ovarian cancer most likely to occur during <a href=\"/wiki/Pregnancy\" title=\"Pregnancy\">pregnancy</a>. They are typically diagnosed when an adnexal mass is found on examination (in 1\u20132% of all pregnancies), a tumor is seen on ultrasound, or the parent's level of alpha-fetoprotein is elevated. Dermoid cysts and dysgerminomas are the most common germ cell tumors during pregnancy. Germ cell tumors diagnosed during pregnancy are unlikely to have metastasized and can be treated by surgery and, in some cases, chemotherapy, which carries the risk of birth defects. Yolk sac tumors and immature teratomas grow particularly quickly and are usually treated with chemotherapy even during pregnancy; however, dysgerminomas that have been optimally debulked may be treated after childbirth.<sup id=\"cite_ref-:8_22-39\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Other_animals\">Other animals</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=74\" title=\"Edit section: Other animals\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Ovarian tumors have been reported in <a href=\"/wiki/Equine\" class=\"mw-redirect\" title=\"Equine\">equine</a> <a href=\"/wiki/Mare\" title=\"Mare\">mares</a>. Reported tumor types include teratoma,<sup id=\"cite_ref-pmid15065985_80-0\" class=\"reference\"><a href=\"#cite_note-pmid15065985-80\">&#91;80&#93;</a></sup><sup id=\"cite_ref-pmid16363331_81-0\" class=\"reference\"><a href=\"#cite_note-pmid16363331-81\">&#91;81&#93;</a></sup> <a href=\"/wiki/Cystadenocarcinoma\" title=\"Cystadenocarcinoma\">cystadenocarcinoma</a>,<sup id=\"cite_ref-pmid15957389_82-0\" class=\"reference\"><a href=\"#cite_note-pmid15957389-82\">&#91;82&#93;</a></sup> and particularly <a href=\"/wiki/Granulosa_cell_tumor\" class=\"mw-redirect\" title=\"Granulosa cell tumor\">granulosa cell tumor</a>.<sup id=\"cite_ref-pmid17542368_83-0\" class=\"reference\"><a href=\"#cite_note-pmid17542368-83\">&#91;83&#93;</a></sup><sup id=\"cite_ref-pmid12867740_84-0\" class=\"reference\"><a href=\"#cite_note-pmid12867740-84\">&#91;84&#93;</a></sup><sup id=\"cite_ref-pmid9364230_85-0\" class=\"reference\"><a href=\"#cite_note-pmid9364230-85\">&#91;85&#93;</a></sup><sup id=\"cite_ref-pmid3507181_86-0\" class=\"reference\"><a href=\"#cite_note-pmid3507181-86\">&#91;86&#93;</a></sup><sup id=\"cite_ref-pmid2835223_87-0\" class=\"reference\"><a href=\"#cite_note-pmid2835223-87\">&#91;87&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Research\">Research</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=75\" title=\"Edit section: Research\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Screening_2\">Screening</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=76\" title=\"Edit section: Screening\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Screening by hysteroscopy to obtain cell samples obtained for histological examination is being developed. This is similar to the current pap smear that is used to detect cervical cancer.<sup id=\"cite_ref-GizzoNoventa2016_88-0\" class=\"reference\"><a href=\"#cite_note-GizzoNoventa2016-88\">&#91;88&#93;</a></sup> The UK Collaborative Trial of Ovarian Cancer Screening is testing a screening technique that combines CA-125 blood tests with transvaginal ultrasound.<sup id=\"cite_ref-Jayson_18-51\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Other studies suggest that this screening procedure may be effective.<sup id=\"cite_ref-:6_62-1\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup> Although results published in 2015 were not conclusive, there was some evidence that screening may save lives in the long-term. <sup id=\"cite_ref-89\" class=\"reference\"><a href=\"#cite_note-89\">&#91;89&#93;</a></sup> As a result, the trial has been extended and will publish definitive results at the end of 2019. One major problem with screening is no clear progression of the disease from stage I (noninvasive) to stage III (invasive) is seen, and it may not be possible to find cancers before they reach stage III. Another problem is that screening methods tend to find too many suspicious lesions, most of which are not cancer, but malignancy can only be assessed with surgery.<sup id=\"cite_ref-Jayson_18-52\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> The ROCA method combined with transvaginal ultrasonography is being researched in high-risk women to determine if it is a viable screening method. It is also being investigated in normal-risk women as it has shown promise in the wider population.<sup id=\"cite_ref-Hoffman35_19-71\" class=\"reference\"><a href=\"#cite_note-Hoffman35-19\">&#91;19&#93;</a></sup> Studies are also in progress to determine if screening helps detect cancer earlier in people with BRCA mutations.<sup id=\"cite_ref-:6_62-2\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Prognosis_research\">Prognosis research</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=77\" title=\"Edit section: Prognosis research\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Research into various <a href=\"/w/index.php?title=Prognostic_factor&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Prognostic factor (page does not exist)\">prognostic factors</a> for ovarian cancer is also going on. Recent research shows that <a href=\"/wiki/Thrombocytosis\" class=\"mw-redirect\" title=\"Thrombocytosis\">thrombocytosis</a> predicts lower survival and higher stage cancer.<sup id=\"cite_ref-Jayson_18-53\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Ongoing research is also investigating the benefits of surgery for recurrent ovarian cancer.<sup id=\"cite_ref-:6_62-3\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Immunotherapy_2\">Immunotherapy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=78\" title=\"Edit section: Immunotherapy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>While an active area of research, no <a href=\"/wiki/Immunotherapy\" title=\"Immunotherapy\">immunotherapy</a> has been shown to be effective as of 2013.<sup id=\"cite_ref-90\" class=\"reference\"><a href=\"#cite_note-90\">&#91;90&#93;</a></sup> However, trials of the antibody and <a href=\"/wiki/VEGF\" class=\"mw-redirect\" title=\"VEGF\">VEGF</a> inhibitor <a href=\"/wiki/Bevacizumab\" title=\"Bevacizumab\">bevacizumab</a>, which can slow the <a href=\"/wiki/Angiogenesis\" title=\"Angiogenesis\">growth of new blood vessels</a> in the cancer, have shown promising results, especially in combination with <a href=\"/wiki/Pazopanib\" title=\"Pazopanib\">pazopanib</a>, which also slows the process of blood vessel growth. Bevacizumab has been particularly effective in preliminary studies on stage-III and -IV cancer<sup id=\"cite_ref-Jayson_18-54\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> and has been cited as having at least a 15% response rate.<sup id=\"cite_ref-Harrisons_16-55\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> It is being investigated particularly in mucinous ovarian cancers.<sup id=\"cite_ref-:6_62-4\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Pharmacology\">Pharmacology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=79\" title=\"Edit section: Pharmacology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/MTOR_inhibitor\" class=\"mw-redirect\" title=\"MTOR inhibitor\">mTOR inhibitors</a> were a highly investigated potential treatment in the 2000s and 2010s, but the side effects of these drugs (particularly <a href=\"/wiki/Hyperglycemia\" title=\"Hyperglycemia\">hyperglycemia</a> and <a href=\"/wiki/Hyperlipidemia\" title=\"Hyperlipidemia\">hyperlipidemia</a>) were not well tolerated and the survival benefit not confirmed. PI3 kinase inhibitors have been of interest, but they tend to be highly toxic and cause <a href=\"/wiki/Diarrhea\" title=\"Diarrhea\">diarrhea</a>. Another investigated drug is <a href=\"/wiki/Selumetinib\" title=\"Selumetinib\">selumetinib</a>, a <a href=\"/wiki/MAPK\" class=\"mw-redirect\" title=\"MAPK\">MAPK</a> inhibitor. It improved survival, but did not correlate with any mutations found in tumors.<sup id=\"cite_ref-Jayson_18-55\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup>\n</p><p>Bevacizumab can also be combined with platinum chemotherapy, a combination that has had positive preliminary results in PFS, but equivocal results regarding overall survival. One disadvantage to these treatments is the side effect profile, which includes <a href=\"/wiki/Hypertension\" title=\"Hypertension\">high blood pressure</a> and <a href=\"/wiki/Proteinuria\" title=\"Proteinuria\">proteinuria</a>. The drug can also exacerbate bowel disease, leading to <a href=\"/wiki/Fistula\" title=\"Fistula\">fistulae</a> or <a href=\"/wiki/Bowel_perforation\" class=\"mw-redirect\" title=\"Bowel perforation\">bowel perforation</a>. <a href=\"/wiki/Vintafolide\" title=\"Vintafolide\">Vintafolide</a>, which consists of an <a href=\"/wiki/Antifolate\" title=\"Antifolate\">antifolate</a> conjugated with <a href=\"/wiki/Vinblastine\" title=\"Vinblastine\">vinblastine</a>, is also in clinical trials; it may prove beneficial because <a href=\"/wiki/Folate_receptor\" title=\"Folate receptor\">folate receptors</a> are overexpressed in many ovarian cancers.<sup id=\"cite_ref-Jayson_18-56\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Another potential immunotherapy is <a href=\"/wiki/Trastuzumab\" title=\"Trastuzumab\">trastuzumab</a>, which is active against tumors positive for Her2/neu mutations.<sup id=\"cite_ref-Harrisons_16-56\" class=\"reference\"><a href=\"#cite_note-Harrisons-16\">&#91;16&#93;</a></sup> Other angiogenesis inhibitors are also being investigated as potential ovarian cancer treatments. <a href=\"/wiki/Combretastatin\" title=\"Combretastatin\">Combretastatin</a> and <a href=\"/wiki/Pazopanib\" title=\"Pazopanib\">pazopanib</a> are being researched in combination for recurrent ovarian cancer. <a href=\"/w/index.php?title=Trebananib&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Trebananib (page does not exist)\">Trebananib</a> and <a href=\"/wiki/Tasquinimod\" title=\"Tasquinimod\">tasquinimod</a> are other angiogenesis inhibitors being investigated. The <a href=\"/wiki/Monoclonal_antibody\" title=\"Monoclonal antibody\">monoclonal antibody</a> <a href=\"/wiki/Farletuzumab\" title=\"Farletuzumab\">farletuzumab</a> is being researched as an adjuvant to traditional chemotherapy. Another type of immunotherapy involves <a href=\"/wiki/Vaccines\" class=\"mw-redirect\" title=\"Vaccines\">vaccines</a>, including <a href=\"/wiki/TroVax\" title=\"TroVax\">TroVax</a>.<sup id=\"cite_ref-:6_62-5\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p><p>An alternative to BEP chemotherapy, a regimen of 3 cycles of <a href=\"/wiki/Carboplatin\" title=\"Carboplatin\">carboplatin</a> and <a href=\"/wiki/Etoposide\" title=\"Etoposide\">etoposide</a>, is a current topic of research for germ cell malignancies.<sup id=\"cite_ref-:8_22-40\" class=\"reference\"><a href=\"#cite_note-:8-22\">&#91;22&#93;</a></sup>\n</p><p><a href=\"/wiki/Intraperitoneal_chemotherapy\" class=\"mw-redirect\" title=\"Intraperitoneal chemotherapy\">Intraperitoneal chemotherapy</a> has also been under investigation during the 2000s and 2010s for its potential to deliver higher doses of cytotoxic agent to tumors. Preliminary trials with cisplatin and paclitaxel have shown it is not well tolerated, but does improve survival, and more tolerable regimens are being researched.<sup id=\"cite_ref-Jayson_18-57\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Cisplatin and paclitaxel are both being researched as intraperitoneal chemotherapy agents. A specific chemotherapy regimen for rare clear-cell cancers is also under investigation: <a href=\"/wiki/Irinotecan\" title=\"Irinotecan\">irinotecan</a> combined with cisplatin.<sup id=\"cite_ref-:6_62-6\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p><p><a href=\"/wiki/PARP_inhibitor\" title=\"PARP inhibitor\">PARP inhibitors</a> have also shown promise in early trials, particularly in people with <i>BRCA</i> gene mutations, since the BRCA protein interacts with the PARP pathway. It is also being studied in recurrent ovarian cancer in general, where preliminary studies have shown longer PFS. Specifically, <a href=\"/wiki/Olaparib\" title=\"Olaparib\">olaparib</a> has shown greater survival compared to doxorubicin, though this treatment is still being investigated. It is not clear yet which <a href=\"/wiki/Biomarker\" title=\"Biomarker\">biomarkers</a> are predictive of responsiveness to PARP inhibitors.<sup id=\"cite_ref-Jayson_18-58\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> <a href=\"/wiki/Rucaparib\" title=\"Rucaparib\">Rucaparib</a> is another PARP inhibitor being researched in BRCA-positive and BRCA-negative recurrent advanced ovarian cancer. <a href=\"/wiki/Niraparib\" title=\"Niraparib\">Niraparib</a> is a PARP inhibitor being tested in BRCA-positive recurrent ovarian cancer.<sup id=\"cite_ref-:6_62-7\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p><p><a href=\"/wiki/Tyrosine_kinase_inhibitors\" class=\"mw-redirect\" title=\"Tyrosine kinase inhibitors\">Tyrosine kinase inhibitors</a> are another investigational drug class that may have applications in ovarian cancer. Angiogenesis inhibitors in the <a href=\"/wiki/Receptor_tyrosine_kinase\" title=\"Receptor tyrosine kinase\">receptor tyrosine kinase</a> inhibitor group, including <a href=\"/wiki/Pazopanib\" title=\"Pazopanib\">pazopanib</a>, <a href=\"/wiki/Cediranib\" title=\"Cediranib\">cediranib</a>, and <a href=\"/wiki/Nintedanib\" title=\"Nintedanib\">nintedanib</a>, have also been shown to increase progression free survival (PFS), but their benefit for overall survival has not been investigated as of 2015.<sup id=\"cite_ref-Jayson_18-59\" class=\"reference\"><a href=\"#cite_note-Jayson-18\">&#91;18&#93;</a></sup> Preliminary research showed that cediranib combined with platins in recurrent ovarian cancer increased the time to second recurrence by 3\u20134 months and increased survival by 3 months.<sup id=\"cite_ref-:6_62-8\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup> <a href=\"/w/index.php?title=MK-1775&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"MK-1775 (page does not exist)\">MK-1775</a> is a tyrosine kinase inhibitor that is being used in combination with paclitaxel and carboplatin in platinum-sensitive cancers with p53 mutations. <a href=\"/wiki/Nintedanib\" title=\"Nintedanib\">Nintedanib</a> is being researched as a potential therapy in combination with cyclophosphamide for people with recurrences.<sup id=\"cite_ref-:6_62-9\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Hormones_and_radiation\">Hormones and radiation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=80\" title=\"Edit section: Hormones and radiation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Hormone therapies are a topic of current research in ovarian cancer, particularly, the value of certain medications used to treat breast cancer. These include <a href=\"/wiki/Tamoxifen\" title=\"Tamoxifen\">tamoxifen</a>, <a href=\"/wiki/Letrozole\" title=\"Letrozole\">letrozole</a>, and <a href=\"/wiki/Anastrozole\" title=\"Anastrozole\">anastrozole</a>. Preliminary studies have showed a benefit for tamoxifen in a small number of people with advanced ovarian cancer. Letrozole may help to slow or stop growth of <a href=\"/wiki/Estrogen_receptor\" title=\"Estrogen receptor\">estrogen receptor</a> positive ovarian cancer. Anastrozole is being investigated in postmenopausal people with estrogen receptor-positive cancer.<sup id=\"cite_ref-:6_62-10\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p><p>Research into mitigating side effects of ovarian cancer treatment is also ongoing. <a href=\"/w/index.php?title=Radiation_fibrosis&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Radiation fibrosis (page does not exist)\">Radiation fibrosis</a>, the formation of scar tissue in an area treated with radiation, may be relieved with <a href=\"/wiki/Hyperbaric_medicine\" title=\"Hyperbaric medicine\">hyperbaric oxygen therapy</a>, but research has not been completed in this area. Treatment of ovarian cancer may also cause people to experience psychiatric difficulties, including <a href=\"/wiki/Depression_(mood)\" title=\"Depression (mood)\">depression</a>. Research is ongoing to determine how counseling and psychotherapy can help people who have ovarian cancer during treatment.<sup id=\"cite_ref-:6_62-11\" class=\"reference\"><a href=\"#cite_note-:6-62\">&#91;62&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Inflammation\">Inflammation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=81\" title=\"Edit section: Inflammation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>There are some indications that pelvic inflammatory disease may be associated with ovarian cancer, especially in non-western countries. It may be due to the inflammatory process present with pelvic inflammatory disease.<sup id=\"cite_ref-IngerslevHogdall2017_91-0\" class=\"reference\"><a href=\"#cite_note-IngerslevHogdall2017-91\">&#91;91&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Clinical_trials\">Clinical trials</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=82\" title=\"Edit section: Clinical trials\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">Clinical trials</a> are monitored and funded by US governmental organizations to test treatment options to see if they are safe and effective. These include NIH Clinical Research Trials and You (<a href=\"/wiki/National_Institutes_of_Health\" title=\"National Institutes of Health\">National Institutes of Health</a>),<sup id=\"cite_ref-92\" class=\"reference\"><a href=\"#cite_note-92\">&#91;92&#93;</a></sup> Learn About Clinical Trials (<a href=\"/wiki/National_Cancer_Institute\" title=\"National Cancer Institute\">National Cancer Institute</a>),<sup id=\"cite_ref-93\" class=\"reference\"><a href=\"#cite_note-93\">&#91;93&#93;</a></sup> Search for Clinical Trials (National Cancer Institute),<sup id=\"cite_ref-94\" class=\"reference\"><a href=\"#cite_note-94\">&#91;94&#93;</a></sup> ClinicalTrials.gov (National Institutes of Health).<sup id=\"cite_ref-95\" class=\"reference\"><a href=\"#cite_note-95\">&#91;95&#93;</a></sup><sup id=\"cite_ref-CDCfeb2017_53-1\" class=\"reference\"><a href=\"#cite_note-CDCfeb2017-53\">&#91;53&#93;</a></sup> Clinical trials are also conducted in Canada.<sup id=\"cite_ref-96\" class=\"reference\"><a href=\"#cite_note-96\">&#91;96&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=83\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-NCI2014TxPt-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NCI2014TxPt_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NCI2014TxPt_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-NCI2014TxPt_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-NCI2014TxPt_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-NCI2014TxPt_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-NCI2014TxPt_1-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-NCI2014TxPt_1-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-NCI2014TxPt_1-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-NCI2014TxPt_1-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-NCI2014TxPt_1-9\"><sup><i><b>j</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page1/AllPages\">\"Ovarian Epithelial Cancer Treatment (PDQ\u00ae)\"</a>. <i>NCI</i>. 2014-05-12. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140705232951/http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page1/AllPages\">Archived</a> from the original on 5 July 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">1 July</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NCI&amp;rft.atitle=Ovarian+Epithelial+Cancer+Treatment+%28PDQ%C2%AE%29&amp;rft.date=2014-05-12&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Ftreatment%2Fovarianepithelial%2FPatient%2Fpage1%2FAllPages&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NCI2016Onset-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NCI2016Onset_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NCI2016Onset_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-risk-factors\">\"What are the risk factors for ovarian cancer?\"</a>. <i>www.cancer.org</i>. 2016-02-04. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160517173135/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-risk-factors\">Archived</a> from the original on 17 May 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 May</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancer.org&amp;rft.atitle=What+are+the+risk+factors+for+ovarian+cancer%3F&amp;rft.date=2016-02-04&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fovariancancer%2Fdetailedguide%2Fovarian-cancer-risk-factors&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-WCR2014-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-WCR2014_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-WCR2014_3-12\"><sup><i><b>m</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\"><a rel=\"nofollow\" class=\"external text\" href=\"http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014\"><i>World Cancer Report 2014</i></a>. World Health Organization. 2014. Chapter 5.12. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/9283204298\" title=\"Special:BookSources/9283204298\">9283204298</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20160919073553/http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014\">Archived</a> from the original on 2016-09-19.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=World+Cancer+Report+2014&amp;rft.pages=Chapter+5.12&amp;rft.pub=World+Health+Organization&amp;rft.date=2014&amp;rft.isbn=9283204298&amp;rft_id=http%3A%2F%2Fpublications.iarc.fr%2FNon-Series-Publications%2FWorld-Cancer-Reports%2FWorld-Cancer-Report-2014&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NCI2014PrePt-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NCI2014PrePt_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NCI2014PrePt_4-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-NCI2014PrePt_4-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-NCI2014PrePt_4-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/Patient/page1/AllPages\">\"Ovarian Cancer Prevention (PDQ\u00ae)\"</a>. <i>NCI</i>. December 6, 2013. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140706002700/http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/Patient/page1/AllPages\">Archived</a> from the original on 6 July 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">1 July</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NCI&amp;rft.atitle=Ovarian+Cancer+Prevention+%28PDQ%C2%AE%29&amp;rft.date=2013-12-06&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Fprevention%2Fovarian%2FPatient%2Fpage1%2FAllPages&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NCI2014PrePro-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NCI2014PrePro_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NCI2014PrePro_5-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-NCI2014PrePro_5-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/HealthProfessional/page1/AllPages\">\"Ovarian Cancer Prevention (PDQ\u00ae)\"</a>. <i>NCI</i>. 2014-06-20. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140706002711/http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/HealthProfessional/page1/AllPages\">Archived</a> from the original on 6 July 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">1 July</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NCI&amp;rft.atitle=Ovarian+Cancer+Prevention+%28PDQ%C2%AE%29&amp;rft.date=2014-06-20&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Fprevention%2Fovarian%2FHealthProfessional%2Fpage1%2FAllPages&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-SEER2014-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-SEER2014_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-SEER2014_6-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://seer.cancer.gov/statfacts/html/ovary.html\">\"SEER Stat Fact Sheets: Ovary Cancer\"</a>. <i>NCI</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140706145616/http://seer.cancer.gov/statfacts/html/ovary.html\">Archived</a> from the original on 6 July 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">18 June</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NCI&amp;rft.atitle=SEER+Stat+Fact+Sheets%3A+Ovary+Cancer&amp;rft_id=http%3A%2F%2Fseer.cancer.gov%2Fstatfacts%2Fhtml%2Fovary.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-GBD2015Pre-7\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-GBD2015Pre_7-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-GBD2015Pre_7-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (8 October 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(16)31678-6\">\"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015\"</a>. <i>Lancet</i>. <b>388</b> (10053): 1545\u20131602. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0140-6736%2816%2931678-6\">10.1016/S0140-6736(16)31678-6</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577\">5055577</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27733282\">27733282</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Global%2C+regional%2C+and+national+incidence%2C+prevalence%2C+and+years+lived+with+disability+for+310+diseases+and+injuries%2C+1990%E2%80%932015%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2015.&amp;rft.volume=388&amp;rft.issue=10053&amp;rft.pages=1545-1602&amp;rft.date=2016-10-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5055577&amp;rft_id=info%3Apmid%2F27733282&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2816%2931678-6&amp;rft.au=GBD+2015+Disease+and+Injury+Incidence+and+Prevalence+Collaborators&amp;rft_id=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0140-6736%2816%2931678-6&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-GBD2015De-8\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-GBD2015De_8-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-GBD2015De_8-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">GBD 2015 Mortality and Causes of Death Collaborators (8 October 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(16)31012-1\">\"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015\"</a>. <i>Lancet</i>. <b>388</b> (10053): 1459\u20131544. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0140-6736%2816%2931012-1\">10.1016/S0140-6736(16)31012-1</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5388903\">5388903</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27733281\">27733281</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Global%2C+regional%2C+and+national+life+expectancy%2C+all-cause+mortality%2C+and+cause-specific+mortality+for+249+causes+of+death%2C+1980%E2%80%932015%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2015.&amp;rft.volume=388&amp;rft.issue=10053&amp;rft.pages=1459-1544&amp;rft.date=2016-10-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5388903&amp;rft_id=info%3Apmid%2F27733281&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2816%2931012-1&amp;rft.au=GBD+2015+Mortality+and+Causes+of+Death+Collaborators&amp;rft_id=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0140-6736%2816%2931012-1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-harrisons9th-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-harrisons9th_9-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Seiden, Michael (2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://accessmedicine.mhmedical.com/content.aspx?bookid=1130&amp;sectionid=79730544\">\"Gynecologic Malignancies, Chapter 117\"</a>. MGraw-Hill Medical. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170910175639/https://accessmedicine.mhmedical.com/content.aspx?bookid=1130&amp;sectionid=79730544\">Archived</a> from the original on September 10, 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">June 24,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gynecologic+Malignancies%2C+Chapter+117&amp;rft.pub=MGraw-Hill+Medical&amp;rft.date=2015&amp;rft.aulast=Seiden&amp;rft.aufirst=Michael&amp;rft_id=https%3A%2F%2Faccessmedicine.mhmedical.com%2Fcontent.aspx%3Fbookid%3D1130%26sectionid%3D79730544&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer\">\"Defining Cancer\"</a>. <i>National Cancer Institute</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140625220940/http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer\">Archived</a> from the original on 25 June 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 June</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=National+Cancer+Institute&amp;rft.atitle=Defining+Cancer&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fcancerlibrary%2Fwhat-is-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ebell, MH; Culp, MB; Radke, TJ (March 2016). \"A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer\". <i>American journal of preventive medicine</i>. <b>50</b> (3): 384\u201394. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.amepre.2015.09.023\">10.1016/j.amepre.2015.09.023</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26541098\">26541098</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=American+journal+of+preventive+medicine&amp;rft.atitle=A+Systematic+Review+of+Symptoms+for+the+Diagnosis+of+Ovarian+Cancer.&amp;rft.volume=50&amp;rft.issue=3&amp;rft.pages=384-94&amp;rft.date=2016-03&amp;rft_id=info%3Adoi%2F10.1016%2Fj.amepre.2015.09.023&amp;rft_id=info%3Apmid%2F26541098&amp;rft.aulast=Ebell&amp;rft.aufirst=MH&amp;rft.au=Culp%2C+MB&amp;rft.au=Radke%2C+TJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Ruddon, Raymond W. (2007). <a rel=\"nofollow\" class=\"external text\" href=\"https://books.google.com/books?id=PymZ1ORk0TcC&amp;pg=PA223\"><i>Cancer biology</i></a> (4th ed.). Oxford: Oxford University Press. p.&#160;223. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/9780195175431\" title=\"Special:BookSources/9780195175431\">9780195175431</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150915231411/https://books.google.com/books?id=PymZ1ORk0TcC&amp;pg=PA223\">Archived</a> from the original on 2015-09-15.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Cancer+biology&amp;rft.place=Oxford&amp;rft.pages=223&amp;rft.edition=4th&amp;rft.pub=Oxford+University+Press&amp;rft.date=2007&amp;rft.isbn=9780195175431&amp;rft.aulast=Ruddon&amp;rft.aufirst=Raymond+W.&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DPymZ1ORk0TcC%26pg%3DPA223&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Piek JM, van Diest PJ, Verheijen RH (2008). \"Ovarian carcinogenesis: an alternative hypothesis\". <i>Adv. Exp. Med. Biol</i>. Advances in Experimental Medicine and Biology. <b>622</b>: 79\u201387. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/978-0-387-68969-2_7\">10.1007/978-0-387-68969-2_7</a>. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-387-68966-1\" title=\"Special:BookSources/978-0-387-68966-1\">978-0-387-68966-1</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18546620\">18546620</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Adv.+Exp.+Med.+Biol.&amp;rft.atitle=Ovarian+carcinogenesis%3A+an+alternative+hypothesis&amp;rft.volume=622&amp;rft.pages=79-87&amp;rft.date=2008&amp;rft_id=info%3Apmid%2F18546620&amp;rft_id=info%3Adoi%2F10.1007%2F978-0-387-68969-2_7&amp;rft.isbn=978-0-387-68966-1&amp;rft.aulast=Piek&amp;rft.aufirst=JM&amp;rft.au=van+Diest%2C+PJ&amp;rft.au=Verheijen%2C+RH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span style=\"position:relative; top: -2px;\"><a href=\"/wiki/Paywall\" title=\"closed access publication \u2013 behind paywall\"><img alt=\"closed access publication \u2013 behind paywall\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/c/c1/Closed_Access_logo_alternative.svg/9px-Closed_Access_logo_alternative.svg.png\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/c/c1/Closed_Access_logo_alternative.svg/14px-Closed_Access_logo_alternative.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/c/c1/Closed_Access_logo_alternative.svg/18px-Closed_Access_logo_alternative.svg.png 2x\" data-file-width=\"640\" data-file-height=\"1000\" /></a></span></span>\n</li>\n<li id=\"cite_note-Gros2018-14\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Gros2018_14-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Gros2018_14-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Grossman, David C.; Curry, Susan J.; Owens, Douglas K.; Barry, Michael J.; Davidson, Karina W.; Doubeni, Chyke A.; Epling, John W.; Kemper, Alex R.; Krist, Alex H.; Kurth, Ann E.; Landefeld, C. Seth; Mangione, Carol M.; Phipps, Maureen G.; Silverstein, Michael; Simon, Melissa A.; Tseng, Chien-Wen (13 February 2018). \"Screening for Ovarian Cancer\". <i>JAMA</i>. <b>319</b> (6): 588. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/jama.2017.21926\">10.1001/jama.2017.21926</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=Screening+for+Ovarian+Cancer&amp;rft.volume=319&amp;rft.issue=6&amp;rft.pages=588&amp;rft.date=2018-02-13&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2017.21926&amp;rft.aulast=Grossman&amp;rft.aufirst=David+C.&amp;rft.au=Curry%2C+Susan+J.&amp;rft.au=Owens%2C+Douglas+K.&amp;rft.au=Barry%2C+Michael+J.&amp;rft.au=Davidson%2C+Karina+W.&amp;rft.au=Doubeni%2C+Chyke+A.&amp;rft.au=Epling%2C+John+W.&amp;rft.au=Kemper%2C+Alex+R.&amp;rft.au=Krist%2C+Alex+H.&amp;rft.au=Kurth%2C+Ann+E.&amp;rft.au=Landefeld%2C+C.+Seth&amp;rft.au=Mangione%2C+Carol+M.&amp;rft.au=Phipps%2C+Maureen+G.&amp;rft.au=Silverstein%2C+Michael&amp;rft.au=Simon%2C+Melissa+A.&amp;rft.au=Tseng%2C+Chien-Wen&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Gib2016-15\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Gib2016_15-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Gib2016_15-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Gib2016_15-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Gibson, Steven J.; Fleming, Gini F.; Temkin, Sarah M.; Chase, Dana M. (2016). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4805611\">\"The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years\"</a>. <i>Frontiers in Oncology</i>. <b>6</b>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3389/fonc.2016.00063\">10.3389/fonc.2016.00063</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4805611\">4805611</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27047797\">27047797</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Frontiers+in+Oncology&amp;rft.atitle=The+Application+and+Outcome+of+Standard+of+Care+Treatment+in+Elderly+Women+with+Ovarian+Cancer%3A+A+Literature+Review+over+the+Last+10+Years&amp;rft.volume=6&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4805611&amp;rft_id=info%3Apmid%2F27047797&amp;rft_id=info%3Adoi%2F10.3389%2Ffonc.2016.00063&amp;rft.aulast=Gibson&amp;rft.aufirst=Steven+J.&amp;rft.au=Fleming%2C+Gini+F.&amp;rft.au=Temkin%2C+Sarah+M.&amp;rft.au=Chase%2C+Dana+M.&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4805611&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Harrisons-16\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Harrisons_16-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-19\"><sup><i><b>t</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-20\"><sup><i><b>u</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-21\"><sup><i><b>v</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-22\"><sup><i><b>w</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-23\"><sup><i><b>x</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-24\"><sup><i><b>y</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-25\"><sup><i><b>z</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-26\"><sup><i><b>aa</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-27\"><sup><i><b>ab</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-28\"><sup><i><b>ac</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-29\"><sup><i><b>ad</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-30\"><sup><i><b>ae</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-31\"><sup><i><b>af</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-32\"><sup><i><b>ag</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-33\"><sup><i><b>ah</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-34\"><sup><i><b>ai</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-35\"><sup><i><b>aj</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-36\"><sup><i><b>ak</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-37\"><sup><i><b>al</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-38\"><sup><i><b>am</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-39\"><sup><i><b>an</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-40\"><sup><i><b>ao</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-41\"><sup><i><b>ap</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-42\"><sup><i><b>aq</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-43\"><sup><i><b>ar</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-44\"><sup><i><b>as</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-45\"><sup><i><b>at</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-46\"><sup><i><b>au</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-47\"><sup><i><b>av</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-48\"><sup><i><b>aw</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-49\"><sup><i><b>ax</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-50\"><sup><i><b>ay</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-51\"><sup><i><b>az</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-52\"><sup><i><b>ba</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-53\"><sup><i><b>bb</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-54\"><sup><i><b>bc</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-55\"><sup><i><b>bd</b></i></sup></a> <a href=\"#cite_ref-Harrisons_16-56\"><sup><i><b>be</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\">Seiden MV (2012). \"Gynecologic Malignancies\".  In Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. <i><a href=\"/wiki/Harrison%27s_Principles_of_Internal_Medicine\" title=\"Harrison&#39;s Principles of Internal Medicine\">Harrison's Principles of Internal Medicine</a></i> (18th ed.). McGraw-Hill. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-174889-6\" title=\"Special:BookSources/978-0-07-174889-6\">978-0-07-174889-6</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Gynecologic+Malignancies&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine&amp;rft.edition=18th&amp;rft.pub=McGraw-Hill&amp;rft.date=2012&amp;rft.isbn=978-0-07-174889-6&amp;rft.aulast=Seiden&amp;rft.aufirst=Michael+V.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-CDCsep2016-17\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CDCsep2016_17-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CDCsep2016_17-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-CDCsep2016_17-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-CDCsep2016_17-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/cancer/ovarian/pdf/ovarian_facts.pdf\">\"Ovarian Cancer, Inside Knowledge, Get the Facts about Gynecological Cancer\"</a> <span style=\"font-size:85%;\">(PDF)</span>. Centers for Disease Control and Prevention. September 2016. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170616220028/https://www.cdc.gov/cancer/ovarian/pdf/ovarian_facts.pdf\">Archived</a> <span style=\"font-size:85%;\">(PDF)</span> from the original on June 16, 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">June 17,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Ovarian+Cancer%2C+Inside+Knowledge%2C+Get+the+Facts+about+Gynecological+Cancer&amp;rft.pub=Centers+for+Disease+Control+and+Prevention&amp;rft.date=2016-09&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fcancer%2Fovarian%2Fpdf%2Fovarian_facts.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png\" width=\"12\" height=\"12\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x\" data-file-width=\"196\" data-file-height=\"196\" />&#160;This article incorporates&#160;<a href=\"/wiki/Copyright_status_of_work_by_the_U.S._government\" title=\"Copyright status of work by the U.S. government\">public domain material</a> from websites or documents of&#32;the <a href=\"/wiki/Centers_for_Disease_Control_and_Prevention\" title=\"Centers for Disease Control and Prevention\">Centers for Disease Control and Prevention</a>.\n</span>\n</li>\n<li id=\"cite_note-Jayson-18\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Jayson_18-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-19\"><sup><i><b>t</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-20\"><sup><i><b>u</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-21\"><sup><i><b>v</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-22\"><sup><i><b>w</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-23\"><sup><i><b>x</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-24\"><sup><i><b>y</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-25\"><sup><i><b>z</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-26\"><sup><i><b>aa</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-27\"><sup><i><b>ab</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-28\"><sup><i><b>ac</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-29\"><sup><i><b>ad</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-30\"><sup><i><b>ae</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-31\"><sup><i><b>af</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-32\"><sup><i><b>ag</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-33\"><sup><i><b>ah</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-34\"><sup><i><b>ai</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-35\"><sup><i><b>aj</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-36\"><sup><i><b>ak</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-37\"><sup><i><b>al</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-38\"><sup><i><b>am</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-39\"><sup><i><b>an</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-40\"><sup><i><b>ao</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-41\"><sup><i><b>ap</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-42\"><sup><i><b>aq</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-43\"><sup><i><b>ar</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-44\"><sup><i><b>as</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-45\"><sup><i><b>at</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-46\"><sup><i><b>au</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-47\"><sup><i><b>av</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-48\"><sup><i><b>aw</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-49\"><sup><i><b>ax</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-50\"><sup><i><b>ay</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-51\"><sup><i><b>az</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-52\"><sup><i><b>ba</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-53\"><sup><i><b>bb</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-54\"><sup><i><b>bc</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-55\"><sup><i><b>bd</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-56\"><sup><i><b>be</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-57\"><sup><i><b>bf</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-58\"><sup><i><b>bg</b></i></sup></a> <a href=\"#cite_ref-Jayson_18-59\"><sup><i><b>bh</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (October 2014). \"Ovarian cancer\". <i>Lancet</i>. <b>384</b> (9951): 1376\u201388. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0140-6736%2813%2962146-7\">10.1016/S0140-6736(13)62146-7</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/24767708\">24767708</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Ovarian+cancer&amp;rft.volume=384&amp;rft.issue=9951&amp;rft.pages=1376-88&amp;rft.date=2014-10&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2813%2962146-7&amp;rft_id=info%3Apmid%2F24767708&amp;rft.aulast=Jayson&amp;rft.aufirst=GC&amp;rft.au=Kohn%2C+EC&amp;rft.au=Kitchener%2C+HC&amp;rft.au=Ledermann%2C+JA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Hoffman35-19\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Hoffman35_19-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-19\"><sup><i><b>t</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-20\"><sup><i><b>u</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-21\"><sup><i><b>v</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-22\"><sup><i><b>w</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-23\"><sup><i><b>x</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-24\"><sup><i><b>y</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-25\"><sup><i><b>z</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-26\"><sup><i><b>aa</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-27\"><sup><i><b>ab</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-28\"><sup><i><b>ac</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-29\"><sup><i><b>ad</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-30\"><sup><i><b>ae</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-31\"><sup><i><b>af</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-32\"><sup><i><b>ag</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-33\"><sup><i><b>ah</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-34\"><sup><i><b>ai</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-35\"><sup><i><b>aj</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-36\"><sup><i><b>ak</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-37\"><sup><i><b>al</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-38\"><sup><i><b>am</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-39\"><sup><i><b>an</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-40\"><sup><i><b>ao</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-41\"><sup><i><b>ap</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-42\"><sup><i><b>aq</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-43\"><sup><i><b>ar</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-44\"><sup><i><b>as</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-45\"><sup><i><b>at</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-46\"><sup><i><b>au</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-47\"><sup><i><b>av</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-48\"><sup><i><b>aw</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-49\"><sup><i><b>ax</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-50\"><sup><i><b>ay</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-51\"><sup><i><b>az</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-52\"><sup><i><b>ba</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-53\"><sup><i><b>bb</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-54\"><sup><i><b>bc</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-55\"><sup><i><b>bd</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-56\"><sup><i><b>be</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-57\"><sup><i><b>bf</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-58\"><sup><i><b>bg</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-59\"><sup><i><b>bh</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-60\"><sup><i><b>bi</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-61\"><sup><i><b>bj</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-62\"><sup><i><b>bk</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-63\"><sup><i><b>bl</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-64\"><sup><i><b>bm</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-65\"><sup><i><b>bn</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-66\"><sup><i><b>bo</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-67\"><sup><i><b>bp</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-68\"><sup><i><b>bq</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-69\"><sup><i><b>br</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-70\"><sup><i><b>bs</b></i></sup></a> <a href=\"#cite_ref-Hoffman35_19-71\"><sup><i><b>bt</b></i></sup></a></span> <span class=\"reference-text\"><cite id=\"CITEREFWilliams_Gynecology2012\" class=\"citation book\">Hoffman, Barbara L.; Schorge, John O.; Schaffer, Joseph I.; Halvorson, Lisa M.; Bradshaw, Karen D.; Cunningham, F. Gary (2012). \"Epithelial Ovarian Cancer\". <i>Williams Gynecology</i> (2nd ed.). McGraw Hill Medical. pp.&#160;853\u2013878. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-171672-7\" title=\"Special:BookSources/978-0-07-171672-7\">978-0-07-171672-7</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Epithelial+Ovarian+Cancer&amp;rft.btitle=Williams+Gynecology&amp;rft.pages=853-878&amp;rft.edition=2nd&amp;rft.pub=McGraw+Hill+Medical&amp;rft.date=2012&amp;rft.isbn=978-0-07-171672-7&amp;rft.aulast=Hoffman&amp;rft.aufirst=Barbara+L.&amp;rft.au=Schorge%2C+John+O.&amp;rft.au=Schaffer%2C+Joseph+I.&amp;rft.au=Halvorson%2C+Lisa+M.&amp;rft.au=Bradshaw%2C+Karen+D.&amp;rft.au=Cunningham%2C+F.+Gary&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:0-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-:0_20-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-symptoms\">\"Ovarian cancer symptoms\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150512172659/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-symptoms\">Archived</a> from the original on 2015-05-12<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Ovarian+cancer+symptoms&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Fabout%2Fovarian-cancer-symptoms&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:7-21\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:7_21-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:7_21-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:7_21-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:7_21-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-:7_21-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-:7_21-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-:7_21-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-:7_21-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-:7_21-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-:7_21-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-:7_21-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-:7_21-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-:7_21-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-:7_21-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-:7_21-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-:7_21-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-:7_21-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-:7_21-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-:7_21-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-:7_21-19\"><sup><i><b>t</b></i></sup></a> <a href=\"#cite_ref-:7_21-20\"><sup><i><b>u</b></i></sup></a> <a href=\"#cite_ref-:7_21-21\"><sup><i><b>v</b></i></sup></a> <a href=\"#cite_ref-:7_21-22\"><sup><i><b>w</b></i></sup></a> <a href=\"#cite_ref-:7_21-23\"><sup><i><b>x</b></i></sup></a> <a href=\"#cite_ref-:7_21-24\"><sup><i><b>y</b></i></sup></a> <a href=\"#cite_ref-:7_21-25\"><sup><i><b>z</b></i></sup></a> <a href=\"#cite_ref-:7_21-26\"><sup><i><b>aa</b></i></sup></a> <a href=\"#cite_ref-:7_21-27\"><sup><i><b>ab</b></i></sup></a> <a href=\"#cite_ref-:7_21-28\"><sup><i><b>ac</b></i></sup></a> <a href=\"#cite_ref-:7_21-29\"><sup><i><b>ad</b></i></sup></a> <a href=\"#cite_ref-:7_21-30\"><sup><i><b>ae</b></i></sup></a> <a href=\"#cite_ref-:7_21-31\"><sup><i><b>af</b></i></sup></a> <a href=\"#cite_ref-:7_21-32\"><sup><i><b>ag</b></i></sup></a> <a href=\"#cite_ref-:7_21-33\"><sup><i><b>ah</b></i></sup></a> <a href=\"#cite_ref-:7_21-34\"><sup><i><b>ai</b></i></sup></a> <a href=\"#cite_ref-:7_21-35\"><sup><i><b>aj</b></i></sup></a> <a href=\"#cite_ref-:7_21-36\"><sup><i><b>ak</b></i></sup></a> <a href=\"#cite_ref-:7_21-37\"><sup><i><b>al</b></i></sup></a> <a href=\"#cite_ref-:7_21-38\"><sup><i><b>am</b></i></sup></a> <a href=\"#cite_ref-:7_21-39\"><sup><i><b>an</b></i></sup></a> <a href=\"#cite_ref-:7_21-40\"><sup><i><b>ao</b></i></sup></a> <a href=\"#cite_ref-:7_21-41\"><sup><i><b>ap</b></i></sup></a> <a href=\"#cite_ref-:7_21-42\"><sup><i><b>aq</b></i></sup></a> <a href=\"#cite_ref-:7_21-43\"><sup><i><b>ar</b></i></sup></a> <a href=\"#cite_ref-:7_21-44\"><sup><i><b>as</b></i></sup></a> <a href=\"#cite_ref-:7_21-45\"><sup><i><b>at</b></i></sup></a> <a href=\"#cite_ref-:7_21-46\"><sup><i><b>au</b></i></sup></a> <a href=\"#cite_ref-:7_21-47\"><sup><i><b>av</b></i></sup></a> <a href=\"#cite_ref-:7_21-48\"><sup><i><b>aw</b></i></sup></a> <a href=\"#cite_ref-:7_21-49\"><sup><i><b>ax</b></i></sup></a> <a href=\"#cite_ref-:7_21-50\"><sup><i><b>ay</b></i></sup></a> <a href=\"#cite_ref-:7_21-51\"><sup><i><b>az</b></i></sup></a> <a href=\"#cite_ref-:7_21-52\"><sup><i><b>ba</b></i></sup></a> <a href=\"#cite_ref-:7_21-53\"><sup><i><b>bb</b></i></sup></a> <a href=\"#cite_ref-:7_21-54\"><sup><i><b>bc</b></i></sup></a> <a href=\"#cite_ref-:7_21-55\"><sup><i><b>bd</b></i></sup></a> <a href=\"#cite_ref-:7_21-56\"><sup><i><b>be</b></i></sup></a> <a href=\"#cite_ref-:7_21-57\"><sup><i><b>bf</b></i></sup></a> <a href=\"#cite_ref-:7_21-58\"><sup><i><b>bg</b></i></sup></a> <a href=\"#cite_ref-:7_21-59\"><sup><i><b>bh</b></i></sup></a> <a href=\"#cite_ref-:7_21-60\"><sup><i><b>bi</b></i></sup></a> <a href=\"#cite_ref-:7_21-61\"><sup><i><b>bj</b></i></sup></a> <a href=\"#cite_ref-:7_21-62\"><sup><i><b>bk</b></i></sup></a> <a href=\"#cite_ref-:7_21-63\"><sup><i><b>bl</b></i></sup></a> <a href=\"#cite_ref-:7_21-64\"><sup><i><b>bm</b></i></sup></a> <a href=\"#cite_ref-:7_21-65\"><sup><i><b>bn</b></i></sup></a> <a href=\"#cite_ref-:7_21-66\"><sup><i><b>bo</b></i></sup></a> <a href=\"#cite_ref-:7_21-67\"><sup><i><b>bp</b></i></sup></a> <a href=\"#cite_ref-:7_21-68\"><sup><i><b>bq</b></i></sup></a> <a href=\"#cite_ref-:7_21-69\"><sup><i><b>br</b></i></sup></a> <a href=\"#cite_ref-:7_21-70\"><sup><i><b>bs</b></i></sup></a> <a href=\"#cite_ref-:7_21-71\"><sup><i><b>bt</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.dynamed.com/topics/dmp~AN~T900705/Ovarian-cancer\">\"Ovarian cancer\"</a>. DynaMed. June 18, 2015. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150621210904/http://www.dynamed.com/topics/dmp~AN~T900705/Ovarian-cancer\">Archived</a> from the original on June 21, 2015. <span style=\"font-size:90%; color:#555\">(Subscription required (<span title=\"The site requires a paid subscription to access this page.\" style=\"border-bottom:1px dotted;cursor:help\">help</span>))</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Ovarian+cancer&amp;rft.pub=DynaMed&amp;rft.date=2015-06-18&amp;rft_id=http%3A%2F%2Fwww.dynamed.com%2Ftopics%2Fdmp~AN~T900705%2FOvarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:8-22\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:8_22-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:8_22-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:8_22-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:8_22-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-:8_22-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-:8_22-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-:8_22-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-:8_22-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-:8_22-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-:8_22-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-:8_22-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-:8_22-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-:8_22-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-:8_22-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-:8_22-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-:8_22-15\"><sup><i><b>p</b></i></sup></a> <a href=\"#cite_ref-:8_22-16\"><sup><i><b>q</b></i></sup></a> <a href=\"#cite_ref-:8_22-17\"><sup><i><b>r</b></i></sup></a> <a href=\"#cite_ref-:8_22-18\"><sup><i><b>s</b></i></sup></a> <a href=\"#cite_ref-:8_22-19\"><sup><i><b>t</b></i></sup></a> <a href=\"#cite_ref-:8_22-20\"><sup><i><b>u</b></i></sup></a> <a href=\"#cite_ref-:8_22-21\"><sup><i><b>v</b></i></sup></a> <a href=\"#cite_ref-:8_22-22\"><sup><i><b>w</b></i></sup></a> <a href=\"#cite_ref-:8_22-23\"><sup><i><b>x</b></i></sup></a> <a href=\"#cite_ref-:8_22-24\"><sup><i><b>y</b></i></sup></a> <a href=\"#cite_ref-:8_22-25\"><sup><i><b>z</b></i></sup></a> <a href=\"#cite_ref-:8_22-26\"><sup><i><b>aa</b></i></sup></a> <a href=\"#cite_ref-:8_22-27\"><sup><i><b>ab</b></i></sup></a> <a href=\"#cite_ref-:8_22-28\"><sup><i><b>ac</b></i></sup></a> <a href=\"#cite_ref-:8_22-29\"><sup><i><b>ad</b></i></sup></a> <a href=\"#cite_ref-:8_22-30\"><sup><i><b>ae</b></i></sup></a> <a href=\"#cite_ref-:8_22-31\"><sup><i><b>af</b></i></sup></a> <a href=\"#cite_ref-:8_22-32\"><sup><i><b>ag</b></i></sup></a> <a href=\"#cite_ref-:8_22-33\"><sup><i><b>ah</b></i></sup></a> <a href=\"#cite_ref-:8_22-34\"><sup><i><b>ai</b></i></sup></a> <a href=\"#cite_ref-:8_22-35\"><sup><i><b>aj</b></i></sup></a> <a href=\"#cite_ref-:8_22-36\"><sup><i><b>ak</b></i></sup></a> <a href=\"#cite_ref-:8_22-37\"><sup><i><b>al</b></i></sup></a> <a href=\"#cite_ref-:8_22-38\"><sup><i><b>am</b></i></sup></a> <a href=\"#cite_ref-:8_22-39\"><sup><i><b>an</b></i></sup></a> <a href=\"#cite_ref-:8_22-40\"><sup><i><b>ao</b></i></sup></a></span> <span class=\"reference-text\"><a href=\"#CITEREFWilliams_Gynecology2012\">Williams Gynecology 2012</a></span>\n</li>\n<li id=\"cite_note-Current-23\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Current_23-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Current_23-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Current_23-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Current_23-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Current_23-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Current_23-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Current_23-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\">DeCherney, Alan; Nathan, Lauren; Goodwin, T. Murphy; Laufer, Neri; Roman, Ashley (2012). \"Pediatric and Adolescent Gynecology\". <i>Current Diagnosis &amp; Treatment Obstetrics &amp; Gynecology</i> (11th ed.). <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0071638562\" title=\"Special:BookSources/978-0071638562\">978-0071638562</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Pediatric+and+Adolescent+Gynecology&amp;rft.btitle=Current+Diagnosis+%26+Treatment+Obstetrics+%26+Gynecology&amp;rft.edition=11th&amp;rft.date=2012&amp;rft.isbn=978-0071638562&amp;rft.aulast=DeCherney&amp;rft.aufirst=Alan&amp;rft.au=Nathan%2C+Lauren&amp;rft.au=Goodwin%2C+T.+Murphy&amp;rft.au=Laufer%2C+Neri&amp;rft.au=Roman%2C+Ashley&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-CRUKRisks-24\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CRUKRisks_24-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-12\"><sup><i><b>m</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-13\"><sup><i><b>n</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-14\"><sup><i><b>o</b></i></sup></a> <a href=\"#cite_ref-CRUKRisks_24-15\"><sup><i><b>p</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-risks-and-causes\">\"Ovarian cancer risks and causes\"</a>. Cancer Research UK. 15 January 2014. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150221095418/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-risks-and-causes\">Archived</a> from the original on 21 February 2015<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">29 January</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Ovarian+cancer+risks+and+causes&amp;rft.pub=Cancer+Research+UK&amp;rft.date=2014-01-15&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Fabout%2Fovarian-cancer-risks-and-causes&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Gong, Ting-Ting; Wu, Qi-Jun; Vogtmann, Emily; Lin, Bei; Wang, Yong-Lai (2013-06-15). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3806278\">\"Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies\"</a>. <i>International Journal of Cancer</i>. <b>132</b> (12): 2894\u20132900. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/ijc.27952\">10.1002/ijc.27952</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0020-7136\">0020-7136</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3806278\">3806278</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23175139\">23175139</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Cancer&amp;rft.atitle=Age+at+menarche+and+risk+of+ovarian+cancer%3A+a+meta-analysis+of+epidemiological+studies&amp;rft.volume=132&amp;rft.issue=12&amp;rft.pages=2894-2900&amp;rft.date=2013-06-15&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3806278&amp;rft.issn=0020-7136&amp;rft_id=info%3Apmid%2F23175139&amp;rft_id=info%3Adoi%2F10.1002%2Fijc.27952&amp;rft.aulast=Gong&amp;rft.aufirst=Ting-Ting&amp;rft.au=Wu%2C+Qi-Jun&amp;rft.au=Vogtmann%2C+Emily&amp;rft.au=Lin%2C+Bei&amp;rft.au=Wang%2C+Yong-Lai&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3806278&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Manson JE, Bassuk SS (2012). \"The Menopause Transition and Postmenopausal Hormone Therapy\".  In Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. <i><a href=\"/wiki/Harrison%27s_Principles_of_Internal_Medicine\" title=\"Harrison&#39;s Principles of Internal Medicine\">Harrison's Principles of Internal Medicine</a></i> (18th ed.). McGraw-Hill. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-174889-6\" title=\"Special:BookSources/978-0-07-174889-6\">978-0-07-174889-6</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=The+Menopause+Transition+and+Postmenopausal+Hormone+Therapy&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine&amp;rft.edition=18th&amp;rft.pub=McGraw-Hill&amp;rft.date=2012&amp;rft.isbn=978-0-07-174889-6&amp;rft.aulast=Manson&amp;rft.aufirst=JoAnn+E.&amp;rft.au=Bassuk%2C+Shari+S.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NCIPrevention-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-NCIPrevention_27-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/healthprofessional\">\"Ovarian Cancer Prevention (PDQ\u00ae)\"</a>. <a href=\"/wiki/National_Cancer_Institute\" title=\"National Cancer Institute\">National Cancer Institute</a>. 2013. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131231100136/http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/healthprofessional\">Archived</a> from the original on 2013-12-31<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2013-12-30</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Ovarian+Cancer+Prevention+%28PDQ%C2%AE%29&amp;rft.pub=National+Cancer+Institute&amp;rft.date=2013&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Fprevention%2Fovarian%2Fhealthprofessional&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kyriakidis I, Papaioannidou P (2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://link.springer.com/article/10.1007%2Fs00404-016-4027-8\">\"Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy\"</a>. <i>Arch Gynecol Oncol</i>. <b>293</b> (6): 1161\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s00404-016-4027-8\">10.1007/s00404-016-4027-8</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26861465\">26861465</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Arch+Gynecol+Oncol&amp;rft.atitle=Estrogen+receptor+beta+and+ovarian+cancer%3A+a+key+to+pathogenesis+and+response+to+therapy&amp;rft.volume=293&amp;rft.issue=6&amp;rft.pages=1161-8&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1007%2Fs00404-016-4027-8&amp;rft_id=info%3Apmid%2F26861465&amp;rft.aulast=Kyriakidis&amp;rft.aufirst=I&amp;rft.au=Papaioannidou%2C+P&amp;rft_id=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%252Fs00404-016-4027-8&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Norquist2015-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Norquist2015_29-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ (2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2015.5495\">\"Inherited mutations in women With ovarian carcinoma\"</a>. <i>JAMA Oncol</i>. <b>30</b>: 1\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/jamaoncol.2015.5495\">10.1001/jamaoncol.2015.5495</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4845939\">4845939</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26720728\">26720728</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA+Oncol&amp;rft.atitle=Inherited+mutations+in+women+With+ovarian+carcinoma&amp;rft.volume=30&amp;rft.pages=1-9&amp;rft.date=2015&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4845939&amp;rft_id=info%3Apmid%2F26720728&amp;rft_id=info%3Adoi%2F10.1001%2Fjamaoncol.2015.5495&amp;rft.aulast=Norquist&amp;rft.aufirst=BM&amp;rft.au=Harrell%2C+MI&amp;rft.au=Brady%2C+MF&amp;rft.au=Walsh%2C+T&amp;rft.au=Lee%2C+MK&amp;rft.au=Gulsuner%2C+S&amp;rft.au=Bernards%2C+SS&amp;rft.au=Casadei%2C+S&amp;rft.au=Yi%2C+Q&amp;rft.au=Burger%2C+RA&amp;rft.au=Chan%2C+JK&amp;rft.au=Davidson%2C+SA&amp;rft.au=Mannel%2C+RS&amp;rft.au=DiSilvestro%2C+PA&amp;rft.au=Lankes%2C+HA&amp;rft.au=Ramirez%2C+NC&amp;rft.au=King%2C+MC&amp;rft.au=Swisher%2C+EM&amp;rft.au=Birrer%2C+MJ&amp;rft_id=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamaoncology%2Ffullarticle%2F10.1001%2Fjamaoncol.2015.5495&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Kuusisto2011-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Kuusisto2011_30-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL (2011). <a rel=\"nofollow\" class=\"external text\" href=\"https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2832\">\"Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals\"</a>. <i>Breast Cancer Res</i>. <b>13</b> (1): R20. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1186/bcr2832\">10.1186/bcr2832</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3109589\">3109589</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21356067\">21356067</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170710051625/http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2832\">Archived</a> from the original on 2017-07-10.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Breast+Cancer+Res&amp;rft.atitle=Screening+for+BRCA1%2C+BRCA2%2C+CHEK2%2C+PALB2%2C+BRIP1%2C+RAD50%2C+and+CDH1+mutations+in+high-risk+Finnish+BRCA1%2F2-founder+mutation-negative+breast+and%2For+ovarian+cancer+individuals&amp;rft.volume=13&amp;rft.issue=1&amp;rft.pages=R20&amp;rft.date=2011&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3109589&amp;rft_id=info%3Apmid%2F21356067&amp;rft_id=info%3Adoi%2F10.1186%2Fbcr2832&amp;rft.aulast=Kuusisto&amp;rft.aufirst=KM&amp;rft.au=Bebel%2C+A&amp;rft.au=Vihinen%2C+M&amp;rft.au=Schleutker%2C+J&amp;rft.au=Sallinen%2C+SL&amp;rft_id=https%3A%2F%2Fbreast-cancer-research.biomedcentral.com%2Farticles%2F10.1186%2Fbcr2832&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-31\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Salehi, Fariba; Dunfield, Lesley; Phillips, Karen P.; Krewski, Daniel; Vanderhyden, Barbara C. (1 March 2008). \"Risk factors for ovarian cancer: an overview with emphasis on hormonal factors\". <i>Journal of Toxicology and Environmental Health. Part B, Critical Reviews</i>. <b>11</b>: 301\u2013321. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1080/10937400701876095\">10.1080/10937400701876095</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18368558\">18368558</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Toxicology+and+Environmental+Health.+Part+B%2C+Critical+Reviews&amp;rft.atitle=Risk+factors+for+ovarian+cancer%3A+an+overview+with+emphasis+on+hormonal+factors&amp;rft.volume=11&amp;rft.pages=301-321&amp;rft.date=2008-03-01&amp;rft_id=info%3Adoi%2F10.1080%2F10937400701876095&amp;rft_id=info%3Apmid%2F18368558&amp;rft.aulast=Salehi&amp;rft.aufirst=Fariba&amp;rft.au=Dunfield%2C+Lesley&amp;rft.au=Phillips%2C+Karen+P.&amp;rft.au=Krewski%2C+Daniel&amp;rft.au=Vanderhyden%2C+Barbara+C.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-32\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-what-causes\">\"Do we know what causes ovarian cancer?\"</a>. <i>www.cancer.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161110052501/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-what-causes\">Archived</a> from the original on 2016-11-10.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancer.org&amp;rft.atitle=Do+we+know+what+causes+ovarian+cancer%3F&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fovariancancer%2Fdetailedguide%2Fovarian-cancer-what-causes&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-33\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hjart\u00e5ker A, Meo MS, Weiderpass E (January 2010). \"Alcohol and gynecological cancers: an overview\". <i>European Journal of Cancer Prevention</i>. <b>19</b> (1): 1\u201310. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/CEJ.0b013e328333fb3a\">10.1097/CEJ.0b013e328333fb3a</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19926999\">19926999</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Journal+of+Cancer+Prevention&amp;rft.atitle=Alcohol+and+gynecological+cancers%3A+an+overview&amp;rft.volume=19&amp;rft.issue=1&amp;rft.pages=1-10&amp;rft.date=2010-01&amp;rft_id=info%3Adoi%2F10.1097%2FCEJ.0b013e328333fb3a&amp;rft_id=info%3Apmid%2F19926999&amp;rft.aulast=Hjart%C3%A5ker&amp;rft.aufirst=A&amp;rft.au=Meo%2C+MS&amp;rft.au=Weiderpass%2C+E&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-34\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-34\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Zhang X, Nicosia SV, Bai W (2006). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.eurekaselect.com/55888/article\">\"Vitamin D receptor is a novel drug target for ovarian cancer treatment\"</a>. <i>Curr Cancer Drug Targets</i>. <b>6</b> (3): 229\u201344. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.2174/156800906776842939\">10.2174/156800906776842939</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/16712459\">16712459</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161028153624/http://www.eurekaselect.com/55888/article\">Archived</a> from the original on 2016-10-28.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr+Cancer+Drug+Targets&amp;rft.atitle=Vitamin+D+receptor+is+a+novel+drug+target+for+ovarian+cancer+treatment&amp;rft.volume=6&amp;rft.issue=3&amp;rft.pages=229-44&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.2174%2F156800906776842939&amp;rft_id=info%3Apmid%2F16712459&amp;rft.aulast=Zhang&amp;rft.aufirst=X&amp;rft.au=Nicosia%2C+SV&amp;rft.au=Bai%2C+W&amp;rft_id=http%3A%2F%2Fwww.eurekaselect.com%2F55888%2Farticle&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Biswas-35\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Biswas_35-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA (2015). \"Sedentary Time and Its Association With Risk for Disease Incidence, Mortality, and Hospitalization in Adults: A Systematic Review and Meta-analysis\". <i>Annals of Internal Medicine</i>. <b>162</b> (2): 123\u201332. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.7326/M14-1651\">10.7326/M14-1651</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25599350\">25599350</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Internal+Medicine&amp;rft.atitle=Sedentary+Time+and+Its+Association+With+Risk+for+Disease+Incidence%2C+Mortality%2C+and+Hospitalization+in+Adults%3A+A+Systematic+Review+and+Meta-analysis&amp;rft.volume=162&amp;rft.issue=2&amp;rft.pages=123-32&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.7326%2FM14-1651&amp;rft_id=info%3Apmid%2F25599350&amp;rft.aulast=Biswas&amp;rft.aufirst=A&amp;rft.au=Oh%2C+PI&amp;rft.au=Faulkner%2C+GE&amp;rft.au=Bajaj%2C+RR&amp;rft.au=Silver%2C+MA&amp;rft.au=Mitchell%2C+MS&amp;rft.au=Alter%2C+DA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-DeVita100-36\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-DeVita100_36-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-DeVita100_36-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\">Odunsi, Kunle; Pejovic, Tanja; Anderson, Matthew L. (2011). <i>Molecular Biology of Gynecologic Cancers</i>. <i>DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology</i>. Wolters Kluwer/Lippincott Williams &amp; Wilkins. pp.&#160;1302\u20131310. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-1-4511-0545-2\" title=\"Special:BookSources/978-1-4511-0545-2\">978-1-4511-0545-2</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Molecular+Biology+of+Gynecologic+Cancers&amp;rft.pages=1302-1310&amp;rft.pub=Wolters+Kluwer%2FLippincott+Williams+%26+Wilkins&amp;rft.date=2011&amp;rft.isbn=978-1-4511-0545-2&amp;rft.aulast=Odunsi&amp;rft.aufirst=Kunle&amp;rft.au=Pejovic%2C+Tanja&amp;rft.au=Anderson%2C+Matthew+L.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NCIGenetics-37\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-NCIGenetics_37-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional\">\"Genetics of Breast and Ovarian Cancer (PDQ\u00ae)\"</a>. National Cancer Institute. 2 October 2014. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20141022060353/http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional\">Archived</a> from the original on 22 October 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">27 October</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Genetics+of+Breast+and+Ovarian+Cancer+%28PDQ%C2%AE%29&amp;rft.pub=National+Cancer+Institute&amp;rft.date=2014-10-02&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Fgenetics%2Fbreast-and-ovarian%2FHealthProfessional&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-38\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-38\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS (2010-01-28). <a rel=\"nofollow\" class=\"external text\" href=\"https://academic.oup.com/jnci/article/102/4/222/2568923\">\"Predictive Value of Symptoms for Early Detection of Ovarian Cancer\"</a>. <i>J Natl Cancer Inst</i>. <b>102</b> (4): 222\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1093/jnci/djp500\">10.1093/jnci/djp500</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2826180\">2826180</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20110551\">20110551</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J+Natl+Cancer+Inst&amp;rft.atitle=Predictive+Value+of+Symptoms+for+Early+Detection+of+Ovarian+Cancer&amp;rft.volume=102&amp;rft.issue=4&amp;rft.pages=222-9&amp;rft.date=2010-01-28&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2826180&amp;rft_id=info%3Apmid%2F20110551&amp;rft_id=info%3Adoi%2F10.1093%2Fjnci%2Fdjp500&amp;rft.aulast=Rossing&amp;rft.aufirst=MA&amp;rft.au=Wicklund%2C+KG&amp;rft.au=Cushing-Haugen%2C+KL&amp;rft.au=Weiss%2C+NS&amp;rft_id=https%3A%2F%2Facademic.oup.com%2Fjnci%2Farticle%2F102%2F4%2F222%2F2568923&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Miller-39\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Miller_39-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Miller_39-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Miller_39-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Miller RW, Ueland FR (March 2012). \"Risk of malignancy in sonographically confirmed ovarian tumors\". <i>Clinical obstetrics and gynecology</i>. <b>55</b> (1): 52\u201364. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/GRF.0b013e31824970cf\">10.1097/GRF.0b013e31824970cf</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/22343229\">22343229</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+obstetrics+and+gynecology&amp;rft.atitle=Risk+of+malignancy+in+sonographically+confirmed+ovarian+tumors.&amp;rft.volume=55&amp;rft.issue=1&amp;rft.pages=52-64&amp;rft.date=2012-03&amp;rft_id=info%3Adoi%2F10.1097%2FGRF.0b013e31824970cf&amp;rft_id=info%3Apmid%2F22343229&amp;rft.aulast=Miller&amp;rft.aufirst=RW&amp;rft.au=Ueland%2C+FR&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-40\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-40\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/diagnosis/ovarian-cancer-tests\">\"Ovarian cancer tests\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150518091201/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/diagnosis/ovarian-cancer-tests\">Archived</a> from the original on 2015-05-18<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Ovarian+cancer+tests&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Fdiagnosis%2Fovarian-cancer-tests&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NICE2011-41\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-NICE2011_41-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20130922075958/http://publications.nice.org.uk/ovarian-cancer-cg122/appendix-d-risk-of-malignancy-index-rmi-i\">\"Guideline CG122. Ovarian cancer: The recognition and initial management of ovarian cancer, Appendix D: Risk of malignancy index (RMI I)\"</a>. <i>NICE clinical guidelines</i>. April 2011. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://publications.nice.org.uk/ovarian-cancer-cg122/appendix-d-risk-of-malignancy-index-rmi-i\">the original</a> on 2013-09-22.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NICE+clinical+guidelines&amp;rft.atitle=Guideline+CG122.+Ovarian+cancer%3A+The+recognition+and+initial+management+of+ovarian+cancer%2C+Appendix+D%3A+Risk+of+malignancy+index+%28RMI+I%29.&amp;rft.date=2011-04&amp;rft_id=http%3A%2F%2Fpublications.nice.org.uk%2Fovarian-cancer-cg122%2Fappendix-d-risk-of-malignancy-index-rmi-i&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-42\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-42\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Geomini, Peggy; Kruitwagen, Roy; Bremer, G\u00e9rard L.; Cnossen, Jeltsje; Mol, Ben W. J. (Feb 2009). \"The accuracy of risk scores in predicting ovarian malignancy: a systematic review\". <i>Obstetrics and Gynecology</i>. <b>113</b> (2 Pt 1): 384\u2013394. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/AOG.0b013e318195ad17\">10.1097/AOG.0b013e318195ad17</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0029-7844\">0029-7844</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19155910\">19155910</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Obstetrics+and+Gynecology&amp;rft.atitle=The+accuracy+of+risk+scores+in+predicting+ovarian+malignancy%3A+a+systematic+review&amp;rft.volume=113&amp;rft.issue=2+Pt+1&amp;rft.pages=384-394&amp;rft.date=2009-02&amp;rft.issn=0029-7844&amp;rft_id=info%3Apmid%2F19155910&amp;rft_id=info%3Adoi%2F10.1097%2FAOG.0b013e318195ad17&amp;rft.aulast=Geomini&amp;rft.aufirst=Peggy&amp;rft.au=Kruitwagen%2C+Roy&amp;rft.au=Bremer%2C+G%C3%A9rard+L.&amp;rft.au=Cnossen%2C+Jeltsje&amp;rft.au=Mol%2C+Ben+W.+J.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-43\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-43\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kaijser, Jeroen; Bourne, Tom; De Rijdt, Sylvie; Van Holsbeke, Caroline; Sayasneh, Ahmad; Valentin, Lil; Van Calster, Ben; Timmerman, Dirk (August 2012). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5025098\">\"Key findings from the International Ovarian Tumor Analysis (IOTA) study: an approach to the optimal ultrasound based characterisation of adnexal pathology\"</a>. <i>Australasian Journal of Ultrasound in Medicine</i>. <b>15</b> (3): 82\u201386. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/j.2205-0140.2012.tb00011.x\">10.1002/j.2205-0140.2012.tb00011.x</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1836-6864\">1836-6864</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5025098\">5025098</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28191150\">28191150</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Australasian+Journal+of+Ultrasound+in+Medicine&amp;rft.atitle=Key+findings+from+the+International+Ovarian+Tumor+Analysis+%28IOTA%29+study%3A+an+approach+to+the+optimal+ultrasound+based+characterisation+of+adnexal+pathology&amp;rft.volume=15&amp;rft.issue=3&amp;rft.pages=82-86&amp;rft.date=2012-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5025098&amp;rft.issn=1836-6864&amp;rft_id=info%3Apmid%2F28191150&amp;rft_id=info%3Adoi%2F10.1002%2Fj.2205-0140.2012.tb00011.x&amp;rft.aulast=Kaijser&amp;rft.aufirst=Jeroen&amp;rft.au=Bourne%2C+Tom&amp;rft.au=De+Rijdt%2C+Sylvie&amp;rft.au=Van+Holsbeke%2C+Caroline&amp;rft.au=Sayasneh%2C+Ahmad&amp;rft.au=Valentin%2C+Lil&amp;rft.au=Van+Calster%2C+Ben&amp;rft.au=Timmerman%2C+Dirk&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5025098&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-SEER6215ch16-44\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-SEER6215ch16_44-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-SEER6215ch16_44-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\">Kosary, Carol L. (2007). <a rel=\"nofollow\" class=\"external text\" href=\"http://seer.cancer.gov/publications/survival/surv_ovary.pdf\">\"Chapter 16: Cancers of the Ovary\"</a> <span style=\"font-size:85%;\">(PDF)</span>.  In Baguio, RNL; Young, JL; Keel, GE; Eisner, MP; Lin, YD; Horner, M-J. <a rel=\"nofollow\" class=\"external text\" href=\"http://seer.cancer.gov/publications/survival/\"><i>SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988\u20132001, Patient and Tumor Characteristics</i></a>. SEER Program. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp.&#160;133\u2013144. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131010123756/http://seer.cancer.gov/publications/survival/\">Archived</a> from the original on 2013-10-10.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Chapter+16%3A+Cancers+of+the+Ovary&amp;rft.btitle=SEER+Survival+Monograph%3A+Cancer+Survival+Among+Adults%3A+US+SEER+Program%2C+1988%E2%80%932001%2C+Patient+and+Tumor+Characteristics&amp;rft.place=Bethesda%2C+MD&amp;rft.series=SEER+Program&amp;rft.pages=133-144&amp;rft.pub=National+Cancer+Institute&amp;rft.date=2007&amp;rft.aulast=Kosary&amp;rft.aufirst=Carol+L.&amp;rft_id=http%3A%2F%2Fseer.cancer.gov%2Fpublications%2Fsurvival%2Fsurv_ovary.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:1-45\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:1_45-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:1_45-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:1_45-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:1_45-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-:1_45-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-:1_45-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-:1_45-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-:1_45-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-:1_45-8\"><sup><i><b>i</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/types-of-ovarian-cancer\">\"Types of ovarian cancer\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150518091024/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/types-of-ovarian-cancer\">Archived</a> from the original on 2015-05-18<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Types+of+ovarian+cancer&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Fabout%2Ftypes-of-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Levy-46\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Levy_46-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Levy_46-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Levy_46-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\">Levy, Gary; Purcell; Karen (2013).  DeCherney, AH; Nathan, L; Laufer, N;  et al., eds. <a rel=\"nofollow\" class=\"external text\" href=\"http://accessmedicine.mhmedical.com/content.aspx?bookid=498&amp;sectionid=41008645\"><i>Premalignant &amp; Malignant Disorders of the Ovaries &amp; Oviducts</i></a>. <i>CURRENT Diagnosis &amp; Treatment: Obstetrics &amp; Gynecology, 11e</i>. McGraw-Hill. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-163856-2\" title=\"Special:BookSources/978-0-07-163856-2\">978-0-07-163856-2</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170910175639/http://accessmedicine.mhmedical.com/content.aspx?bookid=498&amp;sectionid=41008645\">Archived</a> from the original on 2017-09-10.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Premalignant+%26+Malignant+Disorders+of+the+Ovaries+%26+Oviducts&amp;rft.pub=McGraw-Hill&amp;rft.date=2013&amp;rft.isbn=978-0-07-163856-2&amp;rft.aulast=Levy&amp;rft.aufirst=Gary&amp;rft.au=Purcell&amp;rft.au=Karen&amp;rft_id=http%3A%2F%2Faccessmedicine.mhmedical.com%2Fcontent.aspx%3Fbookid%3D498%26sectionid%3D41008645&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-47\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-47\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/rare-cancers/rare-cancers-name/primary-peritoneal-carcinoma\">\"Primary peritoneal carcinoma\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150520031318/http://www.cancerresearchuk.org/about-cancer/type/rare-cancers/rare-cancers-name/primary-peritoneal-carcinoma\">Archived</a> from the original on 2015-05-20<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Primary+peritoneal+carcinoma&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Frare-cancers%2Frare-cancers-name%2Fprimary-peritoneal-carcinoma&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-SGO-48\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-SGO_48-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-SGO_48-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.sgo.org/wp-content/uploads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf\">\"Ovarian Cancer Staging\"</a> <span style=\"font-size:85%;\">(PDF)</span>. Society for Gynecologic Oncology. 1 January 2014. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20141105012607/https://www.sgo.org/wp-content/uploads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf\">Archived</a> <span style=\"font-size:85%;\">(PDF)</span> from the original on 5 November 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Ovarian+Cancer+Staging&amp;rft.pub=Society+for+Gynecologic+Oncology&amp;rft.date=2014-01-01&amp;rft_id=https%3A%2F%2Fwww.sgo.org%2Fwp-content%2Fuploads%2F2012%2F09%2FFIGO-Ovarian-Cancer-Staging_1.10.14.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-A-49\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-A_49-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-staging\">\"How is ovarian cancer staged?\"</a>. American Cancer Society. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161124070854/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-staging\">Archived</a> from the original on November 24, 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">June 17,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=How+is+ovarian+cancer+staged%3F&amp;rft.pub=American+Cancer+Society&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fovariancancer%2Fdetailedguide%2Fovarian-cancer-staging&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-50\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-50\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/stages-of-ovarian-cancer\">\"Stages of ovarian cancer\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150518132114/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/stages-of-ovarian-cancer\">Archived</a> from the original on 2015-05-18<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Stages+of+ovarian+cancer&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fstages-of-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Harrisons82-51\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Harrisons82_51-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Harrisons82_51-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Harrisons82_51-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\">Croswell JM, Brawley OW, Kramer BS (2012). \"Prevention and Early Detection of Cancer\".  In Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. <i><a href=\"/wiki/Harrison%27s_Principles_of_Internal_Medicine\" title=\"Harrison&#39;s Principles of Internal Medicine\">Harrison's Principles of Internal Medicine</a></i> (18th ed.). McGraw-Hill. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-174889-6\" title=\"Special:BookSources/978-0-07-174889-6\">978-0-07-174889-6</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Prevention+and+Early+Detection+of+Cancer&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine&amp;rft.edition=18th&amp;rft.pub=McGraw-Hill&amp;rft.date=2012&amp;rft.isbn=978-0-07-174889-6&amp;rft.aulast=Croswell&amp;rft.aufirst=Jennifer+M.&amp;rft.au=Brawley%2C+Otis+W.&amp;rft.au=Kramer%2C+Barnett+S.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-CibulaWidschwendter2010-52\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-CibulaWidschwendter2010_52-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cibula, D.; Widschwendter, M.; Majek, O.; Dusek, L. (2010). <a rel=\"nofollow\" class=\"external text\" href=\"https://academic.oup.com/humupd/article-lookup/doi/10.1093/humupd/dmq030\">\"Tubal ligation and the risk of ovarian cancer: review and meta-analysis\"</a>. <i>Human Reproduction Update</i>. <b>17</b> (1): 55\u201367. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1093/humupd/dmq030\">10.1093/humupd/dmq030</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20634209\">20634209</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170910175639/https://academic.oup.com/humupd/article-lookup/doi/10.1093/humupd/dmq030\">Archived</a> from the original on 2017-09-10.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Human+Reproduction+Update&amp;rft.atitle=Tubal+ligation+and+the+risk+of+ovarian+cancer%3A+review+and+meta-analysis&amp;rft.volume=17&amp;rft.issue=1&amp;rft.pages=55-67&amp;rft.date=2010&amp;rft_id=info%3Adoi%2F10.1093%2Fhumupd%2Fdmq030&amp;rft_id=info%3Apmid%2F20634209&amp;rft.aulast=Cibula&amp;rft.aufirst=D.&amp;rft.au=Widschwendter%2C+M.&amp;rft.au=Majek%2C+O.&amp;rft.au=Dusek%2C+L.&amp;rft_id=https%3A%2F%2Facademic.oup.com%2Fhumupd%2Farticle-lookup%2Fdoi%2F10.1093%2Fhumupd%2Fdmq030&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-CDCfeb2017-53\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CDCfeb2017_53-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CDCfeb2017_53-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/cancer/ovarian/basic_info/treatment.htm\">\"How Is Ovarian Cancer Treated?\"</a>. Centers for Disease Control and Prevention. February 13, 2017. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170616220128/https://www.cdc.gov/cancer/ovarian/basic_info/treatment.htm\">Archived</a> from the original on June 16, 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">June 17,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=How+Is+Ovarian+Cancer+Treated%3F&amp;rft.pub=Centers+for+Disease+Control+and+Prevention&amp;rft.date=2017-02-13&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fcancer%2Fovarian%2Fbasic_info%2Ftreatment.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png\" width=\"12\" height=\"12\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x\" data-file-width=\"196\" data-file-height=\"196\" />&#160;This article incorporates&#160;<a href=\"/wiki/Copyright_status_of_work_by_the_U.S._government\" title=\"Copyright status of work by the U.S. government\">public domain material</a> from websites or documents of&#32;the <a href=\"/wiki/Centers_for_Disease_Control_and_Prevention\" title=\"Centers for Disease Control and Prevention\">Centers for Disease Control and Prevention</a>.\n</span>\n</li>\n<li id=\"cite_note-54\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-54\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Marchetti, C; Pisano, C; Facchini, G (2010). \"First line treatment of ovarian cancer: current research and perspectives\". <i>Expert Rev Anticancer ther</i> (10): 47\u201360.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Rev+Anticancer+ther&amp;rft.atitle=First+line+treatment+of+ovarian+cancer%3A+current+research+and+perspectives&amp;rft.issue=10&amp;rft.pages=47-60&amp;rft.date=2010&amp;rft.aulast=Marchetti&amp;rft.aufirst=C&amp;rft.au=Pisano%2C+C&amp;rft.au=Facchini%2C+G&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:2-55\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:2_55-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:2_55-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:2_55-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:2_55-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-:2_55-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/which-treatment-for-ovarian-cancer\">\"Types of treatment for ovarian cancer\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150512164129/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/which-treatment-for-ovarian-cancer\">Archived</a> from the original on 2015-05-12<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Types+of+treatment+for+ovarian+cancer&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fwhich-treatment-for-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-CanadianCS2017-56\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-CanadianCS2017_56-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-CanadianCS2017_56-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-CanadianCS2017_56-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-CanadianCS2017_56-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.ca/en/cancer-information/cancer-type/ovarian/treatment/?region=on\">\"Treatment of ovarian cancer\"</a>. Canadian Cancer Society. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20161026174509/http://www.cancer.ca/en/cancer-information/cancer-type/ovarian/treatment/?region=on\">Archived</a> from the original on 26 October 2016<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 June</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Treatment+of+ovarian+cancer&amp;rft.pub=Canadian+Cancer+Society&amp;rft_id=http%3A%2F%2Fwww.cancer.ca%2Fen%2Fcancer-information%2Fcancer-type%2Fovarian%2Ftreatment%2F%3Fregion%3Don&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-57\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-57\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/surgery-for-ovarian-cancer\">\"Surgery for ovarian cancer\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150518161131/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/surgery-for-ovarian-cancer\">Archived</a> from the original on 2015-05-18<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Surgery+for+ovarian+cancer&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fsurgery-for-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-58\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-58\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Falcetta, Frederico S.; Lawrie, Theresa A.; Medeiros, L\u00eddia Rf; da Rosa, Maria Ines; Edelweiss, Maria I.; Stein, Airton T.; Zelmanowicz, Alice; Moraes, Anaelena B.; Zanini, Roselaine R. (2016-10-13). \"Laparoscopy versus laparotomy for FIGO stage I ovarian cancer\". <i>The Cochrane Database of Systematic Reviews</i>. <b>10</b>: CD005344. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/14651858.CD005344.pub4\">10.1002/14651858.CD005344.pub4</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1469-493X\">1469-493X</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27737492\">27737492</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Laparoscopy+versus+laparotomy+for+FIGO+stage+I+ovarian+cancer&amp;rft.volume=10&amp;rft.pages=CD005344&amp;rft.date=2016-10-13&amp;rft.issn=1469-493X&amp;rft_id=info%3Apmid%2F27737492&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD005344.pub4&amp;rft.aulast=Falcetta&amp;rft.aufirst=Frederico+S.&amp;rft.au=Lawrie%2C+Theresa+A.&amp;rft.au=Medeiros%2C+L%C3%ADdia+Rf&amp;rft.au=da+Rosa%2C+Maria+Ines&amp;rft.au=Edelweiss%2C+Maria+I.&amp;rft.au=Stein%2C+Airton+T.&amp;rft.au=Zelmanowicz%2C+Alice&amp;rft.au=Moraes%2C+Anaelena+B.&amp;rft.au=Zanini%2C+Roselaine+R.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:3-59\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:3_59-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:3_59-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150518091158/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/drugs-used-for-ovarian-cancer\">\"Drugs used for ovarian cancer\"</a>. <i>www.cancerresearchuk.org</i>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/drugs-used-for-ovarian-cancer\">the original</a> on 2015-05-18<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Drugs+used+for+ovarian+cancer&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fdrugs-used-for-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-60\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-60\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Yao, Stephanie (19 December 2014). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm?sf34855004=1\">\"FDA approves Lynparza to treat advanced ovarian cancer: First LDT companion diagnostic test also approved to identify appropriate patients\"</a>. U.S. Food and Drug Administration. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150914092851/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm?sf34855004=1\">Archived</a> from the original on 14 September 2015.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+approves+Lynparza+to+treat+advanced+ovarian+cancer%3A+First+LDT+companion+diagnostic+test+also+approved+to+identify+appropriate+patients&amp;rft.pub=U.S.+Food+and+Drug+Administration&amp;rft.date=2014-12-19&amp;rft.aulast=Yao&amp;rft.aufirst=Stephanie&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm427554.htm%3Fsf34855004%3D1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:4-61\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:4_61-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:4_61-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/radiotherapy-for-ovarian-cancer\">\"Radiotherapy for ovarian cancer\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150518160124/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/radiotherapy-for-ovarian-cancer\">Archived</a> from the original on 2015-05-18<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Radiotherapy+for+ovarian+cancer&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fradiotherapy-for-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:6-62\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:6_62-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:6_62-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:6_62-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:6_62-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-:6_62-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-:6_62-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-:6_62-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-:6_62-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-:6_62-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-:6_62-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-:6_62-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-:6_62-11\"><sup><i><b>l</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/whats-new-in-ovarian-cancer-research\">\"Ovarian cancer research\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150509015810/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/whats-new-in-ovarian-cancer-research\">Archived</a> from the original on 2015-05-09<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Ovarian+cancer+research&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fwhats-new-in-ovarian-cancer-research&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-63\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-63\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/cancer-help/type/ovarian-cancer/treatment/follow-up-for-ovarian-cancer\">\"Follow up for ovarian cancer\"</a>. Cancer Research UK. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170910000000/http://www.cancerresearchuk.org/cancer-help/type/ovarian-cancer/treatment/follow-up-for-ovarian-cancer\">Archived</a> from the original on 2017-09-10.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Follow+up+for+ovarian+cancer&amp;rft.pub=Cancer+Research+UK&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fcancer-help%2Ftype%2Fovarian-cancer%2Ftreatment%2Ffollow-up-for-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ACSfollowup-64\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ACSfollowup_64-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ACSfollowup_64-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-after-follow-up\">Follow-up care</a> <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131225025103/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-after-follow-up\">Archived</a> 2013-12-25 at the <a href=\"/wiki/Wayback_Machine\" title=\"Wayback Machine\">Wayback Machine</a>. from <a href=\"/wiki/American_Cancer_Society\" title=\"American Cancer Society\">American Cancer Society</a>. Last Medical Review: 03/21/2013. Last Revised: 02/06/2014</span>\n</li>\n<li id=\"cite_note-SGOfive-65\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-SGOfive_65-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-SGOfive_65-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-SGOfive_65-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite id=\"CITEREFSociety_of_Gynecologic_Oncology2014\" class=\"citation\"><a href=\"/wiki/Society_of_Gynecologic_Oncology\" title=\"Society of Gynecologic Oncology\">Society of Gynecologic Oncology</a> (February 2014), <a rel=\"nofollow\" class=\"external text\" href=\"http://www.choosingwisely.org/doctor-patient-lists/society-of-gynecologic-oncology/\">\"Five Things Physicians and Patients Should Question\"</a>, <i><a href=\"/wiki/Choosing_Wisely\" title=\"Choosing Wisely\">Choosing Wisely</a>: an initiative of the <a href=\"/wiki/ABIM_Foundation\" class=\"mw-redirect\" title=\"ABIM Foundation\">ABIM Foundation</a></i>, Society of Gynecologic Oncology, <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131201052931/http://www.choosingwisely.org/doctor-patient-lists/society-of-gynecologic-oncology/\">archived</a> from the original on 1 December 2013<span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">19 February</span> 2013</span></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Choosing+Wisely%3A+an+initiative+of+the+ABIM+Foundation&amp;rft.atitle=Five+Things+Physicians+and+Patients+Should+Question&amp;rft.date=2014-02&amp;rft.au=Society+of+Gynecologic+Oncology&amp;rft_id=http%3A%2F%2Fwww.choosingwisely.org%2Fdoctor-patient-lists%2Fsociety-of-gynecologic-oncology%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>, which cites\n<ul><li><cite class=\"citation journal\">Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB (August 2010). \"Clinical Utility of Positron Emission Tomography/Computed Tomography in the Evaluation of Suspected Recurrent Ovarian Cancer in the Setting of Normal CA-125 Levels\". <i>International Journal of Gynecological Cancer</i>. <b>20</b> (6): 936\u2013944. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/IGC.0b013e3181e82a7f\">10.1111/IGC.0b013e3181e82a7f</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20683399\">20683399</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Gynecological+Cancer&amp;rft.atitle=Clinical+Utility+of+Positron+Emission+Tomography%2FComputed+Tomography+in+the+Evaluation+of+Suspected+Recurrent+Ovarian+Cancer+in+the+Setting+of+Normal+CA-125+Levels&amp;rft.volume=20&amp;rft.issue=6&amp;rft.pages=936-944&amp;rft.date=2010-08&amp;rft_id=info%3Adoi%2F10.1111%2FIGC.0b013e3181e82a7f&amp;rft_id=info%3Apmid%2F20683399&amp;rft.aulast=Bhosale&amp;rft.aufirst=P&amp;rft.au=Peungjesada%2C+S&amp;rft.au=Wei%2C+W&amp;rft.au=Levenback%2C+CF&amp;rft.au=Schmeler%2C+K&amp;rft.au=Rohren%2C+E&amp;rft.au=Macapinlac%2C+HA&amp;rft.au=Iyer%2C+RB&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li></ul>\n</span></li>\n<li id=\"cite_note-66\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-66\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/chemotherapy-for-ovarian-cancer\">\"Chemotherapy for ovarian cancer\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150518091204/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/chemotherapy-for-ovarian-cancer\">Archived</a> from the original on 2015-05-18<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Chemotherapy+for+ovarian+cancer&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fchemotherapy-for-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-67\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-67\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140821114944/http://www.asco.org/quality-guidelines/asco-provisional-clinical-opinion-integration-palliative-care-standard-oncology\">\"ASCO Provisional Clinical Opinion: The Integration of Palliative Care into Standard Oncology Care\"</a>. ASCO. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.asco.org/quality-guidelines/asco-provisional-clinical-opinion-integration-palliative-care-standard-oncology\">the original</a> on 21 August 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">20 August</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=ASCO+Provisional+Clinical+Opinion%3A+The+Integration+of+Palliative+Care+into+Standard+Oncology+Care&amp;rft.pub=ASCO&amp;rft_id=http%3A%2F%2Fwww.asco.org%2Fquality-guidelines%2Fasco-provisional-clinical-opinion-integration-palliative-care-standard-oncology&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:5-68\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-:5_68-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/treating-advanced-ovarian-cancer\">\"Treating advanced ovarian cancer\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150519050942/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/treating-advanced-ovarian-cancer\">Archived</a> from the original on 2015-05-19<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Treating+advanced+ovarian+cancer&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Ftreating-advanced-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:9-69\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:9_69-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:9_69-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:9_69-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:9_69-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-:9_69-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Roland, Katherine B.; Rodriguez, Juan L.; Patterson, Jennifer Rees; Trivers, Katrina F. (2013-11-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://onlinelibrary.wiley.com/doi/10.1002/pon.3322/abstract\">\"A literature review of the social and psychological needs of ovarian cancer survivors\"</a>. <i>Psycho-Oncology</i>. <b>22</b> (11): 2408\u20132418. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/pon.3322\">10.1002/pon.3322</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1099-1611\">1099-1611</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Psycho-Oncology&amp;rft.atitle=A+literature+review+of+the+social+and+psychological+needs+of+ovarian+cancer+survivors&amp;rft.volume=22&amp;rft.issue=11&amp;rft.pages=2408-2418&amp;rft.date=2013-11-01&amp;rft_id=info%3Adoi%2F10.1002%2Fpon.3322&amp;rft.issn=1099-1611&amp;rft.aulast=Roland&amp;rft.aufirst=Katherine+B.&amp;rft.au=Rodriguez%2C+Juan+L.&amp;rft.au=Patterson%2C+Jennifer+Rees&amp;rft.au=Trivers%2C+Katrina+F.&amp;rft_id=http%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1002%2Fpon.3322%2Fabstract&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-70\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-70\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Watts, Sam; Prescott, Philip; Mason, Jessica; McLeod, Natalie; Lewith, George (2015-11-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://bmjopen.bmj.com/content/5/11/e007618\">\"Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates\"</a>. <i>BMJ Open</i>. <b>5</b> (11): e007618. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1136/bmjopen-2015-007618\">10.1136/bmjopen-2015-007618</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/2044-6055\">2044-6055</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4679843\">4679843</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26621509\">26621509</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BMJ+Open&amp;rft.atitle=Depression+and+anxiety+in+ovarian+cancer%3A+a+systematic+review+and+meta-analysis+of+prevalence+rates&amp;rft.volume=5&amp;rft.issue=11&amp;rft.pages=e007618&amp;rft.date=2015-11-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4679843&amp;rft.issn=2044-6055&amp;rft_id=info%3Apmid%2F26621509&amp;rft_id=info%3Adoi%2F10.1136%2Fbmjopen-2015-007618&amp;rft.aulast=Watts&amp;rft.aufirst=Sam&amp;rft.au=Prescott%2C+Philip&amp;rft.au=Mason%2C+Jessica&amp;rft.au=McLeod%2C+Natalie&amp;rft.au=Lewith%2C+George&amp;rft_id=http%3A%2F%2Fbmjopen.bmj.com%2Fcontent%2F5%2F11%2Fe007618&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ACS-71\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ACS_71-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ACS_71-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates\">\"Survival rates for ovarian cancer, by stage\"</a>. <i>American Cancer Society</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20141029204610/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates\">Archived</a> from the original on 29 October 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">29 October</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=American+Cancer+Society&amp;rft.atitle=Survival+rates+for+ovarian+cancer%2C+by+stage&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fovariancancer%2Fdetailedguide%2Fovarian-cancer-survival-rates&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-72\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-72\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/statistics-and-outlook-for-ovarian-cancer\">\"Statistics and outlook for ovarian cancer\"</a>. <i>www.cancerresearchuk.org</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150518192429/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/statistics-and-outlook-for-ovarian-cancer\">Archived</a> from the original on 2015-05-18<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-05-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cancerresearchuk.org&amp;rft.atitle=Statistics+and+outlook+for+ovarian+cancer&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ftype%2Fovarian-cancer%2Ftreatment%2Fstatistics-and-outlook-for-ovarian-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-SEER-73\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-SEER_73-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-SEER_73-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Survival rates based on SEER incidence and NCHS mortality statistics, as cited by the National Cancer Institute in <a rel=\"nofollow\" class=\"external text\" href=\"http://seer.cancer.gov/statfacts/html/ovary.html\">SEER Stat Fact Sheets&#160;\u2014 Cancer of the Ovary</a> <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20140706145616/http://seer.cancer.gov/statfacts/html/ovary.html\">Archived</a> 2014-07-06 at the <a href=\"/wiki/Wayback_Machine\" title=\"Wayback Machine\">Wayback Machine</a>.</span>\n</li>\n<li id=\"cite_note-74\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-74\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Gucalp R, Dutcher J (2012). \"Oncologic Emergencies\".  In Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. <i><a href=\"/wiki/Harrison%27s_Principles_of_Internal_Medicine\" title=\"Harrison&#39;s Principles of Internal Medicine\">Harrison's Principles of Internal Medicine</a></i> (18th ed.). McGraw-Hill. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-174889-6\" title=\"Special:BookSources/978-0-07-174889-6\">978-0-07-174889-6</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Oncologic+Emergencies&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine&amp;rft.edition=18th&amp;rft.pub=McGraw-Hill&amp;rft.date=2012&amp;rft.isbn=978-0-07-174889-6&amp;rft.aulast=Gucalp&amp;rft.aufirst=Rasim&amp;rft.au=Dutcher%2C+Janice&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-75\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-75\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/entity/healthinfo/global_burden_disease/gbddeathdalycountryestimates_female_2004.xls?ua=1\">\"WHO Disease and injury country estimates\"</a>. <i>World Health Organization</i>. 2009<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">June 15,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization&amp;rft.atitle=WHO+Disease+and+injury+country+estimates&amp;rft.date=2009&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fentity%2Fhealthinfo%2Fglobal_burden_disease%2Fgbddeathdalycountryestimates_female_2004.xls%3Fua%3D1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> The statistics are from 2004. This weblink opens up with an automatic Excel file download</span>\n</li>\n<li id=\"cite_note-Loz_2012-76\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Loz_2012_76-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY,  et al. (15 December 2012). \"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010\". <i>Lancet</i>. <b>380</b> (9859): 2095\u2013128. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0140-6736%2812%2961728-0\">10.1016/S0140-6736(12)61728-0</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23245604\">23245604</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Global+and+regional+mortality+from+235+causes+of+death+for+20+age+groups+in+1990+and+2010%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2010&amp;rft.volume=380&amp;rft.issue=9859&amp;rft.pages=2095-128&amp;rft.date=2012-12-15&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2812%2961728-0&amp;rft_id=info%3Apmid%2F23245604&amp;rft.aulast=Lozano&amp;rft.aufirst=R&amp;rft.au=Naghavi%2C+M&amp;rft.au=Foreman%2C+K&amp;rft.au=Lim%2C+S&amp;rft.au=Shibuya%2C+K&amp;rft.au=Aboyans%2C+V&amp;rft.au=Abraham%2C+J&amp;rft.au=Adair%2C+T&amp;rft.au=Aggarwal%2C+R&amp;rft.au=Ahn%2C+SY&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-merck-77\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-merck_77-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-merck_77-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Ramirez, Pedro T.; Gershenson, David M. (September 2013). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.merckmanuals.com/professional/gynecology_and_obstetrics/gynecologic_tumors/ovarian_cancer.htm\">\"Ovarian Cancer\"</a>. <i>The Merck Manual for Health Care Professionals</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=The+Merck+Manual+for+Health+Care+Professionals&amp;rft.atitle=Ovarian+Cancer&amp;rft.date=2013-09&amp;rft.aulast=Ramirez&amp;rft.aufirst=Pedro+T.&amp;rft.au=Gershenson%2C+David+M.&amp;rft_id=http%3A%2F%2Fwww.merckmanuals.com%2Fprofessional%2Fgynecology_and_obstetrics%2Fgynecologic_tumors%2Fovarian_cancer.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span style=\"position:relative; top: -2px;\"><a href=\"/wiki/Open_access\" title=\"open access publication \u2013 free to read\"><img alt=\"open access publication \u2013 free to read\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/9px-Open_Access_logo_PLoS_transparent.svg.png\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/14px-Open_Access_logo_PLoS_transparent.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/18px-Open_Access_logo_PLoS_transparent.svg.png 2x\" data-file-width=\"640\" data-file-height=\"1000\" /></a></span></span>\n</li>\n<li id=\"cite_note-78\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-78\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/\">\"Ovarian cancer statistics\"</a>. <i>Cancer Research UK</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20141006122756/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/\">Archived</a> from the original on 6 October 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">28 October</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Cancer+Research+UK&amp;rft.atitle=Ovarian+cancer+statistics&amp;rft_id=http%3A%2F%2Fwww.cancerresearchuk.org%2Fcancer-info%2Fcancerstats%2Ftypes%2Fovary%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-79\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-79\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Hennessy, Bryan T.; Suh, Grace K.; Markman, Maurie (2011).  Kantarjian, HM; Wolff, RA; Koller, CA, eds. <a rel=\"nofollow\" class=\"external text\" href=\"http://accessmedicine.mhmedical.com/content.aspx?bookid=379&amp;Sectionid=39902056\"><i>Ovarian Cancer</i></a>. <i>The MD Anderson Manual of Medical Oncology</i> (2e ed.). McGraw-Hill. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-07-170106-8\" title=\"Special:BookSources/978-0-07-170106-8\">978-0-07-170106-8</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170910175639/http://accessmedicine.mhmedical.com/content.aspx?bookid=379&amp;Sectionid=39902056\">Archived</a> from the original on 2017-09-10.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Ovarian+Cancer&amp;rft.edition=2e&amp;rft.pub=McGraw-Hill&amp;rft.date=2011&amp;rft.isbn=978-0-07-170106-8&amp;rft.aulast=Hennessy&amp;rft.aufirst=Bryan+T.&amp;rft.au=Suh%2C+Grace+K.&amp;rft.au=Markman%2C+Maurie&amp;rft_id=http%3A%2F%2Faccessmedicine.mhmedical.com%2Fcontent.aspx%3Fbookid%3D379%26Sectionid%3D39902056&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid15065985-80\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid15065985_80-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Catone G, Marino G, Mancuso R, Zangh\u00ec A (April 2004). \"Clinicopathological features of an equine ovarian teratoma\". <i>Reprod. Domest. Anim</i>. <b>39</b> (2): 65\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/j.1439-0531.2003.00476.x\">10.1111/j.1439-0531.2003.00476.x</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15065985\">15065985</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Reprod.+Domest.+Anim.&amp;rft.atitle=Clinicopathological+features+of+an+equine+ovarian+teratoma&amp;rft.volume=39&amp;rft.issue=2&amp;rft.pages=65-9&amp;rft.date=2004-04&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1439-0531.2003.00476.x&amp;rft_id=info%3Apmid%2F15065985&amp;rft.aulast=Catone&amp;rft.aufirst=G&amp;rft.au=Marino%2C+G&amp;rft.au=Mancuso%2C+R&amp;rft.au=Zangh%C3%AC%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid16363331-81\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid16363331_81-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Lefebvre R, Theoret C, Dor\u00e9 M, Girard C, Laverty S, Vaillancourt D (November 2005). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1259148\">\"Ovarian teratoma and endometritis in a mare\"</a>. <i>Can. Vet. J</i>. <b>46</b> (11): 1029\u201333. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1259148\">1259148</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/16363331\">16363331</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Can.+Vet.+J.&amp;rft.atitle=Ovarian+teratoma+and+endometritis+in+a+mare&amp;rft.volume=46&amp;rft.issue=11&amp;rft.pages=1029-33&amp;rft.date=2005-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1259148&amp;rft_id=info%3Apmid%2F16363331&amp;rft.aulast=Lefebvre&amp;rft.aufirst=R&amp;rft.au=Theoret%2C+C&amp;rft.au=Dor%C3%A9%2C+M&amp;rft.au=Girard%2C+C&amp;rft.au=Laverty%2C+S&amp;rft.au=Vaillancourt%2C+D&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1259148&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid15957389-82\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid15957389_82-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Son YS, Lee CS, Jeong WI, Hong IH, Park SJ, Kim TH, Cho EM, Park TI, Jeong KS (May 2005). \"Cystadenocarcinoma in the ovary of a Thoroughbred mare\". <i>Aust. Vet. J</i>. <b>83</b> (5): 283\u20134. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/j.1751-0813.2005.tb12740.x\">10.1111/j.1751-0813.2005.tb12740.x</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15957389\">15957389</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Aust.+Vet.+J.&amp;rft.atitle=Cystadenocarcinoma+in+the+ovary+of+a+Thoroughbred+mare&amp;rft.volume=83&amp;rft.issue=5&amp;rft.pages=283-4&amp;rft.date=2005-05&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1751-0813.2005.tb12740.x&amp;rft_id=info%3Apmid%2F15957389&amp;rft.aulast=Son&amp;rft.aufirst=YS&amp;rft.au=Lee%2C+CS&amp;rft.au=Jeong%2C+WI&amp;rft.au=Hong%2C+IH&amp;rft.au=Park%2C+SJ&amp;rft.au=Kim%2C+TH&amp;rft.au=Cho%2C+EM&amp;rft.au=Park%2C+TI&amp;rft.au=Jeong%2C+KS&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid17542368-83\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid17542368_83-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Frederico LM, Gerard MP, Pinto CR, Gradil CM (May 2007). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1852596\">\"Bilateral occurrence of granulosa-theca cell tumors in an Arabian mare\"</a>. <i>Can. Vet. J</i>. <b>48</b> (5): 502\u20135. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1852596\">1852596</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17542368\">17542368</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Can.+Vet.+J.&amp;rft.atitle=Bilateral+occurrence+of+granulosa-theca+cell+tumors+in+an+Arabian+mare&amp;rft.volume=48&amp;rft.issue=5&amp;rft.pages=502-5&amp;rft.date=2007-05&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1852596&amp;rft_id=info%3Apmid%2F17542368&amp;rft.aulast=Frederico&amp;rft.aufirst=LM&amp;rft.au=Gerard%2C+MP&amp;rft.au=Pinto%2C+CR&amp;rft.au=Gradil%2C+CM&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1852596&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid12867740-84\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid12867740_84-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hoque S, Derar RI, Osawa T, Taya K, Watanabe G, Miyake Y (June 2003). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.jstage.jst.go.jp/article/jvms/65/6/65_6_749/_article\">\"Spontaneous repair of the atrophic contralateral ovary without ovariectomy in the case of a granulosa theca cell tumor (GTCT) affected mare\"</a>. <i>J. Vet. Med. Sci</i>. <b>65</b> (6): 749\u201351. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1292/jvms.65.749\">10.1292/jvms.65.749</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/12867740\">12867740</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Vet.+Med.+Sci.&amp;rft.atitle=Spontaneous+repair+of+the+atrophic+contralateral+ovary+without+ovariectomy+in+the+case+of+a+granulosa+theca+cell+tumor+%28GTCT%29+affected+mare&amp;rft.volume=65&amp;rft.issue=6&amp;rft.pages=749-51&amp;rft.date=2003-06&amp;rft_id=info%3Adoi%2F10.1292%2Fjvms.65.749&amp;rft_id=info%3Apmid%2F12867740&amp;rft.aulast=Hoque&amp;rft.aufirst=S&amp;rft.au=Derar%2C+RI&amp;rft.au=Osawa%2C+T&amp;rft.au=Taya%2C+K&amp;rft.au=Watanabe%2C+G&amp;rft.au=Miyake%2C+Y&amp;rft_id=https%3A%2F%2Fwww.jstage.jst.go.jp%2Farticle%2Fjvms%2F65%2F6%2F65_6_749%2F_article&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid9364230-85\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid9364230_85-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Sedrish SA, McClure JR, Pinto C, Oliver J, Burba DJ (November 1997). \"Ovarian torsion associated with granulosa-theca cell tumor in a mare\". <i>J. Am. Vet. Med. Assoc</i>. <b>211</b> (9): 1152\u20134. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/9364230\">9364230</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J.+Am.+Vet.+Med.+Assoc.&amp;rft.atitle=Ovarian+torsion+associated+with+granulosa-theca+cell+tumor+in+a+mare&amp;rft.volume=211&amp;rft.issue=9&amp;rft.pages=1152-4&amp;rft.date=1997-11&amp;rft_id=info%3Apmid%2F9364230&amp;rft.aulast=Sedrish&amp;rft.aufirst=SA&amp;rft.au=McClure%2C+JR&amp;rft.au=Pinto%2C+C&amp;rft.au=Oliver%2C+J&amp;rft.au=Burba%2C+DJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid3507181-86\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid3507181_86-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Moll HD, Slone DE, Juzwiak JS, Garrett PD (1987). <a rel=\"nofollow\" class=\"external text\" href=\"http://www3.interscience.wiley.com/journal/119849124/abstract\">\"Diagonal paramedian approach for removal of ovarian tumors in the mare\"</a>. <i>Vet Surg</i>. <b>16</b> (6): 456\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/j.1532-950X.1987.tb00987.x\">10.1111/j.1532-950X.1987.tb00987.x</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/3507181\">3507181</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Vet+Surg&amp;rft.atitle=Diagonal+paramedian+approach+for+removal+of+ovarian+tumors+in+the+mare&amp;rft.volume=16&amp;rft.issue=6&amp;rft.pages=456-8&amp;rft.date=1987&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1532-950X.1987.tb00987.x&amp;rft_id=info%3Apmid%2F3507181&amp;rft.aulast=Moll&amp;rft.aufirst=HD&amp;rft.au=Slone%2C+DE&amp;rft.au=Juzwiak%2C+JS&amp;rft.au=Garrett%2C+PD&amp;rft_id=http%3A%2F%2Fwww3.interscience.wiley.com%2Fjournal%2F119849124%2Fabstract&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid2835223-87\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid2835223_87-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Doran R, Allen D, Gordon B (January 1988). \"Use of stapling instruments to aid in the removal of ovarian tumours in mares\". <i>Equine Vet. J</i>. <b>20</b> (1): 37\u201340. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/j.2042-3306.1988.tb01450.x\">10.1111/j.2042-3306.1988.tb01450.x</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/2835223\">2835223</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Equine+Vet.+J.&amp;rft.atitle=Use+of+stapling+instruments+to+aid+in+the+removal+of+ovarian+tumours+in+mares&amp;rft.volume=20&amp;rft.issue=1&amp;rft.pages=37-40&amp;rft.date=1988-01&amp;rft_id=info%3Adoi%2F10.1111%2Fj.2042-3306.1988.tb01450.x&amp;rft_id=info%3Apmid%2F2835223&amp;rft.aulast=Doran&amp;rft.aufirst=R&amp;rft.au=Allen%2C+D&amp;rft.au=Gordon%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-GizzoNoventa2016-88\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-GizzoNoventa2016_88-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Gizzo, Salvatore; Noventa, Marco; Quaranta, Michela; Vitagliano, Amerigo; Saccardi, Carlo; Litta, Pietro; Antona, Donato (2016). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5351187\">\"A novel hysteroscopic approach for ovarian cancer screening/early diagnosis (Review)\"</a>. <i>Oncology Letters</i>. <b>13</b>: 549\u2013553. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3892/ol.2016.5493\">10.3892/ol.2016.5493</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5351187\">5351187</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28356928\">28356928</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Oncology+Letters&amp;rft.atitle=A+novel+hysteroscopic+approach+for+ovarian+cancer+screening%2Fearly+diagnosis+%28Review%29&amp;rft.volume=13&amp;rft.pages=549-553&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5351187&amp;rft_id=info%3Apmid%2F28356928&amp;rft_id=info%3Adoi%2F10.3892%2Fol.2016.5493&amp;rft.aulast=Gizzo&amp;rft.aufirst=Salvatore&amp;rft.au=Noventa%2C+Marco&amp;rft.au=Quaranta%2C+Michela&amp;rft.au=Vitagliano%2C+Amerigo&amp;rft.au=Saccardi%2C+Carlo&amp;rft.au=Litta%2C+Pietro&amp;rft.au=Antona%2C+Donato&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5351187&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> <small>subscription required</small></span><small>\n</small></li><small>\n<li id=\"cite_note-89\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-89\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ (2016). <a rel=\"nofollow\" class=\"external text\" href=\"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(15)01224-6\">\"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial\"</a>. <i>Lancet</i>. <b>387</b> (10022): 945\u201356. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0140-6736%2815%2901224-6\">10.1016/S0140-6736(15)01224-6</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4779792\">4779792</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26707054\">26707054</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Ovarian+cancer+screening+and+mortality+in+the+UK+Collaborative+Trial+of+Ovarian+Cancer+Screening+%28UKCTOCS%29%3A+a+randomised+controlled+trial&amp;rft.volume=387&amp;rft.issue=10022&amp;rft.pages=945-56&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4779792&amp;rft_id=info%3Apmid%2F26707054&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2815%2901224-6&amp;rft.aulast=Jacobs&amp;rft.aufirst=IJ&amp;rft.au=Menon%2C+U&amp;rft.au=Ryan%2C+A&amp;rft.au=Gentry-Maharaj%2C+A&amp;rft.au=Burnell%2C+M&amp;rft.au=Kalsi%2C+JK&amp;rft.au=Amso%2C+NN&amp;rft.au=Apostolidou%2C+S&amp;rft.au=Benjamin%2C+E&amp;rft.au=Cruickshank%2C+D&amp;rft.au=Crump%2C+DN&amp;rft.au=Davies%2C+SK&amp;rft.au=Dawnay%2C+A&amp;rft.au=Dobbs%2C+S&amp;rft.au=Fletcher%2C+G&amp;rft.au=Ford%2C+J&amp;rft.au=Godfrey%2C+K&amp;rft.au=Gunu%2C+R&amp;rft.au=Habib%2C+M&amp;rft.au=Hallett%2C+R&amp;rft.au=Herod%2C+J&amp;rft.au=Jenkins%2C+H&amp;rft.au=Karpinskyj%2C+C&amp;rft.au=Leeson%2C+S&amp;rft.au=Lewis%2C+SJ&amp;rft.au=Liston%2C+WR&amp;rft.au=Lopes%2C+A&amp;rft.au=Mould%2C+T&amp;rft.au=Murdoch%2C+J&amp;rft.au=Oram%2C+D&amp;rft.au=Rabideau%2C+DJ&amp;rft.au=Reynolds%2C+K&amp;rft.au=Scott%2C+I&amp;rft.au=Seif%2C+MW&amp;rft.au=Sharma%2C+A&amp;rft.au=Singh%2C+N&amp;rft.au=Taylor%2C+J&amp;rft.au=Warburton%2C+F&amp;rft.au=Widschwendter%2C+M&amp;rft.au=Williamson%2C+K&amp;rft.au=Woolas%2C+R&amp;rft.au=Fallowfield%2C+L&amp;rft.au=McGuire%2C+AJ&amp;rft.au=Campbell%2C+S&amp;rft.au=Parmar%2C+M&amp;rft.au=Skates%2C+SJ&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0140-6736%2815%2901224-6&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-90\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-90\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ, Nijman HW (Sep 17, 2014). \"Antigen-specific active immunotherapy for ovarian cancer\". <i>The Cochrane Database of Systematic Reviews</i>. <b>9</b>: CD007287. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/14651858.CD007287.pub3\">10.1002/14651858.CD007287.pub3</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25229990\">25229990</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Antigen-specific+active+immunotherapy+for+ovarian+cancer&amp;rft.volume=9&amp;rft.pages=CD007287&amp;rft.date=2014-09-17&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007287.pub3&amp;rft_id=info%3Apmid%2F25229990&amp;rft.aulast=Leffers&amp;rft.aufirst=N&amp;rft.au=Daemen%2C+T&amp;rft.au=Helfrich%2C+W&amp;rft.au=Boezen%2C+HM&amp;rft.au=Cohlen%2C+BJ&amp;rft.au=Melief%2C+CJ&amp;rft.au=Nijman%2C+HW&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-IngerslevHogdall2017-91\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-IngerslevHogdall2017_91-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ingerslev, Kasper; Hogdall, Estrid; Schnack, Tine Henrichsen; Skovrider-Ruminski, Wojciech; Hogdall, Claus; Blaakaer, Jan (2017). \"The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis\". <i>Infectious Agents and Cancer</i>. <b>12</b> (1). <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1186/s13027-017-0134-9\">10.1186/s13027-017-0134-9</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1750-9378\">1750-9378</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Infectious+Agents+and+Cancer&amp;rft.atitle=The+potential+role+of+infectious+agents+and+pelvic+inflammatory+disease+in+ovarian+carcinogenesis&amp;rft.volume=12&amp;rft.issue=1&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1186%2Fs13027-017-0134-9&amp;rft.issn=1750-9378&amp;rft.aulast=Ingerslev&amp;rft.aufirst=Kasper&amp;rft.au=Hogdall%2C+Estrid&amp;rft.au=Schnack%2C+Tine+Henrichsen&amp;rft.au=Skovrider-Ruminski%2C+Wojciech&amp;rft.au=Hogdall%2C+Claus&amp;rft.au=Blaakaer%2C+Jan&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-92\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-92\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you\">\"NIH Clinical Research Trials and You\"</a>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170608133010/https://www.nih.gov/health-information/nih-clinical-research-trials-you\">Archived</a> from the original on 8 June 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 June</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=NIH+Clinical+Research+Trials+and+You&amp;rft_id=https%3A%2F%2Fwww.nih.gov%2Fhealth-information%2Fnih-clinical-research-trials-you&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-93\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-93\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cancer.gov/about-cancer/treatment/clinical-trials\">\"Clinical Trials Information for Patients and Caregivers\"</a>. <i>National Cancer Institute</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170616213104/https://www.cancer.gov/about-cancer/treatment/clinical-trials\">Archived</a> from the original on 16 June 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 June</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=National+Cancer+Institute&amp;rft.atitle=Clinical+Trials+Information+for+Patients+and+Caregivers&amp;rft_id=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Ftreatment%2Fclinical-trials&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-94\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-94\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/\">\"Find NCI-Supported Clinical Trials\"</a>. <i>National Cancer Institute</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170701064612/https://www.cancer.gov/about-cancer/treatment/clinical-trials/search\">Archived</a> from the original on 1 July 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 June</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=National+Cancer+Institute&amp;rft.atitle=Find+NCI-Supported+Clinical+Trials&amp;rft_id=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Ftreatment%2Fclinical-trials%2Fsearch%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-95\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-95\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.clinicaltrials.gov/\">\"Home&#160;\u2014 ClinicalTrials.gov\"</a>. <i>www.clinicaltrials.gov</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170616200907/https://www.clinicaltrials.gov/\">Archived</a> from the original on 16 June 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 June</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.clinicaltrials.gov&amp;rft.atitle=Home+%E2%80%94+ClinicalTrials.gov&amp;rft_id=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-96\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-96\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.canadiancancertrials.ca/\">\"Home - Canadian Cancer Trials\"</a>. <i>www.canadiancancertrials.ca</i>. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170626081519/http://canadiancancertrials.ca/\">Archived</a> from the original on 26 June 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 June</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.canadiancancertrials.ca&amp;rft.atitle=Home+-+Canadian+Cancer+Trials&amp;rft_id=http%3A%2F%2Fwww.canadiancancertrials.ca%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</small></ol></div></div><small><h2><span class=\"mw-headline\" id=\"Further_reading\">Further reading</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=84\" title=\"Edit section: Further reading\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2></small><small><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r853264625\"/><div class=\"refbegin\" style=\"\">\n<ul><li><cite class=\"citation journal\">Cannistra SA (December 2004). <a rel=\"nofollow\" class=\"external text\" href=\"http://content.nejm.org/cgi/content/full/351/24/2519\">\"Cancer of the ovary\"</a>. <i>N. Engl. J. Med</i>. <b>351</b> (24): 2519\u201329. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMra041842\">10.1056/NEJMra041842</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15590954\">15590954</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.atitle=Cancer+of+the+ovary&amp;rft.volume=351&amp;rft.issue=24&amp;rft.pages=2519-29&amp;rft.date=2004-12&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMra041842&amp;rft_id=info%3Apmid%2F15590954&amp;rft.aulast=Cannistra&amp;rft.aufirst=SA&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Ffull%2F351%2F24%2F2519&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li></ul>\n</div></small><small><h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ovarian_cancer&amp;action=edit&amp;section=85\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2></small><small><table class=\"infobox\" style=\"width:22em;width:100%; margin:0 0 0.5em 0;\"><tbody><tr><th scope=\"row\">Classification</th><td style=\"text-align:left;\">\n<div style=\"position:relative; float:right; font-size:0.8em;\"><a href=\"https://www.wikidata.org/wiki/Q172341\" class=\"extiw\" title=\"d:Q172341\">D</a></div><div class=\"hlist hlist-separated\" style=\"text-align:left;\"><ul><li><b><a href=\"/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems\" title=\"International Statistical Classification of Diseases and Related Health Problems\">ICD</a>-<a href=\"/wiki/ICD-10\" title=\"ICD-10\">10</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"http://apps.who.int/classifications/icd10/browse/2016/en#/C56\">C56</a></li><li><b><a href=\"/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems\" title=\"International Statistical Classification of Diseases and Related Health Problems\">ICD</a>-<a href=\"/wiki/List_of_ICD-9_codes\" title=\"List of ICD-9 codes\">9-CM</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"http://www.icd9data.com/getICD9Code.ashx?icd9=183\">183</a>, <a rel=\"nofollow\" class=\"external text\" href=\"http://www.icd9data.com/getICD9Code.ashx?icd9=220\">220</a></li><li><b><a href=\"/wiki/International_Classification_of_Diseases_for_Oncology\" title=\"International Classification of Diseases for Oncology\">ICD-O</a></b>: varied</li><li><b><a href=\"/wiki/Medical_Subject_Headings\" title=\"Medical Subject Headings\">MeSH</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&amp;term=D010051\">D010051</a></li><li><b><a href=\"/wiki/Diseases_Database\" title=\"Diseases Database\">DiseasesDB</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"http://www.diseasesdatabase.com/ddb9418.htm\">9418</a></li></ul></div></td></tr><tr><th scope=\"row\">External resources</th><td style=\"text-align:left;\">\n<div class=\"hlist hlist-separated\" style=\"text-align:left;\"><ul><li><b><a href=\"/wiki/MedlinePlus\" title=\"MedlinePlus\">MedlinePlus</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000889.htm\">000889</a></li><li><b><a href=\"/wiki/EMedicine\" title=\"EMedicine\">eMedicine</a></b>: <a rel=\"nofollow\" class=\"external text\" href=\"http://www.emedicine.com/med/topic1698.htm\">med/1698</a></li><li><b><a href=\"/wiki/Patient_UK\" title=\"Patient UK\">Patient UK</a></b>:\n<a rel=\"nofollow\" class=\"external text\" href=\"https://patient.info/doctor/ovarian-cancer-pro\">Ovarian cancer</a></li></ul></div></td></tr></tbody></table></small><small><ul><li><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cancer.gov/types/ovarian/hp\">\"Ovarian, Fallopian Tube, and Primary Peritoneal Cancer - Patient Version\"</a>. National Cancer Institute<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">30 March</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Ovarian%2C+Fallopian+Tube%2C+and+Primary+Peritoneal+Cancer+-+Patient+Version&amp;rft.pub=National+Cancer+Institute&amp;rft_id=https%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fovarian%2Fhp&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><cite class=\"citation book\">Petrucelli N, Daly MB, Feldman GL (2013). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/books/NBK1247/\"><i>BRCA1 and BRCA2 Hereditary Breast/Ovarian Cancer</i></a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20301425\">20301425</a>. NBK1247.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=BRCA1+and+BRCA2+Hereditary+Breast%2FOvarian+Cancer&amp;rft.date=2013&amp;rft_id=info%3Apmid%2F20301425&amp;rft.aulast=Petrucelli&amp;rft.aufirst=N&amp;rft.au=Daly%2C+MB&amp;rft.au=Feldman%2C+GL&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1247%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOvarian+cancer\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.mountsinai.org/patient-care/service-areas/obgyn-and-reproductive-services/areas-of-care/gynecologic-oncology/ovarian-cancer/infographic/ovariancancerinfo\">What is Ovarian Cancer Infographic, information on ovarian cancer</a> - <a href=\"/wiki/Mount_Sinai_Hospital,_New_York\" class=\"mw-redirect\" title=\"Mount Sinai Hospital, New York\">Mount Sinai Hospital, New York</a></li></ul></small><small><div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Tumors:_female_urogenital_neoplasia_(C51\u2013C58/D25\u2013D28,_179\u2013184/218\u2013221)\" style=\"padding:3px\"><table class=\"nowraplinks collapsible autocollapse navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Female_genital_neoplasia\" title=\"Template:Female genital neoplasia\"><abbr title=\"View this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Female_genital_neoplasia\" title=\"Template talk:Female genital neoplasia\"><abbr title=\"Discuss this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Female_genital_neoplasia&amp;action=edit\"><abbr title=\"Edit this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"Tumors:_female_urogenital_neoplasia_(C51\u2013C58/D25\u2013D28,_179\u2013184/218\u2013221)\" style=\"font-size:114%;margin:0 4em\"><a href=\"/wiki/Tumor\" class=\"mw-redirect\" title=\"Tumor\">Tumors</a>: female <a href=\"/wiki/Urogenital_neoplasm\" title=\"Urogenital neoplasm\">urogenital neoplasia</a> (<a href=\"/wiki/ICD-10_Chapter_II:_Neoplasms#(C50\u2013C58)_Malignant_neoplasms,_breast_and_female_genital_organs\" title=\"ICD-10 Chapter II: Neoplasms\">C51\u2013C58/D25\u2013D28</a>, <a href=\"/wiki/List_of_ICD-9_codes_140%E2%80%93239:_neoplasms#Malignant_neoplasm_of_genitourinary_organs_(179\u2013189)\" title=\"List of ICD-9 codes 140\u2013239: neoplasms\">179\u2013184/218\u2013221</a>)</div></th></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Adnexa_of_uterus\" class=\"mw-redirect\" title=\"Adnexa of uterus\">Adnexa</a></th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a class=\"mw-selflink selflink\">Ovaries</a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Glandular_and_epithelial_neoplasm\" title=\"Glandular and epithelial neoplasm\">Glandular and epithelial</a>/<br /><a href=\"/wiki/Surface_epithelial-stromal_tumor\" title=\"Surface epithelial-stromal tumor\">surface epithelial-<br />stromal tumor</a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th id=\"CMS:\" scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Cystic,_mucinous,_and_serous_neoplasms\" title=\"Cystic, mucinous, and serous neoplasms\">CMS</a>:</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Ovarian_serous_cystadenoma\" title=\"Ovarian serous cystadenoma\">Ovarian serous cystadenoma</a></li>\n<li><a href=\"/wiki/Mucinous_cystadenoma\" title=\"Mucinous cystadenoma\">Mucinous cystadenoma</a></li>\n<li><a href=\"/wiki/Cystadenocarcinoma\" title=\"Cystadenocarcinoma\">Cystadenocarcinoma</a>\n<ul><li><a href=\"/wiki/Papillary_serous_cystadenocarcinoma\" title=\"Papillary serous cystadenocarcinoma\">Papillary serous cystadenocarcinoma</a></li></ul></li>\n<li><a href=\"/wiki/Krukenberg_tumor\" title=\"Krukenberg tumor\">Krukenberg tumor</a></li></ul>\n</div></td></tr><tr><td colspan=\"2\" class=\"navbox-list navbox-even\" style=\"width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Endometrioid_tumor\" title=\"Endometrioid tumor\">Endometrioid tumor</a></li>\n<li><a href=\"/wiki/Clear-cell_ovarian_carcinoma\" title=\"Clear-cell ovarian carcinoma\">Clear-cell ovarian carcinoma</a></li>\n<li><a href=\"/wiki/Brenner_tumour\" title=\"Brenner tumour\">Brenner tumour</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Sex_cord-gonadal_stromal_tumour\" class=\"mw-redirect\" title=\"Sex cord-gonadal stromal tumour\">Sex cord-gonadal stromal</a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Leydig_cell_tumour\" title=\"Leydig cell tumour\">Leydig cell tumour</a></li>\n<li><a href=\"/wiki/Sertoli_cell_tumour\" title=\"Sertoli cell tumour\">Sertoli cell tumour</a></li>\n<li><a href=\"/wiki/Sertoli-Leydig_cell_tumour\" class=\"mw-redirect\" title=\"Sertoli-Leydig cell tumour\">Sertoli-Leydig cell tumour</a></li>\n<li><a href=\"/wiki/Thecoma\" title=\"Thecoma\">Thecoma</a></li>\n<li><a href=\"/wiki/Granulosa_cell_tumour\" title=\"Granulosa cell tumour\">Granulosa cell tumour</a></li>\n<li><a href=\"/wiki/Luteoma\" title=\"Luteoma\">Luteoma</a></li>\n<li><a href=\"/wiki/Sex_cord_tumour_with_annular_tubules\" title=\"Sex cord tumour with annular tubules\">Sex cord tumour with annular tubules</a></li>\n<li><a href=\"/w/index.php?title=Steroid_cell_tumor_(NOS)&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Steroid cell tumor (NOS) (page does not exist)\">Steroid cell tumor (NOS)</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Germ_cell_tumor\" title=\"Germ cell tumor\">Germ cell</a></th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Dysgerminoma\" title=\"Dysgerminoma\">Dysgerminoma</a></li>\n<li><a href=\"/wiki/Germ_cell_tumor#Nongerminomatous\" title=\"Germ cell tumor\">Nongerminomatous</a>\n<ul><li><a href=\"/wiki/Embryonal_carcinoma\" title=\"Embryonal carcinoma\">Embryonal carcinoma</a></li>\n<li><a href=\"/wiki/Endodermal_sinus_tumor\" title=\"Endodermal sinus tumor\">Endodermal sinus tumor</a></li>\n<li><a href=\"/wiki/Gonadoblastoma\" title=\"Gonadoblastoma\">Gonadoblastoma</a></li>\n<li><a href=\"/wiki/Teratoma\" title=\"Teratoma\">Teratoma</a>/<a href=\"/wiki/Struma_ovarii\" title=\"Struma ovarii\">Struma ovarii</a></li>\n<li><a href=\"/wiki/Choriocarcinoma\" title=\"Choriocarcinoma\">Choriocarcinoma</a></li></ul></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Ovarian_fibroma\" title=\"Ovarian fibroma\">Fibroma</a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Meigs_syndrome\" class=\"mw-redirect\" title=\"Meigs syndrome\">Meigs syndrome</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Fallopian_tube_cancer\" title=\"Fallopian tube cancer\">Fallopian tube</a></th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Adenomatoid_tumor\" title=\"Adenomatoid tumor\">Adenomatoid tumor</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Uterine_cancer\" title=\"Uterine cancer\">Uterus</a></th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\"></div><table class=\"nowraplinks navbox-subgroup\" style=\"border-spacing:0\"><tbody><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Myometrium\" title=\"Myometrium\">Myometrium</a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Uterine_fibroid\" title=\"Uterine fibroid\">Uterine fibroids/leiomyoma</a></li>\n<li><a href=\"/wiki/Leiomyosarcoma\" title=\"Leiomyosarcoma\">Leiomyosarcoma</a></li>\n<li><a href=\"/wiki/Adenomyoma\" title=\"Adenomyoma\">Adenomyoma</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Endometrial_cancer\" title=\"Endometrial cancer\">Endometrium</a></th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Endometrioid_tumor\" title=\"Endometrioid tumor\">Endometrioid tumor</a></li>\n<li><a href=\"/wiki/Uterine_serous_carcinoma\" title=\"Uterine serous carcinoma\">Uterine papillary serous carcinoma</a></li>\n<li><a href=\"/wiki/Endometrial_intraepithelial_neoplasia\" title=\"Endometrial intraepithelial neoplasia\">Endometrial intraepithelial neoplasia</a></li>\n<li><a href=\"/wiki/Uterine_clear-cell_carcinoma\" title=\"Uterine clear-cell carcinoma\">Uterine clear-cell carcinoma</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Cervical_cancer\" title=\"Cervical cancer\">Cervix</a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Cervical_intraepithelial_neoplasia\" title=\"Cervical intraepithelial neoplasia\">Cervical intraepithelial neoplasia</a></li>\n<li><a href=\"/wiki/Clear_cell_adenocarcinoma_of_the_vagina\" class=\"mw-redirect\" title=\"Clear cell adenocarcinoma of the vagina\">Clear cell carcinoma</a></li>\n<li><a href=\"/wiki/Squamous-cell_carcinoma#Vagina_and_cervix\" class=\"mw-redirect\" title=\"Squamous-cell carcinoma\">SCC</a></li>\n<li><a href=\"/wiki/Glassy_cell_carcinoma_of_the_cervix\" title=\"Glassy cell carcinoma of the cervix\">Glassy cell carcinoma</a></li>\n<li><a href=\"/wiki/Villoglandular_adenocarcinoma_of_the_cervix\" title=\"Villoglandular adenocarcinoma of the cervix\">Villoglandular adenocarcinoma</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Placenta\" title=\"Placenta\">Placenta</a></th><td class=\"navbox-list navbox-even\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Choriocarcinoma\" title=\"Choriocarcinoma\">Choriocarcinoma</a></li>\n<li><a href=\"/wiki/Gestational_trophoblastic_disease\" title=\"Gestational trophoblastic disease\">Gestational trophoblastic disease</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\">General</th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Uterine_sarcoma\" title=\"Uterine sarcoma\">Uterine sarcoma</a></li>\n<li><a href=\"/wiki/Mixed_M%C3%BCllerian_tumor\" title=\"Mixed M\u00fcllerian tumor\">Mixed M\u00fcllerian tumor</a></li></ul>\n</div></td></tr></tbody></table><div></div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Vaginal_cancer\" title=\"Vaginal cancer\">Vagina</a></th><td class=\"navbox-list navbox-even hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Squamous-cell_carcinoma_of_the_vagina\" title=\"Squamous-cell carcinoma of the vagina\">Squamous-cell carcinoma of the vagina</a></li>\n<li><a href=\"/wiki/Sarcoma_botryoides\" title=\"Sarcoma botryoides\">Botryoid rhabdomyosarcoma</a></li>\n<li><a href=\"/wiki/Clear_cell_adenocarcinoma_of_the_vagina\" class=\"mw-redirect\" title=\"Clear cell adenocarcinoma of the vagina\">Clear cell adenocarcinoma of the vagina</a></li>\n<li><a href=\"/wiki/Vaginal_intraepithelial_neoplasia\" title=\"Vaginal intraepithelial neoplasia\">Vaginal intraepithelial neoplasia</a></li>\n<li><a href=\"/wiki/Vaginal_cysts\" title=\"Vaginal cysts\">Vaginal cysts</a></li></ul>\n</div></td></tr><tr><th scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Vulvar_cancer\" title=\"Vulvar cancer\">Vulva</a></th><td class=\"navbox-list navbox-odd hlist\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Squamous-cell_carcinoma\" class=\"mw-redirect\" title=\"Squamous-cell carcinoma\">SCC</a></li>\n<li><a href=\"/wiki/Melanoma\" title=\"Melanoma\">Melanoma</a></li>\n<li><a href=\"/wiki/Papillary_hidradenoma\" title=\"Papillary hidradenoma\">Papillary hidradenoma</a></li>\n<li><a href=\"/wiki/Extramammary_Paget%27s_disease\" title=\"Extramammary Paget&#39;s disease\">Extramammary Paget's disease</a></li>\n<li><a href=\"/wiki/Vulvar_intraepithelial_neoplasia\" title=\"Vulvar intraepithelial neoplasia\">Vulvar intraepithelial neoplasia</a></li>\n<li><a href=\"/wiki/Bartholin_gland_carcinoma\" title=\"Bartholin gland carcinoma\">Bartholin gland carcinoma</a></li></ul>\n</div></td></tr></tbody></table></div></small><small><div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Authority_control_frameless_&amp;#124;text-top_&amp;#124;10px_&amp;#124;alt=Edit_this_at_Wikidata_&amp;#124;link=https&amp;#58;//www.wikidata.org/wiki/Q172341&amp;#124;Edit_this_at_Wikidata\" style=\"padding:3px\"><table class=\"nowraplinks hlist navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th id=\"Authority_control_frameless_&amp;#124;text-top_&amp;#124;10px_&amp;#124;alt=Edit_this_at_Wikidata_&amp;#124;link=https&amp;#58;//www.wikidata.org/wiki/Q172341&amp;#124;Edit_this_at_Wikidata\" scope=\"row\" class=\"navbox-group\" style=\"width:1%\"><a href=\"/wiki/Help:Authority_control\" title=\"Help:Authority control\">Authority control</a> <a href=\"https://www.wikidata.org/wiki/Q172341\" title=\"Edit this at Wikidata\"><img alt=\"Edit this at Wikidata\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/73/Blue_pencil.svg/10px-Blue_pencil.svg.png\" width=\"10\" height=\"10\" style=\"vertical-align: text-top\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/73/Blue_pencil.svg/15px-Blue_pencil.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/73/Blue_pencil.svg/20px-Blue_pencil.svg.png 2x\" data-file-width=\"600\" data-file-height=\"600\" /></a></th><td class=\"navbox-list navbox-odd\" style=\"text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><span class=\"nowrap\"><a href=\"/wiki/Library_of_Congress_Control_Number\" title=\"Library of Congress Control Number\">LCCN</a>: <span class=\"uid\"><a rel=\"nofollow\" class=\"external text\" href=\"http://id.loc.gov/authorities/subjects/sh2010104661\">sh2010104661</a></span></span></li>\n<li><span class=\"nowrap\"><a href=\"/wiki/National_Diet_Library\" title=\"National Diet Library\">NDL</a>: <span class=\"uid\"><a rel=\"nofollow\" class=\"external text\" href=\"https://id.ndl.go.jp/auth/ndlna/00569292\">00569292</a></span></span></li></ul>\n</div></td></tr></tbody></table></div></small><p><small>\n</small></p>\n<!-- \nNewPP limit report\nParsed by mw2271\nCached time: 20180921220452\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 1.848 seconds\nReal time usage: 2.054 seconds\nPreprocessor visited node count: 9430/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 282571/2097152 bytes\nTemplate argument size: 4686/2097152 bytes\nHighest expansion depth: 11/40\nExpensive parser function count: 6/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 218217/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.663/10.000 seconds\nLua memory usage: 7.37 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00% 1461.776      1 -total\n 51.08%  746.641      1 Template:Reflist\n 17.27%  252.447     39 Template:Cite_journal\n 15.25%  222.940     44 Template:Cite_web\n  9.08%  132.786      2 Template:Infobox\n  7.22%  105.571      1 Template:Infobox_medical_condition_(new)\n  5.39%   78.795     13 Template:Cite_book\n  4.71%   68.814      3 Template:Fix\n  3.73%   54.506      1 Template:Medical_resources\n  3.44%   50.280      1 Template:Cn\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:414192-0!canonical and timestamp 20180921220450 and revision id 860575868\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D8%B3%D8%B1%D8%B7%D8%A7%D9%86_%D8%A7%D9%84%D9%85%D8%A8%D9%8A%D8%B6","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u0633\u0631\u0637\u0627\u0646 \u0627\u0644\u0645\u0628\u064a\u0636"},{"lang":"bs","url":"https://bs.wikipedia.org/wiki/Rak_jajnika","langname":"Bosnian","autonym":"bosanski","*":"Rak jajnika"},{"lang":"ca","url":"https://ca.wikipedia.org/wiki/C%C3%A0ncer_d%27ovari","langname":"Catalan","autonym":"catal\u00e0","*":"C\u00e0ncer d'ovari"},{"lang":"cs","url":"https://cs.wikipedia.org/wiki/Rakovina_vaje%C4%8Dn%C3%ADk%C5%AF","langname":"Czech","autonym":"\u010de\u0161tina","*":"Rakovina vaje\u010dn\u00edk\u016f"},{"lang":"cy","url":"https://cy.wikipedia.org/wiki/Canser_ofaraidd","langname":"Welsh","autonym":"Cymraeg","*":"Canser ofaraidd"},{"lang":"de","url":"https://de.wikipedia.org/wiki/Ovarialkarzinom","langname":"German","autonym":"Deutsch","*":"Ovarialkarzinom"},{"lang":"dv","url":"https://dv.wikipedia.org/wiki/%DE%84%DE%A8%DE%90%DE%B0%DE%83%DE%A6%DE%88%DE%A6%DE%87%DE%A8%DE%8E%DE%AC_%DE%86%DE%AC%DE%82%DE%B0%DE%90%DE%A6%DE%83%DE%AA","langname":"Divehi","autonym":"\u078b\u07a8\u0788\u07ac\u0780\u07a8\u0784\u07a6\u0790\u07b0","*":"\u0784\u07a8\u0790\u07b0\u0783\u07a6\u0788\u07a6\u0787\u07a8\u078e\u07ac \u0786\u07ac\u0782\u07b0\u0790\u07a6\u0783\u07aa"},{"lang":"el","url":"https://el.wikipedia.org/wiki/%CE%9A%CE%B1%CF%81%CE%BA%CE%AF%CE%BD%CE%BF%CF%82_%CF%84%CF%89%CE%BD_%CF%89%CE%BF%CE%B8%CE%B7%CE%BA%CF%8E%CE%BD","langname":"Greek","autonym":"\u0395\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03ac","*":"\u039a\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03c2 \u03c4\u03c9\u03bd \u03c9\u03bf\u03b8\u03b7\u03ba\u03ce\u03bd"},{"lang":"es","url":"https://es.wikipedia.org/wiki/C%C3%A1ncer_de_ovario","langname":"Spanish","autonym":"espa\u00f1ol","*":"C\u00e1ncer de ovario"},{"lang":"eu","url":"https://eu.wikipedia.org/wiki/Obulutegiko_minbizi","langname":"Basque","autonym":"euskara","*":"Obulutegiko minbizi"},{"lang":"fa","url":"https://fa.wikipedia.org/wiki/%D8%B3%D8%B1%D8%B7%D8%A7%D9%86_%D8%AA%D8%AE%D9%85%D8%AF%D8%A7%D9%86","langname":"Persian","autonym":"\u0641\u0627\u0631\u0633\u06cc","*":"\u0633\u0631\u0637\u0627\u0646 \u062a\u062e\u0645\u062f\u0627\u0646"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/Cancer_de_l%27ovaire","langname":"French","autonym":"fran\u00e7ais","*":"Cancer de l'ovaire"},{"lang":"fy","url":"https://fy.wikipedia.org/wiki/Aaist%C3%B4kkanker","langname":"Western Frisian","autonym":"Frysk","*":"Aaist\u00f4kkanker"},{"lang":"gl","url":"https://gl.wikipedia.org/wiki/Cancro_de_ovario","langname":"Galician","autonym":"galego","*":"Cancro de ovario"},{"lang":"ko","url":"https://ko.wikipedia.org/wiki/%EB%82%9C%EC%86%8C%EC%95%94","langname":"Korean","autonym":"\ud55c\uad6d\uc5b4","*":"\ub09c\uc18c\uc554"},{"lang":"id","url":"https://id.wikipedia.org/wiki/Kanker_ovarium","langname":"Indonesian","autonym":"Bahasa Indonesia","*":"Kanker ovarium"},{"lang":"it","url":"https://it.wikipedia.org/wiki/Carcinoma_dell%27ovaio","langname":"Italian","autonym":"italiano","*":"Carcinoma dell'ovaio"},{"lang":"he","url":"https://he.wikipedia.org/wiki/%D7%A1%D7%A8%D7%98%D7%9F_%D7%94%D7%A9%D7%97%D7%9C%D7%94","langname":"Hebrew","autonym":"\u05e2\u05d1\u05e8\u05d9\u05ea","*":"\u05e1\u05e8\u05d8\u05df \u05d4\u05e9\u05d7\u05dc\u05d4"},{"lang":"kk","url":"https://kk.wikipedia.org/wiki/%D0%90%D0%BD%D0%B0%D0%BB%D1%8B%D2%9B_%D0%B1%D0%B5%D0%B7_%D0%BE%D0%B1%D1%8B%D1%80%D1%8B","langname":"Kazakh","autonym":"\u049b\u0430\u0437\u0430\u049b\u0448\u0430","*":"\u0410\u043d\u0430\u043b\u044b\u049b \u0431\u0435\u0437 \u043e\u0431\u044b\u0440\u044b"},{"lang":"ht","url":"https://ht.wikipedia.org/wiki/Kans%C3%A8_nan_ov%C3%A8_a","langname":"Haitian Creole","autonym":"Krey\u00f2l ayisyen","*":"Kans\u00e8 nan ov\u00e8 a"},{"lang":"lt","url":"https://lt.wikipedia.org/wiki/Kiau%C5%A1id%C5%BEi%C5%B3_v%C4%97%C5%BEys","langname":"Lithuanian","autonym":"lietuvi\u0173","*":"Kiau\u0161id\u017ei\u0173 v\u0117\u017eys"},{"lang":"hu","url":"https://hu.wikipedia.org/wiki/Petef%C3%A9szekr%C3%A1k","langname":"Hungarian","autonym":"magyar","*":"Petef\u00e9szekr\u00e1k"},{"lang":"mk","url":"https://mk.wikipedia.org/wiki/%D0%A0%D0%B0%D0%BA_%D0%BD%D0%B0_%D1%98%D0%B0%D1%98%D0%BD%D0%B8%D1%86%D0%B8","langname":"Macedonian","autonym":"\u043c\u0430\u043a\u0435\u0434\u043e\u043d\u0441\u043a\u0438","*":"\u0420\u0430\u043a \u043d\u0430 \u0458\u0430\u0458\u043d\u0438\u0446\u0438"},{"lang":"ml","url":"https://ml.wikipedia.org/wiki/%E0%B4%85%E0%B4%A3%E0%B5%8D%E0%B4%A1%E0%B4%BE%E0%B4%B6%E0%B4%AF_%E0%B4%85%E0%B5%BC%E0%B4%AC%E0%B5%81%E0%B4%A6%E0%B4%82","langname":"Malayalam","autonym":"\u0d2e\u0d32\u0d2f\u0d3e\u0d33\u0d02","*":"\u0d05\u0d23\u0d4d\u0d21\u0d3e\u0d36\u0d2f \u0d05\u0d7c\u0d2c\u0d41\u0d26\u0d02"},{"lang":"ms","url":"https://ms.wikipedia.org/wiki/Kanser_ovari","langname":"Malay","autonym":"Bahasa Melayu","*":"Kanser ovari"},{"lang":"nl","url":"https://nl.wikipedia.org/wiki/Ovariumcarcinoom","langname":"Dutch","autonym":"Nederlands","*":"Ovariumcarcinoom"},{"lang":"new","url":"https://new.wikipedia.org/wiki/%E0%A4%93%E0%A4%AD%E0%A4%B0%E0%A4%BF%E0%A4%AF%E0%A4%A8_%E0%A4%95%E0%A5%8D%E0%A4%AF%E0%A4%BE%E0%A4%A8%E0%A5%8D%E0%A4%B8%E0%A4%B0","langname":"Newari","autonym":"\u0928\u0947\u092a\u093e\u0932 \u092d\u093e\u0937\u093e","*":"\u0913\u092d\u0930\u093f\u092f\u0928 \u0915\u094d\u092f\u093e\u0928\u094d\u0938\u0930"},{"lang":"ja","url":"https://ja.wikipedia.org/wiki/%E5%8D%B5%E5%B7%A3%E8%85%AB%E7%98%8D","langname":"Japanese","autonym":"\u65e5\u672c\u8a9e","*":"\u5375\u5de3\u816b\u760d"},{"lang":"no","url":"https://no.wikipedia.org/wiki/Eggstokkreft","langname":"Norwegian","autonym":"norsk","*":"Eggstokkreft"},{"lang":"or","url":"https://or.wikipedia.org/wiki/%E0%AC%93%E0%AC%AD%E0%AC%BE%E0%AC%B0%E0%AC%BF_%E0%AC%95%E0%AC%B0%E0%AD%8D%E0%AC%95%E0%AC%9F","langname":"Odia","autonym":"\u0b13\u0b21\u0b3c\u0b3f\u0b06","*":"\u0b13\u0b2d\u0b3e\u0b30\u0b3f \u0b15\u0b30\u0b4d\u0b15\u0b1f"},{"lang":"pl","url":"https://pl.wikipedia.org/wiki/Rak_jajnika","langname":"Polish","autonym":"polski","*":"Rak jajnika"},{"lang":"pt","url":"https://pt.wikipedia.org/wiki/C%C3%A2ncer_ovariano","langname":"Portuguese","autonym":"portugu\u00eas","*":"C\u00e2ncer ovariano"},{"lang":"ro","url":"https://ro.wikipedia.org/wiki/Cancer_ovarian","langname":"Romanian","autonym":"rom\u00e2n\u0103","*":"Cancer ovarian"},{"lang":"ru","url":"https://ru.wikipedia.org/wiki/%D0%A0%D0%B0%D0%BA_%D1%8F%D0%B8%D1%87%D0%BD%D0%B8%D0%BA%D0%B0","langname":"Russian","autonym":"\u0440\u0443\u0441\u0441\u043a\u0438\u0439","*":"\u0420\u0430\u043a \u044f\u0438\u0447\u043d\u0438\u043a\u0430"},{"lang":"sq","url":"https://sq.wikipedia.org/wiki/Kanceri_ovarian","langname":"Albanian","autonym":"shqip","*":"Kanceri ovarian"},{"lang":"simple","url":"https://simple.wikipedia.org/wiki/Ovarian_cancer","langname":"Simple English","autonym":"Simple English","*":"Ovarian cancer"},{"lang":"sk","url":"https://sk.wikipedia.org/wiki/Rakovina_vaje%C4%8Dn%C3%ADkov","langname":"Slovak","autonym":"sloven\u010dina","*":"Rakovina vaje\u010dn\u00edkov"},{"lang":"sl","url":"https://sl.wikipedia.org/wiki/Rak_jaj%C4%8Dnika","langname":"Slovenian","autonym":"sloven\u0161\u010dina","*":"Rak jaj\u010dnika"},{"lang":"fi","url":"https://fi.wikipedia.org/wiki/Munasarjasy%C3%B6p%C3%A4","langname":"Finnish","autonym":"suomi","*":"Munasarjasy\u00f6p\u00e4"},{"lang":"sv","url":"https://sv.wikipedia.org/wiki/%C3%84ggstockscancer","langname":"Swedish","autonym":"svenska","*":"\u00c4ggstockscancer"},{"lang":"ta","url":"https://ta.wikipedia.org/wiki/%E0%AE%9A%E0%AF%82%E0%AE%B2%E0%AF%8D%E0%AE%AA%E0%AF%88%E0%AE%AA%E0%AF%8D_%E0%AE%AA%E0%AF%81%E0%AE%B1%E0%AF%8D%E0%AE%B1%E0%AF%81%E0%AE%A8%E0%AF%8B%E0%AE%AF%E0%AF%8D","langname":"Tamil","autonym":"\u0ba4\u0bae\u0bbf\u0bb4\u0bcd","*":"\u0b9a\u0bc2\u0bb2\u0bcd\u0baa\u0bc8\u0baa\u0bcd \u0baa\u0bc1\u0bb1\u0bcd\u0bb1\u0bc1\u0ba8\u0bcb\u0baf\u0bcd"},{"lang":"th","url":"https://th.wikipedia.org/wiki/%E0%B8%A1%E0%B8%B0%E0%B9%80%E0%B8%A3%E0%B9%87%E0%B8%87%E0%B8%A3%E0%B8%B1%E0%B8%87%E0%B9%84%E0%B8%82%E0%B9%88","langname":"Thai","autonym":"\u0e44\u0e17\u0e22","*":"\u0e21\u0e30\u0e40\u0e23\u0e47\u0e07\u0e23\u0e31\u0e07\u0e44\u0e02\u0e48"},{"lang":"tr","url":"https://tr.wikipedia.org/wiki/Yumurtal%C4%B1k_kanseri","langname":"Turkish","autonym":"T\u00fcrk\u00e7e","*":"Yumurtal\u0131k kanseri"},{"lang":"uk","url":"https://uk.wikipedia.org/wiki/%D0%A0%D0%B0%D0%BA_%D1%8F%D1%94%D1%87%D0%BD%D0%B8%D0%BA%D0%B0","langname":"Ukrainian","autonym":"\u0443\u043a\u0440\u0430\u0457\u043d\u0441\u044c\u043a\u0430","*":"\u0420\u0430\u043a \u044f\u0454\u0447\u043d\u0438\u043a\u0430"},{"lang":"ur","url":"https://ur.wikipedia.org/wiki/%D9%85%D8%A8%DB%8C%D8%B6%DB%8C_%D8%B3%D8%B1%D8%B7%D8%A7%D9%86","langname":"Urdu","autonym":"\u0627\u0631\u062f\u0648","*":"\u0645\u0628\u06cc\u0636\u06cc \u0633\u0631\u0637\u0627\u0646"},{"lang":"vi","url":"https://vi.wikipedia.org/wiki/Ung_th%C6%B0_bu%E1%BB%93ng_tr%E1%BB%A9ng","langname":"Vietnamese","autonym":"Ti\u1ebfng Vi\u1ec7t","*":"Ung th\u01b0 bu\u1ed3ng tr\u1ee9ng"},{"lang":"zh","url":"https://zh.wikipedia.org/wiki/%E5%8D%B5%E5%B7%A2%E7%99%8C","langname":"Chinese","autonym":"\u4e2d\u6587","*":"\u5375\u5de2\u764c"}],"categories":[{"sortkey":"","hidden":"","*":"Wikipedia_articles_incorporating_text_from_the_Centers_for_Disease_Control_and_Prevention"},{"sortkey":"","hidden":"","*":"Pages_containing_links_to_subscription-only_content"},{"sortkey":"","hidden":"","*":"Webarchive_template_wayback_links"},{"sortkey":"Ovarian Cancer","hidden":"","*":"Infobox_medical_condition_(new)"},{"sortkey":"Ovarian Cancer","hidden":"","*":"All_articles_with_unsourced_statements"},{"sortkey":"Ovarian Cancer","hidden":"","*":"Articles_with_unsourced_statements_from_March_2018"},{"sortkey":"Ovarian Cancer","hidden":"","*":"Articles_with_unsourced_statements_from_November_2014"},{"sortkey":"Ovarian Cancer","hidden":"","*":"Articles_with_unsourced_statements_from_November_2017"},{"sortkey":"Ovarian Cancer","hidden":"","*":"Wikipedia_articles_with_LCCN_identifiers"},{"sortkey":"Ovarian Cancer","hidden":"","*":"Wikipedia_articles_with_NDL_identifiers"},{"sortkey":" ","*":"Ovarian_cancer"},{"sortkey":"Ovarian Cancer","hidden":"","*":"RTT"},{"sortkey":"Ovarian Cancer","*":"Gynaecological_cancer"},{"sortkey":"Ovarian Cancer","*":"Gynaecology"},{"sortkey":"Ovarian Cancer","*":"Oncology"}],"links":[{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from March 2018"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from November 2014"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from November 2017"},{"ns":14,"exists":"","*":"Category:Wikipedia articles with LCCN identifiers"},{"ns":14,"exists":"","*":"Category:Wikipedia articles with NDL identifiers"},{"ns":0,"exists":"","*":"Centers for Disease Control and Prevention"},{"ns":0,"exists":"","*":"Paywall"},{"ns":0,"exists":"","*":"Open access"},{"ns":0,"exists":"","*":"ABIM Foundation"},{"ns":0,"exists":"","*":"AKT1"},{"ns":0,"exists":"","*":"AKT2"},{"ns":0,"exists":"","*":"ARID1A"},{"ns":0,"exists":"","*":"Abdominal cavity"},{"ns":0,"exists":"","*":"Abdominal pain"},{"ns":0,"exists":"","*":"Abdominal wall"},{"ns":0,"exists":"","*":"Abscess"},{"ns":0,"exists":"","*":"Acute abdomen"},{"ns":0,"exists":"","*":"Adenocarcinoma"},{"ns":0,"exists":"","*":"Adenomatoid tumor"},{"ns":0,"exists":"","*":"Adenomyoma"},{"ns":0,"exists":"","*":"Adhesion (medicine)"},{"ns":0,"exists":"","*":"Adnexa of uterus"},{"ns":0,"exists":"","*":"Adnexal mass"},{"ns":0,"exists":"","*":"Age adjustment"},{"ns":0,"exists":"","*":"Allele"},{"ns":0,"exists":"","*":"Alpha-fetoprotein"},{"ns":0,"exists":"","*":"Amenorrhea"},{"ns":0,"exists":"","*":"Amenorrhoea"},{"ns":0,"exists":"","*":"American Cancer Society"},{"ns":0,"exists":"","*":"Amniotic sac"},{"ns":0,"exists":"","*":"Anaplasia"},{"ns":0,"exists":"","*":"Anastrozole"},{"ns":0,"exists":"","*":"Androstenedione"},{"ns":0,"exists":"","*":"Anemia"},{"ns":0,"exists":"","*":"Angiogenesis"},{"ns":0,"exists":"","*":"Anorexia (symptom)"},{"ns":0,"exists":"","*":"Antifolate"},{"ns":0,"exists":"","*":"Anxiety"},{"ns":0,"exists":"","*":"Apolipoprotein A1"},{"ns":0,"exists":"","*":"Apoptosis"},{"ns":0,"exists":"","*":"Appendectomy"},{"ns":0,"exists":"","*":"Appendiceal cancer"},{"ns":0,"exists":"","*":"Arrhenoblastoma"},{"ns":0,"exists":"","*":"Ascites"},{"ns":0,"exists":"","*":"Ashkenazi Jew"},{"ns":0,"exists":"","*":"Ashkenazi Jews"},{"ns":0,"exists":"","*":"Aspirin"},{"ns":0,"exists":"","*":"Auscultation"},{"ns":0,"exists":"","*":"Axillary lymph nodes"},{"ns":0,"exists":"","*":"BECN1"},{"ns":0,"exists":"","*":"BHCG"},{"ns":0,"exists":"","*":"BRAF (gene)"},{"ns":0,"exists":"","*":"BRCA1"},{"ns":0,"exists":"","*":"BRCA2"},{"ns":0,"exists":"","*":"BRIP1"},{"ns":0,"exists":"","*":"Barium enema"},{"ns":0,"exists":"","*":"Bartholin gland carcinoma"},{"ns":0,"exists":"","*":"Basal-cell carcinoma"},{"ns":0,"exists":"","*":"Benign"},{"ns":0,"exists":"","*":"Beta-2 microglobulin"},{"ns":0,"exists":"","*":"Beta-HCG"},{"ns":0,"exists":"","*":"Bevacizumab"},{"ns":0,"exists":"","*":"Biomarker"},{"ns":0,"exists":"","*":"Biopsies"},{"ns":0,"exists":"","*":"Biopsy"},{"ns":0,"exists":"","*":"Black people"},{"ns":0,"exists":"","*":"Bladder carcinoma"},{"ns":0,"exists":"","*":"Bladder diverticulum"},{"ns":0,"exists":"","*":"Bleomycin"},{"ns":0,"exists":"","*":"Bloating"},{"ns":0,"exists":"","*":"Blood transfusion"},{"ns":0,"exists":"","*":"Body image"},{"ns":0,"exists":"","*":"Bone scan"},{"ns":0,"exists":"","*":"Bowel"},{"ns":0,"exists":"","*":"Bowel obstruction"},{"ns":0,"exists":"","*":"Bowel perforation"},{"ns":0,"exists":"","*":"Bowel resection"},{"ns":0,"exists":"","*":"Brain metastasis"},{"ns":0,"exists":"","*":"Breast cancer"},{"ns":0,"exists":"","*":"Breast enlargement"},{"ns":0,"exists":"","*":"Breast examination"},{"ns":0,"exists":"","*":"Breast feeding"},{"ns":0,"exists":"","*":"Breast pain"},{"ns":0,"exists":"","*":"Brenner tumor"},{"ns":0,"exists":"","*":"Brenner tumour"},{"ns":0,"exists":"","*":"Broad ligament of the uterus"},{"ns":0,"exists":"","*":"Broccoli"},{"ns":0,"exists":"","*":"C-reactive protein"},{"ns":0,"exists":"","*":"CA-125"},{"ns":0,"exists":"","*":"CA125"},{"ns":0,"exists":"","*":"CA15-3"},{"ns":0,"exists":"","*":"CA19-9"},{"ns":0,"exists":"","*":"CCND1"},{"ns":0,"exists":"","*":"CCND2"},{"ns":0,"exists":"","*":"CCNE1"},{"ns":0,"exists":"","*":"CD117"},{"ns":0,"exists":"","*":"CDH1 (gene)"},{"ns":0,"exists":"","*":"CDK12"},{"ns":0,"exists":"","*":"CHEK2"},{"ns":0,"exists":"","*":"CTNNB1"},{"ns":0,"exists":"","*":"CT scanning"},{"ns":0,"exists":"","*":"Cancer"},{"ns":0,"exists":"","*":"Carboplatin"},{"ns":0,"exists":"","*":"Carcinoembryonic antigen"},{"ns":0,"exists":"","*":"Carcinogen"},{"ns":0,"exists":"","*":"Carcinoid"},{"ns":0,"exists":"","*":"Carcinoma"},{"ns":0,"exists":"","*":"Carotene"},{"ns":0,"exists":"","*":"Case-control study"},{"ns":0,"exists":"","*":"Cediranib"},{"ns":0,"exists":"","*":"Cell (biology)"},{"ns":0,"exists":"","*":"Cell cycle"},{"ns":0,"exists":"","*":"Cells (biology)"},{"ns":0,"exists":"","*":"Cellular differentiation"},{"ns":0,"exists":"","*":"Cervical cancer"},{"ns":0,"exists":"","*":"Cervical intraepithelial neoplasia"},{"ns":0,"exists":"","*":"Chemotherapy"},{"ns":0,"exists":"","*":"Chest radiograph"},{"ns":0,"exists":"","*":"Choosing Wisely"},{"ns":0,"exists":"","*":"Choriocarcinoma"},{"ns":0,"exists":"","*":"Choriocarcinomas"},{"ns":0,"exists":"","*":"Cisplatin"},{"ns":0,"exists":"","*":"Clear-cell ovarian carcinoma"},{"ns":0,"exists":"","*":"Clear-cell ovarian tumor"},{"ns":0,"exists":"","*":"Clear cell"},{"ns":0,"exists":"","*":"Clear cell adenocarcinoma of the vagina"},{"ns":0,"exists":"","*":"Clear cell carcinoma"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Cohort study"},{"ns":0,"exists":"","*":"Colon cancer"},{"ns":0,"exists":"","*":"Colostomy"},{"ns":0,"exists":"","*":"Combined oral contraceptive"},{"ns":0,"exists":"","*":"Combretastatin"},{"ns":0,"exists":"","*":"Congenital disorder"},{"ns":0,"exists":"","*":"Constipation"},{"ns":0,"exists":"","*":"Copyright status of work by the U.S. government"},{"ns":0,"exists":"","*":"Corpus luteum"},{"ns":0,"exists":"","*":"Cushing's syndrome"},{"ns":0,"exists":"","*":"Cyclooxygenase 2"},{"ns":0,"exists":"","*":"Cyclophosphamide"},{"ns":0,"exists":"","*":"Cyprus"},{"ns":0,"exists":"","*":"Cystadenocarcinoma"},{"ns":0,"exists":"","*":"Cystadenoma"},{"ns":0,"exists":"","*":"Cystic, mucinous, and serous neoplasms"},{"ns":0,"exists":"","*":"Cytopathology"},{"ns":0,"exists":"","*":"Cytoplasm"},{"ns":0,"exists":"","*":"Czech Republic"},{"ns":0,"exists":"","*":"DICER1"},{"ns":0,"exists":"","*":"DNA mismatch repair"},{"ns":0,"exists":"","*":"DYNLRB1"},{"ns":0,"exists":"","*":"Dactinomycin"},{"ns":0,"exists":"","*":"Death anxiety (psychology)"},{"ns":0,"exists":"","*":"Debulking"},{"ns":0,"exists":"","*":"Dehydroepiandrosterone sulfate"},{"ns":0,"exists":"","*":"Depression (mood)"},{"ns":0,"exists":"","*":"Dermoid cyst"},{"ns":0,"exists":"","*":"Diagnosis"},{"ns":0,"exists":"","*":"Diagnostic method"},{"ns":0,"exists":"","*":"Diarrhea"},{"ns":0,"exists":"","*":"Dicer"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Digital rectal exam"},{"ns":0,"exists":"","*":"Diseases Database"},{"ns":0,"exists":"","*":"Distress in cancer caregiving"},{"ns":0,"exists":"","*":"Docetaxel"},{"ns":0,"exists":"","*":"Doxorubicin"},{"ns":0,"exists":"","*":"Drain (surgery)"},{"ns":0,"exists":"","*":"Drosha"},{"ns":0,"exists":"","*":"Dysfunctional uterine bleeding"},{"ns":0,"exists":"","*":"Dysgerminoma"},{"ns":0,"exists":"","*":"Dyspareunia"},{"ns":0,"exists":"","*":"EMedicine"},{"ns":0,"exists":"","*":"EPH receptor A1"},{"ns":0,"exists":"","*":"ERBB2"},{"ns":0,"exists":"","*":"ESR2"},{"ns":0,"exists":"","*":"Ectoderm"},{"ns":0,"exists":"","*":"Ectopic pregnancy"},{"ns":0,"exists":"","*":"Edema"},{"ns":0,"exists":"","*":"Embryo"},{"ns":0,"exists":"","*":"Embryonal carcinoma"},{"ns":0,"exists":"","*":"Embryonic disc"},{"ns":0,"exists":"","*":"Embryonic germ cell"},{"ns":0,"exists":"","*":"Endoderm"},{"ns":0,"exists":"","*":"Endodermal sinus tumor"},{"ns":0,"exists":"","*":"Endometrial biopsy"},{"ns":0,"exists":"","*":"Endometrial cancer"},{"ns":0,"exists":"","*":"Endometrial hyperplasia"},{"ns":0,"exists":"","*":"Endometrial intraepithelial neoplasia"},{"ns":0,"exists":"","*":"Endometrioid tumor"},{"ns":0,"exists":"","*":"Endometriosis"},{"ns":0,"exists":"","*":"Enterocutaneous fistula"},{"ns":0,"exists":"","*":"Epidermal growth factor receptor"},{"ns":0,"exists":"","*":"Epirubicin"},{"ns":0,"exists":"","*":"Epithelium"},{"ns":0,"exists":"","*":"Equine"},{"ns":0,"exists":"","*":"Estrogen"},{"ns":0,"exists":"","*":"Estrogen receptor"},{"ns":0,"exists":"","*":"Etoposide"},{"ns":0,"exists":"","*":"European Jews"},{"ns":0,"exists":"","*":"External iliac lymph nodes"},{"ns":0,"exists":"","*":"Extramammary Paget's disease"},{"ns":0,"exists":"","*":"FOXM1"},{"ns":0,"exists":"","*":"Fallopian tube"},{"ns":0,"exists":"","*":"Fallopian tube cancer"},{"ns":0,"exists":"","*":"False positives and false negatives"},{"ns":0,"exists":"","*":"Farletuzumab"},{"ns":0,"exists":"","*":"Fatigue (medical)"},{"ns":0,"exists":"","*":"Fertility medication"},{"ns":0,"exists":"","*":"Fiber"},{"ns":0,"exists":"","*":"Fibroblast"},{"ns":0,"exists":"","*":"Fibroblast growth factor 23"},{"ns":0,"exists":"","*":"Fimbria (female reproductive system)"},{"ns":0,"exists":"","*":"First-degree relative"},{"ns":0,"exists":"","*":"Fistula"},{"ns":0,"exists":"","*":"Five-year survival"},{"ns":0,"exists":"","*":"Five-year survival rate"},{"ns":0,"exists":"","*":"Folate receptor"},{"ns":0,"exists":"","*":"Follicular cyst of ovary"},{"ns":0,"exists":"","*":"Forkhead box L2"},{"ns":0,"exists":"","*":"Founder effect"},{"ns":0,"exists":"","*":"Frameshift mutations"},{"ns":0,"exists":"","*":"Frustration"},{"ns":0,"exists":"","*":"Gastrointestinal cancer"},{"ns":0,"exists":"","*":"Gastrointestinal stromal tumor"},{"ns":0,"exists":"","*":"Gastrostomy"},{"ns":0,"exists":"","*":"Gemcitabine"},{"ns":0,"exists":"","*":"Genetic counselor"},{"ns":0,"exists":"","*":"Genetic mutation"},{"ns":0,"exists":"","*":"Genomic instability"},{"ns":0,"exists":"","*":"Genomics"},{"ns":0,"exists":"","*":"Germ cell tumor"},{"ns":0,"exists":"","*":"Germ cells"},{"ns":0,"exists":"","*":"Germ layer"},{"ns":0,"exists":"","*":"Germline mutation"},{"ns":0,"exists":"","*":"Gestational trophoblastic disease"},{"ns":0,"exists":"","*":"Glandular and epithelial neoplasm"},{"ns":0,"exists":"","*":"Glassy cell carcinoma of the cervix"},{"ns":0,"exists":"","*":"Glycogen"},{"ns":0,"exists":"","*":"Gonadal dysgenesis"},{"ns":0,"exists":"","*":"Gonadoblastoma"},{"ns":0,"exists":"","*":"Granulosa cell tumor"},{"ns":0,"exists":"","*":"Granulosa cell tumour"},{"ns":0,"exists":"","*":"Greater omentum"},{"ns":0,"exists":"","*":"Growing teratoma syndrome"},{"ns":0,"exists":"","*":"Guilt (emotion)"},{"ns":0,"exists":"","*":"Gynecology"},{"ns":0,"exists":"","*":"H&E stain"},{"ns":0,"exists":"","*":"HE4"},{"ns":0,"exists":"","*":"HIF1A"},{"ns":0,"exists":"","*":"Hair loss"},{"ns":0,"exists":"","*":"Harrison's Principles of Internal Medicine"},{"ns":0,"exists":"","*":"Heartburn"},{"ns":0,"exists":"","*":"Hemorrhage"},{"ns":0,"exists":"","*":"Herbicides"},{"ns":0,"exists":"","*":"Hereditary breast\u2013ovarian cancer syndrome"},{"ns":0,"exists":"","*":"Hereditary nonpolyposis colon cancer"},{"ns":0,"exists":"","*":"Hereditary nonpolyposis colorectal cancer"},{"ns":0,"exists":"","*":"High-grade serous carcinoma"},{"ns":0,"exists":"","*":"Hirsutism"},{"ns":0,"exists":"","*":"Hispanic people"},{"ns":0,"exists":"","*":"Histology"},{"ns":0,"exists":"","*":"Histopathology"},{"ns":0,"exists":"","*":"Hobnail cell"},{"ns":0,"exists":"","*":"Hope"},{"ns":0,"exists":"","*":"Hormonal birth control"},{"ns":0,"exists":"","*":"Hormone"},{"ns":0,"exists":"","*":"Hormone therapy"},{"ns":0,"exists":"","*":"Hospice care"},{"ns":0,"exists":"","*":"Human chorionic gonadotropin"},{"ns":0,"exists":"","*":"Human papilloma virus"},{"ns":0,"exists":"","*":"Human papillomavirus infection"},{"ns":0,"exists":"","*":"Hungarian people"},{"ns":0,"exists":"","*":"Hydrosalpinx"},{"ns":0,"exists":"","*":"Hydrothorax"},{"ns":0,"exists":"","*":"Hyperbaric medicine"},{"ns":0,"exists":"","*":"Hypercalcaemia"},{"ns":0,"exists":"","*":"Hyperglycemia"},{"ns":0,"exists":"","*":"Hyperlipidemia"},{"ns":0,"exists":"","*":"Hypertension"},{"ns":0,"exists":"","*":"Hypoactive sexual desire disorder"},{"ns":0,"exists":"","*":"Hyponatremia"},{"ns":0,"exists":"","*":"Hysterectomy"},{"ns":0,"exists":"","*":"ICD-10"},{"ns":0,"exists":"","*":"ICD-10 Chapter II: Neoplasms"},{"ns":0,"exists":"","*":"Icelandic people"},{"ns":0,"exists":"","*":"Ileostomy"},{"ns":0,"exists":"","*":"Immature teratoma"},{"ns":0,"exists":"","*":"Immunohistochemistry"},{"ns":0,"exists":"","*":"Immunotherapy"},{"ns":0,"exists":"","*":"Indigestion"},{"ns":0,"exists":"","*":"Inflammation"},{"ns":0,"exists":"","*":"Inflammatory bowel disease"},{"ns":0,"exists":"","*":"Inguinal lymph node"},{"ns":0,"exists":"","*":"Inhibin"},{"ns":0,"exists":"","*":"Inhibin-beta subunits"},{"ns":0,"exists":"","*":"Inhibin A"},{"ns":0,"exists":"","*":"Inhibin B"},{"ns":0,"exists":"","*":"International Classification of Diseases for Oncology"},{"ns":0,"exists":"","*":"International Federation of Gynecology and Obstetrics"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"International Statistical Classification of Diseases and Related Health Problems"},{"ns":0,"exists":"","*":"Intestinal lumen"},{"ns":0,"exists":"","*":"Intraperitoneal chemotherapy"},{"ns":0,"exists":"","*":"Ireland"},{"ns":0,"exists":"","*":"Irinotecan"},{"ns":0,"exists":"","*":"Iron supplement"},{"ns":0,"exists":"","*":"Irregular menstruation"},{"ns":0,"exists":"","*":"Irritable bowel syndrome"},{"ns":0,"exists":"","*":"Isochromosome"},{"ns":0,"exists":"","*":"Isozyme"},{"ns":0,"exists":"","*":"JAG1"},{"ns":0,"exists":"","*":"JAG2"},{"ns":0,"exists":"","*":"Joy"},{"ns":0,"exists":"","*":"KRAS"},{"ns":0,"exists":"","*":"Karyotype"},{"ns":0,"exists":"","*":"Keyhole surgery"},{"ns":0,"exists":"","*":"Krukenberg tumor"},{"ns":0,"exists":"","*":"Lactate dehydrogenase"},{"ns":0,"exists":"","*":"Laparoscopy"},{"ns":0,"exists":"","*":"Laparotomy"},{"ns":0,"exists":"","*":"Latvia"},{"ns":0,"exists":"","*":"Leiomyoma"},{"ns":0,"exists":"","*":"Leiomyosarcoma"},{"ns":0,"exists":"","*":"Letrozole"},{"ns":0,"exists":"","*":"Leydig cell tumour"},{"ns":0,"exists":"","*":"Library of Congress Control Number"},{"ns":0,"exists":"","*":"List of ICD-9 codes"},{"ns":0,"exists":"","*":"List of ICD-9 codes 140\u2013239: neoplasms"},{"ns":0,"exists":"","*":"Lithuania"},{"ns":0,"exists":"","*":"Liver"},{"ns":0,"exists":"","*":"Liver disease"},{"ns":0,"exists":"","*":"Lungs"},{"ns":0,"exists":"","*":"Luteoma"},{"ns":0,"exists":"","*":"Lymph node"},{"ns":0,"exists":"","*":"Lymph nodes"},{"ns":0,"exists":"","*":"Lymphadenectomy"},{"ns":0,"exists":"","*":"Lymphadenopathy"},{"ns":0,"exists":"","*":"Lymphatic system"},{"ns":0,"exists":"","*":"Lysophosphatidic acid"},{"ns":0,"exists":"","*":"MAML1"},{"ns":0,"exists":"","*":"MAML2"},{"ns":0,"exists":"","*":"MAPK"},{"ns":0,"exists":"","*":"MLH1"},{"ns":0,"exists":"","*":"MSH2"},{"ns":0,"exists":"","*":"MSH6"},{"ns":0,"exists":"","*":"MTOR inhibitor"},{"ns":0,"exists":"","*":"Maffucci syndrome"},{"ns":0,"exists":"","*":"Magnetic resonance imaging"},{"ns":0,"exists":"","*":"Maintenance chemotherapy"},{"ns":0,"exists":"","*":"Mammography"},{"ns":0,"exists":"","*":"Mare"},{"ns":0,"exists":"","*":"Meaning of life"},{"ns":0,"exists":"","*":"Medical Subject Headings"},{"ns":0,"exists":"","*":"Medical diagnosis"},{"ns":0,"exists":"","*":"Medical sign"},{"ns":0,"exists":"","*":"MedlinePlus"},{"ns":0,"exists":"","*":"Meigs syndrome"},{"ns":0,"exists":"","*":"Melanoma"},{"ns":0,"exists":"","*":"Menarche"},{"ns":0,"exists":"","*":"Menometrorrhagia"},{"ns":0,"exists":"","*":"Menopause"},{"ns":0,"exists":"","*":"Menstrual cycle"},{"ns":0,"exists":"","*":"Menstruation"},{"ns":0,"exists":"","*":"Mesenchyme"},{"ns":0,"exists":"","*":"Mesentery"},{"ns":0,"exists":"","*":"Mesoderm"},{"ns":0,"exists":"","*":"Mesothelin"},{"ns":0,"exists":"","*":"Mesothelioma"},{"ns":0,"exists":"","*":"Metastasis"},{"ns":0,"exists":"","*":"Micrograph"},{"ns":0,"exists":"","*":"Microsatellite instability"},{"ns":0,"exists":"","*":"Million Women Study"},{"ns":0,"exists":"","*":"Miscarriage"},{"ns":0,"exists":"","*":"Mixed M\u00fcllerian tumor"},{"ns":0,"exists":"","*":"Monoclonal antibody"},{"ns":0,"exists":"","*":"Mount Sinai Hospital, New York"},{"ns":0,"exists":"","*":"Mucinous"},{"ns":0,"exists":"","*":"Mucinous adenocarcinoma"},{"ns":0,"exists":"","*":"Mucinous cystadenocarcinoma"},{"ns":0,"exists":"","*":"Mucinous cystadenoma"},{"ns":0,"exists":"","*":"Mucinous tumor"},{"ns":0,"exists":"","*":"Mucositis"},{"ns":0,"exists":"","*":"Mucus"},{"ns":0,"exists":"","*":"Mullerian inhibiting substance"},{"ns":0,"exists":"","*":"Mullerian tumor"},{"ns":0,"exists":"","*":"Multiparity"},{"ns":0,"exists":"","*":"Myometrium"},{"ns":0,"exists":"","*":"NOTCH3"},{"ns":0,"exists":"","*":"NSAIDs"},{"ns":0,"exists":"","*":"National Cancer Institute"},{"ns":0,"exists":"","*":"National Diet Library"},{"ns":0,"exists":"","*":"National Institutes of Health"},{"ns":0,"exists":"","*":"Nausea"},{"ns":0,"exists":"","*":"Necrosis"},{"ns":0,"exists":"","*":"Nephrostomy"},{"ns":0,"exists":"","*":"Nerve sheath tumor"},{"ns":0,"exists":"","*":"Neuroblastoma RAS viral oncogene homolog"},{"ns":0,"exists":"","*":"Neuroectoderm"},{"ns":0,"exists":"","*":"Neuroectodermal tumor"},{"ns":0,"exists":"","*":"Neuroglia"},{"ns":0,"exists":"","*":"Neuron-specific enolase"},{"ns":0,"exists":"","*":"Nevoid basal cell carcinoma syndrome"},{"ns":0,"exists":"","*":"Nintedanib"},{"ns":0,"exists":"","*":"Niraparib"},{"ns":0,"exists":"","*":"Notch signaling pathway"},{"ns":0,"exists":"","*":"Nuclear atypia"},{"ns":0,"exists":"","*":"Nuclear factor 1"},{"ns":0,"exists":"","*":"Nucleolus"},{"ns":0,"exists":"","*":"Nulliparity"},{"ns":0,"exists":"","*":"Obesity"},{"ns":0,"exists":"","*":"Octreotide"},{"ns":0,"exists":"","*":"Olaparib"},{"ns":0,"exists":"","*":"Oligomenorrhea"},{"ns":0,"exists":"","*":"Ollier disease"},{"ns":0,"exists":"","*":"Omentectomy"},{"ns":0,"exists":"","*":"Oncology"},{"ns":0,"exists":"","*":"Onion"},{"ns":0,"exists":"","*":"Optimism"},{"ns":0,"exists":"","*":"Osteopontin"},{"ns":0,"exists":"","*":"Osteoporosis"},{"ns":0,"exists":"","*":"Ovarian cyst"},{"ns":0,"exists":"","*":"Ovarian cysts"},{"ns":0,"exists":"","*":"Ovarian epithelium"},{"ns":0,"exists":"","*":"Ovarian fibroma"},{"ns":0,"exists":"","*":"Ovarian follicle"},{"ns":0,"exists":"","*":"Ovarian serous cystadenoma"},{"ns":0,"exists":"","*":"Ovarian torsion"},{"ns":0,"exists":"","*":"Ovary"},{"ns":0,"exists":"","*":"Overall survival"},{"ns":0,"exists":"","*":"Ovulate"},{"ns":0,"exists":"","*":"Ovulation"},{"ns":0,"exists":"","*":"Oxaliplatin"},{"ns":0,"exists":"","*":"P16 (gene)"},{"ns":0,"exists":"","*":"P53"},{"ns":0,"exists":"","*":"PALB2"},{"ns":0,"exists":"","*":"PARP inhibitor"},{"ns":0,"exists":"","*":"PIK3C3"},{"ns":0,"exists":"","*":"PIK3CA"},{"ns":0,"exists":"","*":"PMS1"},{"ns":0,"exists":"","*":"PMS2"},{"ns":0,"exists":"","*":"PPP2R1A"},{"ns":0,"exists":"","*":"PTEN (gene)"},{"ns":0,"exists":"","*":"Paclitaxel"},{"ns":0,"exists":"","*":"Palliative care"},{"ns":0,"exists":"","*":"Palliative surgery"},{"ns":0,"exists":"","*":"Pap test"},{"ns":0,"exists":"","*":"Papillary hidradenoma"},{"ns":0,"exists":"","*":"Papillary serous cystadenocarcinoma"},{"ns":0,"exists":"","*":"Papilloma"},{"ns":0,"exists":"","*":"Paraaortic lymph node"},{"ns":0,"exists":"","*":"Paracentesis"},{"ns":0,"exists":"","*":"Paracetamol"},{"ns":0,"exists":"","*":"Paraovarian cyst"},{"ns":0,"exists":"","*":"Patient UK"},{"ns":0,"exists":"","*":"Pazopanib"},{"ns":0,"exists":"","*":"Pelvic examination"},{"ns":0,"exists":"","*":"Pelvic exenteration"},{"ns":0,"exists":"","*":"Pelvic inflammatory disease"},{"ns":0,"exists":"","*":"Pelvic kidney"},{"ns":0,"exists":"","*":"Pelvic pain"},{"ns":0,"exists":"","*":"Pelvic washing"},{"ns":0,"exists":"","*":"Penetrance"},{"ns":0,"exists":"","*":"Perineum"},{"ns":0,"exists":"","*":"Perioperative mortality"},{"ns":0,"exists":"","*":"Peristalsis"},{"ns":0,"exists":"","*":"Peritoneal fluid"},{"ns":0,"exists":"","*":"Peritoneal tuberculosis"},{"ns":0,"exists":"","*":"Peritoneum"},{"ns":0,"exists":"","*":"Pesticides"},{"ns":0,"exists":"","*":"Peutz\u2013Jeghers syndrome"},{"ns":0,"exists":"","*":"Placenta"},{"ns":0,"exists":"","*":"Platins"},{"ns":0,"exists":"","*":"Platinum"},{"ns":0,"exists":"","*":"Pleomorphism (cytology)"},{"ns":0,"exists":"","*":"Pleural effusion"},{"ns":0,"exists":"","*":"Pleurodesis"},{"ns":0,"exists":"","*":"Poly ADP ribose polymerase"},{"ns":0,"exists":"","*":"Polycystic ovary syndrome"},{"ns":0,"exists":"","*":"Polyembryoma"},{"ns":0,"exists":"","*":"Polyuria"},{"ns":0,"exists":"","*":"Porta hepatis"},{"ns":0,"exists":"","*":"Portugal"},{"ns":0,"exists":"","*":"Positron emission tomography"},{"ns":0,"exists":"","*":"Precocious puberty"},{"ns":0,"exists":"","*":"Pregnancy"},{"ns":0,"exists":"","*":"Primary peritoneal carcinoma"},{"ns":0,"exists":"","*":"Processed meat"},{"ns":0,"exists":"","*":"Prognosis"},{"ns":0,"exists":"","*":"Progression-free survival"},{"ns":0,"exists":"","*":"Proteinuria"},{"ns":0,"exists":"","*":"Proteomics"},{"ns":0,"exists":"","*":"Psammoma body"},{"ns":0,"exists":"","*":"Pseudomyxoma peritonei"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Puberty"},{"ns":0,"exists":"","*":"Quality of life"},{"ns":0,"exists":"","*":"RAD50 (gene)"},{"ns":0,"exists":"","*":"RAD51C"},{"ns":0,"exists":"","*":"RB1"},{"ns":0,"exists":"","*":"Radiation therapy"},{"ns":0,"exists":"","*":"Radiotherapy"},{"ns":0,"exists":"","*":"Receptor tyrosine kinase"},{"ns":0,"exists":"","*":"Rectovaginal examination"},{"ns":0,"exists":"","*":"Red meat"},{"ns":0,"exists":"","*":"Relative survival rate"},{"ns":0,"exists":"","*":"Retroperitoneal lymph node dissection"},{"ns":0,"exists":"","*":"Risk factor"},{"ns":0,"exists":"","*":"Round ligament of uterus"},{"ns":0,"exists":"","*":"Rucaparib"},{"ns":0,"exists":"","*":"Sadness"},{"ns":0,"exists":"","*":"Salpingo-oophorectomy"},{"ns":0,"exists":"","*":"Salpingoophorectomy"},{"ns":0,"exists":"","*":"Sarcoma"},{"ns":0,"exists":"","*":"Sarcoma botryoides"},{"ns":0,"exists":"","*":"Satiety"},{"ns":0,"exists":"","*":"Scar"},{"ns":0,"exists":"","*":"Schiller\u2013Duval body"},{"ns":0,"exists":"","*":"Screening (medicine)"},{"ns":0,"exists":"","*":"Sebaceous carcinoma"},{"ns":0,"exists":"","*":"Sebaceous gland"},{"ns":0,"exists":"","*":"Secondary sex characteristics"},{"ns":0,"exists":"","*":"Self-esteem"},{"ns":0,"exists":"","*":"Selumetinib"},{"ns":0,"exists":"","*":"Seminoma"},{"ns":0,"exists":"","*":"Serous cancer"},{"ns":0,"exists":"","*":"Serous carcinoma"},{"ns":0,"exists":"","*":"Serous cystadenocarcinoma"},{"ns":0,"exists":"","*":"Serous tumour"},{"ns":0,"exists":"","*":"Sertoli-Leydig cell tumor"},{"ns":0,"exists":"","*":"Sertoli-Leydig cell tumour"},{"ns":0,"exists":"","*":"Sertoli cell tumour"},{"ns":0,"exists":"","*":"Sex cord-gonadal stromal tumour"},{"ns":0,"exists":"","*":"Sex cord-stromal tumor"},{"ns":0,"exists":"","*":"Sex cord-stromal tumour"},{"ns":0,"exists":"","*":"Sex cord stromal tumor"},{"ns":0,"exists":"","*":"Sex cord tumour with annular tubules"},{"ns":0,"exists":"","*":"Sexual intercourse"},{"ns":0,"exists":"","*":"Short bowel syndrome"},{"ns":0,"exists":"","*":"Sister Mary Joseph nodule"},{"ns":0,"exists":"","*":"Sitting"},{"ns":0,"exists":"","*":"Slovakia"},{"ns":0,"exists":"","*":"Small-cell carcinoma"},{"ns":0,"exists":"","*":"Smoking"},{"ns":0,"exists":"","*":"Smoking cessation"},{"ns":0,"exists":"","*":"Social isolation"},{"ns":0,"exists":"","*":"Society of Gynecologic Oncology"},{"ns":0,"exists":"","*":"Specialty (medicine)"},{"ns":0,"exists":"","*":"Spirituality"},{"ns":0,"exists":"","*":"Splenectomy"},{"ns":0,"exists":"","*":"Squamous-cell carcinoma"},{"ns":0,"exists":"","*":"Squamous-cell carcinoma of the vagina"},{"ns":0,"exists":"","*":"Squamous cell carcinoma"},{"ns":0,"exists":"","*":"Standard of care"},{"ns":0,"exists":"","*":"Statistics"},{"ns":0,"exists":"","*":"Stem cell"},{"ns":0,"exists":"","*":"Stomach cancer"},{"ns":0,"exists":"","*":"Stroma (animal tissue)"},{"ns":0,"exists":"","*":"Stromal cancer"},{"ns":0,"exists":"","*":"Struma ovarii"},{"ns":0,"exists":"","*":"Supraclavicular lymph nodes"},{"ns":0,"exists":"","*":"Surface epithelial-stromal tumor"},{"ns":0,"exists":"","*":"Surface epithelial-stromal tumour"},{"ns":0,"exists":"","*":"Surgery"},{"ns":0,"exists":"","*":"Surveillance Epidemiology and End Results"},{"ns":0,"exists":"","*":"Suspensory ligament of ovary"},{"ns":0,"exists":"","*":"Swyer syndrome"},{"ns":0,"exists":"","*":"Symptoms"},{"ns":0,"exists":"","*":"Syncytiotrophoblast"},{"ns":0,"exists":"","*":"Systemic lupus erythematosus"},{"ns":0,"exists":"","*":"TGF-\u03b2"},{"ns":0,"exists":"","*":"TP53"},{"ns":0,"exists":"","*":"Talc"},{"ns":0,"exists":"","*":"Tamoxifen"},{"ns":0,"exists":"","*":"Tasquinimod"},{"ns":0,"exists":"","*":"Teenage pregnancy"},{"ns":0,"exists":"","*":"Teratoma"},{"ns":0,"exists":"","*":"Testosterone"},{"ns":0,"exists":"","*":"Thecoma"},{"ns":0,"exists":"","*":"Thoracentesis"},{"ns":0,"exists":"","*":"Thrombocytosis"},{"ns":0,"exists":"","*":"Tissue biopsy"},{"ns":0,"exists":"","*":"Topotecan"},{"ns":0,"exists":"","*":"Total parenteral nutrition"},{"ns":0,"exists":"","*":"Tranexamic acid"},{"ns":0,"exists":"","*":"Transferrin"},{"ns":0,"exists":"","*":"Transitional cell carcinoma"},{"ns":0,"exists":"","*":"Transitional cell carcinoma of the ovary"},{"ns":0,"exists":"","*":"Transthyretin"},{"ns":0,"exists":"","*":"Transvaginal ultrasound"},{"ns":0,"exists":"","*":"Trastuzumab"},{"ns":0,"exists":"","*":"TroVax"},{"ns":0,"exists":"","*":"Tubal ligation"},{"ns":0,"exists":"","*":"Tumor"},{"ns":0,"exists":"","*":"Tumor markers"},{"ns":0,"exists":"","*":"Tumor staging"},{"ns":0,"exists":"","*":"Turner syndrome"},{"ns":0,"exists":"","*":"Tyrosine kinase inhibitors"},{"ns":0,"exists":"","*":"USP36"},{"ns":0,"exists":"","*":"US FDA"},{"ns":0,"exists":"","*":"Ureteric stent"},{"ns":0,"exists":"","*":"Ureters"},{"ns":0,"exists":"","*":"Urinary bladder"},{"ns":0,"exists":"","*":"Urinary urgency"},{"ns":0,"exists":"","*":"Urogenital neoplasm"},{"ns":0,"exists":"","*":"Uterine cancer"},{"ns":0,"exists":"","*":"Uterine clear-cell carcinoma"},{"ns":0,"exists":"","*":"Uterine fibroid"},{"ns":0,"exists":"","*":"Uterine fibroids"},{"ns":0,"exists":"","*":"Uterine sarcoma"},{"ns":0,"exists":"","*":"Uterine serous carcinoma"},{"ns":0,"exists":"","*":"VEGF"},{"ns":0,"exists":"","*":"Vaccines"},{"ns":0,"exists":"","*":"Vaginal bleeding"},{"ns":0,"exists":"","*":"Vaginal cancer"},{"ns":0,"exists":"","*":"Vaginal cysts"},{"ns":0,"exists":"","*":"Vaginal intraepithelial neoplasia"},{"ns":0,"exists":"","*":"Vaginal ultrasonography"},{"ns":0,"exists":"","*":"Villoglandular adenocarcinoma of the cervix"},{"ns":0,"exists":"","*":"Vinblastine"},{"ns":0,"exists":"","*":"Vincristine"},{"ns":0,"exists":"","*":"Vintafolide"},{"ns":0,"exists":"","*":"Virilization"},{"ns":0,"exists":"","*":"Vitamin"},{"ns":0,"exists":"","*":"Vitamin D"},{"ns":0,"exists":"","*":"Vulvar cancer"},{"ns":0,"exists":"","*":"Vulvar intraepithelial neoplasia"},{"ns":0,"exists":"","*":"WT1"},{"ns":0,"exists":"","*":"Wayback Machine"},{"ns":0,"exists":"","*":"Well-woman examination"},{"ns":0,"exists":"","*":"White people"},{"ns":0,"exists":"","*":"Whole brain radiotherapy"},{"ns":0,"exists":"","*":"Yolk sac"},{"ns":0,"exists":"","*":"Yolk sac tumor"},{"ns":0,"*":"Peritoneal gliomatosis"},{"ns":0,"*":"MLH6"},{"ns":0,"*":"RAD51D"},{"ns":0,"*":"FMS (gene)"},{"ns":0,"*":"CSF-1"},{"ns":0,"*":"MAML3"},{"ns":0,"*":"T\u03b2RI"},{"ns":0,"*":"T\u03b2RII"},{"ns":0,"*":"Serous tubal intraepithelial carcinoma"},{"ns":0,"*":"Cortical inclusion cysts"},{"ns":0,"*":"Tuboovarian abscess"},{"ns":0,"*":"Diverticular abscess"},{"ns":0,"*":"Appendiceal abscess"},{"ns":0,"*":"Ureteral diverticulum"},{"ns":0,"*":"Benign cystic mesothelioma of the peritoneum"},{"ns":0,"*":"CA72-4"},{"ns":0,"*":"Immunosuppressive acidic protein"},{"ns":0,"*":"Haptoglobin-alpha"},{"ns":0,"*":"OVX1"},{"ns":0,"*":"Omental caking"},{"ns":0,"*":"Germinal cell"},{"ns":0,"*":"Ovarian capsule"},{"ns":0,"*":"Germ disk"},{"ns":0,"*":"Papillary projections"},{"ns":0,"*":"Pelvic lymph nodes"},{"ns":0,"*":"Hypogastric lymph node"},{"ns":0,"*":"Obturator lymph nodes"},{"ns":0,"*":"Second-look surgery"},{"ns":0,"*":"Diaphragm resection"},{"ns":0,"*":"Germ-cell tumor"},{"ns":0,"*":"LDH-1"},{"ns":0,"*":"LDH-2"},{"ns":0,"*":"Low-residue diet"},{"ns":0,"*":"Prognostic factor"},{"ns":0,"*":"Let-7b"},{"ns":0,"*":"Trebananib"},{"ns":0,"*":"MK-1775"},{"ns":0,"*":"Radiation fibrosis"},{"ns":0,"*":"Steroid cell tumor (NOS)"},{"ns":10,"exists":"","*":"Template:Female genital neoplasia"},{"ns":4,"exists":"","*":"Wikipedia:Citation needed"},{"ns":4,"exists":"","*":"Wikipedia:Identifying reliable sources (medicine)"},{"ns":11,"exists":"","*":"Template talk:Female genital neoplasia"},{"ns":12,"exists":"","*":"Help:Authority control"}],"templates":[{"ns":10,"exists":"","*":"Template:Infobox medical condition (new)"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:TOC limit"},{"ns":10,"exists":"","*":"Template:Further information"},{"ns":10,"exists":"","*":"Template:Further"},{"ns":10,"exists":"","*":"Template:Cn"},{"ns":10,"exists":"","*":"Template:Citation needed"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Anchor"},{"ns":10,"exists":"","*":"Template:Plainlist"},{"ns":10,"exists":"","*":"Template:="},{"ns":10,"exists":"","*":"Template:Main article"},{"ns":10,"exists":"","*":"Template:Main"},{"ns":10,"exists":"","*":"Template:Medical citation needed"},{"ns":10,"exists":"","*":"Template:Clear"},{"ns":10,"exists":"","*":"Template:Refbegin"},{"ns":10,"exists":"","*":"Template:Refbegin/styles.css"},{"ns":10,"exists":"","*":"Template:Column-count"},{"ns":10,"exists":"","*":"Template:Legend"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Refend"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Closed access"},{"ns":10,"exists":"","*":"Template:CDC"},{"ns":10,"exists":"","*":"Template:Include-USGov"},{"ns":10,"exists":"","*":"Template:Harvid"},{"ns":10,"exists":"","*":"Template:SfnRef"},{"ns":10,"exists":"","*":"Template:Harvnb"},{"ns":10,"exists":"","*":"Template:Harvard citation no brackets"},{"ns":10,"exists":"","*":"Template:Webarchive"},{"ns":10,"exists":"","*":"Template:Citation"},{"ns":10,"exists":"","*":"Template:Open access"},{"ns":10,"exists":"","*":"Template:Medical resources"},{"ns":10,"exists":"","*":"Template:Hlist"},{"ns":10,"exists":"","*":"Template:ICD10"},{"ns":10,"exists":"","*":"Template:ICD9"},{"ns":10,"exists":"","*":"Template:Str find"},{"ns":10,"exists":"","*":"Template:Genital neoplasia"},{"ns":10,"exists":"","*":"Template:Female genital neoplasia"},{"ns":10,"exists":"","*":"Template:Navbox"},{"ns":10,"exists":"","*":"Template:Authority control"},{"ns":10,"exists":"","*":"Template:EditAtWikidata"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:String2"},{"ns":828,"exists":"","*":"Module:WikidataIB/sandbox"},{"ns":828,"exists":"","*":"Module:Complex date"},{"ns":828,"exists":"","*":"Module:I18n/complex date"},{"ns":828,"exists":"","*":"Module:Ordinal"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Roman"},{"ns":828,"exists":"","*":"Module:ISOdate"},{"ns":828,"exists":"","*":"Module:DateI18n"},{"ns":828,"exists":"","*":"Module:I18n/date"},{"ns":828,"exists":"","*":"Module:Calendar"},{"ns":828,"exists":"","*":"Module:I18n"},{"ns":828,"*":"Module:WikidataIB/i18n"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Labelled list hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Anchor"},{"ns":828,"exists":"","*":"Module:TableTools"},{"ns":828,"exists":"","*":"Module:Main"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Footnotes"},{"ns":828,"exists":"","*":"Module:Webarchive"},{"ns":828,"exists":"","*":"Module:Webarchive/data"},{"ns":828,"exists":"","*":"Module:List"},{"ns":828,"exists":"","*":"Module:String"},{"ns":828,"exists":"","*":"Module:Navbox"},{"ns":828,"exists":"","*":"Module:Authority control"},{"ns":828,"exists":"","*":"Module:ResolveEntityId"},{"ns":828,"exists":"","*":"Module:EditAtWikidata"}],"images":["Diagram_showing_stage_1_ovarian_cancer_CRUK_193.svg","Diagram_showing_stage_2A_to_2C_ovarian_cancer_CRUK_214.svg","Diagram_showing_stage_3A_to_3C_ovarian_cancer_CRUK_225.svg","Diagram_showing_stage_4_ovarian_cancer_CRUK_233.svg","Lock-green.svg","Closed_Access_logo_alternative.svg","PD-icon.svg","Open_Access_logo_PLoS_transparent.svg","Mucinous_lmp_ovarian_tumour_intermed_mag.jpg","Site_of_ovarian_cancer.png","PedigreechartC.png","POvarianCA.png","Serous_carcinoma_cytology.jpg","Incidence_of_ovarian_cancers_by_histopathology.png","Ovarian_carcinoma.JPG","Clear_cell_carcinoma_hobnail_cells.png","Tumor_deposet.JPG","Relative_survival_of_ovarian_cancer_by_stage.png","Ovary_cancer_world_map_-_Death_-_WHO2004.svg","Ovarian_cancer_by_age_group.png","Blue_pencil.svg"],"externallinks":["http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page1/AllPages","https://web.archive.org/web/20140705232951/http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page1/AllPages","http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-risk-factors","https://web.archive.org/web/20160517173135/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-risk-factors","http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014","https://web.archive.org/web/20160919073553/http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014","http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/Patient/page1/AllPages","https://web.archive.org/web/20140706002700/http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/Patient/page1/AllPages","http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/HealthProfessional/page1/AllPages","https://web.archive.org/web/20140706002711/http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/HealthProfessional/page1/AllPages","http://seer.cancer.gov/statfacts/html/ovary.html","https://web.archive.org/web/20140706145616/http://seer.cancer.gov/statfacts/html/ovary.html","https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(16)31678-6","//doi.org/10.1016/S0140-6736(16)31678-6","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577","//www.ncbi.nlm.nih.gov/pubmed/27733282","https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(16)31012-1","//doi.org/10.1016/S0140-6736(16)31012-1","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5388903","//www.ncbi.nlm.nih.gov/pubmed/27733281","https://accessmedicine.mhmedical.com/content.aspx?bookid=1130&sectionid=79730544","https://web.archive.org/web/20170910175639/https://accessmedicine.mhmedical.com/content.aspx?bookid=1130&sectionid=79730544","http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer","https://web.archive.org/web/20140625220940/http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer","//doi.org/10.1016/j.amepre.2015.09.023","//www.ncbi.nlm.nih.gov/pubmed/26541098","https://books.google.com/books?id=PymZ1ORk0TcC&pg=PA223","https://web.archive.org/web/20150915231411/https://books.google.com/books?id=PymZ1ORk0TcC&pg=PA223","//doi.org/10.1007/978-0-387-68969-2_7","//www.ncbi.nlm.nih.gov/pubmed/18546620","//doi.org/10.1001/jama.2017.21926","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4805611","//doi.org/10.3389/fonc.2016.00063","//www.ncbi.nlm.nih.gov/pubmed/27047797","https://www.cdc.gov/cancer/ovarian/pdf/ovarian_facts.pdf","https://web.archive.org/web/20170616220028/https://www.cdc.gov/cancer/ovarian/pdf/ovarian_facts.pdf","//doi.org/10.1016/S0140-6736(13)62146-7","//www.ncbi.nlm.nih.gov/pubmed/24767708","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-symptoms","https://web.archive.org/web/20150512172659/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-symptoms","http://www.dynamed.com/topics/dmp~AN~T900705/Ovarian-cancer","https://web.archive.org/web/20150621210904/http://www.dynamed.com/topics/dmp~AN~T900705/Ovarian-cancer","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-risks-and-causes","https://web.archive.org/web/20150221095418/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/ovarian-cancer-risks-and-causes","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3806278","//doi.org/10.1002/ijc.27952","//www.worldcat.org/issn/0020-7136","//www.ncbi.nlm.nih.gov/pubmed/23175139","http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/healthprofessional","https://web.archive.org/web/20131231100136/http://www.cancer.gov/cancertopics/pdq/prevention/ovarian/healthprofessional","https://link.springer.com/article/10.1007%2Fs00404-016-4027-8","//doi.org/10.1007/s00404-016-4027-8","//www.ncbi.nlm.nih.gov/pubmed/26861465","https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2015.5495","//doi.org/10.1001/jamaoncol.2015.5495","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4845939","//www.ncbi.nlm.nih.gov/pubmed/26720728","https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2832","//doi.org/10.1186/bcr2832","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3109589","//www.ncbi.nlm.nih.gov/pubmed/21356067","https://web.archive.org/web/20170710051625/http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2832","//doi.org/10.1080/10937400701876095","//www.ncbi.nlm.nih.gov/pubmed/18368558","http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-what-causes","https://web.archive.org/web/20161110052501/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-what-causes","//doi.org/10.1097/CEJ.0b013e328333fb3a","//www.ncbi.nlm.nih.gov/pubmed/19926999","http://www.eurekaselect.com/55888/article","//doi.org/10.2174/156800906776842939","//www.ncbi.nlm.nih.gov/pubmed/16712459","https://web.archive.org/web/20161028153624/http://www.eurekaselect.com/55888/article","//doi.org/10.7326/M14-1651","//www.ncbi.nlm.nih.gov/pubmed/25599350","http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional","https://web.archive.org/web/20141022060353/http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional","https://academic.oup.com/jnci/article/102/4/222/2568923","//doi.org/10.1093/jnci/djp500","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2826180","//www.ncbi.nlm.nih.gov/pubmed/20110551","//doi.org/10.1097/GRF.0b013e31824970cf","//www.ncbi.nlm.nih.gov/pubmed/22343229","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/diagnosis/ovarian-cancer-tests","https://web.archive.org/web/20150518091201/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/diagnosis/ovarian-cancer-tests","https://web.archive.org/web/20130922075958/http://publications.nice.org.uk/ovarian-cancer-cg122/appendix-d-risk-of-malignancy-index-rmi-i","http://publications.nice.org.uk/ovarian-cancer-cg122/appendix-d-risk-of-malignancy-index-rmi-i","//doi.org/10.1097/AOG.0b013e318195ad17","//www.worldcat.org/issn/0029-7844","//www.ncbi.nlm.nih.gov/pubmed/19155910","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5025098","//doi.org/10.1002/j.2205-0140.2012.tb00011.x","//www.worldcat.org/issn/1836-6864","//www.ncbi.nlm.nih.gov/pubmed/28191150","http://seer.cancer.gov/publications/survival/surv_ovary.pdf","http://seer.cancer.gov/publications/survival/","https://web.archive.org/web/20131010123756/http://seer.cancer.gov/publications/survival/","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/types-of-ovarian-cancer","https://web.archive.org/web/20150518091024/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/about/types-of-ovarian-cancer","http://accessmedicine.mhmedical.com/content.aspx?bookid=498&sectionid=41008645","https://web.archive.org/web/20170910175639/http://accessmedicine.mhmedical.com/content.aspx?bookid=498&sectionid=41008645","http://www.cancerresearchuk.org/about-cancer/type/rare-cancers/rare-cancers-name/primary-peritoneal-carcinoma","https://web.archive.org/web/20150520031318/http://www.cancerresearchuk.org/about-cancer/type/rare-cancers/rare-cancers-name/primary-peritoneal-carcinoma","https://www.sgo.org/wp-content/uploads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf","https://web.archive.org/web/20141105012607/https://www.sgo.org/wp-content/uploads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf","http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-staging","https://web.archive.org/web/20161124070854/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-staging","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/stages-of-ovarian-cancer","https://web.archive.org/web/20150518132114/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/stages-of-ovarian-cancer","https://academic.oup.com/humupd/article-lookup/doi/10.1093/humupd/dmq030","//doi.org/10.1093/humupd/dmq030","//www.ncbi.nlm.nih.gov/pubmed/20634209","https://web.archive.org/web/20170910175639/https://academic.oup.com/humupd/article-lookup/doi/10.1093/humupd/dmq030","https://www.cdc.gov/cancer/ovarian/basic_info/treatment.htm","https://web.archive.org/web/20170616220128/https://www.cdc.gov/cancer/ovarian/basic_info/treatment.htm","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/which-treatment-for-ovarian-cancer","https://web.archive.org/web/20150512164129/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/which-treatment-for-ovarian-cancer","http://www.cancer.ca/en/cancer-information/cancer-type/ovarian/treatment/?region=on","https://web.archive.org/web/20161026174509/http://www.cancer.ca/en/cancer-information/cancer-type/ovarian/treatment/?region=on","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/surgery-for-ovarian-cancer","https://web.archive.org/web/20150518161131/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/surgery-for-ovarian-cancer","//doi.org/10.1002/14651858.CD005344.pub4","//www.worldcat.org/issn/1469-493X","//www.ncbi.nlm.nih.gov/pubmed/27737492","https://web.archive.org/web/20150518091158/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/drugs-used-for-ovarian-cancer","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/drugs-used-for-ovarian-cancer","http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm?sf34855004=1","https://web.archive.org/web/20150914092851/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm?sf34855004=1","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/radiotherapy-for-ovarian-cancer","https://web.archive.org/web/20150518160124/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/radiotherapy-for-ovarian-cancer","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/whats-new-in-ovarian-cancer-research","https://web.archive.org/web/20150509015810/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/whats-new-in-ovarian-cancer-research","http://www.cancerresearchuk.org/cancer-help/type/ovarian-cancer/treatment/follow-up-for-ovarian-cancer","https://web.archive.org/web/20170910000000/http://www.cancerresearchuk.org/cancer-help/type/ovarian-cancer/treatment/follow-up-for-ovarian-cancer","http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-after-follow-up","https://web.archive.org/web/20131225025103/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-after-follow-up","http://www.choosingwisely.org/doctor-patient-lists/society-of-gynecologic-oncology/","https://web.archive.org/web/20131201052931/http://www.choosingwisely.org/doctor-patient-lists/society-of-gynecologic-oncology/","//doi.org/10.1111/IGC.0b013e3181e82a7f","//www.ncbi.nlm.nih.gov/pubmed/20683399","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/chemotherapy-for-ovarian-cancer","https://web.archive.org/web/20150518091204/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/chemotherapy-for-ovarian-cancer","https://web.archive.org/web/20140821114944/http://www.asco.org/quality-guidelines/asco-provisional-clinical-opinion-integration-palliative-care-standard-oncology","http://www.asco.org/quality-guidelines/asco-provisional-clinical-opinion-integration-palliative-care-standard-oncology","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/treating-advanced-ovarian-cancer","https://web.archive.org/web/20150519050942/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/treating-advanced-ovarian-cancer","http://onlinelibrary.wiley.com/doi/10.1002/pon.3322/abstract","//doi.org/10.1002/pon.3322","//www.worldcat.org/issn/1099-1611","http://bmjopen.bmj.com/content/5/11/e007618","//doi.org/10.1136/bmjopen-2015-007618","//www.worldcat.org/issn/2044-6055","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4679843","//www.ncbi.nlm.nih.gov/pubmed/26621509","http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates","https://web.archive.org/web/20141029204610/http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates","http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/statistics-and-outlook-for-ovarian-cancer","https://web.archive.org/web/20150518192429/http://www.cancerresearchuk.org/about-cancer/type/ovarian-cancer/treatment/statistics-and-outlook-for-ovarian-cancer","http://www.who.int/entity/healthinfo/global_burden_disease/gbddeathdalycountryestimates_female_2004.xls?ua=1","//doi.org/10.1016/S0140-6736(12)61728-0","//www.ncbi.nlm.nih.gov/pubmed/23245604","http://www.merckmanuals.com/professional/gynecology_and_obstetrics/gynecologic_tumors/ovarian_cancer.htm","http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/","https://web.archive.org/web/20141006122756/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/","http://accessmedicine.mhmedical.com/content.aspx?bookid=379&Sectionid=39902056","https://web.archive.org/web/20170910175639/http://accessmedicine.mhmedical.com/content.aspx?bookid=379&Sectionid=39902056","//doi.org/10.1111/j.1439-0531.2003.00476.x","//www.ncbi.nlm.nih.gov/pubmed/15065985","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1259148","//www.ncbi.nlm.nih.gov/pubmed/16363331","//doi.org/10.1111/j.1751-0813.2005.tb12740.x","//www.ncbi.nlm.nih.gov/pubmed/15957389","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1852596","//www.ncbi.nlm.nih.gov/pubmed/17542368","https://www.jstage.jst.go.jp/article/jvms/65/6/65_6_749/_article","//doi.org/10.1292/jvms.65.749","//www.ncbi.nlm.nih.gov/pubmed/12867740","//www.ncbi.nlm.nih.gov/pubmed/9364230","http://www3.interscience.wiley.com/journal/119849124/abstract","//doi.org/10.1111/j.1532-950X.1987.tb00987.x","//www.ncbi.nlm.nih.gov/pubmed/3507181","//doi.org/10.1111/j.2042-3306.1988.tb01450.x","//www.ncbi.nlm.nih.gov/pubmed/2835223","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5351187","//doi.org/10.3892/ol.2016.5493","//www.ncbi.nlm.nih.gov/pubmed/28356928","http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(15)01224-6","//doi.org/10.1016/S0140-6736(15)01224-6","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4779792","//www.ncbi.nlm.nih.gov/pubmed/26707054","//doi.org/10.1002/14651858.CD007287.pub3","//www.ncbi.nlm.nih.gov/pubmed/25229990","//doi.org/10.1186/s13027-017-0134-9","//www.worldcat.org/issn/1750-9378","https://www.nih.gov/health-information/nih-clinical-research-trials-you","https://web.archive.org/web/20170608133010/https://www.nih.gov/health-information/nih-clinical-research-trials-you","https://www.cancer.gov/about-cancer/treatment/clinical-trials","https://web.archive.org/web/20170616213104/https://www.cancer.gov/about-cancer/treatment/clinical-trials","https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/","https://web.archive.org/web/20170701064612/https://www.cancer.gov/about-cancer/treatment/clinical-trials/search","https://www.clinicaltrials.gov/","https://web.archive.org/web/20170616200907/https://www.clinicaltrials.gov/","http://www.canadiancancertrials.ca/","https://web.archive.org/web/20170626081519/http://canadiancancertrials.ca/","https://www.wikidata.org/wiki/Q172341","http://content.nejm.org/cgi/content/full/351/24/2519","//doi.org/10.1056/NEJMra041842","//www.ncbi.nlm.nih.gov/pubmed/15590954","http://apps.who.int/classifications/icd10/browse/2016/en#/C56","http://www.icd9data.com/getICD9Code.ashx?icd9=183","http://www.icd9data.com/getICD9Code.ashx?icd9=220","https://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&term=D010051","http://www.diseasesdatabase.com/ddb9418.htm","https://www.nlm.nih.gov/medlineplus/ency/article/000889.htm","http://www.emedicine.com/med/topic1698.htm","https://patient.info/doctor/ovarian-cancer-pro","https://www.cancer.gov/types/ovarian/hp","https://www.ncbi.nlm.nih.gov/books/NBK1247/","//www.ncbi.nlm.nih.gov/pubmed/20301425","http://www.mountsinai.org/patient-care/service-areas/obgyn-and-reproductive-services/areas-of-care/gynecologic-oncology/ovarian-cancer/infographic/ovariancancerinfo","http://id.loc.gov/authorities/subjects/sh2010104661","https://id.ndl.go.jp/auth/ndlna/00569292"],"sections":[{"toclevel":1,"level":"2","line":"Signs and symptoms","number":"1","index":"1","fromtitle":"Ovarian_cancer","byteoffset":11175,"anchor":"Signs_and_symptoms"},{"toclevel":2,"level":"3","line":"Early symptoms","number":"1.1","index":"2","fromtitle":"Ovarian_cancer","byteoffset":11198,"anchor":"Early_symptoms"},{"toclevel":2,"level":"3","line":"Later symptoms","number":"1.2","index":"3","fromtitle":"Ovarian_cancer","byteoffset":13306,"anchor":"Later_symptoms"},{"toclevel":2,"level":"3","line":"Children","number":"1.3","index":"4","fromtitle":"Ovarian_cancer","byteoffset":14580,"anchor":"Children"},{"toclevel":1,"level":"2","line":"Risk factors","number":"2","index":"5","fromtitle":"Ovarian_cancer","byteoffset":15491,"anchor":"Risk_factors"},{"toclevel":2,"level":"3","line":"Hormones","number":"2.1","index":"6","fromtitle":"Ovarian_cancer","byteoffset":17199,"anchor":"Hormones"},{"toclevel":2,"level":"3","line":"Genetics","number":"2.2","index":"7","fromtitle":"Ovarian_cancer","byteoffset":19719,"anchor":"Genetics"},{"toclevel":2,"level":"3","line":"Environmental factors","number":"2.3","index":"8","fromtitle":"Ovarian_cancer","byteoffset":25768,"anchor":"Environmental_factors"},{"toclevel":2,"level":"3","line":"Other","number":"2.4","index":"9","fromtitle":"Ovarian_cancer","byteoffset":27668,"anchor":"Other"},{"toclevel":2,"level":"3","line":"Protective factors","number":"2.5","index":"10","fromtitle":"Ovarian_cancer","byteoffset":30647,"anchor":"Protective_factors"},{"toclevel":1,"level":"2","line":"Pathophysiology","number":"3","index":"11","fromtitle":"Ovarian_cancer","byteoffset":32975,"anchor":"Pathophysiology"},{"toclevel":1,"level":"2","line":"Diagnosis","number":"4","index":"12","fromtitle":"Ovarian_cancer","byteoffset":39594,"anchor":"Diagnosis"},{"toclevel":2,"level":"3","line":"Examination","number":"4.1","index":"13","fromtitle":"Ovarian_cancer","byteoffset":39611,"anchor":"Examination"},{"toclevel":3,"level":"4","line":"Risk scoring","number":"4.1.1","index":"14","fromtitle":"Ovarian_cancer","byteoffset":49536,"anchor":"Risk_scoring"},{"toclevel":2,"level":"3","line":"Pathology","number":"4.2","index":"15","fromtitle":"Ovarian_cancer","byteoffset":53339,"anchor":"Pathology"},{"toclevel":3,"level":"4","line":"Epithelial carcinoma","number":"4.2.1","index":"16","fromtitle":"Ovarian_cancer","byteoffset":56678,"anchor":"Epithelial_carcinoma"},{"toclevel":4,"level":"5","line":"Serous carcinoma","number":"4.2.1.1","index":"17","fromtitle":"Ovarian_cancer","byteoffset":57698,"anchor":"Serous_carcinoma"},{"toclevel":4,"level":"5","line":"Small-cell carcinoma","number":"4.2.1.2","index":"18","fromtitle":"Ovarian_cancer","byteoffset":58988,"anchor":"Small-cell_carcinoma"},{"toclevel":5,"level":"6","line":"Primary peritoneal carcinoma","number":"4.2.1.2.1","index":"19","fromtitle":"Ovarian_cancer","byteoffset":59542,"anchor":"Primary_peritoneal_carcinoma"},{"toclevel":4,"level":"5","line":"Clear-cell carcinoma","number":"4.2.1.3","index":"20","fromtitle":"Ovarian_cancer","byteoffset":60481,"anchor":"Clear-cell_carcinoma"},{"toclevel":4,"level":"5","line":"Clear-cell adenocarcinoma","number":"4.2.1.4","index":"21","fromtitle":"Ovarian_cancer","byteoffset":60820,"anchor":"Clear-cell_adenocarcinoma"},{"toclevel":4,"level":"5","line":"Endometrioid","number":"4.2.1.5","index":"22","fromtitle":"Ovarian_cancer","byteoffset":61463,"anchor":"Endometrioid"},{"toclevel":5,"level":"6","line":"Malignant mixed m\u00fcllerian tumor (carcinosarcoma)","number":"4.2.1.5.1","index":"23","fromtitle":"Ovarian_cancer","byteoffset":61771,"anchor":"Malignant_mixed_m\u00fcllerian_tumor_(carcinosarcoma)"},{"toclevel":4,"level":"5","line":"Mucinous","number":"4.2.1.6","index":"24","fromtitle":"Ovarian_cancer","byteoffset":62008,"anchor":"Mucinous"},{"toclevel":5,"level":"6","line":"Mucinous adenocarcinoma","number":"4.2.1.6.1","index":"25","fromtitle":"Ovarian_cancer","byteoffset":62135,"anchor":"Mucinous_adenocarcinoma"},{"toclevel":5,"level":"6","line":"Pseudomyxoma peritonei","number":"4.2.1.6.2","index":"26","fromtitle":"Ovarian_cancer","byteoffset":62645,"anchor":"Pseudomyxoma_peritonei"},{"toclevel":4,"level":"5","line":"Undifferentiated epithelial","number":"4.2.1.7","index":"27","fromtitle":"Ovarian_cancer","byteoffset":63017,"anchor":"Undifferentiated_epithelial"},{"toclevel":5,"level":"6","line":"Malignant Brenner tumor","number":"4.2.1.7.1","index":"28","fromtitle":"Ovarian_cancer","byteoffset":63473,"anchor":"Malignant_Brenner_tumor"},{"toclevel":5,"level":"6","line":"Transitional cell carcinoma","number":"4.2.1.7.2","index":"29","fromtitle":"Ovarian_cancer","byteoffset":63949,"anchor":"Transitional_cell_carcinoma"},{"toclevel":3,"level":"4","line":"Sex cord-stromal tumor","number":"4.2.2","index":"30","fromtitle":"Ovarian_cancer","byteoffset":64305,"anchor":"Sex_cord-stromal_tumor"},{"toclevel":4,"level":"5","line":"Granulosa cell tumor","number":"4.2.2.1","index":"31","fromtitle":"Ovarian_cancer","byteoffset":66459,"anchor":"Granulosa_cell_tumor"},{"toclevel":5,"level":"6","line":"Adult granulosa cell tumor","number":"4.2.2.1.1","index":"32","fromtitle":"Ovarian_cancer","byteoffset":66896,"anchor":"Adult_granulosa_cell_tumor"},{"toclevel":5,"level":"6","line":"Juvenile granulosa cell tumor","number":"4.2.2.1.2","index":"33","fromtitle":"Ovarian_cancer","byteoffset":67507,"anchor":"Juvenile_granulosa_cell_tumor"},{"toclevel":4,"level":"5","line":"Sertoli-Leydig cell tumor","number":"4.2.2.2","index":"34","fromtitle":"Ovarian_cancer","byteoffset":67552,"anchor":"Sertoli-Leydig_cell_tumor"},{"toclevel":4,"level":"5","line":"Sclerosing stromal tumors","number":"4.2.2.3","index":"35","fromtitle":"Ovarian_cancer","byteoffset":67717,"anchor":"Sclerosing_stromal_tumors"},{"toclevel":3,"level":"4","line":"Germ cell tumor","number":"4.2.3","index":"36","fromtitle":"Ovarian_cancer","byteoffset":67871,"anchor":"Germ_cell_tumor"},{"toclevel":4,"level":"5","line":"Dysgerminoma","number":"4.2.3.1","index":"37","fromtitle":"Ovarian_cancer","byteoffset":71078,"anchor":"Dysgerminoma"},{"toclevel":4,"level":"5","line":"Choriocarcinoma","number":"4.2.3.2","index":"38","fromtitle":"Ovarian_cancer","byteoffset":72855,"anchor":"Choriocarcinoma"},{"toclevel":4,"level":"5","line":"Immature (solid) teratoma","number":"4.2.3.3","index":"39","fromtitle":"Ovarian_cancer","byteoffset":73347,"anchor":"Immature_(solid)_teratoma"},{"toclevel":4,"level":"5","line":"Mature teratoma (dermoid cyst)","number":"4.2.3.4","index":"40","fromtitle":"Ovarian_cancer","byteoffset":75303,"anchor":"Mature_teratoma_(dermoid_cyst)"},{"toclevel":4,"level":"5","line":"Yolk sac tumor/endodermal sinus tumor","number":"4.2.3.5","index":"41","fromtitle":"Ovarian_cancer","byteoffset":76035,"anchor":"Yolk_sac_tumor/endodermal_sinus_tumor"},{"toclevel":4,"level":"5","line":"Embryonal carcinoma","number":"4.2.3.6","index":"42","fromtitle":"Ovarian_cancer","byteoffset":77470,"anchor":"Embryonal_carcinoma"},{"toclevel":4,"level":"5","line":"Polyembryoma","number":"4.2.3.7","index":"43","fromtitle":"Ovarian_cancer","byteoffset":78226,"anchor":"Polyembryoma"},{"toclevel":3,"level":"4","line":"Squamous cell carcinoma","number":"4.2.4","index":"44","fromtitle":"Ovarian_cancer","byteoffset":78618,"anchor":"Squamous_cell_carcinoma"},{"toclevel":3,"level":"4","line":"Mixed tumors","number":"4.2.5","index":"45","fromtitle":"Ovarian_cancer","byteoffset":78928,"anchor":"Mixed_tumors"},{"toclevel":3,"level":"4","line":"Secondary ovarian cancer","number":"4.2.6","index":"46","fromtitle":"Ovarian_cancer","byteoffset":79565,"anchor":"Secondary_ovarian_cancer"},{"toclevel":3,"level":"4","line":"Low malignant potential tumors","number":"4.2.7","index":"47","fromtitle":"Ovarian_cancer","byteoffset":80975,"anchor":"Low_malignant_potential_tumors"},{"toclevel":2,"level":"3","line":"Staging","number":"4.3","index":"48","fromtitle":"Ovarian_cancer","byteoffset":82073,"anchor":"Staging"},{"toclevel":3,"level":"4","line":"FIGO","number":"4.3.1","index":"49","fromtitle":"Ovarian_cancer","byteoffset":83907,"anchor":"FIGO"},{"toclevel":3,"level":"4","line":"AJCC/TNM","number":"4.3.2","index":"50","fromtitle":"Ovarian_cancer","byteoffset":86793,"anchor":"AJCC/TNM"},{"toclevel":3,"level":"4","line":"Grading","number":"4.3.3","index":"51","fromtitle":"Ovarian_cancer","byteoffset":88811,"anchor":"Grading"},{"toclevel":1,"level":"2","line":"Screening","number":"5","index":"52","fromtitle":"Ovarian_cancer","byteoffset":90746,"anchor":"Screening"},{"toclevel":1,"level":"2","line":"Prevention","number":"6","index":"53","fromtitle":"Ovarian_cancer","byteoffset":93011,"anchor":"Prevention"},{"toclevel":1,"level":"2","line":"Management","number":"7","index":"54","fromtitle":"Ovarian_cancer","byteoffset":94896,"anchor":"Management"},{"toclevel":2,"level":"3","line":"Surgery","number":"7.1","index":"55","fromtitle":"Ovarian_cancer","byteoffset":97141,"anchor":"Surgery"},{"toclevel":2,"level":"3","line":"Chemotherapy","number":"7.2","index":"56","fromtitle":"Ovarian_cancer","byteoffset":104625,"anchor":"Chemotherapy"},{"toclevel":3,"level":"4","line":"Platinum-sensitive or platinum-resistant","number":"7.2.1","index":"57","fromtitle":"Ovarian_cancer","byteoffset":109165,"anchor":"Platinum-sensitive_or_platinum-resistant"},{"toclevel":2,"level":"3","line":"Radiation therapy","number":"7.3","index":"58","fromtitle":"Ovarian_cancer","byteoffset":112209,"anchor":"Radiation_therapy"},{"toclevel":2,"level":"3","line":"Hormonal therapy","number":"7.4","index":"59","fromtitle":"Ovarian_cancer","byteoffset":113390,"anchor":"Hormonal_therapy"},{"toclevel":2,"level":"3","line":"Immunotherapy","number":"7.5","index":"60","fromtitle":"Ovarian_cancer","byteoffset":113824,"anchor":"Immunotherapy"},{"toclevel":2,"level":"3","line":"Follow-up","number":"7.6","index":"61","fromtitle":"Ovarian_cancer","byteoffset":114151,"anchor":"Follow-up"},{"toclevel":2,"level":"3","line":"Palliative care","number":"7.7","index":"62","fromtitle":"Ovarian_cancer","byteoffset":118470,"anchor":"Palliative_care"},{"toclevel":2,"level":"3","line":"Psychosocial care","number":"7.8","index":"63","fromtitle":"Ovarian_cancer","byteoffset":122384,"anchor":"Psychosocial_care"},{"toclevel":1,"level":"2","line":"Prognosis","number":"8","index":"64","fromtitle":"Ovarian_cancer","byteoffset":125209,"anchor":"Prognosis"},{"toclevel":2,"level":"3","line":"Prognostic factors","number":"8.1","index":"65","fromtitle":"Ovarian_cancer","byteoffset":129763,"anchor":"Prognostic_factors"},{"toclevel":2,"level":"3","line":"Survival rates","number":"8.2","index":"66","fromtitle":"Ovarian_cancer","byteoffset":131115,"anchor":"Survival_rates"},{"toclevel":2,"level":"3","line":"Recurrence rates","number":"8.3","index":"67","fromtitle":"Ovarian_cancer","byteoffset":133606,"anchor":"Recurrence_rates"},{"toclevel":1,"level":"2","line":"Epidemiology","number":"9","index":"68","fromtitle":"Ovarian_cancer","byteoffset":135692,"anchor":"Epidemiology"},{"toclevel":2,"level":"3","line":"United States","number":"9.1","index":"69","fromtitle":"Ovarian_cancer","byteoffset":138242,"anchor":"United_States"},{"toclevel":2,"level":"3","line":"United Kingdom","number":"9.2","index":"70","fromtitle":"Ovarian_cancer","byteoffset":140238,"anchor":"United_Kingdom"},{"toclevel":2,"level":"3","line":"Ethnicity","number":"9.3","index":"71","fromtitle":"Ovarian_cancer","byteoffset":141978,"anchor":"Ethnicity"},{"toclevel":2,"level":"3","line":"Older women","number":"9.4","index":"72","fromtitle":"Ovarian_cancer","byteoffset":142102,"anchor":"Older_women"},{"toclevel":1,"level":"2","line":"In pregnancy","number":"10","index":"73","fromtitle":"Ovarian_cancer","byteoffset":143321,"anchor":"In_pregnancy"},{"toclevel":1,"level":"2","line":"Other animals","number":"11","index":"74","fromtitle":"Ovarian_cancer","byteoffset":144140,"anchor":"Other_animals"},{"toclevel":1,"level":"2","line":"Research","number":"12","index":"75","fromtitle":"Ovarian_cancer","byteoffset":147114,"anchor":"Research"},{"toclevel":2,"level":"3","line":"Screening","number":"12.1","index":"76","fromtitle":"Ovarian_cancer","byteoffset":147129,"anchor":"Screening_2"},{"toclevel":2,"level":"3","line":"Prognosis research","number":"12.2","index":"77","fromtitle":"Ovarian_cancer","byteoffset":150409,"anchor":"Prognosis_research"},{"toclevel":2,"level":"3","line":"Immunotherapy","number":"12.3","index":"78","fromtitle":"Ovarian_cancer","byteoffset":150740,"anchor":"Immunotherapy_2"},{"toclevel":2,"level":"3","line":"Pharmacology","number":"12.4","index":"79","fromtitle":"Ovarian_cancer","byteoffset":151767,"anchor":"Pharmacology"},{"toclevel":2,"level":"3","line":"Hormones and radiation","number":"12.5","index":"80","fromtitle":"Ovarian_cancer","byteoffset":156003,"anchor":"Hormones_and_radiation"},{"toclevel":2,"level":"3","line":"Inflammation","number":"12.6","index":"81","fromtitle":"Ovarian_cancer","byteoffset":157134,"anchor":"Inflammation"},{"toclevel":2,"level":"3","line":"Clinical trials","number":"12.7","index":"82","fromtitle":"Ovarian_cancer","byteoffset":157833,"anchor":"Clinical_trials"},{"toclevel":1,"level":"2","line":"References","number":"13","index":"83","fromtitle":"Ovarian_cancer","byteoffset":159953,"anchor":"References"},{"toclevel":1,"level":"2","line":"Further reading","number":"14","index":"84","fromtitle":"Ovarian_cancer","byteoffset":159983,"anchor":"Further_reading"},{"toclevel":1,"level":"2","line":"External links","number":"15","index":"85","fromtitle":"Ovarian_cancer","byteoffset":160312,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Ovarian cancer","iwlinks":[{"prefix":"d","url":"https://www.wikidata.org/wiki/Q172341","*":"d:Q172341"}],"properties":[{"name":"defaultsort","*":"Ovarian Cancer"},{"name":"wikibase_item","*":"Q172341"}]}}